| Entries |
| Document | Title | Date |
|---|
| 20080213320 | Compositions for treatment of gastro-esophageal reflux disorders - The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and methods of treating subjects against gastro-esophageal reflux disorders, which include administering to a subject a therapeutically effective amount of the compositions of the present invention. | 09-04-2008 |
| 20080213321 | DERMABRASION DEVICES AND SYSTEMS - In general, the invention relates to the design and fabrication of devices and systems suitable for dermabrasion. | 09-04-2008 |
| 20080220026 | Mesoporous material compositions and methods of their use for improving the appearance of biological surfaces - The present invention relates to compositions and methods for treating and improving the aesthetic appearance of a biological surface by altering the optical properties of the biological surface, thereby resulting in a natural appearance. The compositions of the invention may be topically applied to the biological surface, including but not limited to skin, in an amount effective in improving the aesthetic and natural appearance of the biological surface. | 09-11-2008 |
| 20080220027 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases - Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases. | 09-11-2008 |
| 20080220028 | ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS - The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions comprising an antigen and a self-adjuvanting carrier, useful for inducing antigen-specific mucosal and systemic immune responses in the host upon immunization via a mucosal route such as intranasal. The vaccine compositions comprise multivalent cations in association with a plurality of spherical archaeal polar lipid aggregates containing aqueous compartments, the AMVAD structure, formed by the interaction of archaeosomes and antigen(s) with multivalent cations such as Ca | 09-11-2008 |
| 20080233156 | Pharmaceutical compositions - Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition. | 09-25-2008 |
| 20080233157 | INHIBITING SURFACE ENHANCED CRYSTALLIZATION OF AMORPHOUS PHARMACEUTICALS WITH ULTRATHIN COATINGS - The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over extended periods of time, relative to uncoated pharmaceuticals. | 09-25-2008 |
| 20080241197 | MINOCYCLINE DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20080241198 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases - Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases. | 10-02-2008 |
| 20080241199 | "Micro-Patch" for Assessment of the Local Microvasculature and Microcirculatory Vasoreactivity - A method for interrogating the microcirculation of a subject for use in characterizing function in health and disease, monitor changes in microcirculation over time, and identify responses in microcirculation to potentially harmful or beneficial interventions. The method includes delivering a study agent to a study surface for trans-surface delivery to the microvasculature of the subject and monitoring the microvasculature of the subject in the area of the study surface. A system is also provided which includes a micro-patch for delivery of study agent to a study surface for trans-surface delivery to the microvasculature of the subject and a monitoring probe for monitoring the microvasculature of the subject in the area of the study surface. | 10-02-2008 |
| 20080248069 | Dosage Forms of Active Ingredients Containing Hydroxystilbene for Treating Menopausal Complaints - The invention relates to novel dosage forms containing hydroxystilbene, to a method for producing said dosage forms and to their use for treating female menopausal complaints, juvenile oligomenorrhoea and dysmenorrhoea, primary and secondary amenorrhoea or endometritis. | 10-09-2008 |
| 20080248070 | HDL-Boosting Combination Therapy Complexes - A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent. | 10-09-2008 |
| 20080254073 | Transdermal Patch Comprising Paroxetine - Disclosed relates to a transdermal patch comprising paroxetine that is useful to reduce the side effects accompanied with the initial high drug concentration after oral administration of paroxetine and decrease the broad metabolism of the drug in the liver. Moreover, the transdermal patch comprising paroxetine of the present invention has an excellent skin permeation rate and shows high bioavailability compared with oral administration of the drug. | 10-16-2008 |
| 20080260785 | PAROXETINE COMPOSITIONS - The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered dose. | 10-23-2008 |
| 20080274146 | Application System for a Plaster Containing an Active Ingredient and a Controlled-Release Agent for Said Active Ingredient - The present invention relates to an application system for an active ingredient release system, comprising a film-form application strip, which is in each case bonded detachably to an active ingredient-containing plaster and a separate active ingredient release regulator separate there from. | 11-06-2008 |
| 20080279898 | Biologically Degradable Compositions For Medical Applications - A medical article is disclosed, comprising a biologically degradable AB block copolymer and a biologically degradable polymer that is capable, at equilibrium and at room temperature, of absorbing less than about 5 mass % water. | 11-13-2008 |
| 20080292664 | Hydrogels and Hyaluronic Acid and Alpha, Beta-Polyaspartyl-Hydrazide and Their Biomedical and Pharmaceutical Uses - Compositions and products based on the chemical crosslinking of hyaluronic acid with a polyfunctional polymer having a protein-like structure, bearing hydrazido pendent groups along the polymeric chain. The polymer is preferably, alpha-beta-polyaspartylhydrazide, a biocompatible macromolecule. The materials obtained after crosslinking, specifically hydrogels, undergo a reduced chemical and enzymatic degradation, unlike the starting hyaluronic acid, and they can be used to prepare systems for applications in the biomedical and pharmaceutical field. | 11-27-2008 |
| 20080292665 | Simple mechanical procedure and product for deterring substance abuse - Simple mechanical methods improve safety of a substance that is at risk for abuse. The substance is made in a specified form that tends to deter conversion to powder: and in this form commercially distributed, e.g. wholesale or retail. Preferably that form is enclosed in a harmless container. Preferably the method also includes putting the substance into or onto a harmless carrier. Preferably the carrier does not dissolve in. It may e oil or solid—for example paper or similarly thin medium, or a sponge or other medium that has generally course cellular structure. | 11-27-2008 |
| 20080292666 | Preparation for Preventing or Treating Calcium Deficiency Conditions In Mammals - An essentially dry powdered preparation containing a calcium source for the prevention and treatment of calcium deficiency conditions in mammals, e.g. dairy cows, is enclosed in a substantially water soluble, dispersible or disintegrable casing mainly composed of a cellulose material such as e.g. paperboard, cardboard, millboard, or pasteboard, or a gelatinized starch material. The calcium source is preferably a mixture of calcium chloride and calcium propionate enclosed in a cylindrical paperboard or cardboard tube or a gelatinized starch shell closed at both ends, which is administered to an animal with a bolus or bullet gun. The administration is safe and clean and the powdered mixture is quickly released in the stomach or rumen without causing erosion, irritation or inflammation of the mucosa. | 11-27-2008 |
| 20080292667 | Nonwoven Nanofibrous Membranes of Silk Fibroin for Guided Bone Tissue Regeneration and Their Preparation Method - The present invention relates to a membrane for guided bone tissue regeneration and, more particularly, to a membrane for guided bone tissue regeneration having a structure that silk fibroin nanofibers obtained by removing sericin from silk fibers are formed as a nonwoven, and a manufacturing method thereof. | 11-27-2008 |
| 20080311160 | Clear Pharmaceutical Aqueous Emulsion Composition Which Comprises Propofol and Process for Preparing this Composition - The present invention concerns a clear pharmaceutical aqueous emulsion composition which comprises Propofol and a surfactant system and which is particularly usable for a safe administration through intravenous injection. A composition according to the invention is characterized in that the surfactant system comprises in combination at least one pharmaceutically acceptable monovalent metal salt of a fatty acid having from 5 to 23 carbon atoms, and at least one polyethylene glycol hydroxystearate. This combination allows to use a mass ratio (w/w) surfactant system/Propofol which is less than 4 and preferably less than or equal to 2.8, while obtaining such a clear composition. | 12-18-2008 |
| 20080311161 | Compositions and Methods for Enhanced Gastrointestinal Stability of Oligopeptides and Polypeptides - Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided. | 12-18-2008 |
| 20090004228 | BORON COMPOUND-LAYERED DOUBLE HYDROXIDE NANOHYBRID, METHOD OF PREPARING THE BORON COMPOUND-LDH NANOHYBRID, AND PHARMACEUTICAL COMPOSITION COMPRISING THE BORON COMPOUND-LDH NANOHYBRID - Provided are a boron compound-layered double hydroxide (LDH) nanohybrid in which a boron compound for boron neutron capture therapy is intercalated in between layers of LDH, a method of preparing the boron compound-LDH nanohybrid, and a pharmaceutical composition including the boron compound-LDH nanohybrid, which can be used in boron neutron capture therapy. | 01-01-2009 |
| 20090004229 | RUPTURING CONTROLLED RELEASE DEVICE COMPRISING A SUBCOAT - The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane. | 01-01-2009 |
| 20090004230 | Thermosetting Neutralized Chitosan Composition Forming a Hydrogel, Lyophilizate, and Processes for Producing the Same - The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w/w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w/w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation. | 01-01-2009 |
| 20090004231 | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring - Nanomaterials fabricated to pharmaceutical dosage forms used to monitor quality of the drug product enclosed therein are disclosed. The nanomaterials are useful to provide a plurality of quality analysis to the dosage form. Consequently, the nanomaterials provide a means to perform quality testing on a continuous basis throughout the supply chain, including the cold chain whereby manufacturers and distributors can achieve greater product integrity and longer shelf life and ultimately minimize cost. The end user benefits in obtaining the highest quality drugs at the time of need. | 01-01-2009 |
| 20090017078 | Anhydrous topical formulation for polyphenols - The present invention discloses a composition of matter, and method to formulate same, which is an anhydrous topical cream, gel or ointment base, a polyphenol and a suitable adsorbent binding carrier to which the polyphenol will bind for purposes of even disbursement within the cream, gel or base and which will not inhibit the ability of the polyphenols to be released on and into the aqueous environment of the skin when the topical mixture is applied thereto. The binding carrier provides the ability to disperse a hydrophilic polyphenol in a non-aqueous medium for purposes of topical application to the body. In particular, the present invention discloses the use of polyphenols such as tea catechins, and in particular green tea catechins, disbursed in an anhydrous base consisting of either saturated or unsaturated plant oils or waxes through the use of a variety of binding carriers including, but is not limited to, talcs and clays, alginates, algae, agars, gums, gelatins, celluloses, silica, silica gels, simethicone, salicylates, silicates and silicone resins, tragacanths, calcium carbonates and magnesium or zinc oxides. Such binding carriers are particularly useful when polyphenol concentrations exceed 0.2% w/w in the mixture, and their use is preferred when concentrations are between 1.0 to 20% w/w polyphenols. | 01-15-2009 |
| 20090035331 | Systems and Methods for Targeted and Controlled Delivery of Agents - An Agent Delivery System allows for targeted and controlled delivery of an agent or agents to target site, such as specific cells or a specific tissue of an individual. An exemplary Agent Delivery System includes a platform, having a silica crystal lattice base plate, coated with a collagen-containing layer. At least one agent of interest is disposed within the platform, for delivering to the target site. The agent is released when the Agent Delivery Platform is exposed to collagen-degrading compounds. Collagen-degrading compounds can be secreted by cells within a target site. | 02-05-2009 |
| 20090035332 | PHARMACEUTICAL FORMULATION - This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, and one or more suitable pharmaceutical excipients, wherein the composition is coated with a coating comprising polyvinyl alcohol. | 02-05-2009 |
| 20090041810 | Immunostimulating polyphosphazene compounds for intradermal immunization - Disclosed are intradermally administered products and methods for producing an immune response in a human or in an animal comprising an antigen and a polyphosphazene polyelectrolyte adjuvant in an amount effective to elicit an immune response in the human or in the animal against said antigen. | 02-12-2009 |
| 20090041811 | Oil-In-Water Emulsion Composition - The present invention is an oil-in-water emulsion composition containing a hydrophilic non-ionic surfactant or hydrophilic anionic surfactant, a higher aliphatic alcohol, water, and an oil ingredient which meets specific conditions. This is an oil-in-water emulsion composition with good high temperature stability and usability, and can be used as a cream-like endermic liniment such as a cosmetic. | 02-12-2009 |
| 20090060955 | Drug delivery vehicle that mimics viral properties - A drug delivery vehicle for targeted delivery of a drug mimics viral properties of size, capsid-like protein capsule, cell-specific entry, toxin release, destruction of infected cells, and migration to neighboring cells. This vehicle, termed a virogel, contains a hydrophobic polymeric core, a hydrophilic inner shell, a hydrophilic outer shell, and a ligand. An illustrative drug-loaded virogel includes poly(L-histidine-co-phenylalanine) as the core, doxorubicin loaded in the core, polyethylene glycol as the inner shell, bovine serum albumin as the outer shell, and folic acid as the ligand. | 03-05-2009 |
| 20090060956 | AGENT FOR REDUCING THE USEABLE CALORIE CONTENT OF FOOD AND FOR THERAPEUTIC REDUCTION OF WEIGHT, IN PARTICULAR FOR USE IN THE CASE OF ADIPOSITY (OBESITY) - An agent for reducing the useable calorie content of food is described which contains a compound effecting the dehydrogenation of fructose to 5-keto-D-fructose. In addition, a combination agent is described which also contains a compound that converts glucose to fructose. These agents can be used in particular in the therapy of adiposity (obesity). | 03-05-2009 |
| 20090060957 | Oral compositions - A multi-phase oral composition, wherein at least one phase has a filling viscosity from about 1.5 to about 5.0 Pa·s at a shear rate of 1000/sec and an after-filling viscosity from about 160 to about 190 Pa·s at a shear rate of 4/sec, and wherein the phases form a visual appearance selected from the group consisting of a pattern, alternating bands, at least one coil, at least one character, and combinations thereof. | 03-05-2009 |
| 20090068236 | Oral Cephalotaxine Dosage Forms - The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations. | 03-12-2009 |
| 20090068237 | Dry eye treatment - This invention relates to an emulsion composition for the formation of an artificial tear film over the ocular surface of the eye capable of providing mechanical lubrication for the ocular surface while reducing evaporation of fluid therefrom. The emulsion is desirably in the form of a meta stable emulsion and is characterized by the use of a surfactant comprising a combination of a primary and secondary surfactant where the primary surfactant permits formation of the emulsion and the secondary surfactant permits autoclaving of the surfactant. The invention also includes a method for the formation of such an emulsion. | 03-12-2009 |
| 20090074819 | POLYMERIC NANO-SHELLS - The present invention provides a method for manufacturing polymeric nano-structures (nano-shells), wherein the nano-structures are hollow and respond to a temperature change by reversibly changing their volume, and the method comprises the steps of providing a polymer forming supramolecular structures when dispersed in a liquid environment, dispersing the polymer in a liquid environment to form the supramolecular structures and crosslinking the supramolecular structures, where the crosslinking occurs with the structures, whereby the nano-shells are obtained. The nano-structures manufactured according to the present invention are useful in sequestering, transporting, or scavenging hydrophobic or hydrophilic materials. | 03-19-2009 |
| 20090074820 | AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF - The invention relates to the use of at least one agent for screening out light radiation with a wavelength ranging from 370 to 500 nm as an agent for inhibiting the degradation of endogenous carotenoids present in the skin. The invention is useful for treating skin disorders caused by sunlight (e.g., solar urticaria, actinic dermatitis and pigmentation marks). The invention also relates to novel aminoaryl-vinyl-s-triazine compounds and to the use thereof as agents for screening out light radiation ranging from 370 to 500 nm. | 03-19-2009 |
| 20090087460 | SOLID COMPOSITION, MICROPARTICLES, MICROPARTICLE DISPERSION LIQUID, AND MANUFACTURING METHODS FOR THESE - In a dissolving step, in a container | 04-02-2009 |
| 20090098168 | MULTIPLE-LAYER MICROBUBBLE LIPOSPHERE DRUG DELIVERY VEHICLE AND SYSTEM - A multiple layer microbubble drug delivery system, multiple layer microbubble drug delivery vehicle, method thereof and fabrication method is disclosed. The microfluidic drug delivery system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which receives a first liquid containing a drug substance and flow focuses the first liquid around the gas and a third inlet which receives a second liquid and flow focuses the second liquid around the first liquid. The multiple layer microbubble drug delivery vehicle includes a gas core, a first liquid layer containing a drug and surrounding the gas core and a second liquid layer surrounding the first liquid layer to stabilize the first liquid layer. | 04-16-2009 |
| 20090104235 | Method for Producing of a Preparation of a Solid Dmso-Containing Silicone Oil Emulsion for the Binding of Reactive Oxygen Compounds in Human and Animal Bodies - The invention relates to a method for production of an oral, rectal or vaginal preparation comprising a solid silicone oil emulsion, characterized in that said preparation comprises 0.01-85 wt. % dimethicone and 0.01-45 wt. % dimethylsulphoxide, whereby the preparation dissolves after application and the emulsion is released. The dimethylsulphoxide is then resorbed and the remaining components of the preparation remain in the gut or vagina as a result of the molecular size thereof and subsequently are totally deposited. The invention further relates to a preparation and a method for production of a preparation made from a silicone oil emulsion. | 04-23-2009 |
| 20090104236 | PHARMACEUTICAL SOLID HYBRIDS - The invention provides solid pharmaceutical hybrids that are useful in the treatment or diagnosis of diseases, as well as methods of producing the solid pharmaceutical hybrids. | 04-23-2009 |
| 20090104237 | METHOD FOR INCREASING TISSUE OXYGENATION - Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections. | 04-23-2009 |
| 20090117158 | Transdermal sustained release drug delivery - Provided herein are microprojections and microprojection arrays wherein a microprojection is coated with at least two layers. One layer comprises a biologically active agent, for example, a PTH agent and optionally other excipients. Another layer, which is generally, initially devoid of active agent comprises a polymer or a mix of polymers to provide controlled release, for example sustained release, of the biologically active agent contained in the first layer. Microprojections coated with multiple layers, some layers containing a biologically active agent and other layers containing a polymer for controlled release are also contemplated herein. | 05-07-2009 |
| 20090117159 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 05-07-2009 |
| 20090136549 | TRANSDERMAL PATCH CONTAINING RASAGILINE FOR TREATMENT OR PROPHYLAXIS OF NERVOUS SYSTEM DISEASE AND ITS PREPARATION PROCESS - The present invention relates to a rasagiline transdermal patch for treatment or prophylaxis of nervous system diseases, in which the patch comprises an inert backing layer chemically inert to substrate ingredients, a substrate layer comprising rasagiline or a pharmaceutically acceptable salt thereof, and a protective layer to be peeled off before use. The substrate layer is an adhesive system comprising an organic polymer material as basis and an inorganic or organic material as filler, and a plurality of micro-reservoirs containing rasagiline. The substrate further comprises one or more substances for enhancing the transdermal absorption of rasagiline, in which the above organic polymer material in the substrate is used for the reservoir of rasagiline and as adhesive. | 05-28-2009 |
| 20090142377 | Immunogenic compositions - Described are means and methods for producing and/or selecting immunogenic compositions, comprising providing the composition with at least one cross-beta structure and testing at least one immunogenic property. | 06-04-2009 |
| 20090142378 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 06-04-2009 |
| 20090142379 | Coated Products Containing Hydrogenated Indigestible Starch Syrup as a Binding Agent - An object of the present invention is to provide a coated product with increased stiffness to reduce the chipping after manufacturing and several days of storage, and before wrapping. A coated product such as confectioneries such as chewing gum, medicines and medicinal tablets wherein the product is coated with a coating composition comprising hydrogenated indigestible starch syrup as a binding agent. | 06-04-2009 |
| 20090148480 | SUSTAINED RELEASE PREPARATION - The invention provides a preparation which shows a satisfactory gastric residence time, has such a size that allows for easy ingestion, can quickly disintegrate after expelled from the stomach, and can be prepared readily in an industrial scale. A gastric retentive preparation having a gastric resident layer and a drug release layer is provided, wherein the gastric resident layer does not disintegrate in the stomach and disintegrates in the intestine. Preferably, the gastric resident layer has a minimum diameter of 7 mm or more as measured after stirring the preparation in the first fluid at 200 rpm at 37° C. for 15 hours under the conditions of the paddle method in the dissolution test in accordance with Japanese Pharmacopoeia and has a maximum diameter of 6 mm or less as measured after further stirring the preparation in the second fluid at 200 rpm at 37° C. for 9 hours under the same conditions. | 06-11-2009 |
| 20090155315 | PHARMACEUTICAL PRODUCT - A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single product. | 06-18-2009 |
| 20090162406 | WOUND HEALING WITH ZEOLITE-BASED HEMOSTATIC DEVICES - A method for decreasing the time it takes for a wound to heal includes applying hemostatic agent to the wound, inflaming tissue surrounding the wound to facilitate the deposition of fibroblast, thereby accelerating the subsequent contraction of the wound and the onset of the proliferative healing stage, and causing the re-epithelization of the tissue at a faster rate than if no hemostatic agent was applied. A method for promoting the healing of a bleeding wound includes coating a hemostatic agent onto a substrate, applying the substrate to the bleeding wound so that an effective amount of the hemostatic agent is applied to the wound, inflaming the tissue, and causing the re-epithelization of the tissue at a faster rate than if no hemostatic agent was applied. In at least some methods, a clotting cascade and platelet aggregation within the bleeding wound is accelerated, and blood loss from the wound is decreased. | 06-25-2009 |
| 20090169583 | Solid Adsorbates of Hydrophobic Drugs - A solid pharmaceutical composition comprises a solid adsorbate comprising a hydrophobic drug, a lipophilic vehicle, and a porous substrate, wherein the hydrophobic drug and lipophilic vehicle are adsorbed to the porous substrate. | 07-02-2009 |
| 20090169584 | Treatment of sleep disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 07-02-2009 |
| 20090169585 | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity - The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to a recipient, increases the concentration or activity of a survival/longevity gene product and/or decreases the concentration or activity of a gene product that induces or causes cellular damage. Most preferably, the resveratrol-stabilizing composition will comprise the chelator phytic acid (inositol hexaphosphate; IP6), hyaluronic acid, and vitamin D. The invention further pertains to the use of such compositions in the treatment or prevention of cancer, cardiovascular disease, diseases associated with aging, and other conditions and illnesses. | 07-02-2009 |
| 20090169586 | STABLE PACKAGED DOSAGE FORM AND PROCESS THEREFOR - A process for preparing a stable packaged dosage form, said dosage form comprising an oxidation-sensitive material, for example carotenes and carotenoids in whole dried algae of the genus | 07-02-2009 |
| 20090169587 | Chronotherapeutic dosage forms - A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. | 07-02-2009 |
| 20090175914 | Salts or Complexes of Methyl Donors With Phytic Acid or Its Derivatives and Method for the Synthesis Thereof - The invention concerns the production of salts or chelates of methyl donors, in particular S-adenosyl-L-methionine or SAMe and betaine or N,N,N-trimethylglycine, with phytic acid or with phosphorylate inositol, possibly partially salified with metal cations, with the formation of stable, totally natural, compounds having a biological activity typical of the starting methyl donors and also combined with, and enhanced by, the biological activity typical of phytic acid or of inositol. | 07-09-2009 |
| 20090191243 | High unsaponifiables and methods of using the same and its derivatives and uses thereof - Materials with high levels of unsaponifiable matter, such as extracts from plants, result in Hydrolysates with unique properties. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6% by total weight of the material) produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6% by weight of unsaponifiables. The resulting Hydrolysates from the practice of the present invention are substantive, resisting both physical and aqueous-based removal from skin and hair, exhibit a very unique surfactant property, and are not foaming agents with water. Addition of extra alkali metal hydroxides to these Hydrolysates according to the present invention may thus be used to neutralized acidic gelling agents and thereby providing a gel with enhanced the performance for cosmetics and pharmaceuticals. | 07-30-2009 |
| 20090191244 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY - Compositions containing a carrier and microbubles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs. The microbubbles may be administered alone or in combination with other treatments as an adjuctive therapy. | 07-30-2009 |
| 20090196889 | CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE - The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet. | 08-06-2009 |
| 20090196890 | PHARMACEUTICAL COMPOSITIONS - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 08-06-2009 |
| 20090196891 | PROCESS FOR PREPARING WATER SOLUBLE ARTICLES - A process for preparing a water-soluble article comprising a water-soluble primary thermoformed component and a water-soluble secondary component arranged therein comprises:
| 08-06-2009 |
| 20090196892 | PROCESS FOR PREPARING WATER SOLUBLE ARTICLES - A process for preparing a water-soluble article comprising a water-soluble primary thermoformed component and a water-soluble secondary component arranged therein comprises:—
| 08-06-2009 |
| 20090202596 | PHARMACEUTICAL COMPOSITIONS WITH BIOLOGICAL BARRIERS PERMEATION ENHANCING PROPERTIES - Pharmaceutical compositions comprising a water/oil/water (W1/O2/W3) or an oil/water/oil (O1/W2/O3) double microemulsion, with droplets size below one micron, with the drug included in the internal water phase W1 or internal oil phase 01, whereas the external oil 02 and second water phase W3 or the external water phase W2 and second oil phase 03 contain substances able to inhibit the enzymes, present in the mucosa or biological barrier to be permeated or physiological environment of administration, capable to degrade the drug or to cause its efflux from the barrier; alternatively the external oil and second water phase or external water phase and second oil phase contain permeation enhancing agents, i.e., substances able to increase the diffusion of the drug through the biological barrier. | 08-13-2009 |
| 20090202597 | Ache-Nmda Combination Wafer - Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should be chosen from the group comprising acetyl cholinesterase inhibitors (AChE inhibitors) and NMDA antagonists (n-methyl-D-asparaginic acid antagonists). The use of such an active agent combination for producing an orally administrable pharmaceutical product for the treatment of dementia-related illnesses such as Alzheimer's disease, as well as a procedure for the symptomatic treatment of Alzheimer's disease by the oral administration of one of the above pharmaceutical products is also provided. | 08-13-2009 |
| 20090208539 | STABLE ATORVASTATIN FORMULATIONS - A simple yet efficient formulation for providing excellent bioefficacy, wherein the formulation includes atorvastatin or a salt thereof, in crystalline or amorphous form, with at least one pharmaceutical excipient selected to a form of atorvastatin that has beneficial properties, such as enhanced stability. These formulations do not need to include a stabilizer. | 08-20-2009 |
| 20090208540 | IMPLANTABLE DEVICE FOR THE DELIVERY OF NALTREXONE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver naltrexone and formulations thereof at a constant rate for an extended period of time. The devices and methods of use thereof are biocompatible and biostable, and useful for the delivery of naltrexone in patients (humans and animals). | 08-20-2009 |
| 20090214599 | PROTON PUMP INHIBITOR FORMULATIONS, AND METHODS OF PREPARING AND USING SUCH FORMULATIONS - Pharmaceutical formulation comprising at least one proton pump inhibitor structured and arranged to provide an initial pH-dependent delayed release, and a pH-dependent extended release of the at least one proton pump inhibitor. | 08-27-2009 |
| 20090214600 | METHODS AND COMPOSITIONS FOR GASTRIC RESISTANT ORAL FORMULATIONS FOR INTESTINAL DELIVERY - An oral formulation for mammalian administration and treatment utilizing bioactive pharmaceuticals in need of gastric resistance to promote intestinal absorption. The oral formulation utilizes lower dosages to achieve higher plasma levels and delivers permeable solubilized bioactive pharmaceuticals directly to intestinal mucosa, avoiding premature gastric disintegration. Further, it delivers water and lipid soluble bioactives directly to the intestines overcoming the molecular characteristics previously limiting the therapeutic administration. Upon oral ingestion of the formulation, a disaccharide component is hydrolyzed by intestinal enzymes to bring the bioactive pharmaceutical in contact with the surface of intestinal mucosa. A method of administering oral bioactive pharmaceuticals as well as a method for manufacturing the formulation is disclosed. | 08-27-2009 |
| 20090214601 | Porous Drug Delivery Devices and Related Methods - The invention relates to porous drug delivery devices and related methods. In an embodiment, the invention includes an active agent delivery system including a reservoir body defining a plurality of interconnected pores, an active agent disposed within the interconnected pores, and a first polymeric layer disposed over the reservoir body. In an embodiment, the invention includes an implantable medical device including a porous substrate defining a plurality of interconnected pores, an active agent disposed within the interconnected pores, and a first polymeric layer disposed over the reservoir body. In an embodiment, the invention includes a method of making an active agent delivery system including forming a porous reservoir body, inserting an active agent within the porous reservoir body, and applying a polymeric layer over the porous reservoir body. Other embodiments are also included herein. | 08-27-2009 |
| 20090214602 | ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ENTERICALLY COATED ACID INHIBITOR - The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an enterically coated acid inhibitor. | 08-27-2009 |
| 20090214603 | SYNTHETIC PEPTIDES - The present invention provides streptococcal SspB Adherence Region (BAR) peptides, nucleic acids encoding the BAR peptides, and methods of using the BAR peptides, and methods of screening BAR peptide mimetics. | 08-27-2009 |
| 20090220552 | FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS - The invention relates to new formulations and dosage units of solid crystalline pantoprazole free acid and its salts (e.g., pantoprazole sodium sesquihydrate) that are resistant to gastric juice digestion and are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same | 09-03-2009 |
| 20090220553 | Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent - The application relates, in part, to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent. | 09-03-2009 |
| 20090220554 | Transglutaminase Inhibitors and Methods of Use Thereof - Transglutaminase inhibitors and methods of use thereof are provided. | 09-03-2009 |
| 20090232853 | TREATMENT OF LAMINITIS - The present invention provides a composition comprising one or more of a matrix metalloprotease inhibitor, a de-carboxylase inhibitor, a fructanase enzyme and/or a flavonoid for use in the prevention of laminitis | 09-17-2009 |
| 20090232854 | USES OF BISPECIFIC ANTIBODY COATED DENDRITIC CELLS PULSED WITH ANTIGENS AND GM-CSF IN IMMUNE REGULATION - GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG. | 09-17-2009 |
| 20090238846 | S/O type external preparation - The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of the present invention comprises a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a hydrophilic medicine covered with a surfactant and is in a form of a solid. | 09-24-2009 |
| 20090238847 | Deodorant Particle - Disclosed is a deodorant particle having a BET specific surface area of 10 m | 09-24-2009 |
| 20090246231 | Formulations containing borojo - The present invention relates to a cosmetic and skin care formulation comprising: borojo; and at least one humectant; and at least one emollient. The present invention also provides for a dietary and nutritional supplement comprising: borojo; at least one mineral; at least one vitamin and at least one protein. | 10-01-2009 |
| 20090246232 | Pharmaceutical composition - Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes. | 10-01-2009 |
| 20090246233 | Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists - The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia. | 10-01-2009 |
| 20090252767 | Water dispersible enteric coating formulation of nutraceutical and pharmaceutical dosage forms - The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a dry blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form. | 10-08-2009 |
| 20090252768 | USE OF STILBENE DERIVATIVES FOR TREATMENT AND PREVENTION OF AQUATIC MOLD INFECTIONS - The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4′-bis-(1,3,5-triazinylamino)stilbene-2,2′-disulfonic acid derivatives. | 10-08-2009 |
| 20090252769 | PREVENTIVE AND THERAPEUTIC VACCINE FOR STORKE AND NEUROLOGICAL DISORDERS - A method for producing therapeutic vaccine which consist of NMDA-NR1 subunit expressed in insect cells to produce recombinant protein and was encapsulated in poly(D-L-lactide-co-glycolic-acid) (PGLA) microparticles by solvent exchange and used for oral immunization. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NR1 sub units, their protective and therapeutic potential for treatment of the neurological disorder of stroke in animals and its practicability for therapy in humans. | 10-08-2009 |
| 20090252770 | NON-DIGESTIBLE SUGAR-COATED PRODUCTS AND PROCESS - A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the stomach and small intestine without being degraded, and delivers the component to the colon where the coating is digested by microbial fermentation and the component is released. | 10-08-2009 |
| 20090258038 | WATER-SOLUBLE COMPOSITIONS OF BIOACTIVE LIPOPHILIC COMPOUNDS - Water-soluble compositions comprising a lipophilic compound and a solubilizing agent of the general formula:
| 10-15-2009 |
| 20090258039 | Method of administering a pharmaceutical active ingredient - A method for reducing the friability of soft substrates by applying an effective amount of a water soluble, polymeric dispersion to at least a portion of a treatment surface of the substrate, such that less than about 90% of the exterior surface has the dispersion applied thereto. | 10-15-2009 |
| 20090258040 | STEROID TREATMENT FOR HOT FLASHES - Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the individual. In many embodiments, the method for treating individuals suffering with hot flashes is provided by administering a steroid agent containing an estrene compound, such as 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one, to the individual. In other embodiments, pharmaceutical compositions containing the steroid agent may be used to treat individuals suffering with hot flashes. Embodiments include methods for treating male castrates, as well as postmenopausal women and men, suffering from hot flashes by vomeronasally administering a steroid agent containing 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one to levitate the hot flashes. | 10-15-2009 |
| 20090263429 | Method of Preparing a Hydrogel - A method of preparing a hydrogel comprises: (i) reacting a first molecule comprising a carboxylic acid group and second molecule comprising an amine group or an alcohol group with a hydrolase enzyme to form a product comprising an amide bond or ester bond, wherein the hydrolase enzyme would normally catalyse the production of an amine or an alcohol from an amide or an ester under physiological conditions; and (ii) maintaining the product comprising an amide or ester bond under conditions suitable to allow hydrogel formation. | 10-22-2009 |
| 20090263430 | Multilayer Silk Protein Films - The present invention is directed to a method of forming multilayer silk protein films and a multilayer film obtained therefrom. The invention is further directed to various materials, products and compositions containing said multilayer film and to the use of Said multilayer film in several applications. | 10-22-2009 |
| 20090263431 | POLYURETHANE FOAMS FOR WOUND MANAGEMENT - The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and specific coagulants is frothed and dried. | 10-22-2009 |
| 20090263432 | STABLE COMBINATIONS OF AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. | 10-22-2009 |
| 20090269373 | Saposin C-DOPS: A Novel Anti-Tumor Agent - Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor. | 10-29-2009 |
| 20090274730 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 11-05-2009 |
| 20090274731 | PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS - A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described. | 11-05-2009 |
| 20090274732 | Type-2 Diabetes Combination Wafer - Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed. | 11-05-2009 |
| 20090274733 | Pharmaceutical preparation containing copolyvidone - A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated. | 11-05-2009 |
| 20090285862 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN - The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor. | 11-19-2009 |
| 20090285863 | Coating Composition Comprising Starch - The present invention provides a coating composition comprising an aqueous medium and, dispersed therein, starch and a film-forming agent which controls swelling of the starch by the aqueous medium. Formulations comprising the coating composition are also provided. The formulations may be useful in the treatment or diagnosis of colonic disease. | 11-19-2009 |
| 20090285864 | THERAPEUTIC FORMULATION - The invention provides compositions and formulations comprising catechol and/or acetogenins and various combinations thereof; including various combinations with other ingredients including botanical preparations containing acetogenin, an extract of green tea or a therapeutically active flavanoid contained in green tea; and one or more quinones. The invention includes a pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and optionally, an acetogenin and an extract of green tea. The compositions and formulations demonstrate positive effects against a broad variety of cancer, autoimmune diseases, viruses and provides antioxidant protection against peroxyl hydrophilic, peroxyl lipophilic, hydroxyl, peroxynitrite and super oxide radicals. The compositions and formulations can be used for nutritional and nutraceutical uses, and used as dietary supplements. | 11-19-2009 |
| 20090285865 | Palatable, solid oral formulations for male chemical sterilization - Palatable, solid oral formulations or compositions include at least one bioactive agent capable of chemical sterilization of human and animal males. Depending on the targeted species, the bioactive formulations comprise suitable additives, excipients, water-swellable compositions, and/or processing aids and can be made into uncoated or coated forms to modulate the release profile of the bioactive agents. Among the bioactive agents are zinc compounds and complexes and organic drugs with established pharmacological activities, which are traditionally unrelated to any form of contraception. | 11-19-2009 |
| 20090291104 | NOVEL CONOTOXIN FRAMEWORK WITH A HELIX-LOOP-HELIX FOLD - A new family Here we report a new family of four-cystine/three-loop conotoxins (designated framework 14). Three peptides of this family (flf14a-c) were isolated from the venom of | 11-26-2009 |
| 20090291105 | Instant Vesicular Product - A powder of reversed vesicles, which comprises one or more non-ionic surfactants and optionally a lipophilic stabilising factor and a bio-active agent, is provided. The product is prepared by making a dispersion of reversed vesicles in a suitable apolar vehicle, which vehicle is subsequently removed. In admixture with one or more excipients the product can be incorporated in compositions. | 11-26-2009 |
| 20090291106 | BIODEGRADABLE BLOCK COPOLYMERS WITH MODIFIABLE SURFACE - A block copolymer containing a) a hydrophobic biodegradable polymer, b) a hydrophilic polymer and c) at least one reactive group for covalent binding of a surface-modifying substance d) to the hydrophilic polymer b) is disclosed. Shaped bodies are formed to consist of the block copolymer and are utilized as carriers for tissue culture and active substances and for controlled release and targeted administration of active substances. | 11-26-2009 |
| 20090297565 | METHOD AND DEVICE FOR PRODUCING VERY FINE PARTICLES AND COATING SUCH PARTICLES - Disclosed are methods and devices for producing very fine particles which are then coated with protective polymers in another step of the process. The particles are produced using a method in which a liquid flow comprising a particle-free liquid 1 that contains the active substance in a dissolved form is combined with a second liquid flow comprising a liquid 2 in a high-energy zone or no sooner than two seconds before reaching the high-energy zone. Said two liquids can be mixed with each other while the active substance dissolved in liquid 1 is insoluble or more difficult to dissolve in liquid 2 than in liquid 1 and settles in the form of particles in the high-energy zone or within a maximum of 2 seconds before reaching the high-energy zone when the two liquids are mixed. The obtained particles are introduced into an aqueous outer phase which contains the coating materials in a dissolved form and are then subjected to a drying step such that said materials settle on the particles as a closed coating. The coated particles are protected from damaging influences and are provided with modified release kinetics compared to uncoated particles. | 12-03-2009 |
| 20090297566 | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions - The present invention provides stabilized thyroid hormone pharmaceutical compositions, and methods of packaging and storing thyroid hormone pharmaceutical compositions, such as levothyroxine (T | 12-03-2009 |
| 20090297567 | Method For Ultrasound Triggered Drug Delivery Using Hollow Microbubbles With Controlled Fragility - A method is provided for site specific delivering therapeutic or diagnostic agents to a region in a fluid-filled cavity, vessel or tissue using an agent-loaded microbubble population. The population has controlled fragility characterized by a uniform wall thickness to diameter ratio which defines the discrete threshold intensity value of ultrasonic power where microbubble rupture occurs in the population. The location of the microbubble population may be monitored by ultrasound to determine its presence at the region prior to application of the ultrasonic power to rupture to microbubbles. | 12-03-2009 |
| 20090304753 | Method and Apparatus For Forming Delivery Devices For Oral Intake of an Agent - Methods, systems and apparatuses are provided for producing delivery devices, preferably for oral intake of an agent. In the broadest aspect, the method comprises assembling one or more layers comprising one or more materials with an agent or an agent-releasing formulation to form an intergraded, preferably laminated device; folding said integrated delivery device to form a folded integrated delivery device; and at least partially enclosing said folded delivery device to a form suitable for oral delivery. Preferably, the integrated device comprise a first external layer of a first material; a frame of a second material mounted on the first external layer; an agent-releasing formulation housed within the frame; and a second external layer of the first material mounted on the frame. | 12-10-2009 |
| 20090304754 | Pegylated glutenase polypeptides - Glutenase proteins, such as prolyl endopeptidases, are stabilized by covalent PEG modification. | 12-10-2009 |
| 20090304755 | PHARMACEUTICAL FORMULATION OF LOSARTAN - A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50μ and/or specific surface area is more than 0.6 m | 12-10-2009 |
| 20090311292 | PROCESS FOR SYNTHESIS AND INCORPORATION OF NITRIC OXIDE DONORS IN MACROMOLECULAR COMPOSITIONS - The present invention describes a process for the synthesis of S-nitrosothiols and the subsequent incorporation of these compounds in hydrophilic macromolecular compositions. By the process described herein, the S-nitrosothiols are synthesized in a device (FIG. | 12-17-2009 |
| 20090317429 | Aloe vera cotton swab tips - This paper describes how implementing an | 12-24-2009 |
| 20100003289 | Controlled Release Complex Formulation For Oral Administration of Medicine For Diabetes and Method For The Preparation Thereof - A controlled release combination formulation for oral administration comprising a) a controlled release portion containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient, and a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and b) a rapid-release portion containing a sulfonylurea-based medicine for treating diabetes as an active ingredient coated on the controlled release portion is useful for the treatment of diabetes, for it is capable of maintaining an effective concentration of the medicines in blood at a constant level. | 01-07-2010 |
| 20100008956 | COMPOSITION AND COMBINATIONS OF CARBOXYLIC ACID LOSARTAN IN DOSAGE FORMS - Compositions comprising a Carboxylic Acid Losartan in a dosage form are provided. Such compositions may be employed for treatment of hypertension, congestive heart failure, diabetic nephropathy, and myocardial infarction. The compositions may further include one or more additional therapeutic agents based on the condition to be treated. | 01-14-2010 |
| 20100015183 | TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE - The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment. | 01-21-2010 |
| 20100015184 | Methods of Making Pharmaceutical Components for Customized Drug Products - Methods and systems for developing and manufacturing componentized drug product precursor modules that can be simply assembled to create customized drug products are disclosed. Each module contains components of a final drug product (e.g., active pharmaceutical ingredients, nutritional ingredients, and/or excipients) in a fixed mixture selected to maximize desired pharmaceutical characteristics (e.g., stability, manufacturing efficiency) and minimize cost. The modules can be extensively tested for quality and assembled immediately, or at a later time, in multiple combinations to customize the final drug product characteristics (e.g., multiple active ingredients, doses, flavor, viscosity, etc.) to meet individual patient/consumer needs and/or preferences while assuring high quality. Permitted combinations may be maintained in a database to enable networked drug product selection, prescribing, and ordering. Each resulting customized drug product dose can be labeled to facilitate compliance and reduce the number of drug products administered per day. | 01-21-2010 |
| 20100015185 | BIODEGRADABLE MATERIAL BASED ON OPENED STARCH - The present application relates to a biodegradable material comprising opened starch or a mixture of opened starch and destructurised starch. The biodegradable material comprises about 50 to about 100 wt. % of opened starch or of a mixture of opened starch and destructurised starch, based on the total weight of the biodegradable material, said biodegradable material having a bulk density of 1.0 to 1.5 kg/dm. The biodegradable material is used for manufacturing biodegradable shaped articles, wherein said biodegradable shaped articles are suitable for delivery of a biologically or pharmaceutically active component in or to a vertebrate, e.g. a mammal. | 01-21-2010 |
| 20100021505 | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients - Method of preventing or reducing diarrhea and/or steatorrhea in HIV-positive patients being treated with High Activity Antiretroviral drugs containing protease inhibitors, nucleoside reverse transcriptase inhibitors or non-nucleoside reverse transcriptase inhibitors. The method includes the steps of: administering to the HIV-positive patient a High Activity Antiretroviral drug containing a protease inhibitor, a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor; and co-administering with the HAART drug a gastric acid-resistant polymer-coated and buffered digestive enzyme composition containing pancreatic proteases, lipases, co-lipases, nucleases, amylases and other bio-active substances produced by the pancreatic gland. | 01-28-2010 |
| 20100021506 | NITRIC OXIDE GEL APPARATUS AND METHOD - Gel strips containing reactants capable of reacting to form nitric oxide are maintained separate until application. Upon application, the gel strips are placed in contact with one another, and may mix, or operate by diffusion, to deliver nitric oxide directly to the stream of breathing air of a user. Adhesive strips bonded to a substrate supporting the gel strips may provide for securing the nitric oxide generator directly to an upper lip of a user for breathing the nitric oxide through the nostrils. | 01-28-2010 |
| 20100021507 | Method and Composition for Making an Orally Disintegrating Dosage Form - The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms. | 01-28-2010 |
| 20100028387 | Biocompatible Coated Nanostructured Titanium Surfaces - Bioactive molecules have been coated on nanotubular structured titanium substrates by molecular plasma deposition. The coatings promote cell adhesion and are particularly suited for orthopedic implants that provide improved bone cell adhesion and new tissue growth. Nanodimensional features on titanium substrates are engineered using electrochemical anodization techniques. The nanostructured surfaces provide superior support for a wide selection of polypeptide coatings. | 02-04-2010 |
| 20100028388 | SYSTEM AND METHOD FOR TRANSDERMAL DRUG DELIVERY - In the preferred embodiment, the invention is a system for creating micropores in the skin for transdermal drug delivery through the micropores and includes: a chemical that dissolves or breaks down superficial layers of skin; a chemical delivery element that holds and delivers controlled volumes of the chemical to skin, creating micropores; and a base that is able to temporarily couple to skin, contains the chemical delivery elements, and may activate the chemical delivery elements to administer the chemical to skin. In the preferred embodiment, the invention is a method for delivering drugs transdermally that includes providing a carrier containing a chemical delivery element with a chemical to break down superficial layers of skin; placing the carrier into contact with skin; activating the chemical delivery element; allowing the chemical to break down superficial layers of skin and creating micropores; and providing a drug to be delivered transdermally through the micropores. | 02-04-2010 |
| 20100028389 | HYDROMORPHONE THERAPY - A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain. | 02-04-2010 |
| 20100028390 | Transdermal Delivery Device - A dermal, transdermal, mucosal or transmucosal delivery device includes a backing layer overlying an ingredient containing reservoir, and having a microprotrusion array attached thereto, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the skin or mucosa. | 02-04-2010 |
| 20100047290 | FUNCTIONAL PROTEIN CRYSTALS CONTAINING A CORE NANO-PARTICLE AND USES THEREOF - A functional protein crystal, wherein each protein in the crystal comprises a cavity containing a core nano-particle, the core nano-particle formed from an elemental metal, a metal alloy, or a metal compound, with the proviso that the protein is not apoferritin Dpr or | 02-25-2010 |
| 20100068233 | Modifiable dosage form - Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for delivering a medicament to an animal is provided. The final dosage form includes an outer layer. The final dosage form also includes a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a stimulus. The final dosage form further includes a chamber at least substantially within the outer layer and configured to carry the medicament. The final dosage form includes the medicament. The final dosage form may include an indicator element configured to indicate an exposure of the release element to the stimulus. | 03-18-2010 |
| 20100068234 | Laser-Markable Compositions - A laser-markable composition comprises a marking component and an organic compound, wherein the organic compound absorbs laser radiation at 780 to 2000 nm and thereby causes the marking component to change colour, and wherein the organic compound has an absorptivity ratio, A r, of at least 1.25, wherein the absorptivity ratio is defined as formula (I): wherein: A | 03-18-2010 |
| 20100074926 | MODULES, NEW ASSEMBLAGE KITS AND NEW ASSEMBLES FOR THE CONTROLLED RELEASE OF SUBSTANCES - A module which is destroyed in the presence of water solution, composed of a compressed powdery mixture, the said powdery mixture comprising a matrix building component, suitable to release an optionally included active substance into a surrounding aqueous liquid, and one or more tabletting aids chosen from the group consisting of lubricants, glidants, and anti-adherent agents, the said module being provided with particular male topological features allowing its connection to a corresponding female module, giving raise to an assembly that can be safely handled on industrial scale, wherein, in the composition of the male module, the percentage ratio between the tabletting aid and the matrix building component is comprised between 1:2.5 and 1:999. The module can be employed to convey pharmaceuticals, nutraceuticals, agrochemicals or other active principles to the intended site of action. | 03-25-2010 |
| 20100074927 | DELIVERY OF THERAPEUTIC COMPOUNDS VIA MICROPARTICLES OR MICROBUBBLES - Microparticle carriers, particularly protein-encapsulated microbubbles, are used to deliver antiproliferative drugs to target sites in a subject. In particular, antirestenotic drugs are delivered to areas of vascular injury for treatment or prevention of hyperproliferative disease, e.g. stenosis, in blood vessels; and antineoplastic drugs are targeted to tumor sites. | 03-25-2010 |
| 20100080829 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption. | 04-01-2010 |
| 20100080830 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS - The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiological or pharmacological effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and allowing the agent to pass through the device to the desired area of treatment. In some embodiments, the method is for treating or reducing the risk of retroviral or lentiviral infection. In certain embodiments, the method is for preventing or reducing the risk of mother-to-child transmission of HIV, wherein the therapeutic agent is an antiviral agent. | 04-01-2010 |
| 20100086572 | RATIONAL PPI DOSAGE FORMS - The invention herein provides for a continuous release dosage form (which is referred to as “dosage forms”) comprising a continuous release dosage form, which releases PPI in a first release portion directly to the gastric mucosa and a second release portion to provide for sustained plasma levels resulting in increased therapeutic efficacy. | 04-08-2010 |
| 20100092525 | MEDICAL DEVICE - A medical device for delivery of a therapeutic agent to a physiological target site includes a flexible receptacle containing said therapeutic agent, wherein at least a part of the receptacle is formed of a water-soluble or water-dispersible material. The therapeutic agent may include a haemostatic agent and the physiological target site may be a wound. | 04-15-2010 |
| 20100092526 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a | 04-15-2010 |
| 20100098731 | Hollow sphere from amphiphilic chitosan derivatives and method of preparing amiphiphilic chitosan derivative complex for medical use - A hollow sphere from amphiphilic chitosan derivatives and a method of preparing an amphiphilic chitosan derivative complex for medical use are disclosed, and the hollow sphere from amphiphilic chitosan derivatives comprises: chitosan derivatives represented by the following formula (I), which self-assemble and form a hollow sphere in a solvent; | 04-22-2010 |
| 20100104607 | ANTI-BACTERIAL PEPTIDES AND METHODS OF TREATING DISEASES USING SAME - Isolated peptides comprising no more than ten amino acids and having anti-bacterial properties are disclosed. In one embodiment the peptides have a consensus amino acid sequence X | 04-29-2010 |
| 20100104608 | REACTIVE SURGICAL IMPLANT - Biocompatible implants include a polymer substrate and a reactive component selectively applied to the substrate. The reactive component in combination with the substrate creates crosslinked regions on a surface of the substrate. The crosslinked regions may provide a visual aid and/or stiffening element to the implant. | 04-29-2010 |
| 20100112014 | NOVEL HYDROGEL COMPOSITIONS AND METHODS OF USING - Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels. | 05-06-2010 |
| 20100112015 | Orally administered agent and an orally administered agent/supporting substrate complex - With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent | 05-06-2010 |
| 20100112016 | OPHTHALMIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS - The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature. | 05-06-2010 |
| 20100119557 | Frozen compositions and methods for piercing a substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-13-2010 |
| 20100119558 | NGNA COMPOSITIONS AND METHODS OF USE - The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold. | 05-13-2010 |
| 20100119559 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 05-13-2010 |
| 20100136062 | USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY - The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis. | 06-03-2010 |
| 20100136063 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides - The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof. | 06-03-2010 |
| 20100136064 | NUTRACEUTICAL COMPOSITION - A nutraceutical substance comprising | 06-03-2010 |
| 20100143419 | Storage of Ampoules Containing Pharmaceutical Formulations Using a Sealed Container Comprising an Oxygen Scavenger - Ampoules made of plastics material and containing 0.5 to 5 ml of a pharmaceutical formulation are sealed, together with an oxygen scavenger, within a pouch. | 06-10-2010 |
| 20100143420 | MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY - Pharmaceutical formulations are disclosed comprising a multi-phasic pharmaceutical composition comprising an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is in a particulate state, a solubilized state, or in both a particulate state and in a solubilized state; a solvent; a non-miscible liquid; a stabilizer, and water; wherein the pharmaceutical formulation is an oral dosage form. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and improved oral bioavailability. | 06-10-2010 |
| 20100150970 | Administration of Enoxoparin Sodium to Patients 75 Years and Older With ST-Segment Elevation Myocardian Infarction - Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. The methods may include fibrinolytic therapy. The treatment methods may be used to prevent one or more of, mortality, myocardial re-infarction, myocardial ischemia, stroke, or severe congestive heart failure. Articles of manufacture for use in connection with treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older are also disclosed. The articles of manufacture comprise enoxaparin sodium, and instructions designed to achieve administration to a patient of a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium, by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. | 06-17-2010 |
| 20100158956 | MULTIPLE UNIT DOSAGE FORM HAVING A THERAPEUTIC AGENT IN COMBINATION WITH A NUTRITIONAL SUPPLEMENT - Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described. | 06-24-2010 |
| 20100158957 | AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described. | 06-24-2010 |
| 20100158958 | GASTRIC REFLUX RESISTANT DOSAGE FORMS - Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally. | 06-24-2010 |
| 20100158959 | Stable Combinations of Amlodipine Besylate and Benazepril Hydrochloride - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. | 06-24-2010 |
| 20100166806 | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency - The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors). | 07-01-2010 |
| 20100166807 | METHODS FOR REDUCING THE INCIDENCE OF MASTITIS - The invention encompasses methods of reducing the incidence of mastitis in an animal, and compositions and devices therefor. The methods and other aspects of the invention can be used to reduce the incidence of infection in the teat or mammary gland. In particular, but not exclusively, the invention encompasses a method of applying to the teat canal and/or teat sinus a composition comprising exogenous keratin. | 07-01-2010 |
| 20100166808 | Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands - A method of facilitating intracellular uptake or transcellular transport of cargo comprising: contacting target cells with a composition comprising an effective amount of cargo incorporated in a nanocarrier having a surface, wherein the nanocarrier surface comprises integrin-specific ligands having a surface density of approximately 5 to 50,000 integrin-specific ligands per μm | 07-01-2010 |
| 20100166809 | METHODS OF TREATING OR PREVENTING BIOFILM ASSOCIATED INFECTIONS WITH FREE AVAILABLE CHLORINE FREE AVAILABLE CHLORINE WATER - The invention provides methods of treating or reducing the incidence of an infection in a mammal due to a biofilm associated infectious microorganism comprising administering a therapeutically effective amount of free available chlorine (FAC) water to a site populated with biofilm associated infectious microorganism. | 07-01-2010 |
| 20100166810 | COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis. | 07-01-2010 |
| 20100166811 | GRAS COMPOSITION FOR INTRANASAL DELIVERY OF PARATHYROID HORMONE - What is described is an aqueous pharmaceutical composition for intranasal delivery of PTH, comprising a PTH molecule, and one or more excipients selected from the group consisting of a chelating agent, an alcohol, and a surface active agent, wherein the PTH molecule selected from the group consisting of SEQ NO: 1, SEQ NO: 2, and SEQ NO: 3. | 07-01-2010 |
| 20100172942 | MULTI-MEMBRANE IMMUNOISOLATION SYSTEM FOR CELLULAR TRANSPLANT - This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animal models. | 07-08-2010 |
| 20100178304 | METHOD FOR SILK FIBROIN GELATION USING SONICATION - This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment. Biological materials, including viable cells, or therapeutic agents can be encapsulated in the hydrogels formed from the process and be used as delivery vehicles. | 07-15-2010 |
| 20100178305 | ULTRASONIC NANOTHERAPY OF SOLID TUMORS WITH BLOCK COPOLYMERS STABILIZED PERFLUOROCARBON NANODROPLETS - Described herein are methods of treating a tumor by contacting the tumor with a therapeutic agent encapsulated in a first nanoemulsion and exposing the tumor to a first ultrasonic radiation of less than 300 kHz to the tumor. In some aspects, the tumor can be contacted with a second nanoemulsion. In some aspects, the second emulsion can be injected directly into the tumor via intratumoral injection before exposing the tumor to the first ultrasonic radiation. In some aspects, the tumor is exposed to a second ultrasonic radiation from about 1 to 5 MHz after the first ultrasonic radiation. The methods described herein can be used to treat numerous tumors including, but not limited to, multidrug resistant tumors and inoperable tumors. These tumors may include, but are not limited to, breast cancers, ovarian cancers, pancreatic cancers, or any combination thereof. | 07-15-2010 |
| 20100178306 | PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF RAPIDLY DISINTEGRATING TABLETS - Pharmaceutical formulation in the form of agglomerates comprising | 07-15-2010 |
| 20100178307 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME - Transdermal anti-dementia active agent systems are provided. Aspects of systems include a transdermal preparation, first overlay and second overlay. Also provided are methods of using the systems, e.g. for administering an anti-dementia active agent to a subject. | 07-15-2010 |
| 20100183685 | TUMOR AND INFECTIOUS DISEASE THERAPEUTIC COMPOSITIONS - A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer. | 07-22-2010 |
| 20100183686 | Method to maintain the efficacy of Orlistat - A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone. | 07-22-2010 |
| 20100189751 | PERCUTANEOUS ABSORPTION TYPE PATCH - A percutaneous absorption type patch adapted to be applied to a skin surface of a patient. The percutaneous absorption type patch comprises: a stratum-corneum release member constituted from a sheet-like first supporting substrate and a pressure-sensitive adhesive layer laminated on the first supporting member; a medicinal-components administration member constituted from a sheet-like second supporting substrate, a medicinal-components retention layer laminated on the second supporting substrate, and a protect layer laminated on the medicinal-components retention layer; and a sheet-like handling member interposed between the stratum-corneum release member and the medicinal-components administration member. An edge portion of the handling member is coupled to or integrated with both the first supporting substrate and the protect layer. Operations of peeling the stratum-corneum release member from the skin surface of the patient and peeling the protect layer from the medicinal-components retention layer are carried out at a time by pulling the handling member toward an operating direction. | 07-29-2010 |
| 20100189752 | PELLETED MINERAL SUPPLEMENT FOR LAND ANIMALS - A pelleted mineral supplement for land animals is provided. Each of the pellets is a cohesive mass of mineral components that when consumed by a land animal promotes the health and/or growth of the animal, and each of the cohesive masses has a largest dimension less than 0.5 inches. In certain aspects of the invention, the pelleted mineral supplement can be combined with a conventional animal feed to provide a mineral-supplemented animal feed. | 07-29-2010 |
| 20100196424 | STABILIZATION OF LONG CHAIN POLYUNSATURATED OILS - Compositions that include an oxidizable fatty acid-containing oil and wax capable of limiting oxidation of the oil are disclosed. Also disclosed are compositions that include an ingestible fatty acid-containing oil and an ingestible wax. Polyunsaturated fatty acid-containing oils may be stabilized by mixing the oil with a melted wax capable of limiting oxidation of the oil, and allowing the mixture to cool. | 08-05-2010 |
| 20100196425 | OROS PUSH-STICK FOR CONTROLLED DELIVERY OF ACTIVE AGENTS - A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. | 08-05-2010 |
| 20100196426 | USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. | 08-05-2010 |
| 20100196427 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE - The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 08-05-2010 |
| 20100203088 | Silver Nanoparticle Dispersion Formulation - A topical semisolid (gel) formulation of nanoparticles of silver comprising about 0.001% w/w to about 1% w/w of silver by weight of the total mass of the formulation with its particle size in the range of 0.1 to 150 nanometer; about 0.5% w/w to about 25% w/w of at least one gel forming agent by weight of the total mass of the formulation; about 25% w/w to 60% w/w of at least of one co-solvent by weight of the total mass of the formulation; about 1% w/w to 50% w/w of purified water by weight of the total mass of the formulation and other optional adjuvants wherein the nanoparticle size of the silver enhances the therapeutic action of the formulation. | 08-12-2010 |
| 20100203089 | SELECTIVE CHEMOKINE MODULATION - The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions. | 08-12-2010 |
| 20100203090 | ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE - An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 08-12-2010 |
| 20100203091 | Decorative printing on polymeric gel air freshener and methods - The present invention relates to provide decorative printing on a surface of polymeric gel materials. The printing methods can be pad printing, or screen-printing and heat transfer printing. The polymeric gel material is also capable of releasing a fragrance. The gel air freshener can be hang on the rear mirror inside the vehicles and also can stick any smooth surface such as window glass, ceramic tile, polished plastic and metals. | 08-12-2010 |
| 20100209458 | AMPHIPHILIC MOLECULE, MOLECULAR ASSEMBLY COMPRISING THE AMPHIPHILIC MOLECULE, AND USE OF THE MOLECULAR ASSEMBLY - The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. According to a preferred embodiment of the present invention, the molecular assembly of the present invention forms a stable vesicular structure under a physiological pH environment to carry a substance of interest in the vesicular structure, and can release the substance of interest to the outside of the vesicular structure when it is deformed under an acidic pH environment. The molecular assembly of the present invention can be used as a carrier for a drug, a probe, a nucleic acid, a protein or the like. | 08-19-2010 |
| 20100209459 | ALKALOID FORMULATIONS - There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents. | 08-19-2010 |
| 20100209460 | ANTI-ODOR AGENT HAVING DISINFECTING OR BACTERICIDAL EFFECT - A liquid-based anti-odor agent is provided that has a disinfectant or bactericidal effect for the interiors of shoes and for shoe parts, particularly for shoe insoles, characterized in that the anti-odor agent comprises copper or copper compounds. | 08-19-2010 |
| 20100209461 | PURIFIED COMPONENT OF BLUE-GREEN ALGAE AND METHOD OF USE - Disclosed herein are extracts of blue green algae, such as | 08-19-2010 |
| 20100215699 | LACTOFERRIN AS A RADIOPROTECTIVE AGENT - This present invention relates to the field of protecting against, or rectifying the effects of damaging ionizing irradiation. The method of treatment involves oral administration of a lactoferrin composition, alone or in combination with other treatments, both in combination with other radio-protective agents and/or the standard of care. Further, the method of treatment provides for a topical administration of lactoferrin to treat lesions caused by local damaging irradiation. | 08-26-2010 |
| 20100221291 | COLLAGEN TUBES - The invention relates to collagen tubes, characterized in that they include a wall formed by a succession of continuous, cylindrical and coaxial collagen films. The invention also relates to tubules, bundles of tubules and combinations of tubes, tubules and bundles. These tubes are designed to be used in surgery, particularly in order to promote nerve regeneration. | 09-02-2010 |
| 20100221292 | INJECTION MOLDING PROCESS FOR THE PREPARATION OF AN ORAL DELIVERY DEVICE FOR THE PHARMACEUTICALLY ACTIVE AGENT - An injection moulding process for the preparation of an oral delivery device comprising a core which contains a pharmaceutically active agent, having a coating with one or more openings leading to such a core. The invention also relates to devices produced by the process, and to injection moulds suitable for performing the process. | 09-02-2010 |
| 20100226943 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL - Disclosed herein is an article that includes a first plurality of spaced features. The spaced features are arranged in a plurality of groupings; the groupings of features include repeat units; the spaced features within a grouping are spaced apart at an average distance of about 1 nanometer to about 500 micrometers; each feature having a surface that is substantially parallel to a surface on a neighboring feature; each feature being separated from its neighboring feature; the groupings of features being arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20. | 09-09-2010 |
| 20100226944 | PROCESS FOR THE PREPARATION OF CONTROLLED-RELEASE SOLID FORMULATIONS CONTAINING OXCARBAZEPINE, AND FORMULATIONS OBTAINABLE BY SAID PROCESS - The present invention relates to a process for the preparation of controlled-release solid oral pharmaceutical formulations of oxcarbazepine, and the pharmaceutical formulations obtainable by said process. | 09-09-2010 |
| 20100226945 | DYE-FREE PHARMACEUTICAL SUSPENSIONS AND RELATED METHODS - A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods. | 09-09-2010 |
| 20100233217 | ORGANIC COMPOUNDS - A depot formulation comprising iloperidone and a biodegradable, biocompatible polymer. Preferably, the polymer is a star polymer. | 09-16-2010 |
| 20100233218 | COMBINATION ENZYME FOR CYSTIC FIBROSIS - A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients. | 09-16-2010 |
| 20100239616 | CONTROLLED ACTIVATION INGESTIBLE IDENTIFIER - Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc. | 09-23-2010 |
| 20100239617 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 09-23-2010 |
| 20100247582 | METHOD OF PREPARING FIBRE-CONTAINING PECTIN PRODUCT AND PECTIN PRODUCTS HEREOF - The present invention relates to a method for providing a fibre-containing pectin product from a plant material. The method comprises the steps of: (i) providing a plant material comprising pectin, where said pectin is having a degree of esterification of 55% or less, (ii) adding an acidic aqueous solution to the pectin containing plant material obtained in step (i) and providing a suspension of the plant material, where the suspended plant material provides an in situ system by swelling the plant material under conditions where the pectin is kept within the plant material, and (iii) obtaining the fibre-containing pectin product from the suspension provided in step (ii), wherein the plant material is substantially depleted from divalent cations. | 09-30-2010 |
| 20100247583 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 09-30-2010 |
| 20100247584 | COMPOSITIONS USEFUL FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE - The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg. | 09-30-2010 |
| 20100247585 | STABILIZED PHARMACEUTICAL PRODUCT - Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. | 09-30-2010 |
| 20100255041 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS - Disclosed is the use of inhibitors of β-catenin expression or activity or modulators downregulating β-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells. | 10-07-2010 |
| 20100255042 | Process for Producing Particles Loaded with Growth Factors as Well as the Particles Thus Obtained - The present invention refers to a process for preparing a particulate material (particles) being loaded with growth factors, the thus obtained particles and the use for improving the ingrowth of implant material into the bone substance. | 10-07-2010 |
| 20100255043 | Methods for preparing T-cells for cell therapy - T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities. | 10-07-2010 |
| 20100260809 | Preparation For Wound Healing And Prevention Of Bandage Adhesion To The Wound, Containing Chitosan-Glucan - The invention relates to a preparation containing a pharmacologically suitable chitosan-glucan complex or a salt thereof, either alone or in combination with one or more polysaccharides or suitable salts thereof and an antiseptic agent, that is intended for wound healing and that, besides accelerating wound healing, is at the same time able to prevent a bandage adhesion to the wound. The preparation according to the invention, having been applied, indirectly supports the healing processes in the wound and drains the redundant secretion together with the tissue mediators and enzymes that support the healing. By doing this, it provides for the necessary hydration of the wound and its surroundings, without any maceration of the surrounding skin or drying and sticking to the wound. An addition of antiseptic agents prevents a further infection. The preparation contains 0.01 to 100% by weight of chitosan-glucan complex, 0 to 99.99% by weight of another polysaccharide and 0 to 50% by weight of an antiseptic agent. | 10-14-2010 |
| 20100260810 | ANTIDEPRESSANT DOSAGE FORM - The invention pertains to a dosage form | 10-14-2010 |
| 20100266643 | PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P - The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided. | 10-21-2010 |
| 20100266644 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 10-21-2010 |
| 20100266645 | PHARMACEUTICAL COMPOSITIONS - Provided herein are formulations and methods for treating pain in human beings. Also provide are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both an opioid and an opioid antagonist within a single pharmaceutical dosing unit. | 10-21-2010 |
| 20100272761 | SYNTHESIS OF LIPOAMIDE-GRAFTED HIGH MOLECULAR COMPOUND AND METHOD THEREFOR - The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products. | 10-28-2010 |
| 20100272762 | Freeze-Dried Coated Molded Article - The invention relates to freeze-dried molded articles comprising at least one or more active substances and optionally one or more scaffold-forming agents, optionally one or more auxiliary substances, as well as a coating comprising at least one film-forming agent. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application. | 10-28-2010 |
| 20100278876 | HIGH-SOLID ANTIFOULING PAINT COMPOSITION, ANTIFOULING COATING FILM, BASE MATERIAL WITH COATING FILM, ANTIFOULING BASE MATERIAL, METHOD FOR FORMING COATING FILM ON SURFACE OF BASE MATERIAL, ANTIFOULING METHOD FOR BASE MATERIAL, AND HIGH-SOLID MULTI-PACKAGE ANTIFOULING PAINT COMPOSITION SET - Disclosed is a high-solid antifouling paint composition characterized by including:
| 11-04-2010 |
| 20100278877 | BODY TISSUE FILLING MATERIAL AND METHOD FOR PRODUCTION THEREOF - There are provided a body tissue filling material having excellent engraftability and repairability, and a method for producing such a body tissue filling material in a simple manner. Specifically disclosed are: a body tissue filling material comprising a gelatin porous carrier, to the surface of which a coating having sulfated hyaluronic acid is applied; and a method for producing a body tissue filling material, comprising: a step (S | 11-04-2010 |
| 20100278878 | QUETIAPINE SALTS AND THEIR POLYMORPHS - The present invention relates to novel and stable salt forms of quetiapine, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides novel acid addition salts of quetiapine wherein the acid counter ion is provided by an acid selected from the group consisting of benzene sulfonic acid, dibenzoyl-L-(+)-tartaric acid and di-p-toluoyl-L-(+)-tartaric acid. The present invention also provides novel polymorphic forms of quetiapine salts selected from the group consisting of quetiapine hydrobromide, quetiapine sulfate, quetiapine nitrate and quetiapine citrate. | 11-04-2010 |
| 20100278879 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 11-04-2010 |
| 20100278880 | PHARMACEUTICAL FORMULATION FOR ALLERGEN PREPARATION - Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract or a method for the production of a purified extract of natural allergens comprising the steps of hydrolysing a denaturated allergen purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da, in the form of an starch based pellet. | 11-04-2010 |
| 20100278881 | USE OF CALCITONIN IN OSTEOARTHRITIS - The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans. | 11-04-2010 |
| 20100285073 | A MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF - The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease. | 11-11-2010 |
| 20100285074 | PHENOXYALKYLCARBOXYLIC ACID DERIVATIVES IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or prodrugs thereof: | 11-11-2010 |
| 20100285075 | Novel Hemioxalate Salt of Eletriptan - The present invention relates to novel hemioxalate salt of eletriptan, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention relates to solid forms of eletriptan hemioxalate, processes for preparation, pharmaceutical compositions, and method of treating thereof. The solid form of eletriptan hemioxalate is useful for preparing eletriptan free base or a pharmaceutically acceptable salt thereof, particularly eletriptan hydrobromide, in high purity. The present invention also provides a process for preparing substantially pure eletriptan hydrobromide using eletriptan hemioxalate. | 11-11-2010 |
| 20100291157 | COMPOSITION FOR HEADACHE TREATMENT - A nutritional composition for treating severe headaches and comprising a plurality of vitamins and a plurality of minerals that together represent at least a portion of required daily allowance thereof. The plurality of vitamins include at least vitamins A, C, D, E, K, B-1, B-2, B-6, and B-12, niacin, folic acid, biotin, pantothenic acid, and mixtures thereof, while the plurality of minerals include at least selenium, zinc, magnesium, calcium, iron, manganese, copper, chromium, cobalt, phosphorous, iodine, potassium and molybdenum. The composition further includes at least one or both of 125-175 mg of co-enzyme Q-10 and 25-150 mg of purified Butterbur root extract. | 11-18-2010 |
| 20100291158 | SUSTAINED RELEASE ORAL COMPOSITION OF AN ANTIPSYCHOTIC AGENT - A sustained release oral composition of an antipsychotic agent comprising antipsychotic agent, λ-carrageenan and one or more pharmaceutically acceptable excipients; wherein the antipsychotic agent is 2-[2-(4-dibenzo{b,f}[1,4-thiazepin-11yl-1-piperazinyl)ethoxy ethanol] or its pharmaceutically acceptable salt. | 11-18-2010 |
| 20100291159 | FILM COATINGS CONTAINING FINE PARTICLE SIZE DETACKIFIERS AND SUBSTRATES COATED THEREWITH - The present invention is directed to film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a fine particle size detackifier. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either polyvinyl alcohol or a copolymer of polyvinyl alcohol. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed. | 11-18-2010 |
| 20100291160 | PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY - Non-invasive drug delivery systems useful for the absorption of therapeutically active agents through the epithelial membrane are described. The non-invasive drug delivery system delivers a therapeutic active agent with an ionizable, or ionized, metal, transition metal or metal-containing vehicle. The non-invasive drug delivery system may also have a pH adjustable vehicle which facilitates the absorption of the therapeutic agents by altering the pH of the non-invasive drug delivery system at the site of administration. Also disclosed is a method for the pH “sweeping” of the administered therapeutic active agent to provide a consistent and reproducible absorption of the active agent. Certain formulations utilize low doses of active agents without altering the active agents from their current or previous form. | 11-18-2010 |
| 20100291161 | CELLULOSE POWDER - Cellulose powder having an especially excellent balance among moldability, fluidity and disintegrating property is provided. Cellulose powder having an average polymerization degree of 150-450, an average L/D (the ratio of the major axis to the minor axis) value of particles of 75 μm or less of 2.0-4.5, an average particle size of 20-250 μm, an apparent specific volume of 4.0-7.0 cm | 11-18-2010 |
| 20100297190 | IDENTIFICATION FEATURES - Methods for providing pharmaceutical compositions and objects with identification regions and identification features which are difficult to detect. Microlithography, nanolithography, and stamping methods are used. The identification features can be positive protrusions or negative indentations with respect to the surface. The identification regions can comprise bar codes and holograms. DPN printing or other lithographies such as electron beam lithography, optical lithography, or nanoimprint lithography can be used to prepare stamps, which are then used to prepare the identification features. Redundant patterns can be formed. The invention is useful for counterfeit prevention. An apparatus for stamping the identification features is also described. | 11-25-2010 |
| 20100297191 | METHOD FOR MANUFACTURING A CLEANSING AND/OR CARE ARTICLE - The invention relates to the use of a cleansing and/or care composition for impregnating a pile of absorbent supports. | 11-25-2010 |
| 20100297192 | USE OF MICROPARTICLES FOR VACCINES AND THE RELEASE OF BIOLOGICALLY ACTIVE MOLECULES - The invention relates to microparticles based on a PLGA biodegradable polymer and an alginate polymer which encapsulate immunologically active peptides or proteins. Said microparticles, and the pharmaceutical compositions developed from them and the uses thereof, are applicable to the field of human and animal health as a vaccine and system for releasing biologically active molecules. | 11-25-2010 |
| 20100297193 | METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 11-25-2010 |
| 20100297194 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-25-2010 |
| 20100297195 | CONTROLLED RELEASE LAMOTRIGINE FORMULATIONS - The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof. | 11-25-2010 |
| 20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 11-25-2010 |
| 20100303869 | Process for Producing Antimicrobial-Coated Superabsorbents - Superabsorbents having a coating of an antimicrobial agent are produced by a process that comprises contacting the superabsorbent with a solution comprising the anti-microbial agent and a polyol concurrently with or immediately after contacting it with the surface-crosslinking agent and prior to the curing step that completes surface crosslinking, and/or contacting the superabsorbent with a solution comprising the anti-microbial agent and polyalkylene glycol of a molecular mass between 200 and 5 000 g/mol after completion of surface crosslinking. | 12-02-2010 |
| 20100303870 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 12-02-2010 |
| 20100303871 | COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). | 12-02-2010 |
| 20100310607 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 12-09-2010 |
| 20100310608 | SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS - A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent. | 12-09-2010 |
| 20100310609 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD)) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 12-09-2010 |
| 20100310610 | COMPOSITIONS AND METHODS FOR CONTROLLING DRUG LOSS AND DELIVERY IN TRANSDERMAL DRUG DELIVERY SYSTEMS - A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile. | 12-09-2010 |
| 20100310611 | Parenteral and oral formulations of benzimidazoles - Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%. | 12-09-2010 |
| 20100310612 | Medicament for the Treatment of Cancer of the Pancreas - The invention relates to a suspension of red corpuscles encapsulating asparaginase as a medicament for treating pancreatic cancer. It in particular concerns a therapeutic composition or medicament intended for the treatment of pancreatic cancer, containing an effective quantity of such a suspension of red corpuscles. | 12-09-2010 |
| 20100310613 | DRUG DELIVERY SYSTEM - A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl | 12-09-2010 |
| 20100316677 | USE OF BAMBOO LEAF TOTAL FLAVONES IN THE PREPARATION OF MEDICINE AND HEALTH FOOD FOR PREVENTION AND TREATMENT OF PROSTATIC DISEASES - This invention discloses the new uses of | 12-16-2010 |
| 20100316678 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN - The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology. | 12-16-2010 |
| 20100316679 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively. | 12-16-2010 |
| 20100316680 | ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS - Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines. | 12-16-2010 |
| 20100316681 | N-ALKYLATED RIFAMPIN - Compounds of the formula: | 12-16-2010 |
| 20100316682 | Biodegradable Hyaluronic Acid Derivative, Biodegradable Polymeric Micelle Composition and Pharmaceutical or Bioactive Composition - The invention provides a biodegradable hyaluronic acid derivative including at least one modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C | 12-16-2010 |
| 20100322978 | MEDICAL COMPOSITION - It is an object of the present invention to produce a medical composition using a multilayered biopolymer structure. The present invention provides a medical composition of multilayered biopolymer structure of at least two layers, wherein the multilayered biopolymer structure comprises different types of biopolymer structures, and at least one layer of the multilayered biopolymer structure comprises a chemical substance. | 12-23-2010 |
| 20100322979 | Peptidomimetic Resorbable Peptide-Polymer Hybrid Polyester Nanoparticles - In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes a degradable synthetic polymer chain, a sequence of non-polar amino acids, and a sequence of ionic amino acids. The nanoparticle has a diameter of from about 50 nm to about 150 nm. | 12-23-2010 |
| 20100322980 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 - The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis. | 12-23-2010 |
| 20100330129 | Gastroresistant Pharmaceutical Formulations Containing Rifaximin - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 12-30-2010 |
| 20100330130 | SUBSTANTIALLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate. | 12-30-2010 |
| 20100330131 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 12-30-2010 |
| 20110002966 | Vaginal Suppository System and Method - A vaginal suppository system contains a formulation comprising active and inactive ingredients, which active ingredients may be nutraceuticals, herbs, vitamins, minerals and other bioactive agents. In an embodiment, the active ingredients comprise Oak gall, true unicorn root, bitter orange peel, tropical almond, heartsease, and zinc oxide. The formulation may be contained in a soluble encapsulation or a suspension for administration of the formulation in a vagina. A method of preparing a vaginal suppository system and a method of treating a vagina with a formulation comprising active and inactive ingredients are also disclosed. | 01-06-2011 |
| 20110002967 | Methods of Transdermally Administering an Indole Serotonin Receptor Agonist and Transdermal Compositions for Use in the Same - Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that find use in practicing the subject methods. | 01-06-2011 |
| 20110008395 | MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS, AND USES THEREOF - Disclosed are improved pharmaceutical formulations for the delivery of RNA interference agents, such as antisense RNA, micro-RNA and siRNA. The formulations employ mixed micelles including amphipathic conjugates of the iRNA agents and amphipathic micelle-forming molecules with extended hydrophilic chains. Also disclosed are methods of using the pharmaceutical formulations to increase delivery of an iRNA agent to an intracellular target, and to decrease extracellular nuclease degradation of an iRNA agent in the formulations. | 01-13-2011 |
| 20110008396 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR CONDITIONS - The invention provides amphiphilic macromolecule encapsulates that are useful for treating cardiovascular diseases including conditions related to or emanating from atherosclerosis. | 01-13-2011 |
| 20110008397 | COMPARTMENTAL EXTRACT COMPOSITIONS FOR TISSUE ENGINEERING - The present invention concerns biologically-active cell-free scaffolds composed of extracts of cellular and/or extracellular compartments for use in tissue regeneration. The present invention also contemplates the novel concept of redesigning the biological scaffold by seeding cells thereon followed by cell elimination. Cells are seeded on the scaffold for a period of time during which a dynamic interaction occurs between the scaffold and the seeded cells, resulting in reshaping of the scaffold architecture and integration of newly synthesized matrix elements. Redesigning may improve the physical and biological characteristics of the scaffold, and also improve the matching of the scaffold to treat a specific target tissue or a specific patient, by seeding tissue-specific cells or by seeding cells which are autologous to a patient, respectively. | 01-13-2011 |
| 20110008398 | MEDICATED PATCH - Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline. | 01-13-2011 |
| 20110014243 | PHARMACEUTICAL COMPOSITIONS - Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with a basic filler. Such formulation acts to prevent the formation of undesired reaction products. The compositions may be formed into granules or a tablet which may optionally be enterically coated. | 01-20-2011 |
| 20110014244 | Inorganic Shaped Bodies And Methods For Their Production And Use - Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A shaped, inorganic body is formed in situ. Optional, but preferred additional thermal treatment of the shaped, inorganic body removes the organic substrate, leaving an inorganic body that faithfully mimics the porosity, shape, and other physical characteristics of the organic substrate. Inorganic substrates may also be used to good effect. Large varieties of shaped bodies can be prepared in accordance with other embodiments of the invention and such shapes find wide use in surgery, laboratory and industrial processes and otherwise. The invention also provides chemically and morphologically uniform powders, including those having uniformly small sizes. | 01-20-2011 |
| 20110014245 | THERAPEUTIC METHOD OF ADMINISTERING PHARMACEUTICAL TITANIUM DIOXIDE COMPOSITE AND LIGHT IRRADIATION - A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required. | 01-20-2011 |
| 20110014246 | AMORPHOUS ARFORMOTEROL L-(+)-TARTRATE - Disclosed herein is a novel and stable amorphous form of arformoterol L-(+)-tartrate, a process for its preparation, pharmaceutical compositions comprising amorphous arformoterol L-(+)-tartrate, and methods of treating with amorphous arformoterol L-(+)-tartrade. | 01-20-2011 |
| 20110014247 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS - This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same. | 01-20-2011 |
| 20110020407 | TRANSDERMAL THERAPEUTIC SYSTEM WITH HIGH RATE OF UTILIZATION OF ACTIVE SUBSTANCE AND DOSING ACCURACY - Transdermal therapeutic system with which at least one pharmaceutical active substance that is non-volatile at room temperature can be administered at a daily dose of at most 30 mg, comprising a rear surface directed away from the skin and impermeable to the active substance, an adjoining polymer layer located away from the skin and based on polyisobutylene with a coating weight of at least 80 g/m | 01-27-2011 |
| 20110020408 | MULTILAYERED MODIFIED RELEASE FORMULATION COMPRISING AMOXICILLIN AND CLAVULANATE - The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multilayered modified release formulation comprises: an immediate release layer comprising amoxicillin and clavulanate; and a slow release layer comprising amoxicillin and one or more release retarding agents; and one or more non-release controlling inert barrier layers placed in between the immediate release layer and the slow release layer and comprising one or more pharmaceutically acceptable excipients. | 01-27-2011 |
| 20110020409 | Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 01-27-2011 |
| 20110020410 | STABLE SOLID PREPARATIONS - It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer. | 01-27-2011 |
| 20110020411 | FACTOR REPLACEMENT THERAPY - The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis. | 01-27-2011 |
| 20110020412 | NOVEL DOSAGE AND FORMULATION - The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide. | 01-27-2011 |
| 20110027324 | O-DESMETHYL-VENLAFAXINE FOR TREATING MAJOR DEPRESSIVE DISORDER - The present invention provides methods for treating MDD. In general, the methods comprise administering to a patient in need thereof a daily dose of about 50 mg ODV or an equivalent amount of a pharmaceutically acceptable salt thereof. In certain embodiments, a patient in need of treatment is characterized by a primary diagnosis of MDD. In some embodiments, the dose is administered as a single daily dose. In one set of embodiments, the methods involve administering an oral dosage form comprising the succinate salt of ODV. | 02-03-2011 |
| 20110027325 | ORALLY-ADMINISTERED AGENT - An orally-administered agent according to the present invention comprises: a medicine-containing layer containing a medicine and having surfaces; collapse-controlling layers respectively provided on the surfaces of the medicine-containing layer; and gel-forming layers respectively provided on the collapse-controlling layers, wherein the gel-forming layers are swelled and gelatinized by absorbing water to form a gel. The collapse-controlling layers are constituted of a material containing a stomach-soluble material to be dissolved by being in contact with gastric juice. The orally-administered agent according to the present invention can be swallowed with ease and release the medicine in intended parts, in particular, the stomach of a living body. | 02-03-2011 |
| 20110027326 | External Composition for Skin - An external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols. | 02-03-2011 |
| 20110033503 | DRESSING COMPOSITIONS AND METHODS - Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed. | 02-10-2011 |
| 20110033504 | ARTICLES AND METHODS FOR REPAIRING DAMAGED NERVOUS TISSUE - The invention concerns substrates comprising a biocompatible gel and at least one of a plurality of cells, said cells being capable of producing at least one therapeutic agent. Other aspects of the invention concern methods of making such substrates and methods of repairing and regenerating damaged nervous tissue with the substrates. | 02-10-2011 |
| 20110033505 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload. | 02-10-2011 |
| 20110033506 | COMBINATION DOSAGE FORM OF LOW-DOSE MODAFINIL AND LOW-DOSE SILDENAFIL - Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating. | 02-10-2011 |
| 20110038896 | Biodegradable immunomodulatory formulations and methods for use thereof - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier. | 02-17-2011 |
| 20110038897 | ORAL CONTROLLED RELEASE FORMULATIONS - This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy. | 02-17-2011 |
| 20110038898 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine by using said composition is also provided. | 02-17-2011 |
| 20110038899 | Pharmaceutical Solutions and Method for Solublilizing Therapeutic Agents - Pharmaceutical solutions containing hydrophobic or lipophilic therapeutic agents and methods for producing the same are provided. Pharmaceutical solutions of the invention are produced by dissolving the therapeutic agent in one or more tocopherols or tocotrienols and one or more alcohols or glycols. These solutions are used to produce pharmaceutical compositions. | 02-17-2011 |
| 20110038900 | NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS - In various aspects of the present invention, nanoparticle compositions are provided which comprise (a) nanoparticles comprising at least one biodegradable polymer and (b) at least one pharmaceutical associated with the nanoparticles. In other aspects of the present invention, methods of forming nanoparticles compositions are provided, which comprise contacting a first liquid that comprises one or more biodegradable polymers dissolved in a first solvent with a second liquid that comprises a second solvent which is miscible with the first solvent while being a non-solvent for the one or more biodegradable polymers, such that nanoparticles are formed. | 02-17-2011 |
| 20110045028 | SUSTAINED RELEASE PREPARATION - Disclosed is a sustained-release preparation which is prepared by shaping a granule comprising a blood coagulation factor Xa inhibitor and a mixture of at least two hydrophilic polymers. Also disclosed is a pharmaceutical composition comprising a combination of the sustained-release preparation and an immediate release preparation comprising a blood coagulation factor Xa inhibitor. It becomes possible to provide a controlled release preparation comprising a blood coagulation factor Xa inhibitor for the prevention or treatment of thrombosis, which can control the activity of blood coagulation factor Xa for a long term and is excellent in convenience and compliance. It is also becomes possible to provide a method for producing the controlled release preparation. | 02-24-2011 |
| 20110045029 | ORAL FORMULATION FOR DELIVERY OF POORLY ABSORBED DRUGS - A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone). | 02-24-2011 |
| 20110045030 | CROSSLINKABLE POLYISOBUTYLENE-BASED POLYMERS AND MEDICAL DEVICES CONTAINING THE SAME - The present invention pertains to crosslinkable and crosslinked polyisobutylene-based polymers, to compositions that contain such polymers, and to medical devices that are formed using such polymers. According to one aspect, the present invention pertains to crosslinkable and crosslinked compositions that comprise a copolymer that comprises a polyisobutylene segment and two or more reactive groups. According to another aspect, the present invention pertains to medical devices that contain such compositions. According to another aspect, the present invention pertains to methods of making medical devices using such compositions. | 02-24-2011 |
| 20110045031 | Use of Buckysome or Carbon Nanotube for Drug Delivery - Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes. | 02-24-2011 |
| 20110045032 | COMPOSITION, FORMULATIONS & KIT FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE WITH DEHYDROEPIANDROSTERONE(S) STEROID & AN ANTI-MUSCARINIC AGENT(S) - A pharmaceutical or veterinary composition comprises a non-corticosteroids, and/or salts thereof, and an anti-muscarinic (anti-cholinergic) agent, and/or pharmaceutically or veterinarily acceptable salts thereof. The composition is provided in various formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases. | 02-24-2011 |
| 20110045033 | Combination of Itriglumide and Proton Pump Inhibitors in the Treatment of Gastrointestinal and Related Disorders - The invention relates to the combination of the cholecystokinin-2 (CCK-2) receptor antagonist Itriglumide and proton pump inhibitors (PPIs) for the treatment of patients suffering from gastrointestinal and related disorders. | 02-24-2011 |
| 20110045034 | Gelatin Sponge Comprising an Active Ingredient, Its Preparation and Use - The invention relates to an improved dry cross-linked gelatin sponge comprising a layer of an active ingredient, to methods of its preparation and uses thereof. | 02-24-2011 |
| 20110045035 | METHODS OF TREATING OPHTHALMIC DISORDERS - Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude | 02-24-2011 |
| 20110052645 | MANUFACTURE OF MULTIPLE MINICAPSULES - An extrusion process comprises extruding a material that is flowable when heated and passing the extrudate thus formed through a nozzle | 03-03-2011 |
| 20110052646 | POLYMER ADHESIVE FILM FOR DIRECTED CELLULAR GROWTH - The described embodiments relate to a polymer adhesive film having a micro-pattern arranged on a first surface of the polymer adhesive film for application to wounded tissue to promote directional cell growth. The micro-pattern is sized to allow cells of the wounded tissue to grow directionally within the micro-pattern to promote rapid and complete healing. | 03-03-2011 |
| 20110052647 | Antidepressant Oral Pharmaceutical Compositions - Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its pharmaceutical derivatives thereof compressed together, an intermediate and an enteric layer. Duloxetine or its pharmaceutical derivatives thereof may be any pharmaceutically acceptable prodrug, salt, solvate or derivative of Duloxetine. The novel compositions prepared according to the present invention have enhanced stability and bioavailability. | 03-03-2011 |
| 20110052648 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES - An oral modified-release formulation using Quetiapine or pharmaceutically acceptable salts thereof as an active ingredient, while avoiding the use of a gelling material. As used herein, the term “modified release” includes but is not limited to one or more of controlled release, sustained release, prolonged release and extended release. | 03-03-2011 |
| 20110059139 | METHOD FOR LOADING A MOLECULE INTO A POROUS SUBSTRATE - A method for loading a molecule into a porous substrate. The molecule has the formula | 03-10-2011 |
| 20110059140 | EXTRUDED ROD-SHAPED DEVICES FOR CONTROLLED RELEASE OF BIOLOGICAL SUBSTANCES TO HUMANS AND ANIMALS - The present invention relates to an extruded rod-shaped device which comprises at least one biological substance and a lipoid composition that comprises a high melting lipid or lipoid component and a low melting lipid or lipoid component. The extruded rod-shaped device according to the present invention is obtainable by extrusion of a preparation comprising the lipoid composition and the at least one biological substance, the preparation being extruded at a temperature which is at or above the melting point of the low melting lipid or lipoid component but below the melting point of the high melting lipid or lipoid component. Such an extruded rod-shaped device is capable of continuously and homogenously releasing the biological substance into the body of an animal or a human while maintaining the biological activity the biological substance and may for example be used as an implant. | 03-10-2011 |
| 20110059141 | PERCUTANEOUS ABSORPTION PREPARATIONS OF ANTIDEMENTIA DRUGS - Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug. | 03-10-2011 |
| 20110059142 | ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS - The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment. | 03-10-2011 |
| 20110064773 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE - The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3′,5′,3-triiodothyronine (rT3), a rT3 derived hormone, or a precursor of rT3, such as T4 in association with a molecule susceptible to promote the formation of rT3, in association with a pharmaceutically acceptable vehicle. | 03-17-2011 |
| 20110064774 | BULKING AGENT - The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, aneurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents. | 03-17-2011 |
| 20110064775 | METALLO-ORGANIC SYSTEM FOR THE ENCAPSULATION AND RELEASE OF COMPOUNDS OF INTEREST, METHOD FOR OBTAINING SAME AND USES THEREOF - The present invention discloses a metallo-organic system that includes: a metal ion salt or complex; at least one organic ligand; and a substance of interest to be encapsulated, belonging to the group comprising a biological entity, a drug, a vaccine, a diagnostic contrast agent, a marker, an organic compound, an inorganic compound, a metallo-organic compound or a nanomaterial or nanodevices. Also disclose is the process for obtaining same and the uses thereof for the release and/or protection and/or storage of said substances in the pharmaceutical, chemical, environmental, medical and industrial sectors. | 03-17-2011 |
| 20110064776 | DENTAL COMPOSITION CONTAINING ORGANIC NANOTUBE - Disclosed is a dental composition, comprising unsaturated double bond-containing monomers and/or oligomers, a catalytic amount of polymerization initiator to initiate polymerization, and a filler, wherein the dental composition comprises an organic nanotube containing an antibacterial or anticariogenic material to inhibit or prevent tooth decay. | 03-17-2011 |
| 20110070271 | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles - Constructs that are at least partially constructed of allograft cancellous bone are disclosed, along with cartilage particles that may be used with the constructs for repairing articular cartilage defects. A multi-piece construct includes a base member, a cap member and at least one pin that secures the cap member to the base member. The base member may be constructed of mineralized cancellous bone, and is used to replace the subchondral bone removed when a surgeon cuts a bore in the area of an adjacent cartilage defect. The base member includes a blind bore and first and second through-going transverse bores in opposite sides of a wall of the base member. The cap member includes an upper section that has a thickness that is similar to that of a patient's surrounding articular cartilage layer and a stem depending from the upper section that is dimensioned to be received in and by the blind bore of the base member. The stem includes a transverse through-going bore, which may be aligned with the transverse through-going bores of the base member to receive the pin therein when the construct has been assembled. The cap member is at least partially formed of demineralized allograft cancellous bone, into which a mixture containing lyophilized, freeze-milled allograft cartilage particles may be infused for the repair of articular cartilage defects. The cartilage particles have a size within a range of from about 10 microns to about 210 microns. | 03-24-2011 |
| 20110070272 | Materials and Methods for Modulating Metabolism - The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications. | 03-24-2011 |
| 20110076307 | POLYCATIONIC GENE CARRIERS FORMED OF ENDOGENOUS AMINO GROUP-BEARING MONOMERS - The present invention is directed to a design of and a method to synthesize polycations for gene (DNA and RNA) delivery. According to this design, the polycations (also said cationic polymers) are formed by polymerization of endogenous monomers bearing sufficient amino groups through degradable bonds with linker molecules or with themselves. The amino group-bearing monomers are those naturally existing in or nontoxic to human body. The linker molecules are those which are not only degradable to nontoxic fragments but also able to release the amino group-bearing monomers in their native state upon degradation. Some examples for the endogenous amino group-bearing monomers are spermine, spermidine, serine or N,N-dimethyl serine, and histidine. Examples for the degradable chemical bonds formed between the amino group-bearing monomers are carbamate, imine, amide, carbonate, and ester. In order to improve degradability or proton sponging effect, low pKa (<8) amino group(s) or other electron donating group(s) is incorporated in the linker between the two (or three) reactive groups for linking the amino group-bearing monomers. These polycationic carrier systems can be used for nano-encapsulation and transfection of gene materials. | 03-31-2011 |
| 20110076308 | MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailabilty without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations. | 03-31-2011 |
| 20110081384 | METHODS OF WOUND CARE AND TREATMENT - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 04-07-2011 |
| 20110081385 | Compositions and Methods for Sleep Regulation - Compositions and methods for the regulation of sleep and circadian rhythms are provided. The compositions are nutritional supplements containing melatonin and one or more vitamins that enhance the effectiveness of melatonin. Preferred vitamins include folic acid, riboflavin (vitamin B | 04-07-2011 |
| 20110081386 | CONTROLLED RELEASE OF ACTIVE AGENTS FROM OLEOSOMES - The release rate of an active agent from oleosomes can be modulated by formulation of the oleosomes with a release control agent, such as a multihydric alcohol. In this context, oleosomes containing an active agent may be used in the preparation of a variety of formulations, including formulations for topical use. | 04-07-2011 |
| 20110086068 | Compositions and Methods for Tissue Engineering, Tissue Regeneration and Wound Healing - In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein. | 04-14-2011 |
| 20110086069 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 04-14-2011 |
| 20110086070 | Orally disintegrating compositions of rhein or diacerein - The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions. | 04-14-2011 |
| 20110086071 | Pharmaceutical Compositions Comprising Terbinafine - This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration. | 04-14-2011 |
| 20110086072 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 04-14-2011 |
| 20110086073 | NANOMETER-SIZED PRODRUGS OF NSAIDs - The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions. | 04-14-2011 |
| 20110086074 | COMBINATIONS OF NIACIN AND AN OXICAM - Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations. | 04-14-2011 |
| 20110091508 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF - The invention features oligofluorinated cross-linked polymers and their use in the manufacture of articles and coating surfaces. | 04-21-2011 |
| 20110091509 | Benzonatate compositions and methods of use - Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications. | 04-21-2011 |
| 20110091510 | NANOROD MATERIALS AND METHODS OF MAKING AND USING SAME - The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the nanorod is composed of Zinc oxide (ZnO). In a further embodiment, a nanorod of the invention further comprises SiO | 04-21-2011 |
| 20110091511 | TRANSDERMAL DELIVERY OF DRUGS BASED ON CRYSTAL SIZE - A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, providing drug having differing crystal sizes as well as drug which is solublized in the pressure-sensitive adhesive composition controls the rate of drug delivery from the pressure-sensitive adhesive composition. | 04-21-2011 |
| 20110097362 | Transmucosal Administration of Aggregated Antigens - The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The invention sets forth methods and compositions useful in inducing oral tolerance and systemic immunity in a mammal. | 04-28-2011 |
| 20110097363 | Therapeutically Effective Preparations of Insulin - The present invention provides a preparation of a therapeutically effective amount of insulin with a concentration of A21 desamido insulin greater than about 2% (w/w). | 04-28-2011 |
| 20110097364 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-28-2011 |
| 20110104212 | POLYMERIC COMPOSITIONS WITH ENHANCED SALINE HOLDING CAPACITY AND THEIR METHOD OF PREPARATION AND USE - Cross-linked polyelectrolyte polymers that absorb 60-fold or more, including greater than 60-fold, greater than 70-fold, greater than 80-fold, greater than 90-fold, greater than 100-fold, or greater than 110-fold or more, of their mass in a saline solution are disclosed. Methods for preparing such polymers with enhanced saline holding capacity and methods for treating diseases, disorders or conditions involving fluid overload and/or ion imbalances by administering the polymers are disclosed. | 05-05-2011 |
| 20110104213 | Porous Biomolecule-Containing Metal-Organic Frameworks - The present invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the present invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release. | 05-05-2011 |
| 20110104214 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 05-05-2011 |
| 20110104215 | TRANSDERMALLY ABSORBABLE PREPARATION - Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin. | 05-05-2011 |
| 20110104216 | PROCESSES FOR THE PREPARATION OF A BATCH OF AN ACTIVE PHARMACEUTICAL INGREDIENT, A CONTAINER COMPRISING CRYOGRANULES OF AN ALLERGEN PRODUCT, AND A CRYOGRANULE OF AN ALLERGEN PRODUCT - The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying. | 05-05-2011 |
| 20110104217 | Bioactive Peptides and Method of Using Same - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 05-05-2011 |
| 20110110984 | Oral Dosage Form Comprising Tri-Substituted Glycerol Compounds - The present invention relates to pharmaceutical solid dosage forms for oral administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases. | 05-12-2011 |
| 20110110985 | FUNCTIONALIZED NANOMATERIALS FOR CHELATION THERAPIES AND SORBENT DIALYSIS OF TOXINS - A therapy agent is disclosed that is made up of a functionalized nanomaterial that provides solutions to current problems facing the field of chelation therapies and dialysis of metals, radionuclides, and metabolic wastes. Through the coupling of groups tailored to selectively capture specific toxins and rigid porous backbone structures (e.g., mesoporous silica and mesoporous carbon), suitable materials that are highly effective and fast at capturing toxins (metals, radionuclides, and metabolic wastes) in the presence of competing ions and proteins. These materials may be embodied in a variety of treatment devices which allow for treatment and removal of these target materials through a variety of methodologies including oral, dermal and dialysis pathways. | 05-12-2011 |
| 20110110986 | HIGH-YIELD ACTIVATION OF POLYMER SURFACES FOR COVALENT ATTACHMENT OF MOLECULES - Polymer surfaces coated with organometallic layers, wherein the organometallic layers and polymer surfaces have functional groups that react to bond the organometallic layer to the polymer surface with organometallic functional groups remaining unreacted for the subsequent covalent attachment of organic overlayers. Coating methods and coated articles are also disclosed. | 05-12-2011 |
| 20110110987 | AGENT FOR REGENERATING TYMPANIC MEMBRANE OR EXTERNAL AUDITORY CANAL - Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance. | 05-12-2011 |
| 20110117138 | CHARGE-DYNAMIC POLYMERS AND DELIVERY OF ANIONIC COMPOUNDS - The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided. | 05-19-2011 |
| 20110117139 | FULLY SYNTHETIC ALBUMIN ANALOG - The present invention relates to a fully synthetic albumin analog, to a hemocompatible coating for medical devices containing the fully synthetic albumin analog, as well as to medical devices coated with the hemocompatible coating. The albumin analog preferably has two basic structures which are connected with one another via at least one bridging unit, the basic structures respectively having, in a geometrically defined manner, at least two bound joint regions to which at least one residue is covalently bound, wherein the basic structures are, respectively, a benzene carboxylic acid, and wherein the joint regions are formed via acid amide bonds, and wherein each residue, respectively, comprises a lipophilic region and a hydrophilic region. | 05-19-2011 |
| 20110117140 | Zinc Salt Compositions for the Prevention of Dermal and Mucosal Irritation - The present invention provides for compositions and methods that may offer protection from irritants as well as antimicrobial protection. Preferred embodiments of the invention include topical antimicrobial compositions that lack conventional antibiotics or preservatives, wherein the antimicrobial benefit is created by essential oils (or their active ingredients), emollient solvents and, in some instances, anti-inflammatory agents. | 05-19-2011 |
| 20110117141 | METHODS AND COMPOSITIONS COMPRISING NOVEL CATIONIC LIPIDS - Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a cytotoxic bioactive compound to kill a cell. In some of these claims, the cationic lipid enhances the cytotoxic activity of the cytotoxic bioactive compound. Methods for treating a subject afflicted with a disease or unwanted condition are provided, wherein the method comprises administering a delivery system comprising a novel cationic lipid to the subject. The invention further provides methods for making delivery systems comprising the novel cationic lipids of the invention. | 05-19-2011 |
| 20110117142 | METHOD FOR COATING TABLETS - The present invention relates to a polymeric composition for coating solid substrates (S) consisting of:
| 05-19-2011 |
| 20110117143 | TREATMENT OF CELIAC DISEASE WITH IgA - A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. | 05-19-2011 |
| 20110123572 | ACTIVATED FIBROBLASTS FOR TREATING TISSUE AND/OR ORGAN DAMAGE - The invention provides activated fibroblasts for the treatment of tissue and/or organ damage in a patient. Fibroblasts are activated by culturing the cells under conditions that induce the cells to adhere to each other and simultaneously to secrete growth factors, especially hepatocyte growth factor, HGF. The invention also provides a pharmaceutical composition based on the medium in which the activated fibroblasts are cultured. The invention further provides methods for transplantation. | 05-26-2011 |
| 20110123573 | Methods and compositions for treating phenylketonuria - Provided herein are methods for treating a subject suffering from phenylketonuria by administering a phenylalanine hydroxylase (“PAH”) and/or a phenylalanine ammonia lyase (“PAL”) to the subject under conditions effective to deliver the phenylalanine 4-hydroxylase and/or PAL to the subject's small intestine. Also provided are methods for increasing the therapeutic activity of a phenylalanine 4-hydroxylase by thiolating the phenylalanine 4-hydroxylase. In addition, provided are oral dosage forms that include a phenylalanine 4-hydroxylase and/or a PAL and an enteric coating. | 05-26-2011 |
| 20110123574 | INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS - The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties. | 05-26-2011 |
| 20110123575 | MODIFIED RELEASE NIACIN FORMULATIONS - Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations. | 05-26-2011 |
| 20110123576 | INTESTINAL ENVIRONMENT-IMPROVING AGENT - Disclosed is an intestinal environment-improving agent including a lactoferrin and bacteria of | 05-26-2011 |
| 20110123577 | Method Of Delivering Stable Topical Drug Compositions - A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature. | 05-26-2011 |
| 20110129504 | COMPOSITION FOR CONTROLLING LIPASE CATALYZED REACTIONS - The present invention relates to the field of lipolysis mediated by lipases. In particular the present invention relates to the modulation of lipase activity by regulation of the composition of the interface between a hydrophobic and a hydrophilic phase. More particularly the present invention relates to a the use of a formulation comprising at least one surfactant with an interfacial pressure that is sufficiently high to control the access of lipase substrates to the interface between a lipophilic phase and a hydrophilic phase to regulate lipolysis and to a composition comprising at least one oil and enriched with at least one surfactant wherein the surfactant is non-cleavable by at least one lipase, has a higher affinity to the interface between the hydrophilic and lipophilic phase than the at least one lipid and is present in a weight ratio to the at least one lipid of about 1:1000-100:1. | 06-02-2011 |
| 20110129505 | CELLULOSE DERIVATIVE AND HYDROGEL THEREOF - The invention is a cellulose derivative wherein some of the carboxyl groups of the cellulose derivative carboxymethylcellulose are replaced with —CO—NH—X—CO—Y—Z, and a hydrogel of the same. In the formula, X is a C1-10 divalent hydrocarbon group, Y is a divalent group derived from polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R | 06-02-2011 |
| 20110129506 | Colouring using pearlescent pigments in the food and pharmaceutical sectors - The present invention relates to the use of titanium dioxide pigments and/or iron oxide pigments based on platy substrates for colouring food products and pharmaceutical products. | 06-02-2011 |
| 20110129507 | CONTROLLED RELEASE FORMULATIONS EXHIBITING AN ASCENDING RATE OF RELEASE - A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. | 06-02-2011 |
| 20110129508 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF PAIN USING OMEGA-CONOTOXINS - The present invention relates to the management of pain (nociceptive, neuropathic, inflammatory and disease related pains), using omega-conotoxins alone or in combination with neuronal excitation inhibitors (analgesics). The invention in particular provides methods, protocols, compositions and devices which treat, alleviate, prevent, diminish or otherwise ameliorate the sensation of pain. | 06-02-2011 |
| 20110135693 | PATCH - An adhesive patch for attaching to the skin for medical, cosmetic, and/or orthopedic purposes. The patch is formed with a film that includes a carrier material, which is provided with a therapeutically effective coating on both sides. | 06-09-2011 |
| 20110135694 | PARTIAL DIP COATING OF DOSAGE FORMS FOR MODIFIED RELEASE - A dosage form comprising a tablet core containing at least one active ingredient and having at least one modified release coating that partially surrounds the tablet core is disclosed. The tablet core is preferably in the form of a compressed core wherein the at least one modified release coating is provided on a position of the exterior surface of the compressed core using dipping technology. The invention also relates to a method of manufacturing the dosage form and a method of treatment using the dosage form. | 06-09-2011 |
| 20110135695 | ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE - An oral dosage form comprising,
| 06-09-2011 |
| 20110135696 | MULTIPOTENT NEURAL CELLS - The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays. | 06-09-2011 |
| 20110135697 | EDIBLE HOLOGRAPHIC SILK PRODUCTS - The present invention relates to edible silk holographic elements and methods for making the same. Edible silk holographic elements are used to label pharmaceuticals and foods, or may be formulated to deliver pharmaceuticals. | 06-09-2011 |
| 20110135698 | MULTILAYERED BLOOD PRODUCT - A blood product ( | 06-09-2011 |
| 20110142883 | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts - The present invention relates to stable amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts of the present invention have improved physiochemical characteristics that assist in the effective bioavailability | 06-16-2011 |
| 20110142884 | Materials and Methods for Making Improved Micelle Compositions - Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention. | 06-16-2011 |
| 20110142885 | SPRAY-DRIED HUMAN PLASMA - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 06-16-2011 |
| 20110142886 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 06-16-2011 |
| 20110142887 | Methods and compositions for liquidation of tumors - This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication. | 06-16-2011 |
| 20110142888 | FILM COATING COMPOSITIONS BASED ON POLYVINYL ALCOHOL-POLYETHER GRAFT COPOLYMER/POLYVINYL ALCOHOL COMBINATIONS WITH AN IMPROVED MOISTURE BARRIER EFFECT - Film coating compositions based on a co-processed mixture of a polyvinyl alcohol-polyether graft polymer and polyvinyl alcohol (component A), a N-vinylpyrrolidone-vinyl acetate copolymer (component B) and pigments (component C). | 06-16-2011 |
| 20110142889 | COMPOSITIONS AND METHODS FOR ORAL DRUG DELIVERY - The invention provides a pharmaceutical composition for oral drug delivery comprising a solid dosage form containing an effective amount of a therapeutic agent, a permeation enhancer and a pharmaceutically acceptable excipient and a bioadhesive layer containing a bioadhesive polymer, and optionally comprising an impermeable or semi-permeable layer having an opening capable of directing a unidirectional release of the therapeutic agent and the permeation enhancer from the solid dosage form. Methods of making and using the present pharmaceutical composition are also provided. | 06-16-2011 |
| 20110150937 | EXTENDED RELEASE COMPOSITIONS COMPRISING TOLTERODINE - The present invention deals with extended release pharmaceutical composition comprising tolterodine, wherein the composition comprises of: a) a drug layer comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising of extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition. | 06-23-2011 |
| 20110150938 | Supercrystalline Colloidal Particles and Method of Production - The present invention concerns size- and shape-controlled, colloidal superparticles (SPs) and methods for synthesizing the same. Ligand-functionalized nanoparticles such as nonpolar-solvent-dispersible nanoparticles, are used, and the solvophobic interactions can be controlled. Advantageously, supercrystalline SPs having a superlattice structure, such as a face-centered cubic structure, can be produced. Further, the methods of the invention can provide SPs that self-assemble and are monodisperse. The SPs can be doped with organic dyes and further assembled into more complex structures. | 06-23-2011 |
| 20110150939 | Compositions for removing stains from dental surfaces, and methods of making and using the same - A composition for removing stains from dental surfaces comprising a stain removing effective amount of at least two active components selected from a peroxide compound, a polyphosphate, and an anionic surfactant, in combination with an orally acceptable carrier. The present invention is further directed to methods of making and using the same. | 06-23-2011 |
| 20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION - This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 μm and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation. | 06-23-2011 |
| 20110150941 | EPITHELIAL DELIVERY - The present invention relates to composition comprising vesicles and associated with the vesicles, a chemical agent, for use in a method of treatment by therapy wherein the chemical agent is delivered trans- and/or intra-epithelially to a human or animal body, wherein the constructs comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. | 06-23-2011 |
| 20110150942 | GASTRO-RESISTANT PHARMACEUTICAL ORAL COMPOSITIONS COMPRISING DULOXETINE OR ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES - The present invention relates to a pharmaceutical composition comprising an active core comprising duloxetine or its pharmaceutically acceptable derivatives, a separating layer comprising a pH modifier and a gastro-resistant coating comprising a gastro-resistant polymer selected from methacrylic acid copolymers and optionally an over-coating layer. The present invention also relates to a process for the preparation of duloxetine hydrochloride. It also relates to a packaged medicament. | 06-23-2011 |
| 20110150943 | ADHESIVE FOR MEDICAL APPLICATIONS AND MEANS FOR HAEMOSTASIS - The invention relates to adhesives for medical applications and methods of their preparation and use. | 06-23-2011 |
| 20110150944 | STRUCTURED TRIGLYCERIDES AND EMULSIONS COMPRISING SAME - The present invention relates to structured triglycerides, to parenteral nutrition emulsions of the same, and uses thereof. In particular, the invention relates to structured triglycerides that include at least one medium chain C | 06-23-2011 |
| 20110150945 | ORAL PHARMACEUTICAL FORMULATION FOR OMEPRAZOLE COMPRISING A SPECIFIC SEPARATION LAYER - The invention relates to an enteric coated oral pharmaceutical formulation comprising, as the active ingredient, omeprazole, an alkaline salt of omeprazole, an enantiomer of omeprazole, or an alkaline salt of an enantiomer of omeprazole, and a specific separation layer between active ingredient and enteric coating comprising a polyvinyl alcohol/polyethylene glycol graft copolymer and/or optionally modified pea starch. | 06-23-2011 |
| 20110150946 | Transdermal Delivery of Apomorphine Using Microneedles - The present invention relates generally to methods for transdermal delivery of a therapeutically effective amount of apomorphine using microneedles. The invention also provides methods for treatment of erectile dysfunction and Parkinson's disease using apomorphine hydrochloride or any pharmaceutically acceptable salt, and/or apomorphine prodrugs to the microneedle-treated site. | 06-23-2011 |
| 20110159044 | SILVER ION DELIVERY PLATFORM - The present invention pertains to silver ion bearing carriers useful in treating monorrhagia of a mammalian uterus, comprising a physiologically inert, flexible earner, e.g., a coil, bearing a tissue cauterizing amount of a silver ion. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue. The silver ions remaining within the uterine cavity can then be neutralized with a sodium chloride solution delivered to the uterus e.g., by catheter, and the carrier recovered from the uterus. | 06-30-2011 |
| 20110159045 | METHOD OF TREATING DYSGLYCEMIA AND GLUCOSE EXCURSIONS - The present application relates to pharmaceutical compositions for reducing glucose excursions in a normal subject or a subject having an insulin-related disorder or dysglycemia. The pharmaceutical composition contains one or more active agent-containing layers, which each contain a dry blended mixture including a therapeutically effective amount of a polar ionizable insulin-sensitizing oral hypoglycemic agent or a pharmaceutically acceptable salt thereof, and an amphipathic compound in monomelic form consisting of an amphipathic ionic compound in monomelic form. Each dry blended mixture contains a sufficient amount of the amphipathic ionic compound such that upon contact with an aqueous fluid, the amphipathic ionic compound forms a reverse micelle comprising the polar ionizable insulin-sensitizing oral hypoglycemic agent. The present invention also relates to a use of a modified release pharmaceutical composition comprising a therapeutically effective amount of an insulin-sensitizing oral hypoglycemic agent for sensitizing pre-prandial (basal) insulin levels and/or reducing postprandial glucose excursions in a normal patient or a patient having an insulin-related disorder. | 06-30-2011 |
| 20110159046 | CONTROLLED RELEASE FORMULATIONS EXHIBITING AN ASCENDING RATE OF RELEASE - A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. | 06-30-2011 |
| 20110159047 | STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES - The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles to produce dried powder particles. Pharmaceutical compositions comprising a stable powder formulation of an alum-adsorbed vaccine are also disclosed herein. The pharmaceutical compositions are stable at high temperatures and can be reconstituted in a pharmaceutically acceptable carrier to produce a reconstituted liquid vaccine that exhibits little or no particle agglomeration and retains immunogenicity. Methods of using the alum-adsorbed vaccine compositions for preventing and treating a disease in a subject, wherein the disease is associated with the particular immunogen, are further provided. | 06-30-2011 |
| 20110159048 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS - The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain. | 06-30-2011 |
| 20110159049 | PHARMACEUTICAL COMPOSITION - The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube. | 06-30-2011 |
| 20110159050 | AMPHIPHILIC PROTEINS AS MORPHOLOGY MODIFIERS - Disclosed is a process for modifying the morphology and/or polymorphism of an organic substance, which process comprises treating the solid substance, or a solution or dispersion thereof, with one or more amphiphilic proteins. | 06-30-2011 |
| 20110159051 | Composite for Thermo-Sensitive Cell-Tissue Transplanted Scaffold and Use thereof - A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven. | 06-30-2011 |
| 20110159052 | TAXANES COVALENTLY BOUNDED TO HYALURONIC ACID OR HYALURONIC ACID DERIVATIVES - The present invention relates to water-soluble taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives, and in particular to paclitaxel and docetaxel, useful for the preparation of pharmaceutical compositions to be used in the field of oncology, in the treatment of autoimmune disorders and of restenosis. The invention also relates to the process for preparing taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivates by direct synthesis between molecules of hyaluronic acid and of taxane or by indirect synthesis by the introduction of a spacer between the hyaluronic acid derivative and the taxane. | 06-30-2011 |
| 20110159053 | PREPARATION OF A CELL CONCENTRATE FROM A PHYSIOLOGICAL SOLUTION - The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed. | 06-30-2011 |
| 20110159054 | NANOPARTICULATE BICALUTAMIDE FORMULATIONS - The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer. | 06-30-2011 |
| 20110159055 | NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS - A nutritional supplement for use in physiologically stressful conditions is disclosed. The nutritional supplement may include one or more of vitamin A, vitamin E, vitamin D3, vitamin C, vitamin B1, riboflavin, niacin, folic acid, vitamin B | 06-30-2011 |
| 20110159056 | METHODS AND MATERIALS FOR STIMULATING PROLIFERATION OF STEM CELLS - Disclosed herein are methods and materials for influencing proliferation of stem cells. Specifically exemplified herein are compositions comprising cerium oxide nanoparticles which can be used to stimulate proliferation of stem cells under common culture conditions, or which can be utilized to improve therapeutic outcomes. | 06-30-2011 |
| 20110159057 | HYDROXYAPATITE AND BIOGLASS-BASED PELLETS, PRODUCTION PROCESS AND APPLICATIONS OF THEREOF - The disclosed subject matter refers to hydroxyapatite and bioglass-based pellets of homogeneous size and spherical shape, whose interconnective porous structure, in the micrometer range, allows for an enhanced osteoconductivity and osteointegration, with specific application as a synthetic bone graft and to the respective production process. The production process is based on the pharmaceutical technology of extrusion and spheronization employing a porogenic agent and applying a sinterization stage in the presence of a vitreous liquid phase, which reverts on behalf of a higher reproducibility, superior yield and greater production capacity. Therefore, the disclosed subject matter is directed to the production of hydroxyapatite and bioglass-based pellets with applications in osteoregenerative medicine, particularly in the fields of orthopaedic surgery, maxillofacial surgery, dental surgery, implantology and as tissue engineering scaffolds | 06-30-2011 |
| 20110159058 | FILM PREPARATION CONTAINING LOPERAMIDE HYDROCHLORIDE - The film preparation of the present invention includes: a drug-containing intermediate layer containing loperamide hydrochloride, a terpene and a film-forming agent; and coating layers containing a film-forming agent and a plasticizer (but not a terpene) and laminated on both sides of the drug-containing intermediate layer. As a bitter taste derived from loperamide hydrochloride is thereby masked, uncomfortable sensation when taking the film preparation can be reduced. Furthermore, as this film preparation is rapidly dissolved (i.e., has a rapidly dissolving property) only with moisture in the oral cavity, it begins to work quickly and is very convenient when it is carried and taken. | 06-30-2011 |
| 20110165198 | METHOD FOR REDUCING LIPID ABSORPTION BY AN ANIMAL - The invention provides methods for using fatty acid alkanolamides for reducing lipid absorption from the intestine of an animal. Reducing lipid absorption results in fewer lipids available for an animal to convert to body fat. Converting fewer lipids to body fat means that the animal reduces body fat, body weight, and/or body weight gain when consuming an equivalent amount of lipids without the fatty acid alkanolamides. | 07-07-2011 |
| 20110165199 | Composition and Process for Bone Growth and Repair - A composition for the induction of bone growth is disclosed. The composition includes a substrate, bone growth protein, and sources of calcium and phosphate. The composition is acidic which promotes high activity of the bone growth protein. The calcium and phosphate sources can be provided as an acidic calcium phosphate salt. Also disclosed are methods of the making the composition and methods of using it. | 07-07-2011 |
| 20110165200 | NOVEL HYDROGELS AND USES THEREOF - The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the solution that may be changed include pH, ionic strength, temperature, and concentration of one or more specific ions. In addition, hydrogels of the invention may be disassembled by changing one or more characteristic of the hydrogel such as pH, ionic strength, temperature, and concentration of one or more specific ions. | 07-07-2011 |
| 20110165201 | ANTICANCER FORMULATION - This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor. | 07-07-2011 |
| 20110165202 | SOLID STATE FORMS OF FOSAMPRENAVIR CALCIUM SALT AND PROCESSES FOR PREPARATION THEREOF - The present invention relates to solid state forms of fosamprenavir calcium salt, process for preparing said solid state forms, and pharmaceutical compositions thereof. | 07-07-2011 |
| 20110165203 | A TOPICAL COMPOSITION COMPRISING THE ISOLATED NON-POLAR LIPID FRACTION OF LANOLIN4 - A topical composition comprising the isolated non-polar lipid fraction of lanolin, and one or more additional compounds selected from ceramides, cholesterol and free fatty acids. | 07-07-2011 |
| 20110165204 | GASTRIC THERAPIES AND COMPOSITIONS THEREFOR - The invention relates to compositions and methods for the treatment of gastric and/or duodenal | 07-07-2011 |
| 20110171268 | URICASE COMPOSITIONS AND METHODS OF USE - Compositions containing uricase are disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase are also described. Compositions containing uricase and catalase are also disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase and catalase are also described. | 07-14-2011 |
| 20110171269 | METHOD FOR MANUFACTURING UNIFORM SIZE POLYMERIC NANOPARTICLES CONTAINING POORLY SOLUBLE DRUGS - The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, including a first step of dissolving a biodegradable polymer in a non-volatile polar organic solvent, a second step of adding poorly soluble drugs to water and the biodegradable polymer solution to produce a dispersion, and a third step of adding the dispersion to emulsifier solutions in a batch under the condition of low mechanical energy level stirring. The polymeric nanoparticles of the present invention is capable of manufacturing nano-sized small and uniform polymeric nanoparticles through a simple method of employing a non-volatile polar solvent, especially a solvent having a polarity similar to that of water, as a solvent for a mixture solution of biodegradable polymer and poorly soluble materials, and using a low mechanical energy condition and batch-adding of dispersion in an emulsifying process. The polymeric nanoparticles of the present invention are advantageous in that the dissolution rate of the poorly soluble drugs contained in polymeric particles is dramatically improved, and the poorly soluble drugs are gradually and steadily released and maintained at a constant density over a long period of time. | 07-14-2011 |
| 20110171270 | NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT - Provided herein is a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof. Provided also herein are novel amorphous and polymorphic forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof. | 07-14-2011 |
| 20110171271 | Citrate-Based Dialysate Chemical Formulations - The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream. | 07-14-2011 |
| 20110171272 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF PROSTATICALLY BENEFICIAL THERAPEUTIC AGENTS - According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders. | 07-14-2011 |
| 20110171273 | STABLE ANTI-NAUSEA ORAL SPRAY FORMULATIONS AND METHODS - Stable formulations of selective 5-hydroxytryptamine receptor antagonists for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration are provided. A preferred embodiment includes ondansetron in a concentration of about 5.1 to about 5.2% w/w; propylene glycol in a concentration of about 60.1 to about 60.3% w/w; water in a concentration of about 5.3 to about 5.4% w/w; and ethanol in a concentration of about 27.1 to about 27.3% w/w. Additional preferred embodiments are preservative free and/or non-aqueous or primarily non-aqueous. | 07-14-2011 |
| 20110171274 | Fesoterodine Substantially Free of Dehydroxy Impurity - Provided herein is an impurity of fesoterodine, fesoterodine dehydroxy impurity, 2-[(1R)-3-[bis(1-methylethy)amino]-1-phenylpropyl]-4-methylphenyl isobutyrate, and a process for preparing and isolating thereof. Provided further herein is a highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of fesoterodine dehydroxy impurity, process for the preparation thereof, and pharmaceutical compositions comprising highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of dehydroxy impurity. Provided also herein is a pharmaceutical composition comprising solid particles of pure fesoterodine fumarate substantially free of dehydroxy impurity, wherein 90 volume-percent of the particles (D90) have a size of less than about 200 microns. | 07-14-2011 |
| 20110171275 | GASTRORETENTIVE DRUG DELIVERY SYSTEM, PREPARATION METHOD AND USE THEREOF - A gastroretentive drug delivery system is provided. Said system comprises a hollow vesicle and a drug-containing layer which surrounds the hollow vesicle. Said hollow vesicle preferably has a single chamber structure. The size in maximal diameter direction of said hollow vesicle is preferably 0.5-3.5 cm. The gastroretentive drug delivery system preferably contains an isolating layer and/or waterproofing layer between the hollow vesicle and the layer containing drug. | 07-14-2011 |
| 20110171276 | Non-Viral Compositions and Methods for Transfecting Gut Cells In Vivo - The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided. | 07-14-2011 |
| 20110177130 | METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS - Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. | 07-21-2011 |
| 20110177131 | siRNA SILENCING OF FILOVIRUS GENE EXPRESSION - The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid. | 07-21-2011 |
| 20110177132 | Compositions and Methods for Generating Musculoskeletal Tissue - The present disclosure provides compositions comprising musculoskeletal cells and mesenchymal stem cells in discrete regions. The present disclosure provides systems comprising a subject composition; and methods of using a subject composition to generate cartilage, bone, tendon, muscle, intervertebral disc, or other musculoskeletal tissues. | 07-21-2011 |
| 20110177134 | Viable Tissue Repair Implants and Methods of Use - Biocompatible tissue implants are provided for repairing a tissue injury or defect. The tissue implants comprise a biological tissue slice that serves as a source of viable cells capable of tissue regeneration and/or repair. The biological tissue slice can be harvested from healthy tissue to have a geometry that is suitable for implantation at the site of the injury or defect. The harvested tissue slice is dimensioned to allow the viable cells contained within the tissue slice to migrate out and proliferate and integrate with tissue surrounding the injury or defect site. Methods for repairing a tissue injury or defect using the tissue implants are also provided. | 07-21-2011 |
| 20110177135 | METHODS OF TREATING CARTILAGE DEFECTS - The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein. | 07-21-2011 |
| 20110177136 | METHOD AND PRODUCT - The present invention provides a method of producing a co-crystal, the method comprising the steps of providing a first substance and a second substance, wherein the first and second substances are compatible to form a co-crystal, mixing said first and second substances together, and exposing the mixture of said first and second substances to prolonged and sustained conditions of pressure and shear, sufficient to form a co-crystal of said first and second substance. The prolonged and sustained conditions of pressure and shear are preferably applied in an extrusion process. Associated compositions and uses thereof are also provided. | 07-21-2011 |
| 20110177137 | NOVEL DOSAGE FORM OF PALIPERIDONE AND PROCESS FOR PREPARING THE SAME - The present invention relates to an extended release composition of paliperidone for oral administration comprising paliperidone and at least one matrixing agent. The said extended release composition maintains desired therapeutic drug effect over a prolonged period of time and thereby reduces the side effects resulting due to excess drug blood plasma concentration. Further, the invention also relates to process for the preparation of an extended release oral composition of paliperidone. | 07-21-2011 |
| 20110177138 | ALCOHOL-RESISTANT SUSTAINED-RELEASE ORAL PHARMACEUTICAL FORM BASED ON MICROGRANULES - Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer. | 07-21-2011 |
| 20110177139 | SOLID MICROSTRUCTURE THAT ENABLES MULTIPLE CONTROLLED RELEASE AND METHOD OF MAUFACTURING SAME - Provided are a method of manufacturing a solid microstructure capable of controlling multidrug release by mixing a biocompatible or biodegradable material with microparticles or nanoparticles and/or an emulsion as drug carriers and a solid microstructure structure manufactured using the same. | 07-21-2011 |
| 20110182946 | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques - The present invention provides a composition and method of forming an amorphous drug-loaded particle by forming one or more amorphous drug-loaded nanoparticles comprising one or more active agents stabilized by one or more polymers, desolvating the one or more amorphous drug-loaded nanoparticles to form one or more flocculated amorphous drug-loaded nanoparticles, filtering the one or more flocculated amorphous drug-loaded nanoparticles and drying the one or more flocculated amorphous drug-loaded nanoparticles to form amorphous drug-loaded particles. | 07-28-2011 |
| 20110182947 | HYDROGEL-DRIVEN DRUG DOSAGE FORM - A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed. | 07-28-2011 |
| 20110182948 | METHOD FOR TREATING DISEASE CHARACTERIZED BY PLAQUE - The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque. | 07-28-2011 |
| 20110182949 | STABILIZED TRANSDERMAL DRUG DELIVERY SYSTEM - A solid dispersion transdermal drug delivery system comprising a therapeutic agent in a stable amorphous form and a combination polymeric stabilizing and dispersing agent having a hydrogen bond-forming functional group, and a method of manufacturing these systems is provided. The weight ratio of the combination polymeric stabilizing and dispersing agent to the therapeutic agent is also disclosed. | 07-28-2011 |
| 20110182950 | COMBINATION OF BLOOD AND OF BIPHASIC CALCIUM PHOSPHATE CERAMIC PARTICLES - The invention relates to a biomaterial containing coagulated blood or coagulated bone marrow aspirate and biphasic calcium phosphate ceramic particles, to a production method thereof and to the use of same for the production of an implant that enables bone tissue regeneration. | 07-28-2011 |
| 20110182951 | Antimicrobial Coatings Comprising A Complex of An Ionic Fluoropolymer and An Antimicrobial Counter-Ion - The present invention relates to an article comprising a substrate and a coating thereon comprising a complex of an ionic fluoropolymer and a counter-ionic agent comprising ions having antimicrobial activity, to a process for the production of a coating on a polymeric substrate comprising the steps of a) preparing a mixture of an ionic fluoropolymer or a precursor thereof and a counter-ionic agent comprising ions having antimicrobial activity or a precursor thereof and b) applying the mixture prepared in step a) onto the substrate, to the use of such articles for the manufacture of i.a. a garment, a filter element, a venting element or a protective enclosure, and to the use of a coating composition comprising a complex of an ionic fluoropolymer and a counter-ionic agent comprising ions having antimicrobial activity as an antimicrobial coating of a substrate. | 07-28-2011 |
| 20110182952 | DRUG DELIVERY FROM EMBOLIC AGENTS - A pharmaceutical composition for embolization of blood vessels, especially for benign tumours, comprises a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic agent. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer Is a crosslinked polyvinyl alcohol polymer formed by the copolymerization of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of tumours such as uterine fibrioids, leading to size regression as well as pain relief. | 07-28-2011 |
| 20110182954 | ORALLY-ADMINISTERED AGENT - An orally-administered agent is provided. The orally-administered agent comprises an intestinal medicine-containing layer containing a medicine to be released in intestines and having surfaces; intestinal collapse-controlling layers provided directly or through an arbitrary layer on the surfaces of the intestinal medicine-containing layer, respectively, at least a part of the intestinal collapse-controlling layers being collapsed in the intestines, and each of the intestinal collapse-controlling layers having a surface opposite to the intestinal medicine-containing layer; and gel-forming layers provided directly or through an arbitrary layer on the sides of the surfaces of the intestinal collapse-controlling layers, respectively, wherein the gel-forming layers are swelled and gelatinized by absorbing water to form a gel. The intestinal collapse-controlling layers are constituted of a material containing an enteric material to be dissolved by being in contact with a body fluid in the intestines. The orally-administered agent according to the present invention can be swallowed with ease and can release a medicine at intended parts of a living body (in particular, within intestines). | 07-28-2011 |
| 20110189239 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same - Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications. | 08-04-2011 |
| 20110189240 | MICROENCAPSULATED COMPOSITIONS FOR ENDOLUMINAL TISSUE ENGINEERING - A tissue engineering composition adapted for application to an interior surface of a body lumen of a patient. The composition comprises (a) a carrier medium that is adapted to flow and to stably adhere the composition to the body lumen and (b) microcapsules, which are dispersed within the carrier medium and which contain one or more living cells encapsulated within a coating that includes a biodegradable polymer. The composition promotes growth of the cells on the lumen surface subsequent to application of the composition to the lumen. | 08-04-2011 |
| 20110189241 | Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative - The invention relates to a process for tightly controlling the particle size of cinacalcet hydrochloride, i.e. a process for preparing large or small crystals of cinacalcet hydrochloride, which yields cinacalcet hydrochloride in a narrow, reproducible and consistent distribution of particles, which hence does not require to reprocess, rework or destroy material of undesired size, which is efficient and cost-effective, and which is suitable for industrial implementation. | 08-04-2011 |
| 20110189242 | ORAL GALENIC FORM, POLYMER PRODUCTION METHOD AND USE OF SAME - The polymers, according to the invention, comprise a polysaccharide block ( | 08-04-2011 |
| 20110189243 | PHARMACEUTICAL FORMULATION FOR LOWERING PULMONARY BLOOD PRESSURE - The invention relates to pharmaceutical formulations for reducing pulmonary blood pressure containing micronised ambrisentan, preferably in the form of an intermediate together with a hydrophilising agent. The invention also relates to methods of preparing pharmaceutical formulations containing micronised ambrisentan. | 08-04-2011 |
| 20110189244 | APPETISING MEDICAMENT FOR ORAL ADMINISTRATION IN SOLID FORM - The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder. | 08-04-2011 |
| 20110189245 | Smooth, High Solids Tablet Coating Composition - The invention describes a coating composition comprising an effective amount of a water-soluble cellulose ether, a poly(N-vinyl pyrrolidone-co-vinyl acetate) copolymer, a film-forming agent based on D-glucose, and a plasticizer. | 08-04-2011 |
| 20110195095 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine. | 08-11-2011 |
| 20110195096 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided. | 08-11-2011 |
| 20110195097 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE - A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent. | 08-11-2011 |
| 20110200642 | Compositions and Methods to Promote Implantation and Engrafment of Stem Cells - Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells. | 08-18-2011 |
| 20110200643 | EMULSIONS FOR PRODUCING MEDICINAL PRODUCTS - The invention relates to the preparation of stable, polymer-based emulsions which have an ionic strength of more than 10 mM in their aqueous phase, and to processes for preparing them and medicaments that can be obtained using these emulsions. | 08-18-2011 |
| 20110200644 | DHA Ester Emulsions - The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid ethyl ester (DHA-EE) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration. | 08-18-2011 |
| 20110200645 | DHA Free Fatty Acid Emulsions - The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid free fatty acid (DHA-FFA) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration. | 08-18-2011 |
| 20110200646 | The TRPVL Antagonists SB-795498 For Treating Rhinitis - The present invention relates to the use of urea compound in the treatment of rhinitis, to aqueous pharmaceutical compositions containing said compound, in particular to compositions suitable for intranasal administration. | 08-18-2011 |
| 20110200647 | PULMONARY DISEASE TREATMENT - The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of the inhaled particles have sizes equal to or less than 6.5 μm. | 08-18-2011 |
| 20110206737 | PHOTOSENSITIZER-CONTAINING COMPOSITION - Techniques related to a photosensitizer-containing composition, the preparation method and the applications thereof, are generally described. One example photosensitizer-containing composition may include a carrier; and a photosensitizer attached to the surface of the carrier, wherein the carrier includes a first material having a first refractive index and a second material having a second refractive index, and the first refractive index is greater than the second refractive index. | 08-25-2011 |
| 20110206738 | FELINE STIMULANT AND METHOD OF MANUFACTURE - According to various embodiments of the invention, stimulants are provided that result in euphoric behavior in certain animals, such as felines. Specifically, according to one embodiment, the animal stimulant is obtained by a process comprising: growing an | 08-25-2011 |
| 20110206739 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF NANOEMULSIONS - The disclosure relates to compositions and methods of forming nanoemulsions, e.g., containing an active component, in combination with lipophilic components such as oils, hydrophilic components such as water, and one or more surfactants capable of causing a temperature-dependent phase inversion, such as a nonionic polyethoxylated surfactant. Nanoemulsions containing the active component can be produced having average oil droplet sizes of less than 100 nm, 50 nm, or 25 nm without the need for high energy emulsion forming methods (such as microfluidization) by combining the surfactant and the oil in specified weight ratios (e.g., at least 3:1) prior to forming the nanoemulsion. | 08-25-2011 |
| 20110206740 | Cell Membrane Engineering - The present invention is directed to methods and compositions for engineering the surface of a cell, wherein a targeting moiety and/or a particle are attached to the cell membrane. The particle can further comprise a therapeutic agent for drug delivery. The compositions disclosed herein are useful in the treatment of diseased or damaged tissue by targeting cells for the purpose of tissue regeneration, drug delivery or a combination of both. | 08-25-2011 |
| 20110206741 | DHA Triglyceride Emulsions - The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid triglyceride (DHA-TG) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration. | 08-25-2011 |
| 20110206742 | IMMUNOTHERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes Aβ1-42 or an beta amyloid self epitope (e.g. Aβ1-15, or other 7-mer or 15-mer peptide epitopes derived from Aβ1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system. | 08-25-2011 |
| 20110206743 | NUTRITIONAL COMPOSITIONS WITH LIPID GLOBULES WITH A CORE COMPRISING VEGETABLE LIPIDS AND A COATING COMPRISING PHOSPHOLIPIDS OR POLAR LIPIDS - The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to prevent obesity and/or improve body composition later in life. Said lipid component comprises 10-50 wt % vegetable lipids, and the lipid globules have a volume-weighted diameter above 1.0 m and/or a diameter of 2-12 m in an amount of at least 45 vol %. | 08-25-2011 |
| 20110206744 | MODAFINIL FORMULATIONS - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 08-25-2011 |
| 20110206745 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 08-25-2011 |
| 20110212136 | Nanosphere/Microsphere Delivery System for the Treatment of Spinal Cord Injury - A formulation including injectable biodegradable nanospheres and/or microspheres as a delivery system for chondroitinase ABC (cABC) or a functional derivative of cABC to treat acute and chronic spinal chord injury in a mammal having the same is provided. The biodegradable nanosphere/microsphere formulation releases cABC or a functional derivative of cABC in a time-released manner at the site of the spinal cord injury. cABC infusion can promote axon regrowth and some behavioral recovery. The nanospheres and/or microspheres provided herein include cABC or a functional derivative of cABC loaded within and/or on a biodegradable polymer matrix. In some embodiments of the present invention, the surface of the biodegradable polymer matrix can be modified to target a specific scar site. In addition to providing a nanosphere formulation that include polymeric incorporated cABC, a method of treating a mammal having a spinal cord injury is also provided. | 09-01-2011 |
| 20110212137 | INHALABLE PHARMACEUTICAL COMPOSITION - An inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.5-2.0 μm, for maintaining lung function above 60% of baseline FEV | 09-01-2011 |
| 20110212138 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 09-01-2011 |
| 20110212139 | HIGH-DENSITY LIPOPROTEIN COATED MEDICAL DEVICES - Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque. | 09-01-2011 |
| 20110212140 | PRESSURE-SENSITIVE ADHESIVE COMPOSITION APPLICABLE TO NAIL AND ADHESIVE AGENT FOR NAIL - The present invention aims at providing a pressure-sensitive adhesive composition applicable to nail, which shows superior adhesive performance (adhesive force, cohesion etc.), and superior drug releasability and drug stability, and an adhesive agent for nail, which uses this composition. The composition of the present invention contains a condensation polymer of a silicone resin and a silicone rubber. The composition of the present invention preferably contains not less than two kinds of condensation polymers having different resin/rubber ratios. The adhesive agent of the present invention has a support and an adhesive layer formed on one surface of the support, which contains the above-mentioned composition. | 09-01-2011 |
| 20110212141 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 09-01-2011 |
| 20110212142 | CURCUMINOIDS AND ITS METABOLITES FOR THE APPLICATION IN OCULAR DISEASES - Aqueous ophthalmic compositions comprising natural or synthetic curcuminoids either alone or in combination, nonionic surfactant and co-solvent along with suitable ophthalmic excipients, effective in increasing the bioavailability of the active compounds when administered topically to the eye is disclosed herein. | 09-01-2011 |
| 20110217335 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS - Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90. | 09-08-2011 |
| 20110217336 | CHRONOTHERAPEUTIC DOSAGE FORMS AND METHODS OF TREATMENT USING CHRONOTHERAPY - A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. | 09-08-2011 |
| 20110217337 | BIOACTIVE AGENT FOR BONE TISSUE ENGINEERING - Inventors have discovered a method for inducing bone formation in a patient in need thereof comprising administering an effective amount of benzoyladenosine-3′,5′-cyclic monophosphate (6-Bnz-cAMP) to the patient. Systems for bone tissue engineering, comprising a polymer-based scaffold, such as a PLAGA scaffold and an effective amount of 6-Bnz-cAMP are also disclosed herein. | 09-08-2011 |
| 20110217338 | HIV-1 Envelope Based Fragments - The present application relates to a novel HIV-1 envelope fragments containing the B12 epitope which may be utilized as an HIV-1 vaccine immunogen, in particular for eliciting broad neutralizing antibodies following a prime-boost immunization. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 09-08-2011 |
| 20110217339 | MUCOACTIVE AGENTS FOR TREATING A PULMONARY DISEASE - The present invention relates to pharmaceutical compositions which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. | 09-08-2011 |
| 20110217340 | NANODISPERSE COMPOSITIONS - A process for the production of a soluble composition comprising a water-insoluble active which comprises either the steps of: a) providing a liquid mixture comprising: i) a dissolved water-insoluble active, ii) a dissolved water-soluble carrier, iii) a solvent for each of the active and the carrier, and b) spray-granulating the mixture to remove the, or each, solvent and obtain a substantially solvent-free nano-dispersion of the water-insoluble active in the carrier said water-insoluble active being in nano-particles having a size range of 999-20 nm; or, the steps of: a) providing a substantially solvent-free powder comprising a water-insoluble active dispersed in a water soluble carrier, said water-insoluble active being in nano-particles having a size range of 999-20 nm, and, b) spray-granulating the powder to obtain larger and denser particles. The invention also relates to solvent-free, granular products with a particle size in the range 20 microns to 10 mm and a bulk-density of greater than 0.4 g/cm3 comprising a water-soluble carrier material, the carrier material having dispersed therein a water-insoluble active, wherein on addition of water the carrier dissolves to form an aqueous dispersion of the active with a peak (z-average) particle size of below 800 nm, preferably below 500 nm and more preferably below 200 nm. The invention also relates to an analogous “reverse” process in which the active is water soluble and the carrier is oil soluble. | 09-08-2011 |
| 20110217341 | METHOD FOR PREPARING MICROSPHERES AND MICROSPHERES PRODUCED THEREBY - The present invention relates to a method for preparing microspheres and microspheres prepared thereby, more particularly to a method for preparing a polymeric microsphere, including preparing an emulsion including a polymer compound, a drug, a water-insoluble organic solvent and a dispersion solvent and adding to the prepared emulsion a base or an acid to remove the water-insoluble organic solvent from the emulsion, a polymeric microsphere prepared thereby, and a composition for drug delivery including the microsphere. According to the present invention, a drug-containing polymer microsphere may be prepared quickly and simply without the solvent evaporation or solvent extraction process, thereby reducing water consumption and minimizing wastewater generation. | 09-08-2011 |
| 20110217342 | FLASHMELT ORAL DOSAGE FORMULATION - There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds. | 09-08-2011 |
| 20110217343 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS - The present invention provides a water soluble, non-peptidic polymer comprising two or more alkylene oxide-based oligomers linked together by hydrolytically degradable linkages such as carbonates. Typically, the oligomer portion of the polymer is an amphiphilic triblock copolymer having a central propylene oxide block or butylene oxide block positioned between two ethylene oxide blocks. The polymer can be hydrolytically degraded into oligomers under physiological conditions. In aqueous media, the polymer preferably forms thermally reversible, hydrolytically degradable hydrogels that can be used, for example, for drug delivery and related biomedical applications. | 09-08-2011 |
| 20110223201 | Immunonanotherapeutics Providing a Th1-Biased Response - Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable. | 09-15-2011 |
| 20110223202 | CATIONIC CORE-SHELL PEPTIDE NONOPARTICLES - The invention discloses an amphiphilic antimicrobial substance comprising a hydrophobic portion coupled to a cationic oligopeptide portion. The cationic oligopeptide portion may comprise a protein transduction domain coupled to a cationic oligopeptide group. | 09-15-2011 |
| 20110223203 | NANOCLUSTER COMPOSITIONS AND METHODS - Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm. | 09-15-2011 |
| 20110223204 | TREATMENT OF PAIN WITH GAP JUNCTION MODULATION COMPOUNDS - The present invention relates to delivery, including transdermal delivery, of a therapeutically effective amount of a compound useful for modulating gap junction formation and function, including an oligonucleotide for reducing gap junction formation and function, and methods and compositions for treating a subject suffering from pain associated with a disease, disorder or condition and associated with pain, including but not limited to muscle pain, ligament pain, tendon pain, joint pain and post-operative pain. | 09-15-2011 |
| 20110223205 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING UMBILICAL DERIVED CELLS - This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient. | 09-15-2011 |
| 20110223206 | MICELLE COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a micelle composition comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymeric unit X and the hydrophilic block B comprises at least one hydrophilic polymeric unit Y whereby the X and Y blocks alternate. | 09-15-2011 |
| 20110223207 | Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided. | 09-15-2011 |
| 20110223208 | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations - The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations and methods of making and using them. | 09-15-2011 |
| 20110223209 | Oxygen delivering scaffold for tissue engineering - The invention relates to compositions, implantable devices and methods related to tissue engineering. Provided is a composition comprising (i) at least one biocompatible polymer suitable for use in tissue-engineering scaffolds and (ii) at least one metal peroxide. Also provided is an implantable device comprising said composition, and methods for tissue engineering comprising the use of the device. | 09-15-2011 |
| 20110223210 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 09-15-2011 |
| 20110223211 | PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN - The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition. | 09-15-2011 |
| 20110223212 | DRUG ELUTING SUPERHYDROPHOBIC COATINGS - The invention describes nanotextured super hydrophobic coatings that contain active agents which can elute from the coating over a period of time. | 09-15-2011 |
| 20110223213 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein is an impurity of ranolazine, 1-[4-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperazin-1-yl]-3-(2-methoxy-phenoxy)-propan-2-ol (dimer impurity-3), and process for preparing and isolating thereof. Provided further herein is a highly pure ranolazine or a pharmaceutically acceptable salt thereof substantially free of dimer impurity-3, process for the preparation, and pharmaceutical compositions comprising highly pure ranolazine or a pharmaceutically acceptable salt thereof substantially free of dimer impurity-3. | 09-15-2011 |
| 20110223214 | USE OF CARBOXYMETHYLCELLULOSE TO CONTROL EJECTABILITY AND SOLIDIFICATION TIME OF COMPOSITIONS COMPRISING ONE OR MORE BIORESORBABLE CERAMICS - Carboxymethylcellulose, notably sodium carboxymethylcellulose or other alkali metal or alkaline earth metal salts of carboxymethylcellulose, are employed to control solidification time of compositions comprising one or more bioresorbable ceramics, notably a hydratable calcium sulphate, in order to facilitate preparation of a ready-to-use composition for inserting into the body by injection. | 09-15-2011 |
| 20110223215 | PROCESS FOR MAKING A TOPICAL SCRUB - A method of producing a topical scrub includes providing a particle material suitable for producing a customized anisotropic particle; producing a plurality of customized anisotropic particles composed of the particle material, each customized anisotropic particle having a particle shape, a particle volume, and a particle composition; and dispersing the plurality of customized anisotropic particles in a fluid material to form a dispersion of customized anisotropic particles in the fluid material. At least a feature of the particle shape facilitates embedding at least a portion of the plurality of customized anisotropic particles into a topical surface by a scrubbing action. | 09-15-2011 |
| 20110223216 | Nanoparticles and Porous Particles and Methods of Making the Same - The subject matter disclosed herein relates to compositions and methods for engineering porous particles for aerosol formulations for pulmonary drug delivery. Certain embodiments disclosed herein further relate to methods for stabilizing suspension-based formulations in hydrofluoroalkane propellants with nanoparticles. | 09-15-2011 |
| 20110223217 | BLOCK COPOLYMERS AND USES THEREOF - An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is encoded or decoded based on the generated parity-check matrix. | 09-15-2011 |
| 20110229527 | DIRECTLY COMPRESSIBLE HIGH FUNCTIONALITY GRANULAR DIBASIC CALCIUM PHOSPHATE BASED CO-PROCESSED EXCIPIENT - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular dibasic calcium phosphate based excipient is provided. The improved excipient comprises dibasic calcium phosphate, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The improved excipient provides enhanced flowability/good flow properties, an increased API loading and blendability and higher compactibility as compared to the individual components, and as compared to excipients formed from the same materials by conventional methods. | 09-22-2011 |
| 20110229528 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 09-22-2011 |
| 20110229529 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE - The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents. | 09-22-2011 |
| 20110229530 | PHARMACEUTICAL DOSAGE FORMS FOR TIME-SPECIFIC DRUG DELIVERY - The present invention refers to an oral dosage form intended for the time-controlled release of drugs comprising a container for one or more active ingredients optionally in admixture with pharmaceutically acceptable excipients, said container consisting of at least two parts or elements that can be joined together so as to seal the contents, at least one of said elements being composed of one or more hydrophilic polymers that undergo a decrease in the glassy-rubbery transition temperature when in contact with aqueous fluids, except for polymers with pH dependent solubility soluble only at pH values above 5, optionally in admixture with pharmaceutically acceptable excipients, the wall of the elements of the container being of such thickness as to delay the release of the contained drug with respect to the time of administration. | 09-22-2011 |
| 20110229531 | ANTI-PROTOZOA COMPOUNDS - Use of a compound in the control of growth of at least one organism of the order of Amoebida, wherein said compound is capable of modulating the histidine biosynthesis pathway, and/or the methionine biosynthesis pathway and/or a pathway branching from the histidine biosynthesis pathway and/or methionine biosynthesis pathway in said organism. | 09-22-2011 |
| 20110229532 | PROCESS FOR NANOEMULSIFICATION OF CURCUMIN AND DERIVATIVES OF CURCUMIN - A process for nanomulsification of highly lipophillic polyphenols compounds using non-ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein. | 09-22-2011 |
| 20110229533 | EXTENDED RELEASE DOSAGE FORM - A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed. | 09-22-2011 |
| 20110236430 | METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY - The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets. | 09-29-2011 |
| 20110236431 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION (AMI) USING ENCAPSULATED CELLS ENCODING AND SECRETING GLP-1 PEPTIDES OR ANALOGS THEREOF - The present application refers to the use of cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, for the treatment of acute myocardial infarction (AMI or Ml), wherein the cells, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, are encapsulated in a (spherical) microcapsule to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or of a pharmaceutical composition containing these cells or (spherical) microcapsule(s) for the treatment of acute myocardial infarction (AMI or Ml). | 09-29-2011 |
| 20110236432 | Coated Medical Device and Method of Coating a Medical Device to Reduce Fibrosis and Capsule Formation - Coating for a medical device comprising cell-adhesive proteins having the ability to reduce fibrous reaction, said coating being in the form of separate islets having an individual area which is less than 12 μm | 09-29-2011 |
| 20110236433 | WOUND CARE DEVICE - An absorbent wound care device includes two or more materials which individually do not gel when exposed to a fluid but do gel when brought together and exposed to a fluid. The device is particularly intended for haemostatic use and for absorbing bodily fluids being emitted from wounds and physiological target sites. | 09-29-2011 |
| 20110236434 | Polymorphic Forms of ST-246 and Methods of Preparation - Polymorph forms of 4-trifluoromethyl-N-(3,3 | 09-29-2011 |
| 20110236435 | ENHANCED BONE CELLS GROWTH AND PROLIFERATION ON TiO2 NANOTUBULAR SUBSTRATES TREATED BY RADIO-FREQUENCY PLASMA DISCHARGE - A method for growing bone cells. In one aspect, the present invention provides a method for growing bone cells, comprising the steps of (a) anodizing a titanium substrate to form an array of titanium dioxide nanotubes on a surface of the titanium substrate, (b) subjecting the anodized titanium substrate to a radio frequency plasma discharge to chemically modify the array of titanium dioxide nanotubes formed on the surface of the titanium substrate, (c) seeding bone cells onto the surface of the titanium substrate that has an array of titanium dioxide nanotubes thereon after the subjecting step, and (d) incubating the seeded bone cells for a period of time effective for the cells to grow and proliferate. | 09-29-2011 |
| 20110236436 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed. | 09-29-2011 |
| 20110236437 | NANOPARTICLES AND METHODS OF USE - Provided herein are nanoparticles and methods for using nanoparticles. The nanoparticles include at least three antiretroviral agents. When introduced to cells the nanoparticles cause an increase in the intracellular concentration of the antiretroviral agents to a level that is at least the IC50 against HIV-I or HIV-2. This concentration may be maintained for at least 21 days after the cells are contacted with the nanoparticle. When administered to a subject the nanoparticles cause the concentration of the antiretroviral agents to increase to at least 100 ng/ml in the serum of the subject, at least 0.5 μg/gram tissue in an organ of the subject, or a combination thereof. Such a concentration may be maintained for at least 21 days after the administration. | 09-29-2011 |
| 20110236438 | METHOD OF TREATMENT OF DISEASES USING HOODIA EXTRACTS - A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus | 09-29-2011 |
| 20110236439 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 09-29-2011 |
| 20110236440 | MEDICAL TAPE PREPARATION - A medical tape preparation which comprises a support and, superposed on one side thereof in the following order, a pressure-sensitive adhesive layer and a release liner. The pressure-sensitive adhesive layer can contain a large amount of an oleophilic oily matter. The tape preparation is excellent in adhesion, cohesiveness, and stability even when no crosslinking agent is used. The pressure-sensitive adhesive layer in the medical tape preparation comprises a blend of two tacky polymers, which are a tacky polymer (A) comprising a copolymer obtained from 2-acetoacetoxyethyl methacrylate and other vinyl monomer(s) as constituent ingredients and a tacky polymer (B) comprising a copolymer which is obtained from a C | 09-29-2011 |
| 20110236441 | ANTIMICROBIAL SUBSTRATES AND USES THEREOF - A new substrate makes it possible to modify surface properties relating to antimicrobial properties. Said substrate has an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal chosen from gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm | 09-29-2011 |
| 20110243996 | Spray freeze dry of compositions for intranasal administration - This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration. | 10-06-2011 |
| 20110243997 | FILM-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble and a polar organic solvent-soluble edible polymer; and polar organic solvent-insoluble drug particles. | 10-06-2011 |
| 20110243998 | PATCH PREPARATION AND PRODUCTION METHOD THEREOF - The invention provides a patch preparation containing (a) a support and (b) an adhesive layer containing a drug on the surface of the support, wherein a crystal of the drug is formed in the adhesive layer immediately after application of a physical stimulation to the adhesive layer, while a crystal of the drug is formed during preservation after the physical stimulation. The patch preparation which does not require an increase in the area and thickness of an adhesive layer, achieves a sufficiently high skin permeation amount of the drug, shows good adhesiveness to skin, and permits a long-term adhesion to skin. The invention also provides a method of producing the patch preparation. | 10-06-2011 |
| 20110243999 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS - The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma. | 10-06-2011 |
| 20110244000 | ANTIMICROBIAL FILM LAMINATE ASSEMBLIES AND METHODS OF USING AND MANUFACTURING THE SAME - An antimicrobial film laminate assembly is disclosed. The assembly includes an antimicrobial film laminate having a first surface at least partially coated with an adhesive and an opposing second surface, the antimicrobial film laminate includes at least one antimicrobial compound, and a unitary backing positioned upon the first surface of the antimicrobial film laminate. | 10-06-2011 |
| 20110244001 | System and method for the release of nitric oxide using nanoscale media - A composite material containing polymeric nanofibers, themselves containing NO-donor molecules, imbibed with an elastomer matrix is permeable to both water and gas so that dissociation reactions in the presence of water releases NO gas in a sustained manner. The NO-donor nanofibers may be formed by synthesizing acceptable NO-donor molecules, blending such molecules in solution with PVP, PCL or PVAc, electrospinning the blend at relatively high voltage for form fiber mats, applying PDMS rubber to the fiber mat and crosslinking it. The resulting NO-releasing electrospun fiber composite may be used in medical devices such as catheters, stents, or vascular grafts, with the purpose of releasing nitric oxide within a controlled rate and for a sustained period of time, as well as other known medical applications for NO. | 10-06-2011 |
| 20110244002 | MESOPOROUS MATERIAL EXCIPIENTS FOR POORLY AQUEOUS SOLUBLE INGREDIENTS - The present invention encompasses formulations and methods for producing solid dispersions comprising mesoporous materials with poorly aqueous soluble active ingredients. The active ingredient is formed in the amorphous state and entrapped in the nanosized pores of the mesoporous excipients using a co-spray drying process. The pore walls of mesoporous channels stabilize the amorphous form of active ingredient against re-crystallization. The amorphous active ingredient entrapped in mesoporous channels exhibits good stability during extended storage under stress test conditions and possesses significantly enhanced dissolution rates. | 10-06-2011 |
| 20110244003 | Self Standing Nanoparticle Networks/Scaffolds with Controllable Void Dimensions - The present invention discloses a self standing network or scaffold of nanoparticles with controllably variable mesh size between 500 nm and 1 mm having particle volume fraction between 0.5 to 50%. The network comprises nanoparticles, a surfactant capable of forming ordered structured phases and a cross linking agent, wherein the surfactant is washed off leaving the self standing scaffold. The invention further discloses the process for preparing the self standing scaffolds and uses thereof. | 10-06-2011 |
| 20110244004 | ANTIFUNGAL COMPOSITION WITH ENHANCED BIOAVAILABILITY - A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: | 10-06-2011 |
| 20110244005 | CONTROLLED RELEASE CGRP DELIVERY COMPOSITION FOR CARDIOVASCULAR AND RENAL INDICATIONS - The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies. | 10-06-2011 |
| 20110250236 | STEM CELLS DERIVED FROM THE CAROTID BODY AND USES THEREOF - Adult stem cells obtained from the carotid body, characterized in that they are positive for the phenotypic marker GFAP (glial fibrillary acidic protein) and negative for the phenotypic markers TH (tyrosine hydroxylase) and nestin, are described. These stem cells can undergo proliferation, self-renewal and differentiation to progenitor cells and differentiated cells. Said stem cells, progenitor cells and differentiated cells, expanded by any method, can be used in the treatment of neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease. | 10-13-2011 |
| 20110250237 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS - The present application pertains to a composition, comprising (a) amphipathic peptides; (b) lipids and (c) at least one immunogenic species. Respective compositions are suitable for immunogenic species transport and delivery, for example for systemic or local delivery to a mammal. Also provided are pharmaceutical compositions, comprising respective compositions. Methods of forming the foregoing are also provided. | 10-13-2011 |
| 20110250238 | SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT - Said invention refers to a pharmaceutical form for selective colon delivery of drugs or bioactive molecules degraded and/or poorly absorbed in the gastrointestinal tract. The system comprises a core consisting of the active ingredient, and a protease inhibitor layer and/or an absorption enhancer layer, said core being separated from these layers by means of a polymer that swells and/or dissolves and/or is degraded when in contact with the biological fluids present in the gastro-intestinal tract; depending on the thickness of the polymeric layer, the release of the drug can be modulated with respect to the inhibitor and/or promoter. | 10-13-2011 |
| 20110250239 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION FOR TREATING THE SKIN - The present invention concerns the pharmaceutical and cosmetic application of biocolloids, which originate from the mixture of a nanoemulsion and at least one water-soluble plant extract such as an extract from | 10-13-2011 |
| 20110250240 | IMMUNE ENHANCING COMPOSITIONS AND METHODS OF USE THEREOF - A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range. | 10-13-2011 |
| 20110250241 | INJECTION-MOULDED WATER-SOLUBLE CONTAINER - A rigid, water-soluble container is made of an injection molded poly(vinyl alcohol) and/or a cellulose ether, which container encases a fabric care, surface care or dishwashing composition; and a capsule container comprising at least two components made of one or more material(s) that can be molded and which are water soluble or water dispersible or in which a substantial part of the surface of these components is water soluble or water dispersible so as to leave perforations throughout the wall when the capsular container is placed in contact with an aqueous environment. The container has one to six compartments, preferably one, two or three, the content of the various compartments being accessible to the aqueous environment when the capsular container is exposed to such an aqueous environment. The accessibility time of the various compartments is the same or different from one compartment to another compartment, with the proviso that the content of the container is not a fabric care, surface care or dishwashing composition. | 10-13-2011 |
| 20110250243 | NANOPARTICLE COMPOSITIONS - Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described. | 10-13-2011 |
| 20110250244 | MELT-COATED PHARMACEUTICAL COMPOSITION WITH FAST RELEASE - The present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process. The process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release. | 10-13-2011 |
| 20110250245 | USE OF STINGING CELLS/CAPSULES FOR THE DELIVERY OF ACTIVE AGENTS TO KERATINOUS SUBSTANCES - A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed. | 10-13-2011 |
| 20110256182 | GENES ENCODING MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMA VIRUS - The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule. | 10-20-2011 |
| 20110256183 | Hydrogels with network defects enhanced by nanoparticle incorporation - Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability. | 10-20-2011 |
| 20110256184 | Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release - A non-ordered geometric mesoporous structure that provides for enhanced loading of antibodies such as IgG as compared to ordered mesoporous structures. This structure is formed by treating silica precursors at a hydrothermal aging temperature between 100 and 200 degrees C. This creates the non-ordered mesoporous structure. Biomolecules such as IgG can then be spontaneously loaded via non-covalent bonding within the as-made or functionalized mesoporous structure. | 10-20-2011 |
| 20110256185 | REINFORCED TISSUE SHIELDS - Self-reinforced tissue shields are useful as ophthalmic shields, wound dressings, wound barriers, nerve repair, therapeutic drug delivery devices and the like. The self-reinforced tissue protective shields comprise gelatin, chitosan and reinforce and are made by a method comprising forming inter-molecular locking within a solution through electrostatic forces, eliminating the use of extra cross-linking methods, the solution mainly comprising natural existing polymers that are biodegradable and biocompatible. | 10-20-2011 |
| 20110256186 | BIOMATERIAL BASED ON WHARTON'S JELLY FROM THE HUMAN UMBILICAL CORD - The present invention relates to a biomaterial, specifically a hydrogel, formed from the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans isolated exclusively from the Wharton's jelly of the umbilical cord which can optionally contain cells, and also to the methods for the production and use thereof. | 10-20-2011 |
| 20110256187 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS - The present invention relates to coating compositions for modulating biofilm growth on a surface, the composition comprising the reaction product of:
| 10-20-2011 |
| 20110256188 | DRY POWDER PHARMACEUTICAL COMPOSITION FOR INHALATION - There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): | 10-20-2011 |
| 20110256189 | COATING MATERIAL FOR SOLID MEDICINE AND SOLID MEDICINE FORMED WITH SAME - A coating material for a solid formulation is capable of stably retaining the effective ingredient in the solid formulation for a prolonged period even in unpacked condition in such a manner that the solid formulation can be used in a single-dose formulation. The coating material for a solid formulation includes a high hydrogen-bonding resin and a swelling clay and, when coated on a solid formulation and dried, forms a coating film in which the laminated structures of the aforementioned swelling clay are oriented planarly and dispersed in a network fashion. | 10-20-2011 |
| 20110256190 | Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents. | 10-20-2011 |
| 20110262486 | Bone implant and manufacturing method thereof - The invention discloses a bone implant and a manufacturing method thereof. The manufacturing method of the bone implant comprises a step of coating or mixing type II collagen with at least one porous bone material comprising metals, bio-ceramics, natural biopolymers and synthetic polymers. Another manufacturing method of the bone implant comprises the steps of loading type II collagen with or without at least one porous bone material in a container, and lyophilizing the type II collagen to generate a type II collagen sponge construct with or without the porous bone material as the bone material. The manufactured bone implants are effective, with or without loading cells having differentiation tendency towards osteogenesis, to facilitate bone repair upon introduction of the bone implant into various osseous defects. | 10-27-2011 |
| 20110262487 | De Novo Anembryonic Trophoblast Vesicles and Methods of Making and Using Them - De novo, anembryonic trophoblast vesicles and methods of making and using them are provided. | 10-27-2011 |
| 20110262488 | Novel HIV-1 Envelope Glycoprotein - The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 10-27-2011 |
| 20110262489 | HYALURONIC ACID CRYOGEL - COMPOSITIONS, USES, PROCESSES FOR MANUFACTURING - There is provided a process for preparing a HA cryogel, the process comprising the steps of combining HA, a cross-linking agent and a solvent to form a solution, freezing the solution before the formation of less than 10% of the cross-linking bonds of the cross-linked HA cryogel formed and thawing the solution. An HA cryogel is also provided, in particular an HA cryogel obtained from this process. | 10-27-2011 |
| 20110262490 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 10-27-2011 |
| 20110262491 | EMULSIONS AND METHODS OF MAKING NANOCARRIERS - This invention relates, in part, to methods of using emulsions for making synthetic nanocarriers and the synthetic nanocarriers formed by such methods. | 10-27-2011 |
| 20110262492 | CATALYST AND BYPRODUCT-FREE NATIVE CHEMICAL LIGATION USING CYCLIC THIOESTER PRECURSORS - A method of synthesizing a biocompatible hydrogel by covalently cross-linking an effective amount of a first macromonomer including a cyclic thioester group with an effective amount of a second macromonomer including a terminal cysteine group is disclosed. In addition, the synthesis and use of the following specific cyclic thioester macromonomer that can be used in the method, as well as specific hydrogels made using this macromonomer are disclosed. The disclosed method produces a biocompatible hydrogel, while producing substantially no toxic free thiol by-product. Accordingly, the method can be used in making biomedical products, such as sutures and tissue replacement biomaterials, and for encapsulating therapeutic cells and pharmaceuticals. | 10-27-2011 |
| 20110262493 | MULTI-LAYERED HYDROGEL CONSTRUCTS AND ASSOCIATED METHODS - Multi-layered hydrogel constructs comprising: a first layer comprising a first polymerizable material, hyaluronic acid and a plurality of cells; a second layer comprising a second polymerizable material, chondroitin sulfate and a plurality of cells; and a third layer comprising a third polymerizable material, chondroitin sulfate, a matrix metalloprotease sensitive peptide, and a plurality of cells are provided. Associated methods are also provided. | 10-27-2011 |
| 20110262494 | LOW-OIL PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN - Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising:
| 10-27-2011 |
| 20110262495 | PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN - Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising:
| 10-27-2011 |
| 20110262496 | THERAPEUTIC FORMULATION FOR REDUCED DRUG SIDE EFFECTS - The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic. | 10-27-2011 |
| 20110262497 | NOVEL EZETIMIBE FORMULATIONS - Formulations of ezetimibe are described, wherein attention is paid, alternatively or optionally in combination, to (i) the existence of ezetimibe in the form of primary particles, which when blended with a suitable hydrophilic excipient in particulate form are allowed adsorb on the surface of particles of the hydrophilic excipient; (ii) a selection of specific types of excipients; and/or (iii) a careful control of how the formulation of ezetimibe is obtained. | 10-27-2011 |
| 20110262498 | Biologic Scaffold for Prevention of Pulmonary Fibrosis - Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject. | 10-27-2011 |
| 20110262499 | TOPICAL HERBAL FORMULATION FOR TREATMENT OF ACNE AND SKIN DISORDERS - The present invention provides novel herbal nano emulsion based formulations comprising a combination of lemon juice and/or rose water as therapeutically active aqueous phase entrapped in oil phase selected from one or more essential oils and process for the preparation of the same in pharmaceutically acceptable dosage forms for topical treatment of acne and other skin disorder like eczema, psoriasis, aging scaring and the like with increased efficacy, Improved percutaneous penetration, excellent thermodynamic stability ensuring long shelf life, low skin irritation and reservoir effect that promotes drug localization in the skin enabling controlled delivery of the said therapeutic agents. | 10-27-2011 |
| 20110262500 | CONJUGATES COMPRISING NANOPARTICLES COATED WITH PLATINUM CONTAINING COMPOUNDS - The present invention relates to conjugates of formula (I) having colloidal stability in a medium, wherein NP is a gold, silver or platinum nanoparticle; L is a linker selected from the group consisting of formula (II), formula (III), and a stereoisomer of any of the formulas (II) and (III), which is attached to the nanoparticle NP through sulfur atoms; wherein the meanings of X, n, p, Y and s are further specified in the description; and A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt and is attached to the linker L through the single bonded oxygen atoms of the carboxyl groups. It also relates to a process for the preparation of the conjugates of formula (I) and to pharmaceutical compositions containing them. The conjugates of the invention are used for the treatment of cancer. | 10-27-2011 |
| 20110262501 | Osteoblast Stimulating Orthopedic Implant - Nanomaterials for neural and orthopedic prostheses are disclosed. Composite carbon nanofibers enhance neuronal growth and minimize glial scar tissue formation. Methods and compositions to promote neuronal growth and minimize scar tissue formation during prolonged monitoring and treatment of neural tissue are disclosed. Composite polyurethane carbon nanofiber is a suitable material for neural implant. Composite carbon nanomaterials decrease adhesion of astrocytes and fibroblasts | 10-27-2011 |
| 20110262502 | PULMONARY DELIVERY OF 17-HYDROXYPROGESTERONE CAPROATE (17-HPC) - The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend. | 10-27-2011 |
| 20110262503 | Flowable Wound Matrix and its Preparation and Use - This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth. | 10-27-2011 |
| 20110268768 | Compositions and Methods for Treating Atherosclerosis - Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided. | 11-03-2011 |
| 20110268769 | DRUG DELIVERY VEHICLE FOR CANCER THERAPY, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL PREPARATION USING THE SAME - The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral envelope vector is for example HVJ-E derived from a Sendai virus, and cationization can be conducted by binding hyaluronic acid-introduced cationized gelatin or ethylene glycol-introduced cationized gelatin with the viral envelope vector. The drug to be enclosed is a nucleic acid, a vector containing a nucleic acid sequence, a protein based drug or pharmaceutical with a low-molecular compound. | 11-03-2011 |
| 20110268770 | CHEWABLE GELLED EMULSIONS - An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester. | 11-03-2011 |
| 20110268771 | CHEWABLE GELLED EMULSIONS - An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion. | 11-03-2011 |
| 20110268772 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG AND A PRODUCTION METHOD THEREOF - Disclosed are an anionic drug-containing pharmaceutical composition comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The pharmaceutical composition may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs. | 11-03-2011 |
| 20110268773 | INCLUSION BODIES, BACTERIAL CELLS AND COMPOSITIONS CONTAINING THEM AND USES THEREOF - The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic cell. The present invention moreover refers to a composition comprising said inclusion body and animal or plant tissue. The present invention furthermore refers to the uses of said inclusion body as medicaments and cell-proliferation stimulators and tissue regenerators. | 11-03-2011 |
| 20110268774 | PREPARATION OF STEM CELLS WITH REPROGRAMMED CELL SIGNALLING, A METHOD OF PRODUCING THE PREPARATION AND A METHOD OF USE THEREOF - The invention is applied in the therapy of brain and spinal cord tumors, degenerative, hypoxic, ischemic diseases and traumatic injuries of the central nervous system (CNS) and other diseases of humans and animals. Object of invention is to provide target delivery of signaling substance to the pathological area of an organism, triggering in due time and long-time support of active signaling intercellular action of specific therapeutic character of a healthy and well controlled stem cell (SC) onto controlling system of defective cells. The preparation of SC with reprogrammed cell signaling comprises the basic preparation of SC, the membrane, and/or nucleus, and/or cytoplasm of which contains implanted protein or pharmaceutical able to regulate signaling pathways of SC and cells of pathological focus in a mammal organism, provisionally encapsulated in nanocontainers of less than 100 nm size, obtained from biodegradable material, intact for organelles and compartments of SC of the basic preparation. The material has a set biodegradation period in a mammal organism to provide programmed exit of protein or pharmaceutical in intra- or intercellular space thus reprogramming signal transduction of key genes in the desired therapeutic orientation of physiologic events in the cell cycle directly in the pathological area or tissue of an organism. | 11-03-2011 |
| 20110268775 | NANOPARTICLE PHARMACEUTICAL FORMULATIONS - The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare nanoparticles of aqueous-insoluble compounds. | 11-03-2011 |
| 20110268776 | PROGRAMMED-RELEASE, NANOSTRUCTURED BIOLOGICAL CONSTRUCT FOR STIMULATING CELLULAR ENGRAFTMENT FOR TISSUE REGENERATION - A biologically engineered construct comprising of a polymeric biomatrix, designed with a nanophase texture, and a therapeutic agent for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent may be a therapeutic substance or a biological agent, such as antibodies, ligands, or living cells. The nanophase construct is designed to maximize lumen size, promote tissue remodeling, and ultimately make the implant more biologically compatible. The nano-textured polymeric biomatrix may comprise one or more layers containing therapeutic substances and/or beneficial biological agents for the purpose of controlled, physiological, differential substance/drug delivery into the luminal and abluminal surfaces of the vessel or lumen, and the attraction of target molecules/cells that will regenerate functional tissue. The topographic and biocompatible features of this layered biological construct provides an optimal environment for tissue regeneration along with a programmed-release, drug delivery system to improve physiological tolerance of the implant, and to maximize the cellular survival, migration, and integration within the implanted tissues. | 11-03-2011 |
| 20110274724 | DERMATOLOGICAL/COSMETIC GELS COMPRISING AT LEAST ONE RETINOID AND/OR RETINOID SALT AND BENZOYL PEROXIDE - Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor. | 11-10-2011 |
| 20110274725 | DECOMPOSABLE BIOCOMPATIBLE HYDROGELS AND SYSTEM AND METHOD FOR USING SAME - Biocompatible, triggerable degradation, polymerizable hydrogels, uses and delivery devices are disclosed. These hydrogels are at least substantially water soluble macromers, having a variety of uses especially for ocular therapy. The macromers include at least one water soluble region, at least one region which is degradable via a triggering event, usually by hydrolysis, and at least two free radical-polymerizable regions. The regions can, in some embodiments, be both water soluble and trigger able degradable. The macromers are polymerized by exposure of the polymerizable regions to free radicals generated by photosensitive chemicals and dyes. An advantage of these polymer hydrogels is that they can be polymerized rapidly in an aqueous surrounding. Precisely conforming, semi-permeable, biodegradable films or membranes can thus be formed on tissue in situ to serve as biodegradable barriers, as carriers for living cells or other biologically active materials, and as surgical adhesives for the eye. | 11-10-2011 |
| 20110274726 | CHITOSAN FOAM MEDICAL DEVICES AND METHODS - The invention provides a solid foam wound dressing useful for hemorrhage control and wound repair, as well as methods for making such a wound dressing. | 11-10-2011 |
| 20110274727 | DEPIGMENTING TOPICAL COMPOSITIONS AND THEIR USES - Depigmenting topical compositions and their uses are described. In particular, the described compositions can provide improved effectiveness in the dermatological treatment of pigmentation, without disadvantages experienced with other known compositions. The described topical compositions can comprise, in a physiologically acceptable medium, from 3% to 10% of rucinol or one of its salts. Also described, are methods of use treating pigmentation disorders of the skin with the described compositions. | 11-10-2011 |
| 20110274728 | Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort - Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation or xerostomia. Preferred compositions and methods employ one or more plant extracts and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred extracts are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second extract is present, such extract is preferably isolated from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.). | 11-10-2011 |
| 20110274729 | IMPLANTABLE COMPOSITIONS FOR REPAIRING OSTEOCHONDRAL DEFECTS - Compositions are described that are suitable for implantation in a human and that contain a scaffold housing cells having an osteocytic phenotype and, attached to the scaffold, cartilage material containing a population of chondrocytes. | 11-10-2011 |
| 20110274730 | BIOSURFACTANT COMPOSITION PRODUCED BY A NEW BACILLUS LICHENIFORMS STRAIN, USES AND PRODUCTS THEREOF | 11-10-2011 |
| 20110274731 | Production Method Of Fine O/W Emulsion External Preparation - The present invention provides a production method of a fine O/W emulsion external preparation having the emulsion particle size of 50 to 500 nm comprising the steps of: mixing with stirring, at 70 to 80° C., (A) a hydrophilic nonionic surfactant, (B) a linear higher alcohol having 16 or more carbon atoms, (C) an oil component, (D) an aqueous solvent which can be soluble in water, wherein the critical micelle concentration (c.m.c.) of the hydrophilic nonionic surfactant in the aqueous solvent is higher than that in water, and (E) water in the amount of 5 to 25 mass % of the total amount of (A) to (E), to prepare a W/O emulsion; and adding, while mixing with stirring, (F) water or an aqueous formulation at 10 to 35° C. into the W/O emulsion to invert the W/O emulsion to a fine O/W emulsion. The production method needs not to use any cooling apparatus, has excellent economical efficiency, can easily produce a fine O/W emulsion external preparation excellent in safety and stability. | 11-10-2011 |
| 20110274732 | MEDICAL DEVICE LOADED WITH FORMULATION FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE MATERIAL/S AND METHOD OF MANUFACTURE THEREOF - The present invention relates to targeted drug delivery of a drug or therapeutic agent through medical devices coated with formulations comprising of therapeutic agent. The coating on medical devices comprises of therapeutic agent(s), affinity vehicle(s) and additives for targeted drug delivery of biologically active material(s). The invention provides a method of manufacturing the formulation, method of coating the medical devices with such formulations to achieve controlled delivery of optimum drug dose at the target site within the body, desirable drug retention on the medical devices in vivo and in vitro and desirable drug release at the target tissue in-vivo. The invention this provides a mechanism to enhance the bioavailability of the therapeutic agent at the target tissue in the treatment of restenosis thereby reduces the actual dose of the therapeutic agent and provides a very thin layer of coating on the surface of the medical device. | 11-10-2011 |
| 20110274733 | POLYMERS CONTAINING POLY(HYDROXYALKANOATES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME - Embodiments of the present invention provides medical devices comprising poly(hydroxyalkanoates) and agents. | 11-10-2011 |
| 20110274734 | FUNCTIONALIZED CHEMICALLY INERT POLYMERS FOR COATINGS - Provided herein are methods for functionalizing an polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer. | 11-10-2011 |
| 20110280912 | DEGRADABLE POLYMER NANOSTRUCTURE MATERIALS - This invention relates generally to composites comprising a plurality of nanostructures, and methods of making the same. In some embodiments, the composites further comprise a polymer. In some embodiments, the composites may have desirable properties such as, for example, biodegradability, biocompatibility, and/or high tensile strength. In one embodiment, the plurality of nanostructures comprises carbon nanotubes, and the polymer comprises a poly(beta-amino ester). Various methods are provided for preparing the composites. For example, the polymer and the plurality of nanostructures may, in some embodiments, be combined in a layer-by-layer process to form the composite. High throughput methods for preparing composites having different compositions also are provided for screening composites for desirable properties. | 11-17-2011 |
| 20110280913 | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders - Methods and compositions for treating and/or diagnosing a B-cell malignancy are described. | 11-17-2011 |
| 20110280914 | HYDROGELS CROSSLINKED WITH GOLD NANOPARTICLES AND METHODS OF MAKING AND USING THEREOF - Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs. | 11-17-2011 |
| 20110280915 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 11-17-2011 |
| 20110280916 | STABLE HYDROALCOHOLIC ORAL SPRAY FORMULATIONS AND METHODS - Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a viscosity modifying agent, wherein when a unit dose volume of about 25 to 400 mcL of the oral spray composition is sprayed, the spray has a median particle size diameter of about 40 to about 100 microns. | 11-17-2011 |
| 20110280917 | RESORBABLE THIN MEMBRANES - Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.30 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages. | 11-17-2011 |
| 20110287060 | ERYTHRITOL-BASED HARD COATINGS - The present invention relates to a coated product comprising a core and a hard coating surrounding the core, wherein the hard coating is composed of at least one coating layer, which comprises erythritol and one or more crystallization modifiers, a process for preparing such a coated product, and the use of the crystallization modifiers for controlling the crystallization of an erythritol-based hard coating. | 11-24-2011 |
| 20110287061 | Dietary composition and method for promoting healthy hair growth and melanogenesis - A dietary composition for promoting melanogenesis in hair of a user comprising approximately 5,000 IU per day of catalase, a synergistic core component, 5-α-reductase inhibitors, an antioxidant component, and approximately 200 mg per day of L-tyrosine. Preferably, the synergistic core component comprises copper, vitamin B6, biotin, para-aminobenzoic acid, folic acid, zinc, and pantothenic acid. Further, 5-α-reductase inhibitors preferably comprise Saw palmetto, phytosterols, and nettle root extract. The antioxidant component preferably comprises horsetail, Fo-Ti, chlorophyll, and barley grass. | 11-24-2011 |
| 20110287062 | Chewable Formulation Comprising Alginate, Bicarbonate And Carbonate - The present invention relates to a solid, ingestible composition comprising a) an alginate; b) a bicarbonate; and c) a carbonate wherein the composition is in the form of a chewable core, a process for preparing said composition, and its use in the treatment of reflux oesophagitis, gastritis, dyspepsia or peptic ulceration or for use as a sustained releasing or targeted delivery composition. | 11-24-2011 |
| 20110287063 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 11-24-2011 |
| 20110287064 | ANTIBIOTIC COATING - An implant is provided having an antibiotic coating that is inexpensive and easy to manufacture. The antibiotic coating adheres well and in stable manner to the surface of the implant, can be degraded by the body without forming toxic products, prevents the crystallization of the antibiotics in the coating, and ensures a high immediate locally-effective antibiotic concentration at the implant site. A coating solution useful for making the implant and a method for the manufacture of the implant are also described. | 11-24-2011 |
| 20110287065 | NANOPARTICULATE CINACALCET COMPOSITIONS - The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions. | 11-24-2011 |
| 20110287066 | Nanoporous Foamed Active Compound-Containing Preparations Based On Pharmaceutically Acceptable Thermoplastically Workable Polymers - Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which the propellant is in the supercritical state, in stage b) heating of the laden polymer molding compound or melt is carried out under pressure at a temperature which lies in the range from −40 to +60° C., preferably −20 to +55° C., and especially preferably 0 to +50° C. around the glass transition temperature of the unladen (prior to loading) polymeric molding compound and in stage c) a depressurization of the polymeric molding compound or melt laden in stage a) and heated under pressure in stage b) is effected out with a depressurization rate in the range from 15,000 to 200,000 MPa/sec. | 11-24-2011 |
| 20110287067 | REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis of reinforced adhesive complex coacervates and their use thereof. The reinforced adhesive complex coacervates are composed of (a) at least one polycation, (b) at least one polyanion, and (c) a reinforcing component. The adhesive complex coacervates described herein can be subsequently cured to produce strong, cohesive adhesives. The reinforced adhesive complex coacervates have several desirable features when compared to conventional adhesives. The reinforced adhesive complex coacervates are effective in wet or underwater applications. The reinforced adhesive complex coacervates described herein, being phase separated from water, can be applied underwater without dissolving or dispersing into the water. The reinforced adhesive complex coacervates have numerous biological applications as bioadhesives and bioactive delivery devices. In particular, the reinforced adhesive complex coacervates described herein are particularly useful in underwater applications and situations where water is present such as, for example, wet tissues in physiological conditions. | 11-24-2011 |
| 20110287068 | FIBRIN AND FIBRINOGEN MATRICES AND USES OF SAME - There is provided compositions-of-matter comprising fibrin or fibrinogen crosslinked with at least one reducing sugar. | 11-24-2011 |
| 20110287069 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE - A solid oral dosage pharmaceutical formulation of (R)-2-Amino-7-[4-fluoro-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one or its salt; and a surfactant or an acid. | 11-24-2011 |
| 20110287070 | BONE REPAIR MATERIAL AND METHOD FOR PRODUCING THE SAME - Bone repair materials are disclosed, from which ions are hardly eluted in living body and which are superior in apatite-forming ability and resistance to apatite peeling and have a scratch resistance high enough for practical use. The material comprises a substrate made of titanium or titanium alloys, and a surface layer, made substantially of titanium oxide, along the surface of the substrate. The substrate has on the surface thereof irregularities of from 1 nm to 10 μm in average in both width and depth. The layer has a zeta potential of +4.5 mV or more under an aqueous solution environment of pH 6 to 8, and a critical scratch resistance of 35 mN or more when vibration 100 μm in amplitude is added to a stylus with a spring constant of 200 g/mm on the surface layer and the stylus is moved at a rate of 10 mm/sec under a load increasing at a rate of 100 mN/min. | 11-24-2011 |
| 20110287071 | METHODS OF GENERATING TISSUE USING DEVITALIZED, ACELLULAR SCAFFOLD MATRICES DERIVED FROM MICRO-ORGANS - A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided. | 11-24-2011 |
| 20110287072 | PREBIOTIC FORMULATIONS AND METHODS OF USE - The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes. | 11-24-2011 |
| 20110293666 | Bioengineered Tissue Constructs and Methods for Production and Use - Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components, e.g., without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be treated in various ways such that the cells of the bioengineered constructs can be devitalized and/or removed without compromising the structural integrity of the constructs. Moreover, the bioengineered constructs of the invention can be used in conjunction with biocompatible/bioremodelable solutions that allow for various geometric configurations of the constructs. | 12-01-2011 |
| 20110293667 | Bioengineered Tissue Constructs and Methods for Producing and Using Thereof - Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits. | 12-01-2011 |
| 20110293668 | ORAL ODOR CONTROL METHOD AND PRODUCT - A product and method for controlling mouth odor and bad breath using an oral care product containing an odor neutralizer. The product for use in oral care or for use in the mouth to control mouth odors includes an odor neutralizer compound. In a preferred method of manufacture, the O.M. Complex oral compound is mixed into a concentrated flavor material. The concentrated flavor material is then added in small percentages to the product during manufacture so that the resulting product includes the odor neutralizer compound. The product may be used in the ordinary manner by a user and during use the O.M. Complex oral compound serves to capture and neutralize odor causing compounds. | 12-01-2011 |
| 20110293669 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 12-01-2011 |
| 20110293670 | ADHESIVE MATERIAL CONTAINING 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof. | 12-01-2011 |
| 20110293671 | BACTERIOPHAGE COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - A respirable composition for treatment of a bacterial infection includes one or more active bacteriophages in combination with a pharmaceutically acceptable respirable carrier. The composition includes a carbohydrate carrier, and is prepared as fine powder. In another aspect, bacteriophages are provided in a liquid carrier for administration by nebulization. In one aspect, the bacteriophages have anti-bacterial activity against one or more species or strains of | 12-01-2011 |
| 20110293672 | PANCREATIC TUMOUR TREATMENT - There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition. | 12-01-2011 |
| 20110293673 | ORAL FILM-FORM BASE AND ORAL FILM-FORM PREPARATION - The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a solubility parameter of 9.7 or higher, an edible polymer soluble in water and the organic solvent, and particles of one or two or more compounds selected from the group consisting of mono- to hexasaccharide sugars and sugar alcohols thereof which have an average particle size of 0.1 μm to 60 μm and are insoluble in an organic solvent. The present invention can therefore provide oral film-form base and preparation which have a rapid dissolution profile in the mouth and sufficient film strength, and provide a reduced sticky sensation attributed to the water-soluble polymer in the mouth and an improved feel when handled with the fingers. | 12-01-2011 |
| 20110293674 | MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION - The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and/or miR-422a in heart tissue are also disclosed. | 12-01-2011 |
| 20110293675 | COATINGS OF ACRYLAMIDE-BASED COPOLYMERS - An implantable device including conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided. | 12-01-2011 |
| 20110293676 | Oral Cephalotaxine Dosage Forms - The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations. | 12-01-2011 |
| 20110300184 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE CONDITIONS - Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same. | 12-08-2011 |
| 20110300185 | IMMUNOGENIC ESCHERICHIA COLI HEAT STABLE ENTEROTOXIN - The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions. | 12-08-2011 |
| 20110300186 | Functionalized Nano- and Micro-materials for Medical Therapies - Compositions containing an optionally surface-functionalized mesoporous support and a biologically active agent, and pharmaceutical compositions of the same, are provided herein. Such compositions can be useful in the treatment of tumors, for example, by injection of the composition at a location near the site of the tumor. | 12-08-2011 |
| 20110300187 | ANTIOXIDANT CAMPTOTHECIN DERIVATIVES AND ANTIOXIDANT ANTINEOPLASTIC NANOSPHERES THEREOF - The present invention is directed to antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs and the preparation of nanometer-sized camptothecin prodrugs. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant camptothecin nanosphere prodrugs and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these antioxidant camptothecin nanosphere prodrugs for the preparation of delivery devices of other pharmaceuticals and/or drugs. Additionally, methods of treating cancer with the camptothecin and antioxidant derivatives of camptothecin analogs, and nanometer-sized camptothecin prodrugs are also provided. | 12-08-2011 |
| 20110300188 | Glassy calcium phosphate particulates, coatings and related bone graft materials - Calcium phosphate and related coating powder particles comprising a surface component comprising a silicate content, plasma sprayed coatings thereof on implantable medical/dental devices, and bone grafting materials of such coated particles. Optionally, biologically active agents such as bone morphogenetic proteins, growth factors, analgesics, and antibiotics can be incorporated therein. | 12-08-2011 |
| 20110300189 | ANTIMICROBIAL COLLOIDAL SILVER PRODUCTS AND METHOD OF MAKING SAME - Gelatinous materials combined with the Colloidal Silver additive to formulate an antimicrobial product having cushioning properties. Embodiments of the present invention can include gelatinous materials selected from a group consisting of thermosetting polymer, Styrene-Ethylene-Butadiene-Styrene polymer (SEBS), Thermoplastic Elastomer (TPE), and Polyurethane (PU) gelatin with and without a raised geometry on an outer surface. | 12-08-2011 |
| 20110300190 | COMPOUND, COMPOSITION AND USES THEREOF - The disclosure herein provides a compound of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. The steps of synthesis of compound of formula I is described. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treatment of metabolic condition or neurodegenerative disorders or its associated complications. | 12-08-2011 |
| 20110300191 | MULTIPLE-LAYER IMMUNE BARRIER FOR DONOR CELLS - A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described. | 12-08-2011 |
| 20110300192 | MAGNESIUM OXIDE GRANULES - Magnesium oxide granules which are excellent in dissolution property, are palatable, rarely leave any rough feeling in the oral cavity and have a good color in appearance. | 12-08-2011 |
| 20110300193 | AMBIENT STORED BLOOD PLASMA EXPANDERS - A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of, or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described. | 12-08-2011 |
| 20110300194 | Flexible Bone Composite - The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include a calcium compound such as β-Ca | 12-08-2011 |
| 20110300195 | Ophthalmic Compositions Comprising Calcineurin Inhibitors or mTOR Inhibitors - The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles. | 12-08-2011 |
| 20110305731 | PHARMACEUTICAL FORMULATION BETWEEN JASMONATES AND IT DERIVATIVES AND NANOCARRIES OR MICROCARRIES - The present invention refers to pharmaceutical compositions comprising a jasmonic acid derivative and a carrier, preferably cyclodextrin or a polyamidoamine. The compositions may be used for treating cancer. | 12-15-2011 |
| 20110305732 | METHODS AND USES FOR INHIBITING PLATELET COAGULATION - The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with Slit protein or a cell expressing a Slit protein. | 12-15-2011 |
| 20110305733 | PHARMACEUTICAL FORMULATIONS COMPRISING METFORMIN AND A FIBRATE, AND PROCESSES FOR OBTAINING THEM - The present invention relates to granulates comprising particles of metformin and particles of a fibrate. The invention further relates to pharmaceutical compositions containing such granulates. The invention also relates to processes for preparing said granulates and said pharmaceutical compositions. | 12-15-2011 |
| 20110311591 | Antimicrobial Coating - A substrate (100) comprising a sol-gel derived coating (101). The coating, is chemically bonded to the substrate (100) and is derived from a polysiloxane to form a network of silicon-carbon and silicon-oxygen bonds. An antimicrobial is releasably captured within the network and is capable of defusing from the coating in vivo in response to introduction of a fluid into the coating. | 12-22-2011 |
| 20110311592 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds - The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations. | 12-22-2011 |
| 20110311593 | N-HYDROXYLATED AMIDINE-, GUANIDINE- AND/OR AMINOHYDRAZONE-TYPE PRODRUGS FOR APPLICATION ON THE SKIN - The invention relates to N-hydroxylated amidines, guanidines and aminohydrazones for application on the skin. In particular, the invention relates to transdermal therapeutic systems containing N-hydroxylated amidines, guanidines and aminohydrazones as a prodrug, and to methods for producing and using such systems. | 12-22-2011 |
| 20110311594 | CONTROLLED RELEASE COMPOSITIONS WITH REDUCED FOOD EFFECT - The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect. | 12-22-2011 |
| 20110311595 | DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH | 12-22-2011 |
| 20110311596 | POLY(AMIDE) AND POLY(ESTER-AMIDE) POLYMERS AND DRUG DELIVERY PARTICLES AND COATINGS CONTAINING SAME - The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers. | 12-22-2011 |
| 20110318389 | HUMAN PANCREATIC BETA CELL LINES FOR DIAGNOSTIC OF DIABETES - The present invention relates to a method for preparing commercial scale quantities of human functional Betacells and to the establishment of cell lines. It also relates to a method of diagnosis using Beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating Betacells, allowing to generate human Betacell lines. Such lines express little amount of insulin and have a gene expression profile that resembles to adult Betacells. In addition, the human Betacell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities. | 12-29-2011 |
| 20110318390 | Bioactive Dose Having a Rapid Release Coating or Rapid Release Layer Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive - A bioactive dose for delivering a bioactive agent to a mammal includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit. The rapid release coating contains a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards a pKa of the at least one bioactive agent and prior to the action of any buffer system internal to the dosage unit. In another embodiment, e.g., to aid oral quick dissolve forms in which it is not desirable to absorb the bioactive in the mouth, the rapid release coating contains a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction away from a pKa of the at least one bioactive agent. | 12-29-2011 |
| 20110318391 | Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive - A bioactive dose for delivering a bioactive agent to a mammal, includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit, the rapid release coating containing a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards an ideal absorptive pH or towards an ideal pH to hinder absorption of the at least one bioactive agent given the pKa that least at one bioactive agent. A modified liquid that is administered prior to, contemporaneous with, or following the delivery of a bioactive agent is also described. The liquid includes a pH modifier selected to control the pH of the liquid to a predetermined range so that the modified liquid rapidly modulates the pH of bodily fluids to enhance or hinder absorption of the bioactive agent. | 12-29-2011 |
| 20110318392 | DRUG COATING PROVIDING HIGH DRUG LOADING AND METHODS FOR PROVIDING THE SAME - The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention. | 12-29-2011 |
| 20110318393 | Substituted Pyrazole Compounds - Provided are substituted pyrazole compounds which are useful as protein kinase inhibitors, compositions comprising the compounds, and methods of use thereof. The protein kinase inhibitors are particularly for inhibition of Aurora A (Aurora-2) protein kinase and are useful in the treatment of diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer. | 12-29-2011 |
| 20110318394 | MULTI-LINKED STAR-SHAPED POLYMERS AND SYNTHETIC METHODS THERFOR - The invention describes new synthetic medical adhesives and antifouling coatings which exploit the key components of natural marine mussel adhesive proteins. | 12-29-2011 |
| 20110318395 | POLYHYDROXYALKANOATE MEDICAL TEXTILES AND FIBERS - Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available, and could offer additional benefits such as anti-adhesion properties, reduced risks of infection or other post-operative problems resulting from absorption and eventual elimination of the device, and competitive cost. The devices may also be particularly suitable for use in pediatric populations where their absorption should not hinder growth, and provide in all patient populations wound healing with long-term mechanical stability. The devices may additionally be combined with autologous, allogenic and/or xenogenic tissues to provide implants with improved mechanical, biological and handling properties. | 12-29-2011 |
| 20120003271 | POLYMER BLENDS - A biocompatible polymer mixture for use as a matrix for cellular attachment includes a mixture of at least two polymers selected from the group consisting of: chitosan (CS), polyethylenimine (PEI), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(2-hydroxy ethyl methacrylate) (PHEMA), poly(ε-caprolactone) (PCL), poly(vinyl acetate) (PVAc), poly(ethylene oxide) (PEO), poly[(R)-3-hydroxybutyric acid)] (PHB), cellulose acetate (CA), poly(lactide-co-glycolide) (PLGA) and poly(N-isopropylacrylamide) (PNIPAM). Implants making use of the polymer mixtures can support cell attachment, growth and differentiation, and tissue regeneration in vivo. | 01-05-2012 |
| 20120003272 | CONCRETE SCAFFOLD CONTAINING BMP-2 AND MADE OF BONE POWDER AND FIBRIN GLUE - The present invention relates to a bone-regenerating scaffold containing bone morphogenic protein 2 (BMP-2), and more particularly, to a bone-regenerating scaffold which is made of a mixture of fibrin glue and bone powder, the interior of which has a plurality of pores for accommodating bone growth factors, and which has a predetermined concrete shape. The bone-regenerating scaffold of the present invention contains BMP-2 as the above-mentioned bone growth factor. | 01-05-2012 |
| 20120003273 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS - The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R | 01-05-2012 |
| 20120003274 | ORAL SUSTAINED RELEASE ANTIDEPRESSANT FORMULATION - Pharmaceutical presentations or phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are capable of sustained release in the digestive tract. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: wherein n is 0, 1 or 2; R | 01-05-2012 |
| 20120003275 | Compositions and Methods for the Treatment of Ophthalmic Disease - Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions. | 01-05-2012 |
| 20120003276 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed. | 01-05-2012 |
| 20120003277 | NANOEMULSION VACCINES - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 01-05-2012 |
| 20120003278 | SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO - The present invention includes single-walled carbon nanotube compositions for the delivery of bioactive agents and methods of making such single-walled carbon nanotube compositions. | 01-05-2012 |
| 20120003279 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 01-05-2012 |
| 20120003280 | CERAMIC/STRUCTURAL PROTEIN COMPOSITES AND METHOD OF PREPARATION THEREOF - Ceramic/structural protein composites and methods of preparation are disclosed, including coatings and films. Ceramic/structural protein coatings can be fabricated on the surface of substrates, including the surface of implantable medical devices. | 01-05-2012 |
| 20120003281 | USE OF AN ACARICIDAL POWDER - Use of a powder comprising more than 40% by weight of sodium bicarbonate, for its acaricidal effects in the storage of cereals. | 01-05-2012 |
| 20120003282 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES - Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof. | 01-05-2012 |
| 20120003283 | Injectable Biomaterials - Injectable biomaterial compositions formed from tropoelastin for tissue repair and restoration. The compositions include a coalescence-controlling agent in the form of a polysaccharide or polysaccharide derivative, in an amount effective for providing the substance with the properties of flow, enabling injection. | 01-05-2012 |
| 20120009223 | COLLAGEN-BASED HYDROGELS LOADED WITH ZnO QDs/pDNA COMPLEXES AS CORNEAL SUBSTITUES - This invention relates to a method of fabricating collagen-based hydrogels loaded with ZnO QDs/pDNA complexes as corneal substitutes. Polycation-modified ZnO Quantum Dots were encapsulated into IPN hydrogels by the adsorption effect of freeze-dried hydrogels. The weight ratio of substitutes and ZnO QDs complex is approximately 425:1. And the weight ratio of ZnO QDs/pDNA is 25:1. This kind of corneal substitutes possess favorable biocompatibility. It is able to induce and promote the regeneration of the cornea and it will degrade along with the regeneration of the cornea. The incorporation of the MPDSAH can enhance the stability of corneal substitutes under the existence of collagenase. ZnO QDs used in this invention can condense DNA effectively and ferry DNA into cells successfully. In the process of transfection, the location and distribution of DNA/vector can be tracked by fluorescence in real time. What's more, the convenience of preparation, long term storage and transportation offers a general method to fabricate a promising corneal substitute. | 01-12-2012 |
| 20120009224 | PARTICULATE CARTILAGE TREATMENT COMPOSITION - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 01-12-2012 |
| 20120009225 | Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration - Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 01-12-2012 |
| 20120009226 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein is an impurity of laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide (deschloro laquinimod impurity), and process for preparation and isolation thereof. Provided further herein is a highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity. | 01-12-2012 |
| 20120009227 | ACTIVE COATING OF PHARMACEUTICAL DOSAGE FORMS - The present invention describes in an embodiment a coating composition which contains in a film coating an active pharmaceutical ingredient, which is defined by a low water solubility of about 10 mg/ml or lower as measured in water at 20° C. at about pH 7, or which is defined by presenting a dispersed state when placed in water at 20° C. at about pH 7, and a co-polymer of polyvinyl alcohol with polyethylene glycol. Preferably the active pharmaceutical ingredient has been applied dispersed in an aqueous coating vehicle onto a core which optionally comprises a same or different active pharmaceutical ingredient. The present invention also describes a process for the preparation of a pharmaceutical single unit dosage form, wherein the process comprised the steps of providing a core of the single unit dosage form, optionally providing one or more subcoating layer(s) on the core, subjecting the core to film coating using a composition comprising an aqueous coating vehicle, a co-polymer of polyvinyl alcohol with polyethylene glycol and at least one active pharmaceutical ingredient dispersed in the aqueous coating vehicle, wherein said co-polymer amounts for at least 7.0 wt. %, preferably at least 9.4 wt. % of said composition and the weight ratio of said co-polymer to said active pharmaceutical ingredient is at least 1:1 to 5:1. Other process embodiments are also described. High drug loads, uniformity of drug load, and fast dissolution rates of active pharmaceutical ingredient from film coatings of pharmaceutical single unit dosage forms can be achieved according to the present invention. | 01-12-2012 |
| 20120009228 | Prebiotic Compositions for use with Probiotics to Increase Probiotic Growth Rate and Activity - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 01-12-2012 |
| 20120009229 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 01-12-2012 |
| 20120009230 | MALLEABLE IMPLANTS CONTAINING DEMINERALIZED BONE MATRIX - Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids can include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising one or more polysaccharides. Also described are methods for making and using such medical compositions. | 01-12-2012 |
| 20120009231 | APPARATUS AND METHOD FOR DEPOSITION OF FUNCTIONAL COATINGS - A method for deposition of functional coatings comprises igniting a non-thermal equilibrium plasma within an ambient pressure plasma chamber having a gas supply inlet and a plasma outlet; and providing a substrate to be coated adjacent to the plasma outlet. A gas phase pre-cursor monomer is provided to the plasma chamber through the gas inlet. A specific energy is coupled into the plasma during the flow of the pre-cursor through the chamber sufficient to disassociate at least the weakest intra-molecular bond required to allow polymerisation of the pre-cursor when deposited on a surface of the substrate adjacent the plasma outlet, the coupled specific energy not exceeding a specific energy required break intra-molecular bonds required for the functionality of the monomer molecule. | 01-12-2012 |
| 20120014999 | Diketopiperazine Microparticles with Defined Specific Surface Areas - Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m | 01-19-2012 |
| 20120015000 | MALARIA VACCINE OF SELF-ASSEMBLING POLYPEPTIDE NANOPARTICLES - The invention is directed to functionalized self-assembling polypeptide nanoparticles, and to methods of using these nanoparticles to vaccinate against malaria. The functionalized SAPN comprises a self-assembling core, and at least one epitope fused to the self-assembling core. The self-assembling core comprises a pentameric coiled-coil domain, a trimeric coiled-coil domain, and a linker. The linker joins the pentameric coiled-coil domain and the trimeric coiled-coil domain. Particular sequences of the epitopes used in the vaccine are from the | 01-19-2012 |
| 20120015001 | METHODS OF TREATING THYROID EYE DISEASE - The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed. | 01-19-2012 |
| 20120015002 | ANTIMICROBIAL COATINGS - The disclosure provides polymers having antimicrobial activity and articles with the polymers coated thereon. The polymers include a first pendant group comprising a first quaternary ammonium component, a second pendant group comprising a nonpolar component, and a third pendant group comprising an organosilane component. The disclosure also includes methods of coating articles with the antimicrobial polymers. The methods further include the use of adhesion-promoting reagents. | 01-19-2012 |
| 20120015003 | Layered Scaffold Suitable for Osteochondral Repair - The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multilayer collagen composite scaffold. | 01-19-2012 |
| 20120015004 | ENCAPSULATED SALTS AND USE IN HIGH ACID BEVERAGES - Encapsulated nutrient salts including nutrient salt particles encapsulated with a water-insoluble chitosan-stearic acid complex are provided. A method for forming encapsulated nutrient salts is provided, including forming a water-in-oil micro-emulsion including an oil and an aqueous salt solution, adding chitosan and stearic acid to the water-in-oil micro-emulsion, where the chitosan and stearic acid form a complex, and collapsing the aqueous phase of the water-in-oil micro-emulsion to form the encapsulated salt particles. | 01-19-2012 |
| 20120015005 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 01-19-2012 |
| 20120015006 | FLOWABLE COLLAGEN MATERIAL FOR DURAL CLOSURE - Flowable graft materials are provided which comprise collagen powder and a liquid in an amount sufficient to impart a flowable consistency to the material. The graft materials are sufficiently formable and pliable so as to provide both superior contact with and easier access to a surgical site than typical, more rigid grafts such as collagen sheets. These flowable materials may also be in a fluidized, paste-like and/or gel-like state and may be moldable and/or ejectable. The flowable collagen materials reduce and/or eliminate post implantation problems associated with other materials, e.g. synthetic dural sealants (hemostasis products), such as product swelling after application and implantation. The flowable graft materials are particularly useful as a dural graft. | 01-19-2012 |
| 20120015008 | ANTI-ADHESIVE COMPOSITION, SOLID PREPARATION, AND PROCESS FOR PRODUCING THE SAME - An adhesion of a preparation | 01-19-2012 |
| 20120021008 | INJECTABLE AND MOLDABLE CERAMIC MATERIALS - Disclosed is an injectable and moldable ceramic material comprising porous calcium phosphate having surface-microporosity, and a water-free carrier, wherein the carrier is selected so as to disintegrate under physiological circumstances. The latter refers to the property of a carrier to dissolve, disassociate, or otherwise disintegrate after placement (e.g. through injection or implantation) into the human body. By selection of a water-free polymer or polymer blend which is combined with surface-microporous calcium phosphates, the favourable osteoinductive properties by virtue of the surface-microporosity can be retained for prolonged shelf life. | 01-26-2012 |
| 20120021009 | PROCESS FOR MAKING GASTRORETENTIVE DOSAGE FORMS - The present disclosure relates to a novel process for making oral solid gastro-retentive forms, including the steps of providing a powder mixture including a hydrophobic powder, overgranulating this powder mixture with a granulating solution into an overgranulated paste, and drying all paste into a solid, as well as to pharmaceutical solid dosage forms which are retained in the stomach or upper gastrointestinal tract for a controlled delivery of a drug. | 01-26-2012 |
| 20120021010 | ANTIPLATELET AGENT AND METHODS OF USING THE SAME - Disclosed herein are compositions and methods for inhibiting platelet aggregation in a patient in need thereof. The compositions and methods use superparamagnetic iron oxide nanoparticles (SPIONs), which are shown to inhibit aggregation of platelets. Such methods are useful in preventing blood clotting in diseases such as acute coronary syndrome. Also disclosed are in vitro methods of sensing platelet function using SPIONs. | 01-26-2012 |
| 20120021011 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING EXTRACTS FROM BROUSSONETIA PAPYRIFERA AND LONICERA JAPONICA - The present invention relates to a pharmaceutical composition for alleviating or treating inflammations and/or pains, the pharmaceutical composition comprising extracts from | 01-26-2012 |
| 20120021012 | NOVEL PHARMACEUTICAL USES FOR NANOPARTICLES - The present invention relates to SiC nanoparticles to be used in the context of cancer treatment, said nanoparticles preferably having a size less than 100 nm. | 01-26-2012 |
| 20120021013 | Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost - An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating diseases, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided. | 01-26-2012 |
| 20120021014 | CORROSION CURRENT-GENERATING METAL PARTICULATES AND USE THEREOF - Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided. | 01-26-2012 |
| 20120021015 | CROSSLINKED FIBERS AND METHOD OF MAKING SAME USING UV RADIATION - Cross-linked fibers include first and second precursors, each possessing a core and at least one functional group known to have click reactivity when exposed to UV radiation. Mixtures of the first and second precursors are extruded to produce a filament and irradiated with UV light during the extrusion process. | 01-26-2012 |
| 20120021016 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
| 20120021017 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
| 20120021018 | MICROSPHERES FOR THE SUSTAINED RELEASE OF OCTREOTIDE WITH A LOW INITIAL BURST - This disclosure features microspheres and a method of making them. The microspheres are for sustained release of an octreotide compound with a low initial burst, comprising a poly(D,L-lactide-co-glycolide) polymer matrix and an octreotide compound dispersed in the polymer matrix. The microspheres release less than 1% of a total amount of the octreotide compound within 1 hour at 37° C. and pH 7.4. | 01-26-2012 |
| 20120021019 | CARDIAC STEM CELL POPULATIONS FOR REPAIR OF CARDIAC TISSUE - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 01-26-2012 |
| 20120021020 | BRANCHED AMPHIPATHIC OLIGO-PEPTIDES THAT SELF-ASSEMBLE INTO VESICLES - The present invention provides branched amphipathic peptides and vesicles formed thereof. The peptides comprise a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N -terminal segments extending from the branch point. The vesicles are formed using a plurality of first and second peptides, wherein the first peptide has a different chain length from the second peptide. When a plurality of the first and second peptides are mixed together, they self-assemble to form small spheres defined by a membrane consisting of an interlocking peptide network bilayer and having a liquid-receiving interior space (i.e., hollow core). In the bi-layer, the respective hydrophobic segments of the peptides form beta-sheet structures having a hydrogen bond-stabilized, anti-parallel orientation in which the opposed sequences interlock to form a zipper-like structure in three dimensions. Thus, the peptide assembly (i.e., vesicle) can be held together at reduced concentrations where lipid vesicles would breakdown. | 01-26-2012 |
| 20120021021 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING FINE PARTICLES OF ACTIVE SUBSTANCE - The present invention relates to a method for preparing solid pharmaceutical compositions comprising fine particles of at least one active substance, dispersed on and (or) within a divided solid. This method is characterized in that a solution is formed which comprises at least one active substance in a fluid at supercritical pressure, said solution then being expanded in a chamber under temperature and pressure conditions for which a part of said fluid is in the liquid state at the time of the expansion, said fluid thus expanded being brought into contact with a divided solid in said chamber. | 01-26-2012 |
| 20120027804 | MEDICAL PRODUCT, IN PARTICULAR FOR MANAGEMENT OF TISSUE REPAIR - A medical product includes at least one elongate body including cells and a method for manufacturing the medical product. | 02-02-2012 |
| 20120027805 | Controlled-Released Peptide Formulations - Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent. | 02-02-2012 |
| 20120027806 | DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods. | 02-02-2012 |
| 20120027807 | TISSUE ENGINEERED MYOCARDIUM AND METHODS OF PRODUCTION AND USES THEREOF - The present invention generally relates to a population of committed ventricular progenitor (CVP) cells and their use to generate a tissue engineered myocardium, in particular two dimensional tissue engineered myocardium which is comparable to functional ventricular heart muscle. One embodiment of present invention provides a composition and methods for the production of a tissue engineered myocardium which has functional properties of cardiac muscle, such as contractibility (e.g. contraction force) and numerous properties of mature fully functional ventricular heart muscle tissue. In particular, in one embodiment, a composition comprising the tissue engineered myocardium comprises committed ventricular progenitor (CVP) cells seeded on a free-standing biopolymer structure to form functional ventricular myocardium tissue. | 02-02-2012 |
| 20120027808 | NICOTINE IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies. | 02-02-2012 |
| 20120027809 | Pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles and uses thereof - The present invention provides pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles, more particularly, pharmaceutical compositions comprising water-soluble sulfonate-protected silver or gold nanoparticles. The pharmaceutical compositions of the invention are useful in prevention or treatment of infections or conditions or disorders caused by microorganisms capable of binding to heparan sulfate, e.g., herpes simplex viruses. | 02-02-2012 |
| 20120027810 | PATCH PRODUCTION - A method for use in producing a patch having a number of projections thereon. The method includes providing a distribution member and filling material on a mold surface, the mold including a number of cavities extending from the mold surface for defining the patch projections, filling the cavities with filling material, at least in part by urging filling material from the distribution member into the cavities, causing the filling material to solidify and separating the solidified filling material and the mold to thereby form the patch. | 02-02-2012 |
| 20120027811 | Formulations of Viable Cells for Oral Delivery - This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine. | 02-02-2012 |
| 20120027812 | INTRAOCULAR LENSES TREATED WITH ALKYLPHOSPHOCHOLINES FOR PHARMACOLOGICAL AFTERCATARACT PROPHYLAXIS - The invention relates to ophthalmological implants which comprise alkylphosphocholines. Implants of this type may in particular advantageously be used for the prophylaxis of aftercataract. | 02-02-2012 |
| 20120027813 | ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 02-02-2012 |
| 20120027814 | Polymeric Fibers Having Tissue Reactive Members - A method for bonding a polymeric fiber to tissue is provided which includes providing a polymeric fiber having a plurality of tissue reactive members linked to a surface of the fiber via a specific binding pair, and contacting the polymeric fiber to biological tissue, to covalently bond the fiber to the tissue. | 02-02-2012 |
| 20120027816 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY - Provided herein is an impurity of eletriptan, eletriptan N-oxide, (R)-5-[2- (phenylsulfonypethyl]-3-[(1-methyl-2-pyrrolidinyl-N-oxide)methyl]-1H-indole, and a process for the preparation and isolation thereof. Provided further herein is a highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity. | 02-02-2012 |
| 20120027817 | Absorbable Implants and Methods for Their Use in Hemostasis - The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered polysaccharide and a biocompatible liquid comprising one or more block copolymers of ethylene oxide and propylene oxide. | 02-02-2012 |
| 20120027818 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment. | 02-02-2012 |
| 20120027819 | Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices - One embodiment provides a medical device comprising a base material and a bioactive in contact with the base material, the bioactive having a proton binding site with a non-ionic form and an ionic form, the bioactive being less soluble in water when the proton binding site is in the non-ionic form than when the proton binding site is in the ionic form, wherein at least 5% w/w of the bioactive is present with the proton binding site in the non-ionic form and wherein the bioactive is not an anesthetic. Another embodiment provides such a medical device where the bioactive is an anesthetic and where the device is not a ureteral stent. Another aspect provides method of manufacturing such devices. | 02-02-2012 |
| 20120027820 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 02-02-2012 |
| 20120027821 | AMINO ACID-CONJUGATED CYANOACRYLATE POLYMER PARTICLES - Disclosed are cyanoacrylate polymer particles which comprise an amino acid(s) and have an average particle diameter of less than | 02-02-2012 |
| 20120027822 | Process for Producing Rapidly Disintegrating Spheroids (Pellets), Granules and/or Mixtures Thereof - Process for producing rapidly disintegrating spheroids (pellets), granules and/or mixtures thereof, which disintegrate in less than 15 minutes. The spheroids comprise at least one active pharmaceutical ingredient, a spheronizing aid material and a solid Polyethylene glycol (PEG) with mean molecular weight (MW) of over 1,000. The process comprises a direct pelletization step in a fluidized bed rotogranulator, using aqueous binding media whilst the temperature of the process does not exceed the melting point of the solid PEG. | 02-02-2012 |
| 20120027823 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 02-02-2012 |
| 20120034271 | INJECTABLE IN-SITU CROSSLINKED HYDROGEL AND METHODS OF MAKING AND USING THEREOF - The present invention discloses an injectable in-situ crosslinked hydrogel and its preparation method. The preparation method is as below: Filling the crosslinking active solution of at least one kind of the biocompatible macromolecules containing more than two thiol groups on the side chains into an injectable container and sealing it, and forming the in-situ disulfide-bond crosslinked hydrogel under the action of the dissolved oxygen; through controlling such parameters as partial pressure of oxygen gas, temperature and time, regulating concentration of the oxygen dissolved in the crosslinking active solution, and optimizing the gelation process and the gel properties. The present invention further relates to application of the injectable in-situ crosslinked hydrogel in pharmaceutics or surgery. The present invention has many advantages, such as no need for a crosslinking agent, simple preparation process, convenient application, containing no impurities, good biocompatibility, no toxic and side effect, and wide application in the medical science. | 02-09-2012 |
| 20120034272 | Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic - The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders. | 02-09-2012 |
| 20120034273 | EXTRUDATE HAVING SPICULAR ACTIVE SUBSTANCES - The invention relates to extrudates containing at least one pharmaceutically active substance in the form of needles, wherein the ratio of the particle size of the needle-shaped pharmaceutically active substance to the strand diameter is at least 1:15, and the use of these extrudates for the production of medicaments. | 02-09-2012 |
| 20120034274 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS - A pharmaceutical controlled release composition comprising one or more fumaric acid esters. | 02-09-2012 |
| 20120034275 | POWDER FORMULATIONS FOR INHALATION, COMPRISING ENANTIOMERICALLY PURE BETA AGONISTS - The present invention relates to powder formulations for inhalation containing enantiomerically pure compounds of general formula 1 | 02-09-2012 |
| 20120034276 | SOLID PREPARATION - A solid preparation | 02-09-2012 |
| 20120034277 | RESUSCITATION FLUID - A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation. | 02-09-2012 |
| 20120034278 | OPHTHALMIC PREPARATION CONTAINING MENTHYL ESTER OF INDOMETHACIN - There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation. | 02-09-2012 |
| 20120034279 | TRANSSCLERAL DELIVERY - Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration. | 02-09-2012 |
| 20120039947 | METHODS AND COMPOSITIONS FOR TREATING PSORIASIS - Methods and compositions including anthralin for treating psoriasis of the skin and scalp are described. | 02-16-2012 |
| 20120039948 | Instant Vesicular Product - A powder of reversed vesicles, which comprises one or more non-ionic surfactants and optionally a lipophilic stabilising factor and a bio-active agent, is provided. The product is prepared by making a dispersion of reversed vesicles in a suitable apolar vehicle, which vehicle is subsequently removed. In admixture with one or more excipients the product can be incorporated in compositions. | 02-16-2012 |
| 20120039949 | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration - Solid, stable formulations of GC-C receptor agonist polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The GC-C receptor agonist polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 02-16-2012 |
| 20120039950 | COLOSTRUM COMPOSITION - The present invention relates to a composition comprising colostrum and at least one agent selected from the group of hydrocolloids, wherein said colostrum and at least one agent are bioconjugated. The bioconjugated composition has improved properties compared to colstrum compositions that are not bioconjugated with a hydrocolloid agent. The composition may be used in a variety of settings, for example for topical application for treating skin diseases and skin conditions. The present invention thus also relates to use of the composition and to a method for the preparation of the composition. | 02-16-2012 |
| 20120039951 | COMPOSITIONS AND METHODS FOR ENHANCING PHYSIOLOGICAL PERFORMANCE AND RECOVERY TIME - Provided are methods for enhancing exercise (e.g., intense, eccentric, elevated temperature, repetitive, aerobic, and high altitude) performance, comprising administering electrokinetically-altered aqueous fluids comprising an ionic aqueous solution of stably configured charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than 100 nanometers. In certain aspects, enhancing exercise performance comprises at least one of: reducing plasma inflammatory cytokines (e.g., IFN-alpha, ENA-78 and BDNF); ameliorating muscle/tendon damage or enhancing muscle/tendon recovery; reducing biomarkers of exercise-induced muscle injury (e.g., CK, plasma myoglobin); ameliorating exercise induced tendinosis, tendonitis, tenosynovitis, avulsion, and tendon strain associated with chronic repetitive movement or enhancing recovering therefrom; increasing VO | 02-16-2012 |
| 20120039952 | COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS - Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. | 02-16-2012 |
| 20120039953 | RILUZOLE AQUEOUS SUSPENSIONS - Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 μm; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole. | 02-16-2012 |
| 20120039954 | METHOD OF TREATING INSOMNIA - A method of treating insomnia comprising administering to a subject a formulation including zaleplon, wherein the formulation is adapted to release the zaleplon after a lag time of at least about one hour after administration of the formulation, and during which substantially no drug substance is released; provide a time of peak plasma concentration of about 3 hours to about 6 hours after administration; provide an elimination half-life after the time of peak plasma concentration of about 0.5 hours to about 0.3 hours; and provide an area under the curve of about 70 ng·h/mL to about 90 ng·h/mL. | 02-16-2012 |
| 20120039955 | Treatment of Diabetes with Pancreatic Endocrine Precursor Cells - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal. | 02-16-2012 |
| 20120039956 | DRY STORAGE STABILIZING COMPOSITION FOR BIOLOGICAL MATERIALS - The present invention includes compositions and drying methods for preserving sensitive bioactive materials, such as peptides, proteins, hormones, nucleic acids, antibodies, drugs vaccines, yeast, bacteria (probiotic or otherwise), viruses and/or cell suspensions, in storage. The compositions include a carbohydrates component and a glass enhancer component, wherein the carbohydrate component includes a mixture of di-, oligo- and polysaccharides and the glass enhancer includes ions of organic acid and protein hydrolysates. The composition is prepared by dispersing all the solid components in a solution and then snap-frozen to form small beads, strings or droplets. The preferred drying method of the frozen beads, strings or droplets is initiated by a short purging and structure stabilizing step of the frozen particles under a vacuum pressure of less than <2000 mTORR followed by a primary drying step under vacuum pressure of more than >2000 mTORR and at a desired temperature. During the secondary and final drying step of the material a full vacuum pressure and elevated temperature are applied, to achieve a final desirable water activity of the dry material. | 02-16-2012 |
| 20120039957 | OPTIMIZED NIACIN COMPOSITIONS IN PHARMACEUTICAL PRODUCTS - The present invention includes compositions and methods related to forms of niacin with enhanced in-vivo absorption and bioavailability. Such enhanced delivery of niacin in the presence of food may be achieved by size reduction of crystalline niacin, use of amorphous forms of niacin, and/or pH modulation in the presence on organic acids. | 02-16-2012 |
| 20120039958 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHY - Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions. | 02-16-2012 |
| 20120039959 | Anti-Adhesion Alginate Barrier of Variable Absorbance - Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated. | 02-16-2012 |
| 20120039960 | DENTAL ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR INTRANASAL ADMINISTRATION - The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations. | 02-16-2012 |
| 20120039961 | IMPLANT AND THERAPEUTIC COMPOSITION FOR TREATING DAMAGE AND/OR DISEASES RELATING TO THE HUMAN ANIMAL MUSCULOSKELETAL SYSTEM - An implant includes a support material, cartilage cells and/or precursor cells thereof, and a cartilage-specific collagen type. A method for preparing the implant, to a therapeutic composition, includes cartilage cells and/or precursor cells thereof and a cartilage-specific collagen type. The implant and the therapeutic composition are suitable in particular for treating damage and/or diseases relating to the human and/or animal musculoskeletal system. | 02-16-2012 |
| 20120039962 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 02-16-2012 |
| 20120039963 | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation - A pharmaceutical dosage form for controlled release of the active substance 3-(2-dimethylaminomethylcyclohexyl)-phenol, preferably (1R,2R)-3-(2-dimethylaminomethylcyclohexyl)-phenol, or a pharmaceutically acceptable salt thereof, which dosage form (i) in vivo produces a peak plasma level of the active substance after 2 to 10 hours, and/or (ii) in vitro releases 3.0 to 37 percent by weight of the active substance originally contained in the dosage form after one-half hour, 5.0 to 56 percent by weight after one hour, 10 to 77 percent by weight after two hours, 15 to 88 percent by weight after 3 hours, at least 30 percent by weight after six hours, at least 50 percent by weight after 12 hours, at least 70 percent by weight after 18 hours, and at least 80 percent by weight after 24 hours when measured according to the European pharmacopoeia using a blade mixer in preferably 900 ml of a buffer solution at a pH value of 6.9, a temperature of 37° C., and 75 rpm. | 02-16-2012 |
| 20120039964 | NOVEL FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS WITH HIGH BIOAVAILABILITY - The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ≧380, preferably of ≧600, most preferably ≧900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ≦30% when pressed to tablets. | 02-16-2012 |
| 20120039965 | ENHANCED ANTIMICROBIAL ACTIVITY COMPOSITIONS OF BLENDS OF PLANT ESSENTIAL OILS - Antimicrobial compositions based on a combination or blend of plant essential oils is of enhanced antimicrobial effectiveness; by adding to the combination of at least two plant essential oils, and preferably adds a small but antimicrobial enhancing effective amount of an enhancer selected from the group consisting of polyionic organic enhancers and polyionic inorganic enhancers. One preferred blended oil composition is a mixture of plant essential oils wherein at least one of the oils is oregano oil. The oil blend is used as a major component in the finished product anti-microbial. | 02-16-2012 |
| 20120045479 | Dry Powder Formulations, Vaccines and Methods - Respirable dry powder formulations comprise myo-inositol and leucine. Dry powder human papillomavirus (HPV) vaccine formulations comprise a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. Methods of administering an HPV vaccine to an individual comprise inhalation administration to the individual of a dry powder HPV vaccine formulation comprising a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. | 02-23-2012 |
| 20120045480 | COMPOSITION COMPRISING SILVER NANOPARTICLES AND EXTRACTS OF POLYGONUM MULTIFLORUM THUNB AND THE USE THEREOF - A pharmaceutical composition comprising effective amount of silver nanoparticles and extracts of | 02-23-2012 |
| 20120045481 | PREVENTIVE AND/OR AMELIORATIVE AGENT FOR DISEASES, STAMINA ENHANCEMENT AGENT, ANTI-FATIGUE AGENT, AND PHARMACEUTICAL AND FOOD AND DRINK USING THEM - A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria. The purple non-sulfur bacteria includes | 02-23-2012 |
| 20120045482 | POLICOSANOL NANOPARTICLES - The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions. | 02-23-2012 |
| 20120045483 | Mannitol and/or Proline for Prevention and Treatment of Ageing Related Symptoms - The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses Mannitol 5 and/or proline containing compositions that are particularly useful for the treatment of premature ageing related symptoms in mammalian subjects suffering from genetic defects in DNA damage response and genome maintenance pathways. Humans suffering from Cockayne syndrome (CS), Xerodema pigmentosum (XP), combined XPCS, trichothiodystrophy (TTD), COFS (cerebro-oculo-facio-skeletal syndrome), 10 XFE disorder (Xpf-Erccl syndrome), Bloom Syndrome (BS), Werner Syndrome (WS), Ataxia telangiectasia (AT), Fanconi Anemia (FA), Hutchinson Guilford Progeria (HGP) may be treated with pharmaceutical compositions comprising mannitol and/or proline according to this invention. | 02-23-2012 |
| 20120045484 | CALCIUM PHOSPHATE/SULFATE-BASED BONE IMPLANT COMPOSITION - A bone graft composition includes beta-tricalcium phosphate and calcium sulphate and slowly soluble sources of calcium ions and hydroxyl ions. | 02-23-2012 |
| 20120045485 | SUSTAINED RELEASE DOSAGE FORM - An osmotic dosage form which comprising:
| 02-23-2012 |
| 20120045486 | DELIVERY SYSTEMS - The present invention provides a delivery system for active and functional ingredients. In particular, the delivery systems of the present invention find particular application in the delivery of active and functional ingredients, such as medicaments, pharmaceuticals, nutritional supplements, botanicals, cosmeceuticals etc. Further, the invention relates to a delivery system for oral or topical administration of such active and functional ingredients. The invention is a delivery system based on a particulate gel precursor that acts both as the bodying agent,as well as the dispersing and suspending agent in the formulation. By modifying the level of precursor and process conditions, a broad range of product consistencies can be achieved ranging from thin liquid suspension to firm or semi solid gel. The precursor gel is a particulate linear chain fuctan gel. Inulin is a preferred fructan. | 02-23-2012 |
| 20120045487 | MULTIPHASIC MICROFIBERS FOR SPATIALLY GUIDED CELL GROWTH - A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and is formed by electrohydrodynamic jetting. Further, such microfibers optionally have one or more biofunctional agents, which may be surface-bound moieties provided in spatial patterns. Multiphasic microfibers formed in accordance with the disclosure may form, in some cases, three-dimensional fiber scaffolds with precisely engineered, micrometer-scaled patterns for cellular contact guidance, which may thus support and/or promote cellular growth, proliferation, differentiation, repair, and/or regeneration for tissue and bioengineering applications. | 02-23-2012 |
| 20120045488 | COMPRESSED SOLID DOSAGE FORM MANUFACTURING PROCESS WELL-SUITED FOR USE WITH DRUGS OF LOW AQUEOUS SOLUBILITY AND COMPRESSED SOLID DOSAGE FORMS MADE THEREBY - A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing the blend into a solid, comminuting the solid into granules, wetting the granules, drying the granules, and tabletting the dried granules to make a solid pharmaceutical formulation. | 02-23-2012 |
| 20120045489 | Nano-Emulsion Injection of Vinca Alkaloids and the Preparation Method Thereof - A nano-emulsion injection of Vinca alkaloids and its preparation method are disclosed. The injection is an oil-in-water emulsion injection comprising Vinca alkaloids or their salts, injectable oil, surfactant(s) and injectable water, wherein the average diameter of the droplets of the emulsion is less than 100 nm and the pH of the emulsion is 7-9. The preparation method comprises the steps of preparing the oil phase and the aqueous phase respectively, homogeneously mixing the oil phase and the aqueous phase with high speed, adding the active ingredient, adjusting the pH to 7-9, adding water to constant volume, and homogenizing the emulsion till the average diameter of the droplets being less than 100 nm. The alternative method comprises the steps of homogeneously mixing the oil phase and the aqueous phase, homogenizing the obtained emulsion under high pressure till the average diameter of the droplets being less than 100 nm, adding the active ingredient, adjusting the pH to 7-9, stirring, and adding water to constant volume. | 02-23-2012 |
| 20120058150 | Methods for Delivering Compositions by Electrospraying a Medical Device - Methods are provided for administering a phospholipid composition to a subject, comprising coating a medical device with at least one layer of a phospholipid composition, wherein the coating is achieved by electrospraying the device with the composition, and wherein the composition is carrying or can carry at least one therapeutic agent. | 03-08-2012 |
| 20120058151 | NANOPARTICULATE COMPOSITIONS OF POORLY SOLUBLE COMPOUNDS - The present invention relates to a method for the production of a nanoparticulate pharmaceutical composition. The method comprises the steps of a) suspending in water a poorly soluble active ingredient without the presence of a detergent, b) mechanically treating said suspension to obtain particles comprising the active ingredient with an effective average size of less than about 5000 nm, c) contacting said active ingredient or suspension with a first polyelectrolyte during and/or before mechanically treating, d) optionally contacting said suspension with a one or more second or further polyelectrolytes during, before and/or after mechanically treating, e) optionally drying said suspension. The invention also pertains to the pharmaceutical compositions obtained by the method of the invention. | 03-08-2012 |
| 20120058152 | BONE REGENERATION MATERIALS BASED ON COMBINATIONS OF MONETITE AND OTHER BIOACTIVE CALCIUM AND SILICON COMPOUNDS - The present invention incorporates new materials for bone regeneration, methods for their manufacture, and application in traumatology surgery, maxillo facial surgery, dental surgery, orthognatic surgery, endodontics, ophthalmology, neurosurgery and/or osteoporotic processes, and other indications where bone regeneration is required. In particular, the present invention incorporates synthetic materials with a 20% to a 95%, preferably between 40% and 90% in mass of monetite [Ca | 03-08-2012 |
| 20120058153 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PROTEINS OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS HEMAGGLUTININ - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include polypeptides obtained or derived from human influenza A virus hemagglutinin. | 03-08-2012 |
| 20120058154 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PEPTIDES OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS M2E - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus M2 protein. | 03-08-2012 |
| 20120058155 | SLOW-DEGRADING POLYMERS FOR UNDELAYED AND SUSTAINED DRUG DELIVERY - The invention provides polymers and methods for their use. Certain embodiments of the invention provide slow degrading microspheres for undelayed and sustained drug delivery. | 03-08-2012 |
| 20120058156 | ACTIVATED LEUKOCYTE COMPOSITION AND USES FOR WOUND HEALING - Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds. | 03-08-2012 |
| 20120058157 | Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis - Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol in the gastrointestinal (GI) tract and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal. Also provided are methods of treating a cardiovascular disorder associated with atherosclerosis in a mammalian subject comprising administering to the subject a layered phyllosilicate material in an amount effective to reduce atherosclerotic lesion formation in the subject. | 03-08-2012 |
| 20120058158 | Sublingual Pharmaceutical Composition Comprising a Neutral Oil - The invention provides pharmaceutical compositions for the sublingual delivery of medicaments comprising a neutral oil and a medicament soluble in said oil, providing that said medicament is not nitroglycerine. The invention also provides delivery devices adapted for sublingual delivery of such compositions. | 03-08-2012 |
| 20120058159 | Treatment of Animal Litter With Ferric Sulfate Granules - Methods of treating animal litter and/or bedding material for control of volatile ammonia and soluble phosphorous include applying granular partially hydrated ferric sulfate to the litter. The partially hydrated ferric sulfate ranges from gray to tan in color and is spread onto the litter at a rate effective to reduce ammonia volatilization and reduce soluble phosphorous. Relative to reagent grade ferric sulfate, the partially hydrated ferric sulfate exhibits lower hygroscopicity and higher deliquescence. The ferric sulfate is prepared by a process comprising oxidizing ferrous sulfate with sulfuric acid using a molecular oxygen oxidizing agent at an elevated pressure relative to atmospheric and at a temperature of 60° C. to 140° C. to produce a gray to tan colored granular product. | 03-08-2012 |
| 20120058160 | PARTICULATE MATERIALS - Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof. In some examples, the alkaloid ergotamine contains dihydroergotamine, such as dihydroergotamine mesylate and the hydrofluorocarbon fluid vehicle contains HFA 134a, HFA 227ea, or mixtures thereof. | 03-08-2012 |
| 20120058161 | ALKYLATED SEMI SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS, AND METHODS FOR MAKING AND USING THEREOF - Described herein are alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated and alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including use for ocular or ophthalmic treatment. | 03-08-2012 |
| 20120058162 | STABLE, SPRAY DRYED, IMMUNOGENIC, VIRAL COMPOSITIONS - Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity. | 03-08-2012 |
| 20120064123 | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye - The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles (Nanopids™), aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use. | 03-15-2012 |
| 20120064124 | MACROLIDE DOSAGE FORMS - Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile. | 03-15-2012 |
| 20120064125 | AGR-MEDIATED INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS - The present invention involves the use of activators of bacterial Agrquoroum-sensing systems to prevent or reverse biofilm formation in methicillin resistant | 03-15-2012 |
| 20120064126 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES - The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. | 03-15-2012 |
| 20120064127 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING OF CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
| 03-15-2012 |
| 20120064128 | NANO-METALLIC ALLOY DELIVERY SYSTEM FOR TREATMENT OF INFECTED CELLS AND LEGIONS - A system for delivering nano-metallic alloys to infected cells in a patient is disclosed. The nano-metallic alloy may be formed from binary, triple, or quadruple elemental compositions complexed in predetermined percentages of monosodium phosphate monohydrate and disodium phosphate heptahydrate. The nano-metallic alloy may be capable of eliminating infectious microorganisms within infect cells or legions without harming the cells or tissues. The system may also include a method of administering a predetermined concentration of the nano-metallic alloy in the complexing solution in the vicinity of the infected cells of legions to kill the foreign matter. | 03-15-2012 |
| 20120064129 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 03-15-2012 |
| 20120064130 | METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2 - The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO | 03-15-2012 |
| 20120064131 | SILVER-BASED INORGANIC ANTIMICROBIAL AGENT AND METHOD FOR PREPARING THE SAME - Disclosed are a powder of a silver-based inorganic antimicrobial agent with superior dispersability or water permeability, composed of silver-supporting hexagonal zirconium phosphate, and an antimicrobial product and a water processing material using the silver-based inorganic antimicrobial agent powder. The silver-based inorganic antimicrobial agent containing hexagonal zirconium phosphate crystals, which has a particle size distribution to enable easy handling as a powder and contribute to exhibition of antimicrobial properties, can be prepared by a preparation method including wet-heating zirconium carbonate. When the silver-based inorganic antimicrobial agent wherein particles with a size of 10 μm to 100 μm are 90% or more on a volume basis is kneaded into resin products, since aggregation or the like may not occur and the silver-based inorganic antimicrobial agent can be easily exposed on the surface of molded articles, antimicrobial effects are thus readily exhibited on the surface. | 03-15-2012 |
| 20120064132 | ANTIBACTERIAL MEDICAL EQUIPMENT AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide an antibacterial medical equipment which has sufficient antibacterial activity in vivo and is excellent in compatibility with living tissues, and also can maintain antibacterial activity over a long period and has high safety. | 03-15-2012 |
| 20120064133 | Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations - Multiparticulate controlled-release selective serotonin reuptake inhibitor (SSRI) formulations for oral administration, which comprise subunits of a SSRI or a pharmaceutically acceptable salt thereof which are not coated with a rate-controlling polymer, are provided. Methods for preparation and use of these formulations are also provided. | 03-15-2012 |
| 20120070465 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed. | 03-22-2012 |
| 20120070466 | Conjugated Polymeric Material and Uses Thereof - Disclosed are compositions comprising collagen covalently bound to particles, wherein covalent bonds are formed between reactive groups of the collagen and reactive groups of the particles, and wherein the particles have an average particle diameter ranging from 20 to 1000 nanometers. Also disclosed are various methods that utilize the compositions. | 03-22-2012 |
| 20120070467 | Ophthalmic Drug Delivery - The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye. | 03-22-2012 |
| 20120070468 | REMOVAL OF TOXINS FROM GASTROINTESTINAL FLUIDS - A process for the removal of toxic cations and anions from gastrointestinal fluids is disclosed. A pH-increasing medication is administered prior to or together with a microporous cation exchanger. An additional feature of the invention is the use of a proton form of the microporous cation exchanger. The acidity of the gastrointestinal fluids is decreased to improve the stability of the microporous cation exchangers, which are represented by the empirical formula: | 03-22-2012 |
| 20120070469 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS - Nanoparticulate assemblies of isolated β-casein are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. The nanoparticulate assemblies can be freeze-dried and re-suspended prior to administration. | 03-22-2012 |
| 20120070470 | HEMOSTATIC COMPOSITIONS, DEVICES, AND METHODS - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery. | 03-22-2012 |
| 20120070471 | ADMINISTRATION OF ENOXOPARIN SODIUM TO PATIENTS 75 YEARS AND OLDER WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION - Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. The methods may include fibrinolytic therapy. The treatment methods may be used to prevent one or more of, mortality, myocardial re-infarction, myocardial ischemia, stroke, or severe congestive heart failure. Articles of manufacture for use in connection with treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older are also disclosed. | 03-22-2012 |
| 20120070472 | CHRONOTHERAPEUTIC COMPOSITIONS AND METHODS OF THEIR USE - Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject:
| 03-22-2012 |
| 20120070473 | Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions - A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results. | 03-22-2012 |
| 20120070474 | POLYMER COMPOUND FOR BIOMEDICAL USE AND BIOCHIP SUBSTRATE USING SUCH A POLYMER COMPOUND - A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate. | 03-22-2012 |
| 20120070475 | Zero Calorie Polyphenol Aqueous Dispersions - A method for stably dispersing microparticulated water insoluble bioactive polyphenol in a beverage by combining the bioactive polyphenol dissolved in an alkaline solution with an aqueous solution of at least one dispersion stabilizer. A composition comprising dispersed microparticulated water insoluble bioactive polyphenol(s) and a dispersion stabilizer. | 03-22-2012 |
| 20120070476 | Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces - The present disclosure includes compositions and methods of inactivating pathogens of a genital tract of a female. The compositions include L-lactic acid substantially free of D-lactic acid. In particular, an intravaginal ring for sustained release of L-lactic acid out of a reservoir containing multi-gram quantities of L-lactic acid, with minimal osmotically induced swelling or pressurization of the reservoir during prolonged use is provided. | 03-22-2012 |
| 20120070477 | DRY POWDER FIBRIN SEALANT - A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica. | 03-22-2012 |
| 20120076830 | DIFFERENTIATION OF STEM CELLS WITH NANOPARTICLES - A method for differentiating mesenchymal stem cells (MSCs) towards osteoblasts and other connective tissue using nanoparticles and electromagnetic stimulation Osteoinductive materials produced using said method may be useful for bone regeneration and reconstruction in treatment of bone trauma and bone related diseases, and to correct birth defects. | 03-29-2012 |
| 20120076831 | COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE - The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions. | 03-29-2012 |
| 20120076832 | SYNTHESIS AND USE OF THERAPEUTIC METAL ION CONTAINING POLYMERIC PARTICLES - Therapeutic particles contain metal ions and are characterized by the use of unique ligand sets capable of making the metal ion complex soluble in biological media to induce selective toxicity in diseased cells. The particles may comprise a polymeric base particle, at least one pharmaceutically active metal ion, including metal ions from more than one metal element, a ligand that is covalently attached to the polymeric base particle and attached to the metal ion via a stimuli-responsive bond, and a cell targeting component. When the metal ion-containing particle enters a pre-defined environment, the ligands binding the metal to the particle are broken, triggering release of the free metal ion while the original ligands remain covalently bound to the particle. | 03-29-2012 |
| 20120076833 | SURFACE-ORIENTED ANTIBODY COATING FOR THE REDUCTION OF POST-STENT RESTENOSIS - A coating for a surface of a surgical implant, the coating including a binding protein for capturing cells to the surface via a bi-functional linker molecule. The linker can have a first functional group (such as a trichlorosilyl group) for covalently linking to the surface, and a second functional group (such as a benzothiosulfonate group) for covalently linking to the binding protein. One exemplary linker molecule is S-(11-trichlorosilyl-undecenyl)benzenethiosulfonate. The coating may be a self-assembled monolayer and may also include a spacer molecule, which can be unreactive with the binding protein. The target cells may be endothelial stem cells (such as endothelial progenitor cells). The binding protein may be an antibody, antibody fragment or non-antibody derived antigen binding molecule. The binding protein may bind a cell surface marker specific to target cell type. Coated surgical implants, and methods of forming such a coating are also contemplated. | 03-29-2012 |
| 20120076834 | Protective Coatings For Acidic Active Ingredients - Dosage forms provided with protective coatings in which a core comprising at least one acidic active ingredient is provided with at least one inner and one outer coating layer, where the outer layer comprises, as component A, a cationic polymer which is an emulsion polymer of N,N-diethylaminoethyl methacrylate and further monomers. | 03-29-2012 |
| 20120076835 | HIV INHIBITING PYRIMIDINES DERIVATIVES - This invention concerns HIV replication inhibitors of formula | 03-29-2012 |
| 20120076836 | POLYION COMPLEX OF DOUBLE-STRANDED RIBONUCLEIC ACID - Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like. A polyion complex in the form of a non-polymeric micelle consisting of a double-stranded ribonucleic acid and a block copolymer represented by the formula (I) or (II) below, which are electrostatically bound together, wherein the polyion complex has an average particle diameter of less than 100 nm as measured by a dynamic light scattering measuring method: | 03-29-2012 |
| 20120076837 | SURFACE ENGINEERING OF TISSUE GRAFT MATERIALS FOR ENHANCED POROSITY AND CELL ADHESION - In one aspect, the invention relates to providing enhanced application tissue graft materials in regenerative medicine through improved cellular interactions. Biocompatible implant materials, methods for preparing biocompatible implant materials, methods for using same, and methods for treating tissue injury are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 03-29-2012 |
| 20120076838 | POORLY SOLUBLE DRUG CONTAINING MICROSPHERE WITH IMPROVED BIOAVAILABILTY AND METHOD OF PREPARING THE SAME - A poorly soluble drug containing microsphere with improved bioavailability, an oral formulation comprising the same, and a method of preparing the same are provided, wherein the poorly soluble drug containing microsphere is a solid dispersion wherein the poorly soluble drug is dispersed in the water-soluble polymer carrier in a noncrystalline form by spray drying, thus increasing bioavailability of the poorly soluble drug. | 03-29-2012 |
| 20120082704 | Oxygenated demineralized bone matrix for use in bone growth - An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone. | 04-05-2012 |
| 20120082705 | Tetra Calcium Phosphate Based Organophosphorus Compositions and Methods - Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least tetra calcium phosphate, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive strength in both wet and dry environments and exhibit significant bond strength upon curing. | 04-05-2012 |
| 20120082706 | MEDICAL DEVICE FOR DRUG DELIVERY - A medical device for safe and sure delivery of drugs to the lesion and a method for production thereof. The medical device has at least part of its surface in contact with the lumen wall tissue of the living body coated with a drug releasing layer containing a drug and a phospholipid, the drug and the phospholipid forming a solid dispersion. | 04-05-2012 |
| 20120087948 | PARTICULATE CARTILAGE SYSTEM - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 04-12-2012 |
| 20120087949 | OLIGONUCLEOTIDE MICELLES - The present invention provides homogenous populations of micelles, methods for preparing these populations, methods for treating or preventing a disease or disorder using the population of micelles of the invention. | 04-12-2012 |
| 20120087950 | FUNCTIONALIZED CALCIUM PHOSPHATE ARTIFICIAL BONE AND JOINT COMPOSITIONS AND METHODS OF USE AND MANUFACTURE - The present invention provides a functionalized composition and resulting functionalized body or prosthesis for in vitro and in vivo use comprising at least one calcium phosphate containing phase that is functionalized with a linker group comprising at least one of an organic acid molecule, a phosphonic acid, an amine, N,N-dicyclohexylcarbodiimide, and 3-maleimidopropionic acid N-hydroxysuccinimide ester, and combinations thereof, and one or more of a chemical and/or a biologically active moieties, wherein the linker group provides for a reactive location for the attachment of the chemical or biologically active moiety, or both, to the calcium phosphate containing phase, and optionally including an unmodified and/or modified calcium aluminate containing phase. The functionalized compositions have a pliable physical property when mixed with water and adhere to natural bone and subsequently harden at ambient temperatures. Methods of manufacturing a functionalized artificial prosthesis that may be used as artificial bones, joints, in-vitro support structures, and in-vivo support structures for cells, tissues, organs, and nerve growth and regeneration are disclosed. Methods of repairing a bone, vertebrae, or tissue structures using the functionalized compositions are provided. | 04-12-2012 |
| 20120087951 | Fabric with Antimicrobial Properties - A method of producing a fabric with antimicrobial properties that includes liquefying bamboo to produce a slurry, adding an antimicrobial element to the slurry, adding a non-bamboo fiber to the slurry to create a mixture and extruding the mixture to produce a fiber. The antimicrobial fabric may include a composition of 69% bamboo, 30% cotton and 1% silver. | 04-12-2012 |
| 20120087952 | Pulmonary Delivery in Treating Disorders of the Central Nervous System - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm | 04-12-2012 |
| 20120087953 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE PHARMACEUTICAL INGREDIENT COMPRISING SULPHONYLUREA MOIETY WITH EXCELLENT DISSOLUTION PROPERTIES - The present invention provides a pharmaceutical composition comprising at least one active pharmaceutical ingredient comprising sulphonylurea moiety, wherein the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is intimately mixed with a basic agent. The weight ratio of the basic agent and the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is from 2.5:1 to 50:1, preferably from 2.5:1 to 25:1, more preferably from 3.5:1 to 15:1, yet more preferably from 3.5:1 to 10:1. The pharmaceutical composition can be obtained by simply mixing active pharmaceutical ingredient comprising sulphonylurea moiety and the basic agent in the aforementioned weight ratio, optionally in the presence of the granulation liquid. Alternatively, the pharmaceutical composition can be obtained by at least partially or fully dissolving the compounds in the granulation liquid or solvent, and at least partly precipitating them. The invention provides improved dissolution properties of the active pharmaceutical ingredient comprising sulphonylurea moiety. | 04-12-2012 |
| 20120087954 | ION SUBSTITUTED CALCIUM PHOSPHATE COATINGS - A method for the formation of a surface coating of an ion substituted calcium phosphate on a substrate, the coating itself and the use of the coating. | 04-12-2012 |
| 20120087955 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 04-12-2012 |
| 20120087956 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES - A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure. | 04-12-2012 |
| 20120087957 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUSPENSIONS FOR INHALATION - Process for preparing sterile suspensions for inhalation comprising an active ingredient insoluble in water and wherein at least 80% of the particles of said active ingredient have a diameter between 3 and 5 μm, comprising the following stages: dissolving the active ingredient in the minimum quantity of an alcoholic solvent, optionally in the presence of a polyol and adding at least one surfactant, filtering the solution obtained in the previous stage through a sterilizing filter, adding the solution from stage (b) to sterile water under sonication to directly obtain a suspension wherein the particles have a reduced diameter. | 04-12-2012 |
| 20120087958 | Multi-Dimensional Biomaterial and Method for Producing the Same - Biomaterial having a multi-dimensional structure and comprising differentiated MSCs tissue and demineralised bone matrix, wherein said demineralised bone matrix is dispersed within the differentiated MSCs tissue, method for producing the same and use thereof. | 04-12-2012 |
| 20120087959 | NANODISPERSION OF A DRUG AND PROCESS FOR ITS PREPARATION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more drugs, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. | 04-12-2012 |
| 20120093876 | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions - The present invention provides process for producing non-aqueous compositions for normalizing meibomian gland secretions. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease. | 04-19-2012 |
| 20120093877 | COLLAGEN SCAFFOLD FOR CELL GROWTH AND A METHOD FOR PRODUCING SAME - A bioscaffold and method of manufacture is described. The bioscaffold comprised greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. The method of manufacture comprises the steps of: (a) isolating collagen fibers or bundles; (b) incubating said fibers or bundles in a mixture of NaOH, alcohol, acetone, HC; and ascorbic acid; and (c) mechanical manipulation of said fibers or bundles to produce a knitted structure. | 04-19-2012 |
| 20120093878 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE - The present invention relates to pharmaceutical compositions that include a combination of a biguanide present in an extended-release form and a thiazolidinedione present in an immediate-release form. The present invention further relates to the processes for preparing such compositions. | 04-19-2012 |
| 20120093879 | CARDIAC STEM CELLS AND USES OF SAME IN CARDIAC REPAIR - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 04-19-2012 |
| 20120093880 | METHOD AND KIT FOR TOPICAL ELIMINATION OF PSORIATIC LESIONS WITH A CAUSTIC APPLICATOR - A method and kit for eliminating a psoriatic lesion involves removal of loose psoriatic scales if present, and moistening remaining scales to a depth to or just above epidermal tissue underlying the scales. The hydrated scales are then contacted with a dry composition of from about 50% to about 95% silver nitrate using a specially configured applicator such that a portion of the moisture of the hydrated psoriatic scales will be absorbed into the dry composition so as to dissolve an outer layer of the silver nitrate into a solution. The solution will then be absorbed into the psoriatic scales to the depth of the moistening thereof to chemically cauterize the moistened scales. The method can be repeated until elimination is achieved. Cauterization of surrounding and underlying tissue is undesirable, and if contacted by moisture, dehydration can be allowed, and the lesion rehydrated as necessary. | 04-19-2012 |
| 20120093881 | DISRUPTIVE POLYMER MICELLE COMPOSITION - A pharmaceutical composition containing a drug encapsulated in a polymer micelle composition containing a first block copolymer having affinity with HDL and a second block copolymer having affinity with a lipoprotein excluding HDL, each block copolymer having a hydrophobic polymer chain segment and a hydrophilic polymer chain segment such that a plurality of block copolymers arrange radially with the hydrophobic segments directed inward and the hydrophilic segments directed outward. In the composition, a detachment of the first block copolymer is induced by HDL adhesion which forms a gap and promotes the release of a drug encapsulated, while the second block copolymer excluding an affinity with HDL controls a release speed of the drug encapsulated. | 04-19-2012 |
| 20120093882 | STABLE PHARMACEUTICAL COMPOSITIONS OF DICLOFENAC - The present invention discloses a stable pharmaceutical composition of diclofenac or salts thereof comprising nano size droplets of diclofenac or salts thereof, wherein the composition exhibits a significant difference in one or both of the rate and extent of absorption of diclofenac or salts thereof as compared to formulation of diclofenac marketed under the trade name Voveran® | 04-19-2012 |
| 20120093883 | METHOD OF TREATING AND PREVENTING NEURO-OLFACTORY TRIGGERED OR AGGRAVATED ILLNESSES OR RELATED CONDITIONS - A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that includes one or more agents adapted to induce a level of anosmia/hyposmia in the subject, which level of anosmia/hyposmia is sufficient to substantially decrease olfactory sensory stimulation within the subject and a neurologic response to the stimulation that is one or both of triggering and aggravating the illness or condition; and b) applying the composition to a nasopharynx region of the subject. | 04-19-2012 |
| 20120093884 | NOROVIRUS CAPSID AND ROTAVIRUS VP6 PROTEIN FOR USE AS COMBINED VACCINE - The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2/VP6 VLPs. In addition, the invention relates to methods of inducing an immune response. | 04-19-2012 |
| 20120093885 | THERAPEUTIC VESICLES - The present technology provides compositions of vesicles, uses of vesicles, and methods relating to vesicles. For example, provided herein are vesicles derived from stem cells for use in regenerative therapies. | 04-19-2012 |
| 20120093886 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 04-19-2012 |
| 20120093887 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES - Disclosed herein is a stable amorphous coprecipitate comprising varenicline tartrate and a pharmaceutically acceptable excipient selected from the group consisting of maltodextrin, lactose monohydrate and 2-hydroxypropyl-β-cyclodextrin, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous coprecipitates of varenicline tartrate disclosed herein have improved physiochemical characteristics that assist in the effective bioavailability. | 04-19-2012 |
| 20120093888 | MICRO-EMULSIONS FOR THE TREATMENT OF RHEUMATIC DISORDERS - A formulation to treat rheumatic disorders and related infections is provided. The formulation is a micro-emulsion including at one or more of an active ingredients. The active ingredient includes one or more of an essential oil mixed with an aqueous phase along with one or more of a surfactant and one or more of a co-surfactant. The co-surfactant is medicated by an extract of one or more of an herb. | 04-19-2012 |
| 20120093889 | LAYERED PHARMACEUTICAL FORMULATIONS - In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine. | 04-19-2012 |
| 20120093890 | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by | 04-19-2012 |
| 20120093891 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-19-2012 |
| 20120093892 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 04-19-2012 |
| 20120093893 | Highly Efficient Delivery of a Large Therapeutic Mass Aerosol - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm | 04-19-2012 |
| 20120093894 | STABLE CYCLOSPORINE CONTAINING OPHTHALMIC EMULSION FOR TREATING DRY EYES - Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 μm including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also include a hydrophilic surfactant having an HLB value between approximately 10 and 14, a vegetable oil-derived hydrophobic non-co-block surfactant having unsaturated side chains that contain less than four oxygen atoms having an HLB value between approximately 4 and 6 and is a liquid at room temperature. The oil-in-water emulsion ophthalmic topical liquid compositions disclosed herein can further include an amount of cyclosporine A or polyphenol in an amount effective to relieve dry eye symptoms. | 04-19-2012 |
| 20120093895 | BONE-REPAIR COMPOSITION - The present invention relates to a bone-repair composition comprising a micro-pulverized demineralized bone matrix; a nonmicro-pulverized demineralized bone matrix; and a hydrating material. The bone-repair composition of the present invention provides easier injectability and shape-maintenance (handling), and exhibits excellent bone-repairing effects due to a large surface area of the micro-pulverized demineralized bone matrix and an early release of the bone growth factors, compared with conventional compositions comprising the nonmicro-pulverized demineralized bone matrix alone. It also has an advantage of being biocompatible and harmless to the human body because there is no use of synthetic materials. | 04-19-2012 |
| 20120100182 | Continuous Cell Programming Devices - The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer. | 04-26-2012 |
| 20120100183 | Topical base and active agent-containing compositions, and methods for improving and treating skin - The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes. | 04-26-2012 |
| 20120100184 | SYNTHESIS OF 1-AMINO-1,3,3,5,5,-CYCLOHEXANE MESYLATE - Process for manufacturing 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate comprising step (i):
| 04-26-2012 |
| 20120100185 | REGENERATION OF TISSUE WITHOUT CELL TRANSPLANTATION - The present invention provides methods and compositions for tissue regeneration without cell transplantation. | 04-26-2012 |
| 20120100186 | NANOPARTICULATE-BASED CONTRACEPTIVE/ANTI-HIV COMPOSITION AND METHODS - Nanoparticulate compositions which employ membrane-integrating peptides to effect contraception and/or protection against infection by sexually transmitted virus are described. | 04-26-2012 |
| 20120100187 | COATINGS AND METHODS FOR CONTROLLED ELUTION OF HYDROPHILIC ACTIVE AGENTS - Embodiments of the invention include multi-layer coatings and methods for controlling the elution of hydrophilic active agents. In an embodiment, the invention includes a medical device including a substrate, a primer polymer layer disposed on the substrate, an expandable layer disposed on the primer polymer layer, and a hydrophilic active agent dispersed within the expandable layer. In an embodiment, the invention includes a method of forming a medical device including depositing a primer layer onto a substrate, the primer layer comprising a primer polymer. The method can further include depositing an expandable layer onto the primer layer, the expandable layer including an expandable polymer, and a hydrophilic active agent. The expandable layer can be deposited with a solvent that is effective to solvate both the expandable polymer and the primer polymer. Other embodiments are also included herein. | 04-26-2012 |
| 20120100188 | SOLID STATE FORMS OF PALIPERIDONE SALTS AND PROCESS FOR THE PREPARATION THEREOF - Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I): More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid selected from the group consisting of L-(+)-tartaric acid, p-toluenesulfonic acid, maleic acid, oxalic acid, fumaric acid, acetic acid and malic acid. Provided also herein is a process for preparing substantially pure paliperidone free base using the solid state forms of paliperidone salts. | 04-26-2012 |
| 20120100189 | DELAYED RELEASE RASAGILINE MALATE FORMULATION - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 04-26-2012 |
| 20120100190 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 04-26-2012 |
| 20120100191 | METHODS AND DEVICES FOR DELIVERY OF PHARMACEUTICAL AGENTS WITHIN ORIFICES OF THE BODY - A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active pharmaceutical ingredient as a result of elastic stressing. | 04-26-2012 |
| 20120100192 | LOCAL THERAPEUTIC RELEASE DEVICE - An oral delivery device for the treatment of periodontal disease, the device being in a solid unit dosage form configured for insertion into a periodontal pocket of a patient. The device consists of: (a) a biodegradable pharmaceutically acceptable water-insoluble polymer in the form of a matrix; (b) a therapeutically effective amount of at least one anti-inflammatory agent dispersed within the matrix; (c) optionally a plasticizing agent; (d) optionally at least one of a wetting agent, a suspending agent and a dispersing agent; and (e) optionally an enzymatically biodegradable pharmaceutically acceptable water soluble polymer dispersed within the matrix. The biodegradable water-insoluble polymer is degradable by enzymatic degradation, physical disintegration or a combination thereof. Also disclosed is a periodontal implant comprising the device and a method for the treatment of periodontal disease comprising administering to a periodontal pocket of a patient in need of such treatment the delivery device. | 04-26-2012 |
| 20120107365 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 05-03-2012 |
| 20120107366 | Block Copolymer Systems and Their Use in Medical Devices - The present disclosure relates to block copolymers, methods for their production, and the use of these copolymers in medical devices. In embodiments, the block copolymers may be used in tissue reinforcement including, for example, in hernia repair. The copolymers possess at least one block that is hydrophilic and fast degrading, and at least one other block that is hydrophobic and slower to degrade. | 05-03-2012 |
| 20120107367 | Site-Specific Intestinal Delivery of Adsorbents, Alone or in Combination with Degrading Molecules - Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon. | 05-03-2012 |
| 20120107368 | COMPRESSIBLE TABLET MATERIAL HAVING AN OIL-CONTAINING ACTIVE SUBSTANCE, TABLET AS WELL AS METHOD AND DEVICE FOR THE PRODUCTION THEREOF - The invention relates to a compressible tablet material comprising the following components:
| 05-03-2012 |
| 20120107369 | Polymers and Hydrogels - Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers. | 05-03-2012 |
| 20120107370 | METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHEA - Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | 05-03-2012 |
| 20120107371 | STIMULI-RESPONSIVE SYSTEMS FOR CONTROLLED DRUG DELIVERY - A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades. | 05-03-2012 |
| 20120107372 | RECOMBINANT GELATINS - The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBEmonomersequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications. | 05-03-2012 |
| 20120107373 | Composites of hydroxyapatite and calcium carbonate and related methods of preparation and use - Carbonated calcium phosphate compositions and methods of preparation, affording enhanced biophysical properties. | 05-03-2012 |
| 20120107374 | COENZYME Q10-CONTAINING COMPOSITION - The coenzyme Q | 05-03-2012 |
| 20120107375 | ANTIMICROBIAL MATERIAL - An antimicrobial material comprises propolis dispersed within a solid carrier. The antimicrobial material is preferably in the form of a film The carrier may be a polymeric material. | 05-03-2012 |
| 20120107376 | METHOD FOR IMPROVING BIOAVAILABILITY OF LATANOPROST - The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating occular hypertension and glaucoma by administering said composition to a subject in need of such treatment. | 05-03-2012 |
| 20120107377 | PARTICULATE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention provides a particulate composition containing: block copolymer units being arranged radially with hydrophobic polymer-chain segments radially inside and hydrophilic polymer-chain segments radially outside; and a charged lipid which carries a charge opposite to the charge of a drug to be encapsulated, the charged lipid being attracted to the hydrophobic polymer-chain segment. In this particulate composition, the drug is retained within the particle via electrostatic binding with the charged lipid, whereby the outer surface of the particle is prevented from being charged to attract a substance which has a charge opposite to that of the charged lipid. | 05-03-2012 |
| 20120107378 | HIGH STRENGTH CARBO SUBSTANCES - A black colouring substance, comprising carbo vegetabilis as a black pigment. The colouring substance may be used as a colouring agent in the manufacture of e.g. food and pharmaceutical products. | 05-03-2012 |
| 20120114702 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) comprising administering a therapeutic composition comprising at least one electrokinetically altered fluid comprising an ionic aqueous solution of charge-stabilized oxygen containing nanostructures as disclosed herein, or comprising administering a nonelectrokinetic superoxygenated aqueous solution The methods preferably comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e g, membrane receptors, (e g, G protein-coupled receptors, and intercellular junctions)) Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent (e g, albuterol, etc). | 05-10-2012 |
| 20120114703 | Botulinum Toxin Administration to Treat Various Conditions - Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a | 05-10-2012 |
| 20120114704 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER AND FIBROTIC DISEASES - The present invention provides antibodies or antigen-binding fragments thereof that specifically hind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression. | 05-10-2012 |
| 20120114705 | WATER SOLUBLE FILM FOR ORAL ADMINISTRATION WITH INSTANT WETTABILITY - A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity. | 05-10-2012 |
| 20120114706 | Endorphin Therapy Compositions and Methods of Use Thereof - Methods and compositions for treating cancer and other disorders by β-endorphin therapy are disclosed. | 05-10-2012 |
| 20120114707 | POLYMER MICROSPHERES/NANOSPHERES AND ENCAPSULATING THERAPEUTIC PROTEINS THEREIN - This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore. | 05-10-2012 |
| 20120114708 | INTEGRIN HETERODIMER AND AN ALPHA SUBUNIT THEREOF - A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines. | 05-10-2012 |
| 20120114709 | FORMULATIONS FOR USE IN INHALER DEVICES - A formulation for use in an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm; fine particles of an excipient material having a mass median aerodynamic diameter of not more than 20 μm; and active particles. The formulation has excellent flowability even at relatively high contents of fine particles. | 05-10-2012 |
| 20120114710 | CARBON NANOTUBES COMPLEXED WITH MULTIPLE BIOACTIVE AGENTS AND METHODS RELATED THERETO - The present invention includes fullerene carbon nanotube compositions complexed with multiple bioactive agents and methods related to such fullerene carbon nanotube compositions. | 05-10-2012 |
| 20120114711 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED SOLUBILITY - It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X (FXa), and is useful as an agent for preventing and/or treating thrombosis, wherein the pharmaceutical composition exhibits favorable dissolution properties. The present invention relates to a solid pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, wherein the content of the compound represented by formula (I) is 0.5% by weight or more and less than 15% by weight with respect to the total weight of the pharmaceutical composition. | 05-10-2012 |
| 20120114712 | UMBILICAL CORD BIOMATERIAL FOR MEDICAL USE - The present invention provides a biomaterial comprising a mammalian umbilical cord membrane. The biomaterial can additionally comprise Wharton's jelly and/or one or more umbilical cord vessels. The biomaterial is preferably dry, and can be flat, tubular, or shaped to fit a particular body structure. The invention further provides laminates comprising at least one layer of an umbilical cord membrane biomaterial. The invention further provides methods of making the biomaterial, and laminates comprising the biomaterial, and methods of using the biomaterial. | 05-10-2012 |
| 20120114713 | COMPOSITIONS OF ADULT DISC STEM CELLS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISC DISEASE - This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention. | 05-10-2012 |
| 20120114715 | USE OF LARCH WOOD FOR TREATING INFLAMMATION - The application of wood material from a tree of the genus | 05-10-2012 |
| 20120114716 | Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site. | 05-10-2012 |
| 20120114717 | TABLETING AGENT HAVING A LOW WATER CONTENT, AND METHOD FOR THE PRODUCTION THEREOF - The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties. | 05-10-2012 |
| 20120121653 | Novel mometasone compositions and methods of making and using the same - The present invention is directed to mometasone furoate compositions comprising mometasone furoate and at least one surface stabilizer. The mometasone furoate particles of the composition preferably have an effective average particle size of less than about 2000 nm. | 05-17-2012 |
| 20120121654 | NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME - The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein. | 05-17-2012 |
| 20120121656 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST NEUROTOXICITY OF A NEUROTOXIC AGENT, AND IMPROVING MOTOR COORDINATION ASSOCIATED WITH A NEURODEGENERATIVE CONDITION OR DISEASE - Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject. | 05-17-2012 |
| 20120121657 | ENHANCING BIOCOMPATIBILITY OF A MEDICAL DEVICE - The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same. | 05-17-2012 |
| 20120121658 | FUNCTIONALIZED RGD PEPTIDOMIMETICS AND THEIR MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING SUCH FUNCTIONALIZED RGD PEPTIDOMIMETICS - At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method. | 05-17-2012 |
| 20120121659 | FUNCTIONALIZED RGD PEPTIDOMIMETICS AND THEIR MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING SUCH FUNCTIONALIZED RGD PEPTIDOMIMETICS - At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method. | 05-17-2012 |
| 20120121660 | BONE VOID FILLERS - A bone void filler composition is described containing an acidic mineral component that contains a calcium source and a phosphate source or a lower alkyl carboxylate source; an osteoinductive component that contains demineralized bone; and a three-dimensional, osteoconductive biologically acceptable carrier component that contains a collagenous material. The bone void filler composition may be in the form of a sponge or in the form of a paste or putty used to form a sponge or is obtained from particulated sponge, or that forms after a sponge is rehydrated. A pre-mixed bone void filler composition is described containing the acidic mineral component or the lower alkyl carboxylate source; the osteoinductive component; and a biologically acceptable carrier component that contains a liquid carrier. Methods of making and using the compositions are also described. The ratio of demineralized bone component to acidic mineral component may range from about 0.5:1 to about 80:1. | 05-17-2012 |
| 20120121661 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY - Phosphorus-based coatings having a plurality of phosphate moieties, a plurality of phosphonate moieties, or both, covalently bonded to an oxide surface of an implantable substrate exhibiting one or more of the following characteristics: (a) the surface phosphorus-containing group density of the coated regions of the substrate is at least about 0.1 nmol/cm | 05-17-2012 |
| 20120121662 | TREATMENT USING DANTROLENE - Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. | 05-17-2012 |
| 20120121663 | TREATMENT USING DANTROLENE - Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. | 05-17-2012 |
| 20120121664 | Gastric Acid Secretion Inhibiting Composition - An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage for in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid. | 05-17-2012 |
| 20120121665 | IMPLANTABLE OR INSERTABLE MEDICAL DEVICE RESISTANT TO MICROBIAL GROWTH AND BIOFILM FORMATION - Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents | 05-17-2012 |
| 20120121666 | COMPOSITIONS OF PARTICLES - Method of making particle compositions exhibiting improved floodability and/or flowability properties. The compositions generally contain particles and non-surface modified nanoparticles. | 05-17-2012 |
| 20120121667 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-17-2012 |
| 20120121668 | COMPOSITIONS FOR ORAL ADMINSTRATION OF ACTIVE PRINCIPLES REQUIRING MASKING OF TASTE - A process for the preparation of a composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 μm. | 05-17-2012 |
| 20120128728 | Compositions Comprising Amphotericin B - The present invention comprises compositions and formulations comprising amphotericin B comprising less than 10% degradants, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions. | 05-24-2012 |
| 20120128729 | Gallium Formulation For The Treatment And Prevention of Infectious Diseases - A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as | 05-24-2012 |
| 20120128730 | COMPOSITIONS AND METHODS FOR ONCE-DAILY TREATMENT OF OBSESSIVE COMPULSIVE DISORDER WITH ONDANSETRON - Compositions for once-daily administration of ondansetron are described. Compositions include a core, a semi-permeable membrane disposed generally around the core, an orifice in the semi-permeable membrane in fluid communication with the core, and a coating having a first therapeutically effective dose of ondansetron or a pharmaceutically acceptable salt disposed generally around the semi-permeable membrane. The core includes first, second, and third layers. The first layer is in fluid communication with the orifice. The second layer includes a second therapeutically effective dose of ondansetron or a pharmaceutically acceptable salt and is located adjacent to the first layer. The third layer is located adjacent the second layer. Methods for treating obsessive compulsive disorder by administering these compositions are also described. | 05-24-2012 |
| 20120128731 | BIOCOMPATIBLE CARRIER AND METHOD FOR FABRICATING THE SAME - The invention provides a biocompatible carrier and method for fabricating the same. The biocompatible carrier includes: a gel, and a plurality of metal nanoparticles, an organic compound or combinations thereof embedded in the gel, wherein the metal nanoparticles, the organic compound or combinations thereof are uniformly distributed in the gel. | 05-24-2012 |
| 20120128732 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal. | 05-24-2012 |
| 20120128733 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE DRUGS, CONTRACEPTIVE KITS COMPRISING ACTIVE DRUGS, AND METHODS OF ADMINISTERING THE SAME - The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone. | 05-24-2012 |
| 20120128734 | Oral Delivery Product - An oral delivery product comprising a semi-permeable pouch designed for delivery of an active agent in the oral cavity of a subject. The pouch encloses multiple particles, and the particles are alginate matrices that comprise an active agent, e.g. nicotine. The alginate is e.g. sodium alginate, such as Protanal LFR 5/60 or Protanal LF 10/60. | 05-24-2012 |
| 20120128735 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 05-24-2012 |
| 20120128736 | OIL-IN-WATER EMULSION OF MOMETASONE - Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, butylene glycol and water and the weight ratio between the butylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3. | 05-24-2012 |
| 20120128737 | COMPOSITIONS FOR TREATING DEGENERATIVE JOINT DISEASES - In order to provide a composition for the treatment of degenerative joint diseases with an improved efficacy, it is proposed that the composition comprises collagen hydrolysate and rosehip powder and/or extract, wherein the weight ratio of collagen hydrolysate to rosehip powder and/or extract, in each case in relation to dry mass, lies in the range of approximately 2:1 to approximately 100:1. | 05-24-2012 |
| 20120128738 | Theobromine for the Treatment of Cough - The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough. | 05-24-2012 |
| 20120128739 | THREE-DIMENSIONAL NANOSTRUCTURED HYBRID SCAFFOLD AND MANUFACTURE THEREOF - A method of making a three-dimensional biocompatible scaffold capable of supporting cell activities such as growth and differentiation, the method includes providing a supporting grid that forms an open network and provides mechanical support of a second biocompatible material. The second biocompatible material has interconnected cavities that allow nutrients, metabolites and soluble factors to diffuse throughout the scaffold. The scaffold design can be understood as a hierarchically organised structure. At the micron to submicron length scale a top/down manufacturing approach is used to make a structure that will constitute the frame into which a bottom/up processing approach is applied to form an open porous scaffold with specific nano sized features. The advantage of this hierarchically organised design is that benefits can be drawn independently from both the micron and the nano sized structures, promoting specific cell activities and providing sufficient mechanical compliance. | 05-24-2012 |
| 20120128740 | NANOSTRUCTURED SILDENAFIL BASE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND CO-CRYSTALS, COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH). | 05-24-2012 |
| 20120128741 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS - The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses. | 05-24-2012 |
| 20120128742 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN - The present disclosure relates to crystalline form of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same. | 05-24-2012 |
| 20120135045 | Antimicrobial Collagenous Constructs - Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed. | 05-31-2012 |
| 20120135046 | CORTICOSTEROID PARTICLES AND METHOD OF PRODUCTION - A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area. | 05-31-2012 |
| 20120135047 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 05-31-2012 |
| 20120135048 | NOVEL FORMULATION OF INDOMETHACIN - The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments. | 05-31-2012 |
| 20120135049 | Decellularized tissue engineered constructs and tissues - Methods for producing tissue engineered constructs and engineered native tissues include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for production of the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. | 05-31-2012 |
| 20120135051 | GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF - The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5−/KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and/or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and/or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors. | 05-31-2012 |
| 20120135052 | METHOD FOR PREPARING AN ORGANIC-COMPATIBLE AND WATER-COMPATIBLE COMPOSITION OF METAL NANOCRYSTALS, AND RESULTING COMPOSITION - A method for preparing a composition of metal nanocrystals from at least one organometallic precursor in a solvent medium in the presence of a PEG ligand, including a carbon chain, at least one end of which is functionalized by a coordination grouping including at least one hetero atom, and having at least one [OCH | 05-31-2012 |
| 20120135053 | NANOPARTICULATE TELMISARTAN COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. | 05-31-2012 |
| 20120135054 | Poly (Ester Ether Amide)s and Uses Thereof - Cationic poly(ester ether amide)s (PEEAs) and compositions comprising PEEAs and biomolecules such as nucleic acids and proteins. Also, a method for intracellular delivery of biomolecules using complexes of the PEEAs and biomolecules. For example, PEEAs can be used as transfection agents for nucleic acids such as DNA and RNA. | 05-31-2012 |
| 20120135055 | Dry Powder Inhaler Formulations - A dpi formulation comprises a solvate of beclomethasone and is substantially free of excipient and free of carrier. The solvate particles are of size 0.5 to 10 microns and are obtained by crystallization of the steroid in the presence of ultrasound. | 05-31-2012 |
| 20120141543 | Carbon Nanotube Based Nanocomposites - Novel methods and compositions of nanocomposites are provided. One exemplary composition comprises a biocompatible polymer, such as polypropylene fumarate, and a carbon nanotube, such as a single walled carbon nanotube, an ultra-short carbon nanotube, or a substituted ultra-short carbon nanotube. An exemplary method comprises providing a biocompatible polymer and a carbon nanotube and combining a biocompatible polymer and a carbon nanotube to form a nanocomposite. Another exemplary method comprises providing a nanocomposite comprising a biocompatible polymer and a carbon nanotube and administering the composition to a subject. | 06-07-2012 |
| 20120141544 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 06-07-2012 |
| 20120141545 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 06-07-2012 |
| 20120141546 | OIL-BASED PREPARATION - The present invention relates to an oil-based preparation comprising a triazine which is active against parasitic protozoans and an anthelmintic cyclodepsipeptide, which preparation is particularly suitable for the oral application of the active substance combination in animals. | 06-07-2012 |
| 20120141547 | METHODS OF MAKING CELL SHEETS, TISSUE SHEETS AND TISSUE ENGINEERED BLOOD VESSELS - Methods of making cell sheets, tissue sheets and tissue-engineered blood vessels are provided. The methods include culturing cells on a nanoimprinted coated scaffold under hypoxic conditions to form an aligned cell sheet and then removing the aligned cell sheet from the scaffold. The cell sheets, tissue sheets and tissue-engineered blood vessels made the methods are also disclosed. The cell sheets, tissue sheets and tissue-engineered blood vessels may be implanted in subjects to treat a variety of conditions. | 06-07-2012 |
| 20120141548 | NOVEL FORMULATION OF MELOXICAM - The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments. | 06-07-2012 |
| 20120141549 | OLIGONUCLEOTIDES TARGETING ASTHMA INFLAMMATION PROCESSES - The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation. | 06-07-2012 |
| 20120141550 | SYSTEM AND METHOD FOR DELIVERY OF DNA-BINDING CHEMOTHERAPY DRUGS USING NANOPARTICLES - System and method for loading the front line anticancer drug, doxorubicin (DOX) onto DNA-capped gold nanoparticles whose duplex DNA has been designed for specific DOX intercalation. Since each AuNP contains about 108 high affinity drug sites, this design allows for a high local DOX concentration on the particle. Drug binding was confirmed by monitoring the increase in DNA melting temperature, the shift in the plasmon resonance maximum, and the increase in the NP hydrodynamic radius as a function of [DOX]/[DNA] ratio. The feasibility of the nanoparticles as a drug delivery system was demonstrated by showing that particle-bound DOX could be transferred to a target DNA. | 06-07-2012 |
| 20120141551 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE - A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a high shear force in the presence of a crosslinker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water. The biopolymer may be functionalized. The aptamer may be conjugated directly to the cross-linked biopolymers. The active agent may be a drug useful for the treatment of cancer. The delivery device survives for a period of time in the body sufficient to allow for the sustained release of a drug and for the transportation and uptake of the conjugate into targeted cells. However, the biopolymer is biocompatible and resorbable. | 06-07-2012 |
| 20120141552 | ULTRASOUND TECHNOLOGY TO CONTROL THE SPATIAL ORGANIZATION OF CELLS AND PROTEINS IN ENGINEERED TISSUES - The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology. | 06-07-2012 |
| 20120141553 | BIOCOMPATIBLE POLYMER FIBRES FOR NEUROIMPLANTS - The present invention relates to a neuroimplant. The neuroimplant comprises biocompatible polymer fibres; the polymer fibres are grouped in a parallel arrangement, and the group of fibres is flexible. The present invention also relates to the use of the neuroimplant to facilitate the repair of damaged brain tissue. | 06-07-2012 |
| 20120141555 | Compound and device for treating bone and/or cartilage defects - The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil. | 06-07-2012 |
| 20120141556 | LYOPHILIZING COMPOSITION OF DRUG-ENCAPSULATING POLYMER MICELLE AND METHOD FOR PREPARATION THEREOF - Provided are a composition for preparing a lyophilized preparation, comprising a drug-encapsulating polymer micelle and saccharides and/or polyethylene glycol as a stabilizing agent, a lyophilized preparation and a process for producing them. The lyophilized preparation thus provided is easily restructured to an aqueous preparation using an aqueous medium. | 06-07-2012 |
| 20120141557 | HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS AND USES THEREOF - Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described. | 06-07-2012 |
| 20120141558 | ALGINATE-BASED NANOFIBERS AND RELATED SCAFFOLDS - Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning. | 06-07-2012 |
| 20120141559 | BIO-MEMBRANE FOR TISSUE REGENERATION - A bio-membrane with angiogenic activity for implant in tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the cell, containing also mesenchymal stem/precursor cells, an implant device for reconstructive surgery of bone tissue, of skin and soft tissue lesions which comprises the bio-membrane, and a method for its obtainment. Use of the gel alone for tissue regeneration and of adhesive plasters that comprise it is also described. | 06-07-2012 |
| 20120141560 | TUMOR AND INFECTIOUS DISEASE THERAPEUTIC COMPOSITIONS - A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer. | 06-07-2012 |
| 20120141561 | NANOPARTICULATE CANDESARTAN CILEXITIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist. | 06-07-2012 |
| 20120141562 | CELL COATED IMPLANTABLE DEVICE - The present invention relates, in general, to a cell-coated implantable medical device and, in particular, to an implantable medical device the blood-contacting surfaces of which are coated with endothelial progenitor cells (EPCs). In a preferred embodiment, the medical device is a titanium or titanium alloy-based medical device. | 06-07-2012 |
| 20120141563 | PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE ADMINISTERED PARENTERALLY - The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition. | 06-07-2012 |
| 20120141564 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATION - A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject. | 06-07-2012 |
| 20120148630 | PREVENTION OF INFARCT EXPANSION - Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof. | 06-14-2012 |
| 20120148631 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 06-14-2012 |
| 20120148632 | METHODS FOR COMPLEX TISSUE ENGINEERING - A simple, highly flexible and scalable platform for making functional complex tissues with heterogeneity and irregularity is provided. The method includes combining undifferentiated cells, such as pluripotent or multipotent stem cells, with a biomaterial to make multiple undifferentiated or naïve subunits, exposing the undifferentiated or naïve subunits to different cell culture environments for induction of differentiation towards different lineages as required by that complex tissue, and combining the then functional subunits with or without the undifferentiated subunits. The differentiated subunits thus combined can be cultured under biological, chemical, and/or physical culture conditions suitable to fine-tune the structural and functional properties of the bioengineered complex tissue to form a bioengineered tissue graft that mimics the structural and functional characteristics of native complex tissue. The bioengineered tissue graft can then used to replace dysfunctional tissue. | 06-14-2012 |
| 20120148633 | BINARY AND TERTIARY GALVANIC PARTICULATES AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials. | 06-14-2012 |
| 20120148634 | NOVEL FORMULATION OF NAPROXEN - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 06-14-2012 |
| 20120148635 | GALLIUM FORMULATION FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES - A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as | 06-14-2012 |
| 20120148636 | MICROPARTICLES AND METHOD OF MAKING MICROPARTICLES - A process for producing micronized dispersed micro-particles and to micro-particles produced by this process. | 06-14-2012 |
| 20120148637 | NANOPARTICULATE OLMESARTAN MEDOXOMIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. | 06-14-2012 |
| 20120148638 | Steroid Solavates - A dpi formulation comprises a solvate of beclomethasone with a non-cyclic, straight or branched C | 06-14-2012 |
| 20120148639 | SUBSTRATE FOR FEEDING CELLS AND/OR TISSUES, CELL/TISSUE-FEEDER AND METHOD FOR THE PRODUCTION OF THE SAME, METHOD FOR THE REGENERATION OF TISSUES, AND METHOD FOR THE PRODUCTION OF POROUS BODIES - A substrate for feeding cells and/or tissues which is composed of a porous body having a thin film surface and a porous surface and which can be used in the regenerative medical techniques. A cell/tissue feeder is produced by cultivating tissues on the porous surface of the porous body. Cells are seeded on the porous surface of the body, followed by the cultivation of the cells to thus form and/or regenerate tissues. An aqueous solution of silk proteins, to which a water-soluble organic solvent is added, is introduced into a mold whose bottom or top surface is surface-roughened, followed by freezing the aqueous solution and then thawing the frozen aqueous solution to form a porous body having a thin film surface and a porous surface. | 06-14-2012 |
| 20120148640 | Pharmaceutical Composition Comprising Pimobendan - The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used. | 06-14-2012 |
| 20120148641 | METHODS OF TREATMENT OF ENDOBRONCHIAL INFECTIONS - The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days. | 06-14-2012 |
| 20120148642 | MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE - Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein. | 06-14-2012 |
| 20120156250 | COMPOSITIONS AND METHODS FOR CARDIAC THERAPY - Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue. | 06-21-2012 |
| 20120156251 | CATIONIC OIL-IN-WATER EMULSIONS - This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines. | 06-21-2012 |
| 20120156252 | METHOD OF PRODUCING MICROBEADS - A method for producing microbeads comprising an active component encapsulated within a gelled polymer matrix comprises the steps of providing a suspension of denatured whey protein and an active component, treating the suspension to generate microbeads, and immediately curing the microbeads by acidification. The microbeads are discrete droplets of gelled whey protein having an average diameter in the micron range (for example, from 80 to 500 microns) and which, suitably have a generally spherical shape. The microbeads are capable of surviving passage through the stomach, and delivering the encapsulated active agent in the instestine. Ex-vivo and in-vivo data shows that active agent encapsulated within microbeads retains its functionality upon delivery to the intestine, and that coating of the microcapsules allows targeted delivery of the active agent to the distal part of the intestine. | 06-21-2012 |
| 20120156253 | Enzyme Treatment of Foodstuffs for Celiac Sprue - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 06-21-2012 |
| 20120156254 | RECOMBINANT LAMININ-521 - The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein. | 06-21-2012 |
| 20120156255 | DRUG ELUTING PATCH FOR THE TREATMENT OF LOCALIZED TISSUE DISEASE OR DEFECT - A polymeric matrix for delivery of an HMG CoA reductase inhibitor such as a statin to tissue such as cardiac tissue in need thereof for the treatment or prevention of a disease or defect such as atrial fibrillation has been developed. In the preferred embodiment, a statin is delivered by means of a patch sutured to cardiac tissue at the time of cardiothoracic surgery. In the most preferred embodiment, the patch is a biodegradable material providing controlled or sustained release over a prolonged period of time, such as a week. Suitable materials include extracellular matrix, or other biodegradable hydrogels or polymeric materials providing sustained or controlled release of statin at the site of application. | 06-21-2012 |
| 20120156256 | NANOPARTICLES HAVING AT LEAST ONE ACTIVE INGREDIENT AND AT LEAST TWO POLYELECTROLYTES - The present invention relates to novel nanoparticles formed by at least one active ingredient and by at least two polyelectrolytes of opposite polarity, in particular characterized in that at least one of the two polyelectrolytes bears hydrophobic side groups and at least one of the two polyelectrolytes bears side groups of the polyalkylene glycol type, said nanoparticles having an average diameter ranging from 10 to 100 nm and comprising a quantity of groups of the polyalkylene glycol type such that the mass ratio w | 06-21-2012 |
| 20120156257 | METHOD FOR THE PREPARATION OF NANOPARTICLES - The present invention relates to a novel method for the preparation of nanoparticles with a diameter smaller than or equal to 500 nm, comprising bringing a solution (1) comprising nanoparticles of a first polyelectrolyte in the charged state, bearing hydrophobic side groups, together with (2) at least one second polyelectrolyte of opposite polarity to that of the first polyelectrolyte, characterized in that the ratio Z of the number of cationic groups relative to the number of anionic groups in the mixture of the two polyelectrolytes is comprised between 0.1 and 0.75 or between 1.3 and 2; and the total mass concentration C of polyelectrolytes is strictly less than 2 mg/g of the mixture. | 06-21-2012 |
| 20120156258 | Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration - An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R | 06-21-2012 |
| 20120156259 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels - The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament. | 06-21-2012 |
| 20120156260 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein an aromatic amine containing biologically active moiety is connected (bound) by an amido bound to a linker. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 06-21-2012 |
| 20120156261 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET - There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions. | 06-21-2012 |
| 20120156262 | N-(CYANOPHENYL)PYRAZOLECARBOXAMIDE AQUEOUS FORMULATION - Disclosed is an insecticidal suspension concentrate composition comprising by weight based on the total weight of the composition: (a) from about 0.3 to about 30% of 3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1H-pyrazole-5-carboxamide; (b) from about 5 to about 70% of a nonionic ethylene oxide-propylene oxide block copolymer component having a water solubility of at least about 5% by weight at 20° C., a hydrophilic-lipophilic balance value ranging from about 5 to about 18 and an average molecular weight ranging from about 900 to about 20000 daltons; and (c) from about 20 to about 95% of water. Also disclosed is a method for controlling an insect pest comprising diluting said suspension concentrate composition with water to form a diluted composition, and contacting the insect pest or its environment with an insecticidally effective amount of said diluted composition. | 06-21-2012 |
| 20120156263 | Ursodeoxycholic Acid-Synthetic Hydrotalcite-Eudragit Hybrid, Pharmaceutical Composition Containing the Same and Method for Preparing the Same - The present invention relates to an ursodeoxycholic acid-synthetic hydrotalcite-Eudragit hybrid, a pharmaceutical composition containing the same and a method for preparing the same. The ursodeoxycholic acid-synthetic hydrotalcite-Eudragit hybrid according to the present invention is very useful as an active ingredient of a pharmaceutical composition because of its bitter-taste-blocking effect and improved body absorption rate with high solubility. | 06-21-2012 |
| 20120156264 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 06-21-2012 |
| 20120156265 | CONFORMABLE TISSUE REPAIR IMPLANT CAPABLE OF INJECTION DELIVERY - A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant. | 06-21-2012 |
| 20120164182 | Botulinum nanoemulsions - The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision. | 06-28-2012 |
| 20120164183 | METHOD FOR DETECTION AND TREATMENT OF ANEURYSMS - The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin. | 06-28-2012 |
| 20120164184 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin - An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier. | 06-28-2012 |
| 20120164185 | ORAL NUTRIENT OR MEDICANT CARRIER HAVING INCREASED SURFACE AREA AND ABSORPTION RATE - A nutrient carrier comprises a body which is particularly suited for delivering nutrients via the oral cavity and pharynx. The body of the nutrient carrier comprises or includes a nutrient carrier element or material/composition. For example, the nutrient carrier body may be constructed from a nutrient carrying composition. In other embodiments, the nutrient carrier body may be constructed from a carrier material which carries a desired nutrient (such as a supplement, vitamin, mineral or medication/drug). | 06-28-2012 |
| 20120164186 | Diketopiperazine Microparticles with Defined Specific Surface Areas - Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m | 06-28-2012 |
| 20120164187 | BIOACTIVE GLASS FOR USE IN CONDITIONS RELATING TO BONE INFECTIONS - The present invention relates to a bioactive glass having the composition of SiO | 06-28-2012 |
| 20120164188 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES - Provided herein are impurities of paliperidone, 3-[2-[4-[1-(4-fluoro-2-hydroxyphenyl)methanoyl]piperidinyl-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (methanoyl impurity), 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (dehydroxy impurity) and 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione (9-keto impurity), and processes for preparing and isolating thereof. Provided further herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of methanoyl, dehydroxy and 9-keto impurities, process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of methanoyl, dehydroxy and 9-keto impurities. Provided also herein are improved and efficient processes for preparing paliperidone intermediates. | 06-28-2012 |
| 20120164189 | Lipidic Compositions for Induction of Immune Tolerance - This invention provides a method for inducing immune tolerance toward an antigen comprising the antigen in lipidic particles or lipidic compositions. The lipidic particles are made up of phosphatidylserine and phosphatidylcholine, or phosphatidylinositol and phosphatidylcholine. The lipidic compositions comprise the antigen and O-phospho-L-serine. Administration of these composition results in inducing immune tolerance to the antigen. | 06-28-2012 |
| 20120164190 | NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME - The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein. | 06-28-2012 |
| 20120164191 | TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE - The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment. | 06-28-2012 |
| 20120171249 | COMPOSITIONS FOR INACTIVATING PATHOGENIC MICROORGANISMS, METHODS OF MAKING THE COMPOSITIONS, AND METHODS OF USE THEREOF - Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided. | 07-05-2012 |
| 20120171251 | SHEET-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a sheet-form preparation that can be easily dissolved intraorally, allows the dissolution time thereof to be easily controlled, and can stably contain an allergenic protein from cedar pollen. | 07-05-2012 |
| 20120171252 | OIL-IN-WATER EMULSION OF MOMETASONE AND PROPYLENE GLYCOL - Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3. | 07-05-2012 |
| 20120171253 | Fibromodulin Peptide - Embodiments of the present invention provide a fibromodulin (FMOD) peptide (FMOD-P), a composition and a formulation comprising a FMOD-P, optionally with a TGF-β isoform, or comprising FMOD with a TGF-β isoform. The present invention also provides methods of making and using the FMOD-P, composition, or formulation. | 07-05-2012 |
| 20120171254 | Process and Apparatuses for Preparing Nanoparticle Compositions with Amphiphilic Copolymers and Their Use - This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired. The invention also discloses two apparatuses for the production of nanoparticles of amphiphilic copolymers by flash precipitation. | 07-05-2012 |
| 20120171255 | SUBSTRATE IMPREGNATED WITH SPRAYED CLAY, AND METHOD FOR MANUFACTURING SAME - The invention relates to the production of a clay-impregnated substrate ( | 07-05-2012 |
| 20120171256 | ELECTROSPUN SILK MATERIAL SYSTEMS FOR WOUND HEALING - The present invention relates to the processes of preparing silkfibroin/polyethylene oxide blended materials, and the resulting materials thereof, which are suitable for biomedical applications such as wound healing. In particular, the electrospun silk fibroin/PEO mats with a silk:PEO blend ratio of 2:1 to 4:1, treated with controlled evaporation, constraint-drying techniques, and/or alcohol treatment, and/or PEO extraction, demonstrate suitable physical and biofunctional properties, such as fiber structure, topography, absorption, water vapor transmission rates, oxygen permeation, and biodegradability, relevant to biomaterial systems with utility for wound dressings. | 07-05-2012 |
| 20120171257 | Cell-guiding fibroinductive and angiogenic scaffolds for periodontal tissue engineering - Disclosed are methods for producing cell-guiding fibroinductive and angiogenic tissue engineering scaffolds composed of biodegradable and biocompatible natural biopolymers, synthetic polymers and/or their combination, incorporating growth and differentiation factors, growth hormone and chemoattractants, with interconnected pores and channels-containing microarchitecture inducing the regenerative cell migration, adhesion, proliferation and differentiation from the healthy tissues surrounding the periodontal defects, thereby facilitating the functional periodontal tissue regeneration. The methods for the application of the cell-guiding fibroinductive and angiogenic scaffolds in the surgical treatment of periodontal tissue defects resulted from destructive periodontal diseases are also provided. | 07-05-2012 |
| 20120171258 | Modular Assembly of Tissue Engineered Constructs - Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue. | 07-05-2012 |
| 20120171259 | ORALLY ABSORBED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION - A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal. | 07-05-2012 |
| 20120171260 | Stent And Delivery System With Reduced Chemical Degradation - Stents and delivery systems with reduced chemical degradation and methods of sterilizing the same are disclosed. | 07-05-2012 |
| 20120171261 | FORMULATIONS OF WATER INSOLUBLE OR POORLY WATER SOLUBLE DRUGS IN LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE FOR DIAGNOSTICS AND THERAPY - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery. | 07-05-2012 |
| 20120171262 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 07-05-2012 |
| 20120177692 | DELIVERY SYSTEMS FOR SOLUBILISING WATER-INSOLUBLE PHARMACEUTICAL ACTIVE INGREDIENTS - A delivery system for water-insoluble pharmaceutical active ingredients is provided. The delivery system includes water-insoluble pharmaceutical active ingredient(s), organic solvent(s) and amphiphilic co-solvent(s), and a mixture of hydrophilic and hydrophobic non-ionic surfactants. Upon dilution in an aqueous medium, this formulation forms spontaneously dispersion of non-ionic surfactant nanoparticles. | 07-12-2012 |
| 20120177693 | DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL - Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible. | 07-12-2012 |
| 20120177694 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 07-12-2012 |
| 20120177695 | Bioerodible Silicon-Based Devices for Delivery of Therapeutic Agents - This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases. | 07-12-2012 |
| 20120177696 | Diffusion-controlled dosage form and method of fabrication including three dimensional printing - The invention includes a core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles of a release-regulating polymer. The shell may be substantially impervious but the release-regulating polymer may become suitable to allow diffusion through it when activated. The core may include a buffer region between the shell and the API-containing portion of the core. The dosage form may include multiple units. The dosage form of the invention is capable of providing a release profile whose time scale can be adjusted by adjusting powder composition, and which may be approximately zero-order release. The invention further includes methods of manufacturing such a dosage form, such as three-dimensional printing. | 07-12-2012 |
| 20120177697 | Excipients In Drug Delivery Vehicles - Injectable depot gel compositions and kits that provide an excipient for modulating a release rate and stabilizing beneficial agents are provided. Methods of administering and preparing such systems are also provided. The gel compositions comprise biodegradable, bioerodible polymers and water-immiscible solvents in amounts effective to plasticize the polymers and form gels with the polymers. Suitable excipients include pH modifiers, reducing agents, and antioxidants. | 07-12-2012 |
| 20120177698 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN - The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component alternatively, can take the role of a drug. The disclosure further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The disclosure also provides methods and favourable conditions for carrier manufacturing and application. | 07-12-2012 |
| 20120177699 | Preparation Method of Drug Loaded Emulsion - A preparation method of drug loaded emulsion is disclosed. The method comprises the steps of: preparing a non-self emulsifying O/W blank emulsion having no active ingredients; then, adding therapeutically effective amount of active ingredients to the 0/W blank emulsion, adjusting pH to distribute the active ingredients through the membrane to obtain the desired emulsion. | 07-12-2012 |
| 20120177700 | Nanonized Iron Compositions and Methods of Use Thereof - Embodiments of the invention provide nanonized iron compositions for treatment of iron deficiency such as iron deficiency anemia. Many embodiments provide nanonized iron compositions which are sized to minimize adverse reaction such as immune response, adverse GI reaction and allergic reaction to iron compound included in the composition. The nanonized iron compositions can be used in a variety of drug delivery forms, including an oral dosage form, a transdermal patch, in an intravenous solution or in a dialysate for treatment of a patient with chronic kidney disease (CKD). Embodiments of the invention also provide methods of using the nanonized iron compositions for the treatment of iron deficiency in a patient in need thereof including patients with iron deficiency anemia and CKD. | 07-12-2012 |
| 20120177701 | COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS - Immunostimulatory compositions include an isolated nucleic acid molecule that includes one or more nucleotide sequences from 5′- or 3′-terminal regions of positive-sense, single-stranded RNA virus genomes and/or or nucleotide sequences from a 5′-terminal regions of negative-sense, single-stranded RNA virus genomes. | 07-12-2012 |
| 20120177702 | Solid Forms for Tissue Repair - This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof. | 07-12-2012 |
| 20120177703 | SOLID LINEAR OLIGO-OR POLY-E-CAPROLACTONE - The present invention relates to linear oligo- or poly-ε-caprolactones di-blockcopolymers, in solid form at room temperature, comprising monoalkyl oligoethyleneglycol residues. The present invention further relates to a drug delivery formulation comprising above materials and a process for the preparation of the drug delivery formulation. The oligoethyleneglycol residues are preferably selected from the group consisting of methyl diethylene glycol, methyl triethyleneglycol or methyl tetraethylene glycol. The oligo- or poly-ε-caprolactone derivatives are prepared via the reaction of mono-hydroxy-oligoethyleneglycol with ε-caprolactone, whereby the mono-hydroxy-oligoethyleneglycol acts as an initiator. | 07-12-2012 |
| 20120177704 | CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 07-12-2012 |
| 20120177705 | COMPOSITION 064 - A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described. | 07-12-2012 |
| 20120177706 | STABLE COMBINATIONS OF AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are not physically separated from one another, and methods for making the same. | 07-12-2012 |
| 20120183580 | Analgesic Composition for Transbuccal Administration - The present invention relates to a pharmaceutical composition comprising a peptide of 5 to 50 amino acids which comprises the amino acid sequence NPFPTX | 07-19-2012 |
| 20120183581 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY - The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP. | 07-19-2012 |
| 20120183582 | Oral Delivery of Peptides - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing an active peptide that is amidated at a site that is not naturally amidated. | 07-19-2012 |
| 20120183583 | Medical Device With Intrapore Films - The present disclosure relates to a medical device and methods of making the same. The medical device includes a porous substrate and at least one film. The film is formed within the pore of the substrate. The film is intra-porous and does not contact adjacent pores or films. | 07-19-2012 |
| 20120183584 | METHOD FOR PREPARING A STABLE OIL-IN-WATER EMULSION - The invention relates to a method for preparing a stable oil-in-water emulsion without adding an emulsifier. According to the method, a mixture of a lipid phase and an aqueous phase is subjected to vibrating energy, in a sealed container, by applying a transducer operating at a frequency of more than 900 kHz. | 07-19-2012 |
| 20120183585 | GEL BASED WOUND DRESSING AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a gel based wound dressing comprising a lyophilized powder and a water-based solvent. The lyophilized powder comprises several nanoparticles and water miscible natural or synthetic polymers. The nanoparticles comprises pectin and a wound healing agent or an anti-microbial agent. The anti-microbial agent is nisin. The lyophilized powder and the water-based solvent are kept in two separate sealed packages and are mixed together before applying on a wound. The embodiments herein also provide a method of synthesizing the gel based wound dressing. The nano-particles control a release of the wound healing agent or the antimicrobial agent to a wound. | 07-19-2012 |
| 20120183586 | METHOD OF OBTAINING VIABLE SMALL TISSUE PARTICLES AND USE FOR TISSUE REPAIR - The invention provides a composition including isolated small living tissue particles, a method of making the tissue particles, and a method of using the composition to ameliorate a tissue defect. The tissue particles are composed of cells and their associated extracellular molecules and are sized, in certain embodiments, to be smaller than about 1 mm. Another aspect of the inventive tissue particles is the large percentage of viable cells. In certain embodiments, the tissue particles are made from cartilage and the composition may also contain additives such as adhesives, solutions, and bioactive agents. | 07-19-2012 |
| 20120189665 | Cosmetic Compositions Comprising Cyanodiphenylacrylates And Film Forming Polmers - A composition comprising at least one α-cyanodiphenylacrylate and at least one organosiloxane-based film forming polymer. | 07-26-2012 |
| 20120189666 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent. | 07-26-2012 |
| 20120189667 | METHOD FOR REPAIRING OR REPLACING DAMAGED TISSUE - A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials. | 07-26-2012 |
| 20120189668 | HYDROGEL BIOSCAFFOLD AND COATING FOR BONE AND TOOTH REPAIR - Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair. | 07-26-2012 |
| 20120189669 | Solid Forms for Tissue Repair - This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof. | 07-26-2012 |
| 20120189670 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 07-26-2012 |
| 20120189671 | Absorbable Implants and Methods for their use in Hemostasis - The invention provides body absorable, mechanically hemostatic putty compositions comprising carboxymethyl cellulose and one or more of polyhydroxy compounds, fatty acids, and esters thereof for use in controlling the bleeding of bone. | 07-26-2012 |
| 20120189672 | USE OF AEROSOLIZED CYCLOSPORINE FOR PREVENTION AND TREATMENT OF PULMONARY DISEASE - The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the invention comprises the administration of aerosolized cyclosporine for prevention of acute and/or chronic refractory rejection in lung transplant patients. The invention further provides for the use of aerosolized cyclosporine to treat subjects having immunologically mediated inflammatory pulmonary disorders including, but not limited to, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis and allergic rhinitis. The present invention, by enabling a method for the use of aerosolized cyclosporine for inhibiting pulmonary inflammation leading to prevention of graft rejection and treatment of pulmonary disorders, provides a safer and less toxic treatment than those methods that utilize systemic administration of cyclosporine. | 07-26-2012 |
| 20120189673 | POLYPEPTIDES AND USES THEREOF - The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof which exhibit an anti-inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation. | 07-26-2012 |
| 20120195932 | Geodate delivery vehicles - The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated. | 08-02-2012 |
| 20120195933 | PHARMACEUTICAL COMPOSITIONS COMPRISING TASOCITINIB - The invention relates to pharmaceutical compositions, preferably tablets, comprising tasocitinib, suitable for immediate release, and processes of preparing such compositions. | 08-02-2012 |
| 20120195934 | POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS - Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint. | 08-02-2012 |
| 20120195935 | MICROBUBBLE ASSISTED VIRAL DELIVERY - Microbubble-assisted delivery of viruses is disclosed. In particular, methods for targeting a virus to cancer cells in an immunocompetent animal by administering a selectively replicating virus to the immunocompetent animal and disrupting the microbubbles in a location of the animal comprising cancer cells are provided. The virus is encompassed in a suspension of microbubbles, and the surface of the suspension does not include any virus. A suspension of microbubbles comprising a selectively replicating virus that is encompassed in a suspension of microbubbles, which does not include any virus on the surface of the suspension, is also provided. | 08-02-2012 |
| 20120195936 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION - The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides. | 08-02-2012 |
| 20120195937 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES - The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of | 08-02-2012 |
| 20120195938 | FORMULATIONS AND METHODS FOR RECOVERY FROM DENTAL SURGERY - Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations disclosed herein preferably include a blood component with a pharmaceutical agent. The blood component is preferably whole blood or platelet-rich plasma. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, betamethasone, triamcinolone hexacetonide, melatonin, purmorphamine, 17β-estradiol, vitamin K | 08-02-2012 |
| 20120195939 | PARENTERAL COMPOSITION COMPRISING MICROSPHERES WITH A DIAMETER BETWEEN 10 AND 20 MICRONS - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. | 08-02-2012 |
| 20120195940 | Nanolipidic Particles - Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries. | 08-02-2012 |
| 20120195941 | AGENT FOR PROTECTION OF TOOTH SURFACES, IN CONJUNCTION WITH CONVENTIONAL BLEACHING METHODS, BY BIOMIMETIC DEPOSITION OF FLUORAPATITE - An agent for protection of tooth surfaces, in conjunction with conventional bleaching methods, by biomimetic deposition of fluorapatite, containing
| 08-02-2012 |
| 20120195942 | DOSAGE FORMS OF ACTIVE INGREDIENTS CONTAINING HYDROXYSTILBENE FOR TREATING MENOPAUSAL COMPLAINTS - The invention provides novel hydroxystilbene-containing dosage forms, processes for producing these dosage forms and the use thereof for the treatment of menopausal symptoms in women, juvenile oligomenorrhea and dysmenorrhea, primary and secondary amenorrhea or endometritis. | 08-02-2012 |
| 20120195943 | Bone delivery device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 08-02-2012 |
| 20120201857 | Transdermal delivery system for therapeutics - The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical compositions for facilitating transdermal delivery of therapeutics without pain by absorption and more particularly a series of pharmaceutical formulations for topical administration of neurotoxins to humans, including a neurotoxin, such as a botulinum toxin, and absorption enhancing agents that facilitate absorption of the neurotoxin through the skin of the patient and do not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and are generally in a cream or gel form. | 08-09-2012 |
| 20120201858 | Multiple-arm peptide compounds, methods of manufacture and use in therapy - The present invention concerns compositions of matter, pharmaceutical compositions and method to produce multiple arm peptides-substrate (MAP-S) as composites having molecules covalently bonded thereto which exhibit enhanced cell adhesion, attachment, proliferation and the like in vivo. The composites MAP-S described herein as compositions and implants improve and accelerate the healing process and tissue implant integration for vascular and soft tissue, joint, bone and combinations thereof. | 08-09-2012 |
| 20120201859 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 08-09-2012 |
| 20120201860 | Ultra-thin metal oxide and carbon-metal oxide films prepared by atomic layer deposition (ALD) - Ultra-thin porous films are deposited on a substrate in a process that includes laying down an organic polymer, inorganic material or inorganic-organic material via an atomic layer deposition or molecular layer deposition technique, and then treating the resulting film to introduce pores. The films are characterized in having extremely small thicknesses of pores that are typically well less than 50 nm in size. | 08-09-2012 |
| 20120201861 | ANTIVIRAL MATERIAL , ANTIVIRAL FILM, ANTIVIRAL FIBER, AND ANTIVIRAL PRODUCT - In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=logC−logA], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours. | 08-09-2012 |
| 20120201862 | PROCESS FOR THE PREPARATION OF COLLOIDAL SYSTEMS FOR THE DELIVERY OF ACTIVE COMPOUNDS - The present invention relates to a process for the preparation of colloidal systems, such as nanocapsules and nanoparticles, which incorporates a homogenization step for reducing particle size. | 08-09-2012 |
| 20120201863 | METHODS FOR THICKENING HYDROPHOBIC LIQUIDS WITH AMPHIPHILIC ESTERS - The present invention relates to a method for thickening a hydrophobic liquid. When a hydrophobic liquid is thickened in accordance with the invention, the liquid becomes significantly denser. Preferably, the hydrophobic liquid becomes a gel. | 08-09-2012 |
| 20120201864 | Method - There is provided a method of producing a mixed metal compound comprising at least Mg | 08-09-2012 |
| 20120201865 | HOT-MELT EXTRUDED COMPOSITIONS CONTAINING PLANT-DERIVED PHENOLIC MATERIALS AND PROCESSES FOR THE PREPARATION THEREOF - A hot-melt extruded composition is disclosed that includes about 20-80% wt. of a plant-derived phenolic material; about 20-85% wt. of one or more edible or bioerodible excipients; about 0-40% wt. of a surface active material; about 0-40% wt. of an oral absorption enhancer; and about 0-10% wt. of one or more pharmaceutical or food grade additives. The composition has been hot-melt extruded at a temperature substantially below the melting point of the plant-derived phenolic material to produce a hot-melt extruded composition wherein substantial degradation of the plant-derived phenolic material has not occurred. | 08-09-2012 |
| 20120201866 | CISTUS EXTRACTS - The present invention relates to the use of a nasal spray made from | 08-09-2012 |
| 20120201867 | DRUG DELIVERY FROM EMBOLIC AGENTS - An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 μm, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver. | 08-09-2012 |
| 20120201868 | TREATMENT AND PREVENTION OF HIV INFECTION - This invention relates to the long term treatment of HIV infection by intermittently administering a parenteral formulation comprising brecanavir at relatively long time intervals. This invention further concerns pharmaceutical compositions for parenteral administration, comprising micro- or nanoparticles of brecanavir, suspended in an aqueous pharmaceutically acceptable carrier, for the treatment and prophylaxis of HIV infection. | 08-09-2012 |
| 20120201869 | MARINE BACTERIAL SUBSTANCES, MEDICAL DEVICES, AND METHODS FOR BIOFILM INHIBITION - Disclosed herein are marine bacterial substances, methods, and medical devices that inhibit biofilm growth and/or formation. Substances of the present disclosure are products or byproducts of P3-2 (ATCC PTA-6763), P4-4 (ATCC PTA-6682), P5-2 (ATCC PTA-6764), or P6-6 (ATCC PTA-6766) marine bacterial isolates. | 08-09-2012 |
| 20120207791 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 08-16-2012 |
| 20120207792 | INJECTABLE FILLER FOR PODIATRIC AND ORTHOPEDIC USES - A podiatric filler composition comprising a pliable biocompatible material and a physiologically acceptable suspending agent. The podiatric filler compositions may be used in methods for treating fat pad atrophy, foot pain, plantar faciitis, metatarsalgia, injury, and rheumatoid arthritis. | 08-16-2012 |
| 20120207793 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications - Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and particularly in one type of embodiment, the peroxide adducts should be able to permeate the material, but water, hydrogen peroxide and inorganic peroxides should be able to permeate the material. The methods and compositions that allow the release of oxygen, H | 08-16-2012 |
| 20120207794 | WATER-SOLUBLE DRUG CARRIER AND PROCESS FOR PRODUCING THE SAME - An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2. | 08-16-2012 |
| 20120207795 | CATIONIC POLYMER COATED MESOPOROUS SILICA NANOPARTICLES AND USES THEREOF - A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene. | 08-16-2012 |
| 20120207796 | POLYMERIC DRUG DELIVERY COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES - Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol compound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units with pendant carboxylic acid groups and poly(alkylene oxide) blocks relative to the weight percentage of the drug in the composition is effective to provide pseudo-zero order release of the drug from the composition during the sustained-release phase of drug delivery under physiological conditions. Ocular treatment methods and manufacturing methods are also disclosed. | 08-16-2012 |
| 20120207797 | DOSAGE FORMS FOR TAMPER PRONE THERAPEUTIC AGENTS - A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form. | 08-16-2012 |
| 20120207798 | Solid Oral Dosage Form Attached to a Handle - The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in contact with a solid oral dosage form, wherein an area of contact between the handle and the solid oral dosage form forms a joint interface; (b) applying high frequency mechanical vibrations to the joint interface until the solid oral dosage form at the joint interface reaches a molten state; and (c) cooling the joint interface in a molten state to allow solidification, thereby attaching the handle to the solid oral dosage form. | 08-16-2012 |
| 20120207799 | ORAL DELIVERY VEHICLE AND MATERIAL - Natural, biodegradable compositions are described as well as methods for their manufacture. Fishing lures and other items made of the biodegradable materials disintegrate over time in fresh or salt water to reduce pollution. The materials are digestable by fish and other aquatic animals, reducing potential harm to the animal from ingesting a fishing lure or other item made from the natural biodegradable materials disclosed. Because the material is digestable, it can also be used as a food source or supplement for fish and aquatic animals. | 08-16-2012 |
| 20120207800 | COMPOSITIONS - Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed. | 08-16-2012 |
| 20120213825 | ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF - An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C | 08-23-2012 |
| 20120213826 | Use of Pro-Inflammatory Compounds for Promoting Bone Formation - The present invention provides methods, uses and compounds for promoting bone formation in a patient at a site in need thereof by the provision of a pro-inflammatory compound at the site. The site is generally a site of injury or a site of surgical intervention in the patient. Exemplary compounds include pro-inflammatory: cytokines. Inhibitors of indoleamine 2, 3, dioxygenase 1 are also provided in the methods and uses of the invention. | 08-23-2012 |
| 20120213827 | PROCESS FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM SUPERCOOLED LIQUID STATE BY HOT MELT EXTRUSION - A process for controlling the crystallization of certain hydrophobic active pharmaceutical ingredients (APIs) from a supercooled liquid state by hot-melt extrusion processing is described. Also described is a pharmaceutical composition comprising a solid crystalline dispersion of a cholesterol ester transfer protein inhibitor in a hydrophilic excipient matrix. In the process of the present invention, the API is fed to an extrusion system in a crystalline state contemporaneously with carrier excipients where it is first converted to a non-crystalline state by the application of heat and then subsequently recrystallized in-situ by the removal of heat and application of shear. Recrystallization of the API is controlled by carrier formulation design and the hot-melt extrusion process parameters; i.e. barrel temperature profile, feed rate, etc. | 08-23-2012 |
| 20120213828 | ADENOVIRUS VACCINE VECTOR AND METHODS OF USE - Ad40-based polynucleotides, viral vectors, methods of making such polynucleotides and viral vectors, pharmaceutical compositions that includes such polynucleotides and viral vectors, and uses of such compositions are disclosed herein. Generally, the Ad40-based polynucleotide includes an Ad40-based vector that includes a genetic modification that decreases expression of an E1 coding region and a heterologous polynucleotide. | 08-23-2012 |
| 20120213829 | DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS - There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof. | 08-23-2012 |
| 20120213830 | SUSPENSION COMPRISING BENZIMIDAZOLE CARBAMATE AND A POLYSORBATE - This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 mm and a Tween-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and use of said composition for the manufacture of a medicament or protecting animal from parasitic infection. | 08-23-2012 |
| 20120213831 | MICROSPHERES FOR ACTIVE EMBOLIZATION - The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions. | 08-23-2012 |
| 20120213832 | REMOVABLE DENTAL CURABLE COMPOSITION - A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A′) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A′) is represented by [a′] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70≦(a)≦99.99, 0.01≦(b)≦5 30, 1≦[a′]/5+(c)/1, 0≦[a′]≦95, and 0≦(c)≦250. | 08-23-2012 |
| 20120213833 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 08-23-2012 |
| 20120219595 | BIODEGRADABLE FIBER AND FIBER WADDING FOR FILLING BONE DEFECTS AND METHOD FOR PRODUCING THE SAME - A fiber wadding formed from a biodegradable polymer fiber containing calcium carbonate fine particles including silicon that is characterized in that hydroxyapatite is precipitated and scattered nearly uniformly on the surface of the biodegradable polymer fiber is disclosed. Further, a method for production of fiber wadding that includes the steps of heating and kneading silicon-containing calcium carbonate fine particles and a biodegradable polymer to produce a composite, dissolving the composite by mixing the composite with a solvent to obtain a spinning solution, processing the spinning solution into fiber wadding by using electrospinning method, and alternatingly immersing the fiber wadding in a calcium aqueous solution and a phosphate aqueous solution to cause precipitation of hydroxyapatite in an approximately uniformly scattered manner on the surface of the fibers is disclosed. | 08-30-2012 |
| 20120219596 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT - Compounds according to formula (I) are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds. The invention also relates to methods of treating or protecting patients having or being prone to develop a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue, the methods comprising administration of a therapeutically effective amount of such compounds | 08-30-2012 |
| 20120219597 | PHARMACEUTICAL FORMULATIONS FOR INDIBULIN - In certain embodiments, the invention relates to pharmaceutical formulations of an indolyl-3-glyoxylic acid derivative or a pharmaceutically acceptable salt thereof, such as indibulin. Methods of preparing such formulations and methods of treatment using these formulations are also described. | 08-30-2012 |
| 20120219598 | POLYMERIC MICELLES FOR REDUCING LDL IN VIVO - The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also includes compounds of the formula I: | 08-30-2012 |
| 20120219599 | OSTEOGENIC PROMOTING IMPLANTS AND METHODS OF INDUCING BONE GROWTH - The present disclosure describes an implant for improving bone growth including an osteoconductive scaffold and an osteoinductive small molecule. The osteoconductive scaffold can further include a polymeric binder. The implant can also include an osteogenic material to provide a viable cell population to assist the bone repair and remodeling. Also disclosed is a system for forming an implant for improving bone growth, as well as methods for forming the implant according to the disclosure, in addition to methods of therapeutic use of the implant. | 08-30-2012 |
| 20120219600 | POLYMER CONJUGATED PROTEIN MICELLES - The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent. | 08-30-2012 |
| 20120219601 | Composition Comprising Biodegradable Hydrating Ceramics for Controlled Drug Delivery - The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable. | 08-30-2012 |
| 20120219602 | METHODS FOR TREATING HERPES VIRUS INFECTIONS - The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties. | 08-30-2012 |
| 20120219603 | Use of Calcitonin for the Treatment of RA - The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. | 08-30-2012 |
| 20120219604 | METHOD OF SOLUBILIZING POORLY SOLUBLE/INSOLUBLE ACTIVE MATERIAL THROUGH FORMATION OF OLIGOMER COMPOSITE - Provided is a method of solubilizing a poorly soluble/insoluble active material through formation of an oligomer composite, in which a structure having a hydrophobic cavity structure is formed by using oligomers derived from two types of hydrophilic natural polymers and a poorly soluble/insoluble component is encapsulated in the cavity structure, and thus, self-aggregation of the poorly soluble/insoluble material is prevented and simultaneously, thermodynamic stability increases to effectively solubilize the poorly soluble/insoluble material. According to the constitution of the present invention, the method may include a first operation of preparing an oligomer composite having a cavity structure formed therein by mixing and dissolving oligomers derived from two types of hydrophilic natural polymers in water, and a second operation of adding a poorly soluble/insoluble material to the oligomer composite to encapsulate the poorly soluble/insoluble material in the hydrophobic cavity structure of the oligomer composite. | 08-30-2012 |
| 20120219605 | ADJUVANTED NANOPARTICULATE INFLUENZA VACCINE - Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions. | 08-30-2012 |
| 20120225098 | BIOFILM INHIBITING COMPOSITION - Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed. | 09-06-2012 |
| 20120225099 | COMPOSITIONS FOR AND METHODS OF ACTIVATING GUANYLYL CYCLASE C - Isolated non-pathogenic bacterium which comprises a nucleic acid molecule that encodes guanylyl cyclase C agonist operably linked to regulatory sequences operable in bacterium and isolated bacterium which comprises a nucleic acid molecule that encodes guanylyl cyclase C agonist operably linked to inducible regulatory sequences operable in bacterium are disclosed. Isolated culture of such bacteria and uses thereof in the prevention and treatment of colonic polyps and/or colorectal cancer as well as methods of activating guanylyl cyclase C in humans are disclosed. | 09-06-2012 |
| 20120225100 | Articlea and processes for Making a Porous Disintegratable Solid Substrate for Personal Health Care Applications - A personal health care article. More particularly, a personal health care article comprising at least one porous disintegratable solid substrate comprising: from about 1% to about 70%, by weight of said substrate, of a surfactant, from about 10% to about 70%, by weight of said substrate, of one or more polymers, from about 0.025% to about 85%, by weight of said substrate, of one or more health care actives, optionally a plasticizer, and optionally an aesthetic agent wherein said article is ingestible. The invention also comprises a process for making a personal health care article. | 09-06-2012 |
| 20120225101 | MULTIFUNCTIONAL IN SITU POLYMERIZED NETWORK VIA THIOL-ENE AND THIOL-MALEIMIDE CHEMISTRY - Biomaterials that support cell attachment and growth are provided. In one aspect, biomaterials are provided comprising a first polymer matrix comprising reactive amino moieties and a second polymer matrix that interpenetrates with the first polymer matrix, where the second polymer matrix comprises a poly(alkylene oxide) comprising two or more alkylene oxide oligomers joined by gamma-thioether carbonyl linkages. In another aspect, biomaterials are provided comprising at least one biopolymer comprising amino groups, thiol groups, and bifunctional modifiers connecting at least some of the amino groups to at least some of the thiol groups; and at least one poly(alkylene oxide) cross-linked to at least two thiol groups of the biopolymer. The biomaterials may further comprise a pharmacologically active agent or cells. Methods of administering such biomaterials to a patient in need thereof are also provided. | 09-06-2012 |
| 20120225102 | PERFLUOROCARBON GEL FORMULATIONS - A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses. | 09-06-2012 |
| 20120225103 | Transdermal Therapeutic System Containing a Pramipexol Active Agent - This invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 days. | 09-06-2012 |
| 20120231036 | CLONED BIOLOGICAL MATERIAL MEDICAL DEVICE AND METHOD THEREOF - A medical device, said medical device, comprises: a first component having a non-biological material; a second component having a cloned biological material, said second component being attached to said first component, wherein said first component and said second component are operatively associated in a non-living medical device for at least one of treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. In another aspect, a method comprises: preparing a cloned biological material from a tissue or an organ; attaching said biological material to a medical device; interfacing said biological material with the non-biological material; providing treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. | 09-13-2012 |
| 20120231037 | CRYSTALLINE DRUG-CONTAINING COATINGS - Articles-of-manufacturing comprising an object having a surface and a therapeutically active agent being deposited onto at least a portion of the surface, while at least a portion of said therapeutically active agent being in a crystalline form thereof are disclosed. Methods utilizing such articles-of-manufacturing for treating medical conditions are also disclosed. Processes of preparing the articles-of-manufacturing by contacting a surface of the object with a solution containing the therapeutically active agent; and cooling the surface to a temperature below a temperature of the solution, and apparatus for performing these processes, are also disclosed. | 09-13-2012 |
| 20120231038 | Wound Healing Compositions Comprising Biocompatible Cellulose Hydrogel Membranes and Methods of Use Thereof - The present invention provides a wound healing composition comprising a biocompatible hydrogel membrane wherein the hydrogel membrane has one or more of the following properties: high water content, high transparency, high permeability, high biocompatibility, high tensile strength and an optimal thickness. The invention further provides methods of treating a wound in a subject in need thereof, comprising contacting the wound with a biocompatible cellulose hydrogel membrane of the invention. | 09-13-2012 |
| 20120231039 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 09-13-2012 |
| 20120231040 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF - Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications. | 09-13-2012 |
| 20120231041 | Immunomodulating Nanoparticulate Composition - The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect. | 09-13-2012 |
| 20120231042 | Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets - Provided are pharmaceutical formulations in the form of granules comprising
| 09-13-2012 |
| 20120231043 | IMMOBILISED BIOLOGICAL ENTITIES - There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto. | 09-13-2012 |
| 20120231044 | VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES - A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell. | 09-13-2012 |
| 20120231045 | SUSTAINED RELEASE COMPOSITIONS OF ALFUZOSIN - The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers. | 09-13-2012 |
| 20120231046 | IMPLANT FOR SUBCUTANEOUS OR INTRADERMAL INJECTION - The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. Said suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years. | 09-13-2012 |
| 20120231047 | THERAPEUTIC AGENT DELIVERY FOR THE TREATMENT OF ASTHMA VIA IMPLANTABLE AND INSERTABLE MEDICAL DEVICES - Methods for the treatment of asthma are provided, which comprise: (a) providing an implantable or insertable medical device that comprises an asthma treatment agent; and (b) inserting or implanting the medical device within the lungs (e.g., the trachea or the bronchial tree) of a patient, whereupon the therapeutic agent is delivered to the patient in an amount effective to reduce or eliminate the symptoms of asthma. Also disclosed herein are medical devices and kits for carrying out such methods. | 09-13-2012 |
| 20120231048 | Medical Devices and Implants from Nb-Ta-W-Zr Alloys - The present invention relates to a medical device or implant made at least in part of a high-strength, low-modulus metal alloy comprising niobium, tantalum, and at least one element selected from the group consisting of zirconium, tungsten, and molybdenum. The medical devices according to the present invention provide superior characteristics with regard to biocompatibility, radio-opacity and MRI compatibility. | 09-13-2012 |
| 20120231049 | Freeze-Thaw Method For Modifying Stent Coating - Methods are disclosed for controlling the morphology and the release-rate of active agent from a coating layer for medical devices comprising a polymer matrix and one or more active agents. The methods comprise exposing a wet or dry coating to a freeze-thaw cycle. The coating layer can be used for controlled delivery of an active agent or a combination of active agents. | 09-13-2012 |
| 20120231050 | Synthetic Lactone Formulations and Method of Use - Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly. | 09-13-2012 |
| 20120231051 | SINGLE UNIT ORAL DOSE PHARMACEUTICAL COMPOSITION COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPONE OR SALTS THEREOF - There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 09-13-2012 |
| 20120231052 | NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE.RTM. - Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration. | 09-13-2012 |
| 20120231053 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient - To provide a therapeutic method using a water soluble, high molecular weight block polymer to enable that an intraperitoneally administered anti-cancer agent may maintain for a long-term retention in the abdominal cavity to enoughly exert the effect of the anti-cancer agent and reduce adverse side-effects thereof. | 09-13-2012 |
| 20120231054 | USE OF AN OLEOGEL CONTAINING TRITERPENE FOR HEALING WOUNDS - An oleogel comprising a non-polar liquid and a powder containing triterpene is provided as an oleogel that may be used for healing wounds. | 09-13-2012 |
| 20120231055 | Polymersomes And Production Method Thereof - It is an object of the invention to provide a polymersome excellent in the safety and feeling in use; in particular, there is no sticky feeling but there is a good refreshing feeling; and with excellent base-agent stability. A polymersome of the present invention comprises a block-type alkylene oxide derivative represented by the following formula (I) as the membrane component: | 09-13-2012 |
| 20120237554 | MICROBIAL CONTROL OF AETHINA TUMIDA WITH METARHIZUM ANISOPLIAE - The fungus | 09-20-2012 |
| 20120237555 | SURFACE COATING FOR BIOMOLECULE IMMOBILISATION AND MINIMISATION OF NON-SPECIFIC BINDING ON SURFACES FOR BIOMEDICAL DIAGNOSTICS - A solid substrate coating capable of swelling by a factor of at least 2 on contact with an aqueous solution. The solid substrate coating may be prepared by activating the surface of a solid substrate by treatment with a plasma, depositing a first layer of siloxane onto the surface of the solid substrate using plasma, and depositing a second layer of at least on chemical functionality on top of the first layer using plasma. | 09-20-2012 |
| 20120237556 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN - The invention provides skin protecting and penetrating, easy-to-administer base and active agent-containing compositions, such as those including hydrocortisone, for treating the skin of mammals for different dermatologic disorders. This is effected by topically administering effective amounts of the compositions thereto in forms that address the skin and mucosa of the mouth and lips, and the rest of the body. Additionally, an optional flavoring addition to these products affords significantly better tasting, and less bitter, compositions, allowing a more pleasant experience and better compliance by patients. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in a form of a solid roll-on stick in a variety of sizes and of a jar or pot. | 09-20-2012 |
| 20120237557 | BIOACTIVE CARBON-NANOTUBE AGAROSE COMPOSITES FOR NEURAL ENGINEERING - Nanocomposite fibers containing one or more carbon nanotubes encapsulated in an polysaccharide gel matrix. | 09-20-2012 |
| 20120237558 | METHOD OF TREATING AN OSTEOCHONDRAL DEFECT - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 09-20-2012 |
| 20120237559 | FORMULATIONS AND METHODS FOR TREATING RHINOSINUSITIS - The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent. | 09-20-2012 |
| 20120237560 | Cardiac Compositions - Embodiments of the present invention provide a composition comprising perivascular stem cells or induced pluripotent cells (iPS) and a NELL-1 factor for cardiac or vascular regeneration and methods of making and using the same. | 09-20-2012 |
| 20120237561 | INJECTABLE FORMULATIONS CONTAINING ASENAPINE AND METHOD OF TREATMENT USING SAME - The present invention provides a formulation comprising asenapine hemipamoate suspended particles, which formulation can be administered via a Depot provided by an IM injection of the formulation, and which depot does not display a particle-size dependent release rate. The present invention provides also methods of treatment using the same. | 09-20-2012 |
| 20120237562 | ANTIBIOTIC DRUG DELIVERY AND POTENTIATION - Disclosed are compositions-of-matter comprising polymer-mediated cochleates, which are formed from a calcium-free mixture of a wide variety of phospholipids that are atypical for forming cochleates. Further disclosed are compositions-of-matter comprising these cochleates which co-encapsulate another bioactive agent. The polymer mediating the formation of these cochleates exhibits a plurality of positively charged amino acid residues and omega-amino-fatty acid moieties, and may further exhibit antimicrobial, anticancerous and drug-potentiating activity. Further disclosed are pharmaceutical compositions and methods using the compositions-of-matter disclosed herein, and processes of preparing same. | 09-20-2012 |
| 20120237563 | CONTROLLED-RELEASE FORMULATIONS OF ANABASEINE COMPOUNDS AND USES THEREOF - The subject invention pertains to controlled-release dosage forms of anabaseine compounds, such as 3-(2,4-dimethoxybenzylidene)-anabaseine (also known as DMXBA or GTS-21) or a pharmaceutically acceptable salt thereof, methods of use, and methods for producing controlled-release dosage forms. | 09-20-2012 |
| 20120237564 | Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease - The present invention relates to methods and compositions for treating obstructive pulmonary disorders. In particular, compositions and methods described herein relate to the use of an aerosolized antibiotic for treating obstructive pulmonary disorders including chronic obstructive pulmonary disorder (COPD) and chronic bronchitis (CB). | 09-20-2012 |
| 20120237565 | PEGYLATED POLYPLEXES CONTAINING TWO OR MORE DIFFERENT POLYMERS FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 09-20-2012 |
| 20120237566 | INHIBITING STOMACH-ACID RELEASE, REDUCING INFLAMMATION AND PREVENTING AND TREATING CANCER: COMPOSITIONS AND METHODS OF USE - The present invention relates to improved methods of preventing or inhibiting the release of acid in the stomach, which are uniquely reversible at the cellular level, through the use of organic isothiocyanates and thiocyanates with divalent cations such as barium, zinc and calcium for human and veterinary applications. The present invention also relates to methods of preventing or treating persistent chronic gastritis, GERDs, ulcer and or stomach cancer by inhibiting the release of stomach acid and by reducing inflammation with fewer and milder side-effects expected than current treatments. A method of screening therapeutics is described. | 09-20-2012 |
| 20120237567 | MODULATING LYMPHATIC FUNCTION - Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed. | 09-20-2012 |
| 20120237568 | Bioactive Load-Bearing Composites - Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described. | 09-20-2012 |
| 20120237569 | EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION - Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. | 09-20-2012 |
| 20120237570 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS - The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects. | 09-20-2012 |
| 20120237571 | SUSTAINED RELEASE COMPOSITIONS OF ALFUZOSIN - The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers. | 09-20-2012 |
| 20120237572 | ANTIVIRAL COMPOSITION COMPRISING A SULFATED POLYSACCHARIDE - The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus, The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus. | 09-20-2012 |
| 20120237573 | METHOD OF TOPICALLY APPLYING GLYCOPYRROLATE SOLUTION USING ABSORBENT PAD TO REDUCE SWEATING - This invention relates to a convenient and safe product and method of applying glycopyrrolate topically in order to reduce excessive sweating in localized areas for those who suffer from this condition. This invention also relates to combining oral and topical delivery of glycopyrrolate to reduce excessive sweating and minimize side effects. This invention also relates to a convenient and safe product and method of applying glycopyrrolate topically to areas of compensatory sweating after endoscopic thoracic sympathectomy. | 09-20-2012 |
| 20120237575 | FILM COATING AGENT FOR SOLID PREPARATION, AND SOLID PREPARATION USING SAME - A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay. | 09-20-2012 |
| 20120244192 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF - The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided. | 09-27-2012 |
| 20120244193 | PASSIVE SOLID TUMOR TARGETING ANTICANCER PRODRUG AND PREPARATION METHOD THEREOF - The invention relates to a passive solid tumor-targeted anticancer prodrug and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method includes the following steps: reacting low molecular weight pectin with Mw of 5,000-45,000 with doxorubicin to obtain a pectin-doxorubicin conjugate with Mw of 100,000-1,000,000, preparing the conjugate into a suspension, and treating the suspension in an ultra-high pressure nano homogenizer to obtain the passive solid tumor-targeted anticancer prodrug with particle size of 100 nm-200 nm and melting point of 220-245°, wherein the pectin and doxorubicin are linked by an amide bond, and the pectin is linked by an ester bond formed by condensing carboxyl groups and hydroxyl groups of pectin molecules. Cell inhibition rate of the anticancer prodrug for humanized lung cancer cells NCI-H446 and A549 is equivalent to that of doxorubicin hydrochloride. In the efficacy research of melanoma B16 pulmonary metastasis model mice, the life span of tumor-bearing mice is 42.3±12.4 days, which is remarkably higher than that of the doxorubicin hydrochloride group (23.1±10.2 days). | 09-27-2012 |
| 20120244194 | Pharmaceutical Compositions Comprising Terbinafine - This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration. | 09-27-2012 |
| 20120244195 | ADSORBENT FOR AN ORAL ADMINISTRATION, AND AGENT FOR TREATING OR PREVENTING RENAL OR LIVER DISEASE - An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, a specific surface area determined by a BET method is 700 m | 09-27-2012 |
| 20120244196 | PHARMACEUTICAL COMPOSITION CONTAINING MEDICAMENT-CONTAINING FINE PARTICLES AND METHOD FOR PRODUCING SAME - The invention provides a pharmaceutical composition that can be used for an efficient administration of a water-soluble polymer drug by a method other than injection, and a method for production of the pharmaceutical composition. The pharmaceutical composition contains a small particle comprised of (a) a water-soluble drug and (b) a pharmaceutically acceptable ionic crystalline compound which is solid at room temperature, wherein the ionic crystalline compound is crystallized in the small particle. | 09-27-2012 |
| 20120244197 | Film-Like Pharmaceutical Dosage Forms - Film-like pharmaceutical dosage forms, comprising, as film formers, amphiphilic copolymers and one or more active substances. | 09-27-2012 |
| 20120244198 | MICROSPHERES OF HYDROLYSED STARCH WITH ENDOGENOUS, CHARGED LIGANDS - Biodegradable microspheres having a diameter of 10-2000 μm having cross-linked hydrolysed starch onto which at least one type of ligand has been coupled via a carboxylic ester bond. The ligand shall be an endogenous, charged molecule with a molecular mass of less than 1000 Da having at least one additional carboxylic acid function in addition to the one utilised for coupling the ligand to the microsphere and/or at least one amine function. On average 0.05-1.5 ligands are coupled to each glucose moiety in the hydrolysed starch. | 09-27-2012 |
| 20120251583 | METHODS OF MAKING NUCLEIC ACID NANOSTRUCTURES - The disclosure relates to methods and composition for generating nanoscale devices, systems, and enzyme factories based upon a nucleic acid nanostructure the can be designed to have a predetermined structure. | 10-04-2012 |
| 20120251584 | Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system - The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. | 10-04-2012 |
| 20120251585 | INHALABLE AZTREONAM LYSINATE FORMULATION FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by | 10-04-2012 |
| 20120251586 | LIGAND-SPECIFIC INHIBITION OF ATTACHMENT OF IMMUNE CELLS TO IMPLANTABLE BIOMATERIALS - Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials. | 10-04-2012 |
| 20120251587 | DIABETES TREATMENT - The invention is directed to a treatment of diabetes, a scaffold and a method of preparing a scaffold. In a first aspect, this object is met by providing a scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern. | 10-04-2012 |
| 20120251588 | Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation - Provided are a coating composition for delayed release preparation capable of releasing a drug promptly in the stomach, without causing a time-dependent change, after a time (lag time) in which a solid preparation does not release the drug; and a solid preparation obtained by coating of the coating composition. More specifically, provided are a coating composition comprising at least a nonionic water-soluble cellulose ether and a cellulose-based enteric base material, wherein a weight ratio of the nonionic water-soluble cellulose ether to the cellulose-based enteric base material is from 95:5 to 65:35; and a solid preparation comprising at least a drug-containing core and the coating composition which covers the core, wherein the preparation can permit prompt dissolution of the drug in a stomach after a lag time. | 10-04-2012 |
| 20120251589 | DEVICES AND METHODS FOR WEIGHT CONTROL AND WEIGHT LOSS - The present invention provides, compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material. In various embodiments, the matrix material is suitable for routine use. The compressible absorbent matrix material has a size, shape and/or geometry configured for efficient packing into a small space, and/or configured to absorb and substantially retain digested material in the stomach. The devices and compositions may further comprise one or more hydrogel(s), soluble or insoluble fibers, waxes and/or gums to provide the desired mechanical properties and/or absorptive or shielding properties. | 10-04-2012 |
| 20120251591 | POLYMER CARRIER - Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in scaffolds for regenerative medicine | 10-04-2012 |
| 20120251592 | ANTIMICROBIAL CONSTRUCTS - The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers. | 10-04-2012 |
| 20120251593 | SILK FIBROIN-DECORIN SCAFFOLDS - Disclosed are silk fibroin scaffolds that are fabricated with decorin proteoglycan, and methods of using these scaffolds in the repair of tissue defects in subjects. The scaffolds have biomechanical properties which makes them suitable for patient-specific design for defects where strong tensile strength is required, such as musculofascia reconstruction. | 10-04-2012 |
| 20120251594 | Delivery of Submicrometer and Nanometer Aerosols to the Lungs Using Hygroscopic Excipients or Dual Stream Nasal Delivery - Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung. | 10-04-2012 |
| 20120251595 | EMULSION TEMPLATE METHOD TO FORM SMALL PARTICLES OF HYDROPHOBIC AGENTS WITH SURFACE ENRICHED HYDROPHILICITY BY ULTRA RAPID FREEZING - The present invention relates to methods and compositions to prepare small size particles of poorly water soluble agents or drugs with surface enriched hydrophilicity. | 10-04-2012 |
| 20120251596 | NANOEMULSION, METHOD FOR ITS PREPARATION AND USE - Nanoemulsions comprising an aqueous phase and a lipid phase, having a micelle size in the range from about 20 to about 900 nm and comprising melatonin as an active agent, are provided. The aqueous phase of such a nanoemulsion comprises a base, the lipid phase comprises one or more polyoxyethylene sorbitan esters, and the aqueous phase or the lipid phase, or both, further comprise ascorbyl palmitate. In addition, pharmaceuticals, cosmetics or foodstuffs comprising the nanoemulsions described herein and methods for making nanoemulsions described herein are also provided. | 10-04-2012 |
| 20120258146 | Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy - The present invention relates to a method of treating organic disease of the nervous system, psychoorganic syndrome or encephalopathy of various genesis by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase. | 10-11-2012 |
| 20120258147 | METHOD FOR INHIBITING ANGIOGENESIS - The present invention relates to a method for inhibiting and/or preventing angiogenesis, the method comprising the step of administering a biocompatible composition, which is polymerizable to a hydrogel-forming material and which is based on a hydrophilic polymer, for inhibiting and/or preventing angiogenesis or endothelial cell proliferation, wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein, in a subject in need of being treated. The invention furthermore relates to a method for inhibiting and/or preventing angiogenesis or endothelial cell proliferation in a subject in need thereof, comprising the step of administering a polymerized hydrogel-material, which has been obtained by polymerizing a serum-albumin- or serum-protein-based composition. | 10-11-2012 |
| 20120258148 | ENDOSSEOUS IMPLANT - Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants. | 10-11-2012 |
| 20120258149 | Methods and Compositions for the Prevention and Treatment of Influenza - This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated. | 10-11-2012 |
| 20120263759 | Coating Comprising An Elastin-Based Copolymer - A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided. The copolymer may be used as a coating on a stent. Methods of using a stent coated with the copolymer are also provided. | 10-18-2012 |
| 20120263760 | NOVEL FORMULATION OF METAXALONE - The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments. | 10-18-2012 |
| 20120263761 | SHELF STABLE PHARMACEUTICAL DEPOT - A pharmaceutical depot includes a biodegradable polymer having a glass transition temperature of 20 degrees centigrade or less and at least 25% wt solid particles suspended in the biodegradable polymer. The pharmaceutical depot also includes a post-operative pain relieving therapeutic agent. | 10-18-2012 |
| 20120263762 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE - The present invention relates to small stabilised particles comprising a crystalline form of an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate and at least one protective agent. Such particles confer stability to the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate, and is conveniently incorporated in unit dosage forms, such as wafers. | 10-18-2012 |
| 20120263763 | REGENERATIVE MATERIALS - Methods of making tissue fillers are provided. In certain embodiments, the tissue is flake-like and has regenerative properties. | 10-18-2012 |
| 20120263764 | COMPOSITIONS AND METHODS FOR INHIBITING AND/OR MODULATING EFFECTOR T-CELLS INVOLVED IN INFLAMMATORY NEURODEGENERATIVE DISEASE - Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of T | 10-18-2012 |
| 20120263765 | AGENTS FROM CELLS - A composition includes an isolated cell; at least one particle within said cell; and at least one active agent associated with the particle, wherein the active agent is capable of being released from the cell. A method includes administration of such a cell to a subject. | 10-18-2012 |
| 20120263766 | Formulations - In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. | 10-18-2012 |
| 20120269866 | Gastroretentive Composition On The Basis Of A Water-Soluble Reaction Product From A Vinyl Group-Containing Precursor - A gastroretentive composition comprises a mixture comprising an active ingredient component and an excipient component. The excipient component comprises a first water-soluble reaction product produced from a precursor comprising a vinyl group, and a copolymer of a polyalkylene glycol and a second water-soluble reaction product produced from a precursor comprising a vinyl group. A method of forming the gastroretentive composition comprises the steps of providing the active ingredient component and the excipient component, and mixing the active ingredient component and the excipient component to form a mixture. The mixture is aggregated to form an aggregation that is dry granulated to form a plurality of granules. The plurality of granules is processed to form the gastroretentive composition. | 10-25-2012 |
| 20120269867 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM TUMORS - The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor. | 10-25-2012 |
| 20120269868 | COMPOSITIONS AND METHODS FOR NUTRITIONAL SUPPLEMENTATION - Disclosed is a nutritional supplement composition including effective amounts of Coenzyme Q10, fish oil, vitamin D and a pharmaceutically acceptable excipient. Described is a method of promoting nutritional health comprising administering a nutritional supplement composition including Coenzyme Q10, fish oil, vitamin D and a pharmaceutically acceptable excipient to a subject. The nutritional supplement composition may further include flax seed oil, borage oil, evening primrose oil, vitamin E, resveratrol, vitamin B6, vitamin B12, folic acid, piperine and combinations. In some embodiments, administering Administering the nutritional supplement may ameliorate nutrient depletion, or promote cardiovascular health, liver health, or both. The nutritional supplement may be used to promote nutritional health taking a cholesterol lowering drug. The nutritional supplement may be used to ameliorate nutrient depletion taking a cholesterol lowering drug. The cholesterol lowering drug may be a statin. | 10-25-2012 |
| 20120269869 | COLON VITAMIN - A colon vitamin includes ingredients that are delivered to different regions of the digestive tract. A first group of ingredients which can include: vitamin D, folic acid, vitamin B2, vitamin B6, beta-carotene, selenium, curcumin, green tea extract, and a portion of the calcium serving can be in a first delivery mechanism that releases these ingredients in the stomach. A second delivery mechanism is used to deliver elemental calcium intact through the stomach and small intestine to the large intestine. The delivery of the ingredients to specific areas of the digestive tract reduces the risk of colorectal adenomatous polyps and colorectal cancers. | 10-25-2012 |
| 20120269870 | SWITCHABLE POLYMERS AND SURFACES WITH REVERSIBLY SWITCHABLE PROPERTIES - Reversibly switchable polymers, surfaces that include the polymers, and methods for making and using the polymers and surfaces. The switchable polymers are non-fouling in their zwitterionic form and are antimicrobial in their cationic form. | 10-25-2012 |
| 20120269871 | SOLID STATE FORMS OF RASAGILINE SALTS - Provided herein are novel crystalline forms of rasagiline salts, processes for their preparation, pharmaceutical compositions, and method of treating thereof. The rasagiline salts include a maleate salt, a mandelate salt, or a salicylate salt. | 10-25-2012 |
| 20120269872 | NOVEL SALT 628 - 6-M ethyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form. | 10-25-2012 |
| 20120269873 | Flexible Bone Composite - The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include a calcium compound such as β-Ca | 10-25-2012 |
| 20120276150 | SOFT TISSUE WRAP - Compositions and methods for treating and healing injured soft tissues such as tendons and ligaments are provided. The composition may be a wrap comprising human collagen in the form of a sheet. The human collagen has been processed so that is retains proteins that are associated with it in its natural state. The sheet may optionally be coated on one or more sides with one or more of additional human collagen, therapeutic agents, additional soft tissue growth factors or hydroxyapatite. | 11-01-2012 |
| 20120276151 | DRUG DELIVERY FROM EMBOLIC AGENTS - An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 μm and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver. | 11-01-2012 |
| 20120276152 | SYSTEMS AND METHODS OF USING ZINC-CHELATOR TO TREAT MYOCARDIAL INFARCTION - Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue. | 11-01-2012 |
| 20120276153 | USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS - Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising | 11-01-2012 |
| 20120276154 | CREATION OF HAIR FOLLICLES IN TISSUE-ENGINEERED SKIN GRAFTS - A living tissue-engineered skin graft having a potential to develop hair follicles includes a multilayered skin-like structure of alternating nanofiber mats and layers of fibroblasts assembled in a layer-by-layer fashion. Aggregates of dermal papilla capable of developing into hair follicles are embedded in the multilayered structure such that the aggregates develop into hair follicles upon culturing the multilayered structure. Keratinocytes are provided as an outer layer of the skin graft. Fibroblasts, keratinocytes and dermal papilla cells are isolated from skin and cultured to form suspensions of cells for fabricating the skin graft. Aggregates of dermal papilla cells are generated using a hanging drop method. Nanofiber mats are formed by electrospinning biocompatible materials onto a culture media or a layer of fibroblast suspension. The skin graft has dermal and epidermal layers and provides a biomimetic environment to promote healing and hair growth. | 11-01-2012 |
| 20120276155 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 11-01-2012 |
| 20120276156 | TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens. | 11-01-2012 |
| 20120276157 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen. | 11-01-2012 |
| 20120276158 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. | 11-01-2012 |
| 20120276159 | TOLEROGENIC SYNTHETIC NANOCARRIERS - This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses. | 11-01-2012 |
| 20120276160 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells. | 11-01-2012 |
| 20120276161 | BIORESORBABLE AND BIOCOMPATIBLE COMPOUNDS FOR SURGICAL USE - A bioresorbable and biocompatible compound for surgical use is composed of functionalized collagen cross-linked with a glycosaminoglycan. | 11-01-2012 |
| 20120276162 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-01-2012 |
| 20120276163 | ANTI-CANCER COMPOSITION COMPRISING ALGINATE - The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon. | 11-01-2012 |
| 20120276164 | IMPLANTABLE PASTE AND ITS USE - The present invention relates to an implantable paste comprising bioactive glass spheres having a size distribution of 50-425 μm, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol and high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol, with the proviso that the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol. | 11-01-2012 |
| 20120276165 | MICRO-COLLOIDAL SILICIC ACID/BORIC ACID COMPOSITION AND A METHOD OF PREPARING A BIOENHANCING SOLUTION AND POWDER - The present invention provides a composition comprising an acidified aqueous solution of (1) micro colloidal silicic acid, (2) boric acid, and (3) a water absorbing additive, having a pH value of equal to or less than 1, wherein the micro colloidal silicic acid has particle sizes in the range of 1-8 nm, especially in the range of 1.5-6 nm. The invention also provides a particulate product obtainable by the method according to claim | 11-01-2012 |
| 20120276166 | ELUTION-STABILIZED PREPARATION - The invention provides a solid preparation which does not undergo the delay of elution of the active ingredient even after long-term storage. The solid preparation independently contains a teneligliptin-containing part containing teneligliptin or a salt thereof, or a solvate of teneligliptin or the salt thereof, in an amount 1.5- to 10-fold larger than that desired for the solid preparation. | 11-01-2012 |
| 20120276167 | IMMUNOPROTECTION BY ORAL ADMINISTRATION OF RECOMBINANT LACTOCOCCUS LACTIS MINI-CAPSULES - In one embodiment, the present invention provides for an edible mini-capsule form of live, non-persisting, recombinant | 11-01-2012 |
| 20120276168 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized bu chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology. | 11-01-2012 |
| 20120276169 | POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY - The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy. | 11-01-2012 |
| 20120276170 | INJECTABLE DRUG CARRIER COMPRISING LAYERED DOUBLE HYDROXIDE - Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug. | 11-01-2012 |
| 20120276171 | MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations. | 11-01-2012 |
| 20120276172 | POLYMERIC MATERIALS FOR MEDICAL DEVICES - The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices. | 11-01-2012 |
| 20120276173 | Glycosaminoglycan Compositions in Combination with Stem Cells - A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided. | 11-01-2012 |
| 20120282297 | METHOD FOR TREATING CONSTIPATION - The invention relates to methods and compositions for the treatment of constipation. The method of the invention involves administration of a suppository containing chlorophyll, chlorophyllin copper complex or chlorophyllin. The suppository contains an outer layer to prevent spillage of chlorophyll or chlorophyllin prior or after administration. Other ingredients that may also be effective treatments may be included. This method may be useful as a new and safer treatment for constipation, including constipation-predominant IBS and other functional anorectal disorders. Chlorophyll, or chlorophyll copper complex and chlorophyllin in the suppository form may improve bowel activity by stimulation of secretion and motility, thus relieving symptoms of constipation. This is the first description of this unique method of delivering these safe, natural products to patients suffering from constipation. | 11-08-2012 |
| 20120282298 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 11-08-2012 |
| 20120282299 | COATINGS COMPRISING BIS-(ALPHA-AMINO-DIOL-DIESTER) CONTAINING POLYESTERAMIDE - The present invention relates to a coating comprising at least one biodegradable polymer, wherein the polymer comprises at least one or a blend of a poly (ester amide) (PEA) having a chemical formula described by structural formula (II), wherein; R | 11-08-2012 |
| 20120282300 | PROTEIN BIOMATERIALS AND BIOCOACERVATES AND METHODS OF MAKING AND USING THEREOF - The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices. | 11-08-2012 |
| 20120282301 | POROUS CALCIUM PHOSPHATE BONE MATERIAL - Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided. | 11-08-2012 |
| 20120282302 | BIOMATERIAL COMPOSITE COMPOSITION AND METHOD OF USE - This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of β-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of β-tricalcium phosphate. | 11-08-2012 |
| 20120282303 | PERCUTANEOUS ABSORPTION PREPARATION COMPRISING ANTI-DEMENTIA DRUG - The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a fatty acid alkyl ester, a styrenic polymer compound, and a tackifier resin. | 11-08-2012 |
| 20120282304 | MULTI-COATED LACTIC ACID BACTERIA AND PREPARING METHOD THEREOF - The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria. | 11-08-2012 |
| 20120282305 | BIOLOGICAL SURFACTANTS FOR CONNECTION TO SILICONE-BASED MATERIALS AND MODULATING LEVELS OF IMMUNOLOGICALLY ACTIVE PROTEINS - Biological surfactants connected to surfaces of silicone-based materials are provided. Compositions of electrolytes and a biological surfactant are also provided. Methods for increasing the surface wettability of a silicone-based material by contacting the silicone-based material with a biological surfactant, methods for increasing evaporation from a silicone-based material by contacting a surface of the silicone-based material with a biological surfactant, methods for increasing levels of interleukin-8 during inflammation by contacting a cell with a biological surfactant, and methods for decreasing expression of a biological surfactant by contacting a cell with an siRNA are further provided. | 11-08-2012 |
| 20120282306 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 11-08-2012 |
| 20120282307 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 11-08-2012 |
| 20120288529 | PHARMACEUTICAL EXCIPIENT, METHOD FOR ITS PREPARATION AND USE THEREOF - The present invention relates to a pharmaceutical excipient comprising a mixture of sugar alcohol and chitin and/or chitin derivatives, a method for its preparation and use thereof. | 11-15-2012 |
| 20120288530 | TISSUE SEALANTS FROM PLASMA DERIVED PROTEINS - The present invention is directed in one embodiment to a tissue adhesive or sealant composition comprising an electrophilic group containing cross-linking compound having a linker moiety of a diglycolic acid, a water soluble core moiety and an electrophilic group that is covalently bonded to the diglycolic acid linker moiety and a nucleophilic group containing protein. In other embodiments, the present invention is directed to a delivery device or a medical device on which the composition has been applied or incorporated therein. The present invention is also directed to a method for sealing tissue using the tissue adhesive or sealant composition. | 11-15-2012 |
| 20120288531 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF FERRIC IRON COMPOUNDS, AND METHODS OF USE THEREOF - The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound. | 11-15-2012 |
| 20120288532 | MULTI-LAYERED, MULTIPLE UNIT PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof. | 11-15-2012 |
| 20120288533 | PROTEIN-POLYSACCHARIDE CONJUGATES AND USE FOR ENCAPSULATING NUTRACEUTICALS FOR CLEAR BEVERAGE APPLICATIONS - The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion. | 11-15-2012 |
| 20120288534 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 11-15-2012 |
| 20120288535 | RARE EARTH NANOPARTICLES - This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided. | 11-15-2012 |
| 20120288536 | Stabilized Stat3 Decoy Oligonucleotides And Uses Therefor - The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer. | 11-15-2012 |
| 20120288537 | ACTIVE SELF-HEALING BIOMATERIAL SYSTEM - Methods and compositions are provided that load and encapsulate an agent, such as a protein, in a porous self-healing polymer. A delivery system includes a porous self-healing polymer, an ionic affinity trap within the pores of the self-healing polymer, and an agent associated with the ionic affinity trap. Methods of encapsulating an agent in a polymer include providing a porous self-healing polymer comprising an ionic affinity trap within the pores. The polymer is incubated with an agent having an affinity for the ionic affinity trap. At least a portion of the pores in the polymer are then healed. Active encapsulation of macromolecules at low concentrations may be achieved due to affinity of the agent for the ionic affinity trap within the pores. | 11-15-2012 |
| 20120288538 | VACCINE AGAINST NEOPLASTIC OR CANCEROUS LESIONS CAUSED BY HUMAN PAPILLOMA VIRUS (HPV), PROCEDURES, USES AND METHODS - Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (HPV), which comprises E7 peptide spherical particles and, as an option, an adjuvant, where spherical particles may be oligomeric. The oligomeric spherical particles may have a diameter in the vicinity of 50 nm and a molecular weight in the vicinity of 700 kDa. The vaccine may be helpful to prevent or treat human papillomavirus (HPV)-related lesions or do both things at the same time. | 11-15-2012 |
| 20120288539 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES - The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition. | 11-15-2012 |
| 20120288540 | NIOSOMES, FREEZE-DRIED POWDER THEREOF AND THEIR USE IN TREATMENT - The present invention relates to a vesicular structure formed of a mixture of a non-ionic surfactant and cholesterol, characterised in that it is freeze-dried in the presence of a cryoprotectant, to a method for the preparation and to the use thereof. | 11-15-2012 |
| 20120288541 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-15-2012 |
| 20120288542 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment. | 11-15-2012 |
| 20120288543 | Wet Granulation Using A Water Sequestering Agent - Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process. | 11-15-2012 |
| 20120288544 | NOVEL RETIGABINE COMPOSITION - The present invention relates to an oral dosage form comprising N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine) or a pharmaceutically acceptable salt or solvate thereof, to a process for preparing such a dosage form and to the use of such a dosage form in medicine. | 11-15-2012 |
| 20120294898 | INJECTABLE DBM FOR SOFT TISSUE REPAIR - An injectable pharmaceutical composition includes demineralized bone matrix (DBM) particles having a particle size in the range of about 25 microns to about 75 microns and a pharmaceutical carrier. The composition can further include adjuncts such as glycosaminoglycans, adjuvants such as chondroitin, and/or active ingredients such as anti-inflammatories. | 11-22-2012 |
| 20120294899 | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to HIV protein, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS. | 11-22-2012 |
| 20120294900 | Phosphorylated and Branched Dihydroxy-Pentane-Dione (DPD) Analogs as Quorum Sensing Inhibitors in Bacteria - Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms. | 11-22-2012 |
| 20120294901 | NOVEL COCHLEATE FORMULATIONS - A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 11-22-2012 |
| 20120294902 | PEPTIDE AMPHIPHILES AND METHODS TO ELECTROSTATICALLY CONTROL BIOACTIVITY OF THE IKVAV PEPTIDE EPITOPE - The present invention is directed to peptide amphiphile compounds, compositions and methods of use, wherein nanofiber bundling or epitope aggregation is inhibited. In certain embodiments, the peptide amphiphiles of the present invention have increased solubility and reduced nanofiber bundling. The molecules may be used in pharmaceutical applications, for example for in vivo administration to human patients, by increasing biological activity of the compositions toward neurite outgrowth and nerve regeneration. | 11-22-2012 |
| 20120294903 | METHODS AND SYSTEMS OF MAKING NANOSTRUCTURES - In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like. | 11-22-2012 |
| 20120294904 | POLYSIALIC ACID-BASED N-TRIMETHYL CHITOSAN GEL NANOPARTICLES FOR SYSTEMIC DRUG DELIVERY - Gel nanoparticles for encapsulating and delivering a pharmaceutical compound to a patient. The nanoparticles are formed from N-trimethyl chitosan and polysialic acid, preferably in the presence of sodium tripolyphosphate. A ratio of polysialic acid to N-trimethyl chitosan of about 0.5 to 1 produces nanoparticles having diameter of about 100 nm (plus or minus 25 nm) and a zero potential above 30 milivolts that can stability contain a pharmaceutical compound, such as methotrexate, for delivery to a patient. | 11-22-2012 |
| 20120294905 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR) - The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 11-22-2012 |
| 20120294906 | SERICIN EXTRACTED FABRICS - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 11-22-2012 |
| 20120294907 | TWO OR MORE SOLIDIFYING AGENT-CONTAINING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS - The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. | 11-22-2012 |
| 20120294908 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 11-22-2012 |
| 20120294909 | METHOD FOR INHIBITING ADHESION FORMATION - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 11-22-2012 |
| 20120294910 | METHOD FOR TREATING A WOUND - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 11-22-2012 |
| 20120301507 | METHOD OF TISSUE REPAIR - The present invention relates to methods of repairing tissue. More specifically, the present invention relates to methods of using cells and an implantable support for the repair of tissue defects, where the implantable support and cells are implanted into the tissue defect less than 2 hours after the cells are applied to the support. | 11-29-2012 |
| 20120301508 | Compositions for Induction of Osteogenesis around an Implant - The invention relates to a composition for induction of osteogenesis around an implant comprises a chitosan having a degree of deacetylation at the range of 70%˜90% and a collagen, wherein the implant is a titanium implant. The composition of the present invention is able to effectively induce osteogenesis in organisms and can be used to promote bone formation and osseointegration of an implant. | 11-29-2012 |
| 20120301509 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 11-29-2012 |
| 20120301510 | TOLEROGENIC SYNTHETIC NANOCARRIERS COUPLED TO CD1D-RESTRICTED ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses. | 11-29-2012 |
| 20120301511 | TOPICAL FORMULATION COMPRISING A CORTICOSTEROID AS ACTIVE INGREDIENT - Formulation in the form of aqueous suspension of drug particles of a corticosteroid for topical administration are effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis. | 11-29-2012 |
| 20120301512 | Tetrary Gene Delivery System for Gene Therapy and Methods of Its Use - Delivery systems and their methods of formation are generally provided. The delivery system can protect a delivery molecule (e.g., DNA/RNA) and deliver it into a cell via serum. In one embodiment, the method can include binding a delivery molecule with polyethylenimine such that an end of the delivery molecule is exposed; capping the end of the delivery molecule with a first biocompatible polymer to form a core; and encapsulating the core with a second biocompatible polymer. The resulting delivery system can include a delivery molecule bonded with polyethylenimine such that an end of the delivery molecule is exposed; a first biocompatible polymer electrostatically bonded to the end of the delivery molecule to form a core; and a second biocompatible polymer encapsulating the core. | 11-29-2012 |
| 20120301513 | COMPOSITION COMPRISING SOLANUM GLAUCOPHYLLUM FOR PREVENTING AND/OR TREATING HYPOCALCAEMIA AND FOR STABILIZING BLOOD CALCIUM LEVELS - The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a | 11-29-2012 |
| 20120301514 | DEVELOPMENT OF BIOACTIVE ELECTROSPUN COATINGS FOR BIOMEDICAL APPLICATIONS - The present invention relates to a bioactive composition obtained through the technique of electrospinning and composed of at least one polymer. Furthermore, the invention also discloses a process for the incorporation of such electrospun bioactive composition, as a coating over a plastic matrix to obtain composite materials for their use in both biodegradable and non-biodegradable biomedical implants and in tissue engineering. | 11-29-2012 |
| 20120301515 | ANTI-ADHESION MATERIAL - An object of the present invention is to provide an anti-adhesion material having sufficient in vivo degradability and excellent anti-adhesion characteristics, and also superior to conventional ones in terms of handling properties under wet conditions. The anti-adhesion material ( | 11-29-2012 |
| 20120301516 | PARTICLE- CONTAINING COMPLEX POROUS MATERIALS - Porous materials and methods for forming them are disclosed. One method for immobilizing micro-particles and/or nano-particles onto internal pore surfaces and/or external pore surfaces of porous materials includes suspending the micro-particles and/or nano-particles in a liquid adapted to swell, soften, and/or deform either the porous materials and/or the particles, thereby forming a liquid-particle suspension. The method further includes adding the suspension to the porous materials; and removing the liquid, thereby forming the porous materials having the micro-particles and/or nano-particles immobilized on the internal pore surfaces and/or the external pore surfaces. | 11-29-2012 |
| 20120301517 | TWO OR MORE NON-VOLATILE SOLVENT-CONTAINING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS - The present invention is drawn to adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can have a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least two non-volatile solvents. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. | 11-29-2012 |
| 20120301518 | BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS - Disclosed herein are biocompatible and biodegradable polymers comprising one or more ECM-mimetic peptides and one or more biodegradable moieties, wherein the moieties do not comprise an amino acid or residue thereof. Further disclosed herein are methods for making and using the disclosed biocompatible polymers. | 11-29-2012 |
| 20120301519 | CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 11-29-2012 |
| 20120301520 | DIRECTLY COMPRESSIBLE MAGNESIUM HYDROXIDE CARBONATE - The present invention relates to a directly compressible magnesium hydroxide carbonate and to a process for the preparation thereof, and to the use thereof. | 11-29-2012 |
| 20120308610 | Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs - Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity. | 12-06-2012 |
| 20120308611 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 12-06-2012 |
| 20120308612 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY - The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration. | 12-06-2012 |
| 20120308613 | FORMULATIONS FOR USE IN INHALER DEVICES - A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents. | 12-06-2012 |
| 20120308614 | COMPOSITION FOR THE CONTROLLED RELEASE OF BUPRENORPHINE - The present invention relates to a novel aqueous liquid pharmaceutical composition for the controlled release of buprenorphine or of an analogue of buprenorphine, comprising at least one prodrug with low aqueous solubility of said buprenorphine or analogue of buprenorphine, and at least one polymer having a linear backbone chosen from the polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, to which one or more hydrophobic groups are grafted. | 12-06-2012 |
| 20120308615 | FORMULATION OF HEPATITIS B VIRUS ANTIGENS FOR CELLULAR STIMULATION FOLLOWED BY THERAPEUTIC IMMUNIZATION - The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients chronically infected with the HBV. | 12-06-2012 |
| 20120308616 | SUBMICRO EMULSION OF PACLITAXEL USING STEROID COMPLEX AS INTERMEDIATE CARRIER - A submicron emulsion of paclitaxel, the preparation method and the use thereof are disclosed. Said paclitaxel submicron emulsion comprises paclitaxel/steroid complex, oil for injection, water for injection, emulsifier, assistant emulsifier and isotonic agent, wherein the mole ratio of paclitaxel to steroid in the complex is 1:0.2˜4; preferably 1:0.25˜2. Said submicron emulsion is useful for the treatment for malignant tumor. The average particle diameter of the submicron emulsion is less than 400 nm and the pH Value is 3.5-6. | 12-06-2012 |
| 20120308617 | PHOSPHOLIPID-BASED INHALATION SYSTEM - The present invention includes a method for delivering medications deeper into the lungs and to the medications' pulmonary targets, which include bronchioles and alveoli. A first particularly preferred embodiment of the invention describes the use of two steps for delivery of a medication. In a first step, an aerosolized therapeutic composition or medication is administered into a patient's respiratory tract, wherein the patient may be any animal or human subject. Following the first step, an aerosolized surfactant is administered into the patient's respiratory tract that facilitates delivery of the aerosolized medication of the first step to the medication's pulmonary target. Another embodiment of the present invention contemplates an apparatus for the delivery of an aerosolized surfactant used that facilitates delivery of previously inhaled aerosolized medication. | 12-06-2012 |
| 20120308618 | IC31 NANOPARTICLES - The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL | 12-06-2012 |
| 20120315300 | INSERTABLE MEDICAL DEVICES WITH A POROUS BED FOR DELIVERING NANO-CARRIERS TO A TARGET SITE AND METHODS OF PREPARING THE SAME - The invention discloses a method of coating a medical device. The method includes applying a coating composition on the medical device to form a layer on the medical device. The coating composition includes one or more of one or more biological agents and heparin dissolved in a mixture of a first solvent and a second solvent. The first solvent and the second solvent have different evaporation temperatures. Subsequently, at least a part of one of the first solvent and the second solvent present in the coating composition is evaporated to create a plurality of pores in the layer. Thereafter, one or more drugs are deposited in the plurality of pores. When the medical device is positioned and expanded at a target site, the one or more drugs are released from the plurality of pores. | 12-13-2012 |
| 20120315301 | Preparation of vesicle-type carbon nanotubes - A method to prepare new morphologies, especially vesicle-type, of carbon nanotubes (CNT) by supramolecular interactions between them and dendritic or linear-dendritic polymers and copolymers. Due to their water solubility, high functionality and unique properties, the prepared hybrid nanomaterials have excellent applicability in different fields especially in nanomedicine in comparison with usual CNTs. | 12-13-2012 |
| 20120315302 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 12-13-2012 |
| 20120315303 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS - Methods and intravascular treatment devices for treating atherosclerosis are provided. | 12-13-2012 |
| 20120315304 | SENSITIZATION OF IMMUNE SYSTEM AGAINST HAPTENIZED MELANOMA ANTIGENS - The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies. | 12-13-2012 |
| 20120315305 | Dry Powder Fibrin Sealant - The present invention relates to a dry powder fibrin sealant which comprises a mixture of fibrinogen and thrombin for use in surgery, trauma and other wounds or injuries. It further relates to novel formulations comprising said dry powder fibrin sealant for use in the treatment of wounds or for surgical intervention or as a topical hemostat. | 12-13-2012 |
| 20120315306 | PHARMACEUTICAL COMPOSITION AND PREPARATION FOR ORAL ADMINISTRATION - A pharmaceutical composition including drug-containing nanoparticles having an average particle diameter of from 10 nm to 150 nm, the pharmaceutical composition being obtained by mixing water with a poorly water soluble drug-containing, water miscible solution that contains a poorly water soluble drug having a water solubility of 50 μg/mL or less, a water soluble copolymer having a repeating unit represented by the following Formula (1), and a water miscible miscible solvent, wherein in Formula (1), n:m is within a range of from 0.25:0.75 to 0.95:0.05, R represents an alkyl group which may have a substituent, R | 12-13-2012 |
| 20120315307 | CELL CULTIVATION IN CHITOSAN ALGINATE HYDROGEL BEADS - The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerised into beads. | 12-13-2012 |
| 20120315308 | METHODS AND DEVICES FOR CONTROLLING PARTICLE SIZE AND PARTICLE SIZE DISTRIBUTION - Methods and apparatus for continuously preparing a particulate material are provided. One method of the invention includes mixing a first solution comprising a solute dissolved in a solvent, with a second solution, thereby providing a first solution-second solution mixture; and introducing the mixture into the high-energy zone of a high shear dispersion system and dispersing the first solution-second solution mixture prior to significant particulate growth, whereby the dispersed mixture forms a suspension of particles of the solute; and wherein significant particulate growth has occurred when the average equivalent spherical diameter of at least one particle in the solution is greater than 10 micrometer. Integrated apparatuses for performing methods of the invention are also provided. | 12-13-2012 |
| 20120315309 | MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them. | 12-13-2012 |
| 20120315310 | BONE TISSUE IMPLANT COMPRISING LITHIUM IONS - The present invention is based on that local administration of lithium ions in bone tissue has been found to improve the bone formation and bone mass upon implantation of a bone tissue implant in said bone tissue. In particular, the invention relates to a bone tissue implant having an implant surface covered by an oxide layer comprising lithium ions and a method for the manufacture thereof. A blasting powder comprising lithium ions, a method for locally increasing bone formation, and the use of lithium ions or a salt thereof for manufacturing a pharmaceutical composition for locally increasing bone formation are also provided by the present invention. | 12-13-2012 |
| 20120315311 | ANTIVIRAL COMPOSITION AND METHOD OF USE - Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient. | 12-13-2012 |
| 20120321670 | FORMULATIONS OF NANO-CARRIERS AND METHODS OF PREPARING THE SAME - A method of preparing nano-carriers is disclosed. The method includes mixing an organic solution of a drug and an organic solution of a biological agent separately with a predetermined amount of water having one or more dissolved surfactants to obtain a first mixture and a second mixture respectively. Subsequently, the first mixture and the second mixture are homogenized separately to obtain a solution of nano-crystals of the drug and a solution of nano-particles of the biological agent respectively. Thereafter, the solution of nano-crystals of the drug and the solution of nano-particles of the biological agent are together subjected to an ultra-sound homogenization to obtain a solution of nano-carriers. An interfacial extraction and/or a dialysis are then performed on the solution of nano-carriers to obtain the nano-carriers. Formulations of the nano-carriers are also disclosed. | 12-20-2012 |
| 20120321671 | Method for reducing heat loss in neonatal mammalian subjects by transplanting brown adipocytes or precursors thereof - A method for modulating heat loss in a neonatal mammalian subject is disclosed herein that includes providing exogenous brown adipocytes, or precursors thereof, to an internal site in the neonatal mammalian subject. | 12-20-2012 |
| 20120321672 | Method of treating attention deficit hyperactivity disorder - The present invention relates to a method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of antibodies to brain-specific protein S-100 and activated-potentiate form of antibodies to endothelial NO synthase. | 12-20-2012 |
| 20120321673 | TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD OF USING THE SAME - A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction. | 12-20-2012 |
| 20120321674 | Technology for Preventing Abuse of Solid Dosage Forms - Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating. | 12-20-2012 |
| 20120321675 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a β | 12-20-2012 |
| 20120321676 | EXOSOMES DERIVED FROM RETICULOCYTES INFECTED WITH PLASMODIUM SP., METHOD FOR OBTAINING THEM AND USES THEREOF - The present invention belongs to the field of vaccines for the prevention and prophylaxis against malaria, more specifically it relates to exosomes isolated from reticulocytes infected with | 12-20-2012 |
| 20120321677 | COATED SOLID PREPARATION - A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7. | 12-20-2012 |
| 20120321678 | INTRA-ARTICULARLY SUPPLEMENTATION METHOD FOR TREATING JOINT DISEASES AND INJURIES - A method of producing a hydrogel for intra-articular supplement comprising the steps of:
| 12-20-2012 |
| 20120328665 | COMPOSITE NANOPARTICLE, AND PREPARATION PROCESS AND USE THEREOF - Disclosed herein are a composite nanoparticle and a process for preparing the same. The composite nanoparticle includes Rev peptides chemically bonded to gold. Also disclosed herein are a pharmaceutical composition including a plurality of the aforesaid composite nanoparticles, and a method of inhibiting tumor/cancer cells by virtue of the aforesaid composite nanoparticle. | 12-27-2012 |
| 20120328666 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 12-27-2012 |
| 20120328667 | IN SITU CONSTITUTING A VACCINE FOR ADMINISTRATION TO A PREDETERMINED HERD OF ANIMALS - The present invention pertains to a method for constituting a vaccine for administration to a predetermined herd of animals, comprising providing a set of multiple distinct non-live antigens, each non-live antigen being present in a lyophilised form and packed in a container, providing a liquid carrier which is pharmaceutically acceptable for the animals, determining health risks in connection with microbial infection for this herd, establishing which one or more non-live antigens in the said set correspond to these health risks, taking one or more of the containers corresponding to the one or more non-live antigens and mixing the lyophilised contents of the said one or more containers with the carrier to constitute the vaccine. The invention also pertains to a method to produce multiple distinct non-live antigens suitable for constituting the vaccine, a kit of parts and a method enabling in situ constitution of the vaccine. | 12-27-2012 |
| 20120328668 | MODIFIED SIRNA MOLECULES AND USES THEREOF - The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided. | 12-27-2012 |
| 20120328669 | High density fibrous polymers suitable for implant - This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers. | 12-27-2012 |
| 20120328670 | Targeted Delivery of Retinoid Compounds to the Sebaceous Glands - Disclosed herein are topical dermal compositions comprising particles, wherein the particles comprise | 12-27-2012 |
| 20120328671 | COMPOSITION - The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections. | 12-27-2012 |
| 20120328672 | COMPOSITION AND METHOD OF SEPARATING BENTONITE INTO PARTICLES HAVING DISCRETE SIZE AND DENSITY RANGES CAPABLE OF BINDING BIOLOGICAL TOXINS AND CHEMOTHERAPEUTIC AGENTS. - A low heavy metal (i.e. cadmium, mercury) containing calcium aluminum silicate product produced by the method of Air Classification. The method comprises using an air classification system for separating a cadmium containing calcium aluminum silicate feed stock into at least a first fraction and a second fraction. The first separation fraction contains material having an average particle size over 100 um, and the second fraction contains material having an average particle size under 100 um. | 12-27-2012 |
| 20120328673 | DENDRITIC AND HYPERBRANCHED POLYMERS FOR CELLULAR ENCAPSULATION AND FUNCTIONALIZATION - A protective coating for covering a biological material, the protective coating having a plurality of interconnected layers covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer. A method of forming a protective coating for covering a biological material, the method can include depositing a plurality of interconnected layers, which are covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer. | 12-27-2012 |
| 20120328674 | NON-TOXIC AND ENVIRONMENTALLY COMPATIBLE PHOTO-PROTECTIVE PREPARATIONS - The present invention relates generally to methods and compositions for prophylaxis and treatment of skin conditions. Topical compositions which protect the skin from UV radiation damage and treat UV radiation damage done to the skin are provided according to embodiments of the present invention which include at least one cyanin derived from a plant and at least one additional agent selected from the group consisting of: a UV radiation reflector, a UV screening agent, niacinamide, and a combination of two or more thereof. | 12-27-2012 |
| 20120328675 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE - Provided is a film preparation in which an unpleasant taste derived from a medicament is masked. The film preparation includes coating layers containing no terpene formed on both sides of a medicament-containing layer containing a medicament having an unpleasant taste and a terpene. | 12-27-2012 |
| 20120328676 | DIKETOPIPERAZINE SALTS FOR DRUG DELIVERY AND RELATED METHODS - Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. | 12-27-2012 |
| 20120328677 | Active Agent Formulations, Methods of Making, and Methods of Use - An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract. | 12-27-2012 |
| 20120328678 | Hydrogel Networks Having Living Cells Encapsulated Therein - The present invention is directed to a hydrogel network comprised of a physically cross-linked polymer and a chemically cross-linked polymer or physically entangled copolymer containing living cells, such as chondrocytes, encapsulated therein. In a preferred aspect, the physically cross-linked polymer is selected from the group consisting of thermally gelling polysaccharides and proteins, such as agarose or gelatin, and the chemically cross-linked or physically entangled polymer is synthesized from a water-soluble vinyl monomer, either as a homopolymer or copolymer, such as polyethylene glycol diacrylate (“PEG-DA”) and 2-hydroxyethyl methacrylate (“HEMA”). | 12-27-2012 |
| 20120328679 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment. | 12-27-2012 |
| 20130004541 | POLYMER NANOFIBER SCAFFOLD FOR A HEPARIN / FIBRIN BASED GROWTH FACTOR DELIVERY SYSTEM - A growth factor delivery scaffold combines a heparin/fibrin-based delivery system (HBDS) with a backbone based on polymer nanofibers for tissue (e.g., tendon and ligament) repair. The scaffold has improved surgical handling properties compared to the gelatinous consistency of the prior art HBDS system and retains the capability for delivering mesenchymal cells and controlling the release of growth factors. One application for the scaffold is mesenchymal stem cell (MSC) therapy for flexor tendon repair. The scaffold can deliver growth factors in a sustained manner, can be implanted for flexor tendon repair, is biocompatible, and is not cytotoxic. The growth factor delivery scaffold may also be used in the surgical repair of an injury to bone, muscle, cartilage, or other tissues. | 01-03-2013 |
| 20130004542 | COMPOSITION - The invention provides a composition for inhalation comprising a pharmaceutically acceptable glassy matrix and at least one bioactive material within the matrix, wherein the glassy matrix comprises a metal ion salt, wherein the composition is substantially free of polyols and is in the form of a powder and wherein the powder comprises particles having a median geometric diameter of less than 10 μm. | 01-03-2013 |
| 20130004543 | FIBRONECTIN: GROWTH FACTOR CHIMERAS - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer. | 01-03-2013 |
| 20130004544 | Synthetic Antibacterial Clay Compositions and Method of Using Same - The present invention is directed to synthetic bactericidal compositions having clay like properties and a method of using these compositions to topically treat bactenally-caused skin infections and skin diseases. The compositions within the scope of the invention compnse a bactericidal effective amount of a reducing agent, such as pyπte, marcasite, pyrrhotite, FeS2, FeS, FeS04—or other reducing agents having like properties, and a natural clay or clay mineral and/or synthetic clay or clay mineral, or other suitable matenals having clay-like properties. The synthetic bactericidal compositions are synthesized by adding the reducing agent to the clay or clay mineral. It is the presence of the reducing agent in said compositions that renders them bacteπcidal. The clays serve as a vehicle within which the reducing agent is dispersed, as a diluent to the reducing agent, and also as an adsorbent and low permeability banner in use of the composition | 01-03-2013 |
| 20130004545 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS OF ILOPERIDONE - A slow release pharmaceutical composition comprising iloperidone or its active metabolites and a slow release agent is described. Also disclosed is slow release pharmaceutical composition comprising iloperidone or its active metabolites, wherein the slow release composition is a combination of a controlled release composition and an immediate release composition. | 01-03-2013 |
| 20130004546 | HYDROGEL OF MICROSPHERES - The invention relates to an injectable composition intended for tissue induction of the soft tissues by a system of immediate and prolonged progressive release. | 01-03-2013 |
| 20130004547 | ORAL VACCINES PRODUCED AND ADMINISTERED USING EDIBLE MICRO-ORGANISMS INCLUDING LACTIC ACID BACTERIAL STRAINS - The invention provides for anti-pathogen vaccines produced in recombinant bacteria and/or transgenic plants and administered through standard vaccine introduction methods or oral administration. In one embodiment, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally. The present invention also provides a method of using genetically modified microorganisms, such as lactic acid bacteria, including | 01-03-2013 |
| 20130004548 | MEDICAL DEVICES HAVING PHARMACOLOGICAL ACTIVE AGENT RELEASING MATERIAL - An embodiment of the present invention relates to a therapeutically active composition for the treatment of arteriosclerosis, and a pharmacological active agent-releasing medical device, the efficiency of which is increased by combination with a compound that releases alkaline-earth metal ions. | 01-03-2013 |
| 20130004549 | CELL SUPPORT AND BONE REGENERATION MATERIAL - An object of the present invention is to provide a three-dimensional cell support that is capable of uniformly distributing cells and retaining the cells in a state without nonuniformity and is made of a biodegradable material. The present invention provides a cell support consisting of a porous body made of a biodegradable material, the porous body having the following properties:
| 01-03-2013 |
| 20130004550 | SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE - It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release matrix preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release preparation obtained by mixing of (A) a pharmacologically active drug, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D | 01-03-2013 |
| 20130004551 | BIOTINYLATED HEXADECASACCHARIDES, PREPARATION AND USE THEREOF - The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R | 01-03-2013 |
| 20130011440 | METHOD AND DEVICE FOR DEPOSITING THIN LAYERS, ESPECIALLY FOR THE PRODUCTION OF MULTIPLE LAYERS, NANOLAYERS, NANOSTRUCTURES AND NANOCOMPOSITES - The present disclosure relates to a method for the deposition of thin layers, particularly for producing multi-layer coatings, nanolayers, nanostructures and nanocomposites by laser deposition from target materials on a substrate surface, which is characterized by the following features: a) the target is divided into segments with materials having most differing physical and/or chemical properties; b) individual segments of said target are irradiated with an in each case different radiation intensity by means of a controlled energetic distribution of the focused laser energy via the laser beam cross section so that each target segment absorbs the quantity of laser energy during the irradiation, which is required to evaporate or desorb the target material present in the respective segment. | 01-10-2013 |
| 20130011441 | TARGETED DELIVERY OF siRNA - The present invention relates to nanostructured bioconjugates and nano-structured network hydrogels used to deliver nucleic acids to targeted biological locations. The present invention further relates to methods of treating clinical conditions using the nanostructured bioconjugates and nano-structured network hydrogels. | 01-10-2013 |
| 20130011442 | METHOD FOR REPAIR OF ARTICULAR CARTILAGE DEFECT AND A DEVICE USED THEREIN - The invention provides a single surgical procedure by using autologous platelet-rich fibrin (PRF) and cartilage fragments to solve problems of contamination during incubation of chondrocytes and transplant rejection in vivo, which has the benefit of a more efficient and shorter recovery time. The invention also provides a device for easily and rapidly cutting cartilage to cartilage fragments so as to reduce contamination of the implant and infection. | 01-10-2013 |
| 20130011443 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE - The present invention relates to RSV vaccines and methods for inducing an immune response to RSV in a subject comprising administering an RSV vaccine. | 01-10-2013 |
| 20130011444 | COMPOSITIONS AND METHODS FOR OVERCOMING RESISTANCE TO TRAMADOL - There is disclosed a composition for oral administration of O-desmethyltramadol. There is further disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Compositions and methods are also provided that are effective for overcoming resistance to tramadol in patients. | 01-10-2013 |
| 20130011445 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 01-10-2013 |
| 20130011446 | CERAMIC COMPOSITION FOR FILLING BONE DEFECTS - The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35. | 01-10-2013 |
| 20130011447 | CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS - Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer. | 01-10-2013 |
| 20130011448 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS - The present invention relates to a system for intracellular cargo delivery comprising: | 01-10-2013 |
| 20130011449 | SOLID PREPARATION - The present invention relates to a solid preparation having an easily controllable elution property of a drug, and a method for improving dissolution of a drug. | 01-10-2013 |
| 20130011450 | DEODORIZING FIBER STRUCTURE - A deodorizing fiber structure contains a material composed of a hydroxy acid derivative is secured to a polyester-based fiber structure, and a method for producing a fiber structure including the steps of immersing a polyester-based fiber structure in a hydroxy acid aqueous solution, subsequently drying, and then heat-treating. | 01-10-2013 |
| 20130017227 | WOUND HEALING COMPOSITIONS AND ASSOCIATED METHODSAANM Lambert, JR.; Cary JakeAACI Winter HavenAAST FLAACO USAAGP Lambert, JR.; Cary Jake Winter Haven FL USAANM Slaughter; ThomasAACI LakelandAAST FLAACO USAAGP Slaughter; Thomas Lakeland FL US - In one embodiment, the present disclosure provides a composition including an aqueous solution comprising about 1% to about 50% weight/volume poloxamer having the general formula HO(C | 01-17-2013 |
| 20130017228 | METHODS AND COMPOSITIONS FOR BONE FORMATION - A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects. | 01-17-2013 |
| 20130017229 | ACTIVE SCAFFOLDS FOR ON-DEMAND DRUG AND CELL DELIVERY - The invention provides a composition whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electromagnetic signal, the composition having a matrix material in which is distributed a magnetic material. | 01-17-2013 |
| 20130017230 | JELLY-FORM PREPARATION AND METHOD FOR PRODUCING JELLY-FORM PREPARATIONAANM SHISHIDO; TakuyaAACI Ibaraki-shiAACO JPAAGP SHISHIDO; Takuya Ibaraki-shi JPAANM Asari; DaisukeAACI Ibaraki-shiAACO JPAAGP Asari; Daisuke Ibaraki-shi JPAANM Hori; MitsuhikoAACI Ibaraki-shiAACO JPAAGP Hori; Mitsuhiko Ibaraki-shi JP - Provided is a jelly preparation which enables easy intraoral dissolution thereof, easy adjustment of the dissolution time, and stable containment of a drug therein. The jelly preparation of the present invention is a jelly preparation including water, a gelatin, a drug, and a trivalent metal ion. | 01-17-2013 |
| 20130017231 | Composition for Forming a Temporary Intestinal Occlusion in a Mammal - The invention relates to a composition for forming a temporary intestinal occlusion in a mammal, said composition being flowable and solidifiable to form a solid plug at a predetermined site in the intestine, the structure of said plug being changeable to allow for a subsequent, at least partial removal of the occlusion, said composition being or comprising a flowable solution, suspension, or dispersion in a solvent or mixed solvent, characterized in that said composition comprises the following: a) a suspension of a solid in water or an aqueous mixed solvent, the suspension having a water content which exceeds the flow limit of the suspension by an amount X; b) a dehydrating agent in an amount which is sufficient to bind the amount X of water, so that, as a consequence of dehydration, the flow limit of the suspension is exceeded; and c) a means for passivating said dehydrating agent. | 01-17-2013 |
| 20130017232 | SYNTHETIC BONE GRAFTS - The disclosure provides Bone-mimetic mineral/polymer composite materials useful for formation of artificial bone grafts and for bone tissue engineering. The disclosure provides a hydrogels, cryogels and macroporous compositions modified with varying lengths of anionic pendant side chains (CH | 01-17-2013 |
| 20130017233 | Tricalcium Phosphate Coarse Particle Compositions and Methods for Making the Same - Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications. | 01-17-2013 |
| 20130017234 | IMPLANT MODIFIED WITH NON-HYDROXYLATED VITAMIN D PRECURSORS - An implant to be used as medical or dental implant, comprising a metallic or polymeric base which is covered by the vitamin D precursor cholecalciferol. The implant can be obtained by direct covering of the polymeric or metallic base with a solution comprising cholecalciferol or also covering the base with the 7-dehydrocholesterol (7-DHC), and subsequently irradiated with UV light to induce the formation of cholecalciferol. Optionally, the coating of the implant may include an antioxidant such as vitamin E. This implant enhances osseointegration in compromised patients by means of the endogenous synthesis and activity of vitamin D in hard and mineralized tissue regeneration. Furthermore, a method to obtain these implants which comprises coating the surface of the implant directly with cholecalciferol or with a specific concentration of 7-DHC and irradiated with UV light to induce the formation of cholecalciferol. | 01-17-2013 |
| 20130017235 | ORALLY ADMINISTERED AGENT AND AN ORALLY ADMINISTERED AGENT/SUPPORTING SUBSTRATE COMPLEX - With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent | 01-17-2013 |
| 20130022643 | Antimicrobial Anti-chafing Chelated Silver Oxide Compound - Described herewithin is a composition comprising an anti-chafing balm with C18-36 acid triglycerides, capric/carprylic triglycerides, and tribehinin together with a chelated silver oxide complex comprising a barrier film when applied to the skin. The film is a dual purpose antibacterial and anti-chafing barrier topically applied to human skin, providing a layer of chelated silver oxide complex further comprised of a dermatologically acceptable carrier, with friction (chafe) reducing properties, selected from the group consisting of organic solutions, gels, liquids, balms, aerosols, emulsifiers, lotions, water-in-oil emulsions, oil-in-water emulsions, surfactants, aloe barbedensis leaf juice and tocopherol acetate. | 01-24-2013 |
| 20130022644 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-24-2013 |
| 20130022645 | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATE WITH ENHANCED ORAL BIOAVAILABILITY - Disclosed is an oral bisphosphonate formulation characterized by an enhanced clinical bioavailability of bisphosphonate and by the use of phytic acid and a delayed release means for releasing bisphosphonate at a site of the lower gastrointestinal tract. Having a low phytic acid content, the oral bisphosphonate formulation guarantees high safety to the patient. Moreover, the oral formulation is designed to allow the patients to take the medicament, together with food intake, at a bioavailability as high as that of an empty stomach, thus improving the convenience of drug administration for the patient. Therefore, the oral formulation is expected to provide higher therapeutic effects for osteoporosis. | 01-24-2013 |
| 20130022647 | POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION - Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. | 01-24-2013 |
| 20130022648 | GRANULES OF POROUS BIOCOMPATIBLE MATERIALS - The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth. | 01-24-2013 |
| 20130022649 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS - The present invention provides methods of preventing, decreasing, or inhibiting the degradation of cationic lipids and/or active agents (e.g., therapeutic nucleic acids) present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods of making these lipid particles, and methods of delivering and/or administering these lipid particles, e.g., for the treatment of a disease or disorder. | 01-24-2013 |
| 20130022650 | COMPOSITIONS CONTAINING SALMETEROL, FLUTICASONE AND CROMOGLICIC ACID - The present invention relates to the use of cromoglicic acid and/or nedocromil salts in pharmaceutically effective amounts in a pharmaceutical composition containing salmeterol or a pharmaceutically acceptable salt thereof as a | 01-24-2013 |
| 20130022651 | HYDROGEL MATERIALS INCORPORATING ELUTING CERAGENIN COMPOUND - A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 μg/ml for at least 3 days. | 01-24-2013 |
| 20130022652 | STABLE MEDICATED CHEWING GUM COMPRISING CYCLODEXTRIN INCLUSION COMPLEX - The present invention provides stable medicament-containing chewing gum compositions comprising an inclusion complex comprising cyclodextrin and one or more active compound(s) according to formula I, such as cetirizine, and methods for preparing such chewing gum. | 01-24-2013 |
| 20130022653 | BIOMIMETIC HYDROXYAPATITE SYNTHESIS - A method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under ambient conditions to produce the hydroxyapatite particles. Nanoscale hydroxyapatite particles are also presented. | 01-24-2013 |
| 20130022654 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL - A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T | 01-24-2013 |
| 20130028937 | CO-CRYSTALS OF VENLAFAXINE AND CELECOXIB - The present invention relates to a co-crystal of celecoxib and venlafaxine, processes for preparation of the same and its use as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain, including chronic pain; or of depression in patients which suffer from chronic pain and/or chronic inflammation or in patients with a chronic musculo-skeletal inflammatory illness, with the inflammatory illness preferably being selected from osteoarthritis or rheumatoid arthritis. | 01-31-2013 |
| 20130028938 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same. | 01-31-2013 |
| 20130028939 | CHIMERIC HUMAN BETA DEFENSINS - The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code. | 01-31-2013 |
| 20130028940 | CASPOFUNGIN FORMULATIONS - The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. Said compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. Said compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product. | 01-31-2013 |
| 20130028941 | SYNTHETIC NANOCARRIERS THAT GENERATE HUMORAL AND CYTOTOXIC T LYMPHOCYTE (CTL) IMMUNE RESPONSES - Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions. | 01-31-2013 |
| 20130028942 | AEROSOLIZED NITRITE AND NITRIC OXIDE-DONATING COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described. | 01-31-2013 |
| 20130028943 | MELATONIN TABLET AND METHODS OF PREPARATION AND USE - The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition. | 01-31-2013 |
| 20130028944 | NOVEL METHODS FOR TARGETING CANCER STEM CELLS - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 01-31-2013 |
| 20130028945 | NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA - The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia. | 01-31-2013 |
| 20130028946 | RELATING TO ANTIVIRAL COMPOSITIONS - The present invention provides a composition and an antiviral drug preparation, each comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water-insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form. The present invention further provides processes for preparing the compositions and drug preparations, and also aqueous nano-dispersions obtained by combining water and the compositions. | 01-31-2013 |
| 20130034589 | pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY - The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good pH-sensitive property with 100-300 nanometer particle size. Significant decrease in blood glucose level is observed in streptozotocin (STZ)-induced diabetic rats and the bioavailability of insulin is more than 10% after oral administration of the insulin-loaded pH-sensitive nanoparticles. | 02-07-2013 |
| 20130034590 | Delivery of Hydrophilic Drugs - Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain. | 02-07-2013 |
| 20130034591 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 02-07-2013 |
| 20130039950 | NETI-POT PACKET MIXTURE - A nasal rinse composition comprising about 54 to 90 wt. % of sodium chloride and about 10 to 46 wt. % of sodium bicarbonate, and a kit comprising a packet that contains the rinse composition and a nasal rinse dispenser. | 02-14-2013 |
| 20130039951 | Process Of Preparing A Stabilized And Solubilized Formulation Of Sirolimus Derivatives - Provided is a process for preparing a solubilized and stabilized formulation of a sirolimus derivative, which comprises the steps of a dissolving a sirolimus derivative in a solvent, and bring a solution of the sirolimus derivative into contact with a water-soluble carrier to disperse the sirolimus derivative in the water-soluble carrier, and a formulation of a sirolimus derivative with improved solubility and stability as prepared by the preparation process as above. | 02-14-2013 |
| 20130039952 | CALCIPOTRIOL MONOHYDRATE NANOCRYSTALS - Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions. | 02-14-2013 |
| 20130039953 | METHOD FOR TREATING A SURFACE WITH A COATING COMPRISING A THERAPEUTIC AGENT AND DEVICE WITH TREATED SURFACE - A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed. | 02-14-2013 |
| 20130039954 | CONTROL OF ANTIBODY RESPONSES TO SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods. | 02-14-2013 |
| 20130039955 | Orally Ingested Metabolic Enhancer in Oral Thin Film Container - An orally ingestible energy-boosting device is provided for facilitating a temporary metabolic increase in a user. The device comprises a small container filled with an energy-enhancing substance. All or a portion of the small container is constructed of a water or saliva-soluble film that dissolves when placed in the mouth of a user. When the film dissolves, energy-enhancing substance is released into the mouth where it is absorbed. The small container may come in a variety of shapes and configurations to meet the varied energy boost needs of users. | 02-14-2013 |
| 20130039956 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS - The invention is directed to implants and medical devices having at least one layer which contains at least one nitrocarboxylic acid. These implants and medical devices shall be used for the prophylaxis and treatment of aggressive healing patterns. Furthermore, this invention relates to the use of nitrocarboxylic acids and their pharmaceutically acceptable salts as a therapeutic agent for the prophylaxis and treatment of a pathophysiological or non-physiological healing pattern due to exposure to a physical, chemical or thermal irritant of tissues, cells or organelles. | 02-14-2013 |
| 20130039957 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BRIVARACETAM - The present invention relates to controlled release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable derivatives thereof. Further disclosed is a controlled release pharmaceutical composition comprising a core and a coating surrounding the core, wherein the core comprises Brivaracetam or pharmaceutically acceptable derivative thereof and the coating comprises hydrophobic release controlling agent. The controlled release pharmaceutical composition comprises Brivaracetam or pharmaceutically acceptable derivatives thereof and hydrophobic release controlling agent, wherein said composition has dissolution of Brivaracetam at least 80% between about 7 to about 24 hours when measured in 900 ml of pH 6 phosphate buffer solution using USP apparatus type II, at 50 rpm and at 37° C. Also disclosed is a controlled release pharmaceutical composition useful for the treatment of epilepsy and treatment of symptomatic myoclonus comprises Brivaracetam or pharmaceutically acceptable derivative thereof and hydrophobic release controlling agent. | 02-14-2013 |
| 20130039958 | METHOD OF VACCINATION - The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen. | 02-14-2013 |
| 20130039959 | METHOD OF INHIBITING HIV AND BARRIER-FORMING COMPOSITION THEREFOR - A method for blocking, neutralizing, or killing human immunodeficiency virus (HIV) beginning prior to or during a human encountering an HIV contaminated environment or item includes: identifying a contaminated environment or item that is known or expected to be contaminated with HIV; and administering an effective amount of a barrier-forming composition to an oral or pharyngeal mucosa of the human prior to or during the human encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the HIV from contacting the mucosa, and provides cidal or static activity against HIV. A method for preventing the transmission of HIV through oral sexual relations, and a sexually transmitted disease prophylactic device are also provided. | 02-14-2013 |
| 20130039960 | COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS - The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticulate, non-nanoparticulate, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects. | 02-14-2013 |
| 20130045237 | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 02-21-2013 |
| 20130045238 | EMULSIONS FOR TRANSDERMAL DELIVERY - The present invention generally relates to transdermal delivery and, in particular, to transdermal delivery using nanoemulsions and other emulsions. In one aspect, the present invention is directed to emulsions comprising a first, continuous phase and a second, discontinuous phase. The first phase may be an aqueous liquid and the second phase may comprise a lipid, such as isopropyl myristate. In some cases, a surfactant, such as Pluronic® L61, is used to stabilize the emulsion. Surprisingly, it has been found that such emulsions are effective at delivering pharmaceutically active agents, such as ciprofloxacin, when the formulation has a very low water content, for example, less than 30 wt % or less than 10 wt %. This is surprising because high water contents—not low water contents—are typically correlated with greater transdermal drug delivery, and thus, a low water content would have been considered to be unfavorable for facilitating transdermal drug delivery. | 02-21-2013 |
| 20130045239 | Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists - A method of modulating the pharmacodynamic effect of a GC-C receptor agonist polypeptide formulation in a subject in need of such treatment is disclosed, The method comprises administering the GC-C receptor agonist polypeptide formulation to the subject before the ingestion of food. | 02-21-2013 |
| 20130045240 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway. | 02-21-2013 |
| 20130045241 | STABILIZED AQUEOUS DISPERSION OF FOLPET ANALOGUES, METHOD OF PREPARING THE SAME AND COMPOSITION THEREOF - An aqueous dispersion having a mixture of a hydrolysis-sensitive biocide, an iodo-derived hydrophobic biocide and an inert carrier dispersed in water. The iodo-derived hydrophobic biocide forms a complex with the inert carrier and the hydrolysis-sensitive biocide that is dispersible in water. The hydrophobic coating includes an inert carrier and the hydrolysis-sensitive biocide may be trihalogenomethylthio phthalimide or an analogue thereof and the iodo-derived hydrophobic biocide may be iodopropynyl butylcarbamate. The aqueous dispersion may also include a water-repelling layer coating the complex. | 02-21-2013 |
| 20130045242 | DEXTRIN HYDROGEL FOR BIOMEDICAL APPLICATIONS - A hydrogel formulation of oxidized dextrin is reticulated with adipic acid dihydrazide, which may embody polysaccharides, proteins, nanogels, granular materials, bioactive molecules and cells for tissue regeneration and controlled drug delivery. A hydrogel can be injectable, highly biocompatible and biodegradable, for tissue regenerative applications, performing simultaneously as a vehicle e.g. for nanogels, granular materials and cells, and as controlled drug delivery systems, e.g. of hydrophobic molecules and therapeutic proteins. | 02-21-2013 |
| 20130045243 | NANOGENOMICS FOR MEDICINE: siRNA ENGINEERING - Described herein are materials and methods for the delivery of siRNA and the production of nanoparticles useful for the delivery of siRNA. Methods of treating a disease or disorder using the nanoparticles described herein also are disclosed. | 02-21-2013 |
| 20130045244 | MODIFIED ADAM DISINTEGRIN DOMAIN POLYPEPTIDES AND USES THEREOF - Modified ADAM (A Disintegrin and Metalloproteinase) Polypeptides (MAPs) are provided. Methods are provided for administering MAPs for anti-angiogenesis and anti-tumor growth activity. Compositions of the invention are also useful for treating endothelial cell dysfunction and for diagnosis of integrin-related conditions. | 02-21-2013 |
| 20130045245 | APIXABAN FORMULATIONS - Compositions comprising crystalline apixaban particles having a D | 02-21-2013 |
| 20130045246 | ENCLOSING MATERIALS IN NATURAL TRANSPORT SYSTEMS - Edible or potable substances can be transported in biodegradable vessel. | 02-21-2013 |
| 20130045247 | FATTY ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided. | 02-21-2013 |
| 20130045248 | PERSONAL CARE COMPOSITIONS COMPRISING AN ANTI-IRRITATION AGENT - A personal care composition comprising an anti-irritation agent such as a zinc pyrithione, a zinc salt or a combination thereof. | 02-21-2013 |
| 20130045249 | Glycosaminoglycans - Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue. | 02-21-2013 |
| 20130045250 | SUSPENSION AND CAKE COMPOSITION CONTAINING CARBOSTYRYL DERIVATIVE AND SILICONE OIL AND/OR SILICONE OIL DERIVATIVE - A suspension and a cake composition are provided in which agglomeration of the active ingredient that is caused when silicone oil and/or silicone oil derivative is contained therein can be suppressed without a special treatment, such as sonication. The suspension contains, in a dispersion medium, an active ingredient of a specific mean primary particle size, and silicone oil and/or silicone oil derivative. The cake composition contains an active ingredient of a specific mean particle size, and silicone oil and/or silicone oil derivative. | 02-21-2013 |
| 20130045251 | PHARMACEUTICAL COMPOSITION FOR IMPROVING SOLUBILITY OF PRASUGREL AND ITS PREPARATION METHOD - A pharmaceutical composition containing prasugrel and its pharmaceutically acceptable salts, and methods for preparing the same are disclosed. The pharmaceutical composition improves the dissolution rate of prasugrel and its salts at high pH by using solid dispersion technology, inclusion technology or adding surfactants. | 02-21-2013 |
| 20130045252 | Apparatus for the Arrestment and Retention of Bromhidrosis - An apparatus for adsorption of body odour comprising: an activated carbon layer for adsorbing body odour; a first material layer; and wherein the activated carbon layer is coupled to the first material layer. | 02-21-2013 |
| 20130045253 | ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD - Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product. | 02-21-2013 |
| 20130052233 | Dry Powder Pharmaceutical Compositions, Its Preparation Process and Stable Aqueous Suspension Obtained from such Composition - Pharmaceutical composition in a dry powder form comprising at least one hydrophobic active principle, at least one water-soluble excipient and at least one surfactant, wherein the particles in said dry powder state have a Volume Mean Diameter VMD | 02-28-2013 |
| 20130052234 | EDIBLE STRIPS - An edible oral strip composition includes a therapeutically effective amount of active agent(s) to provide at least one effect selected from a stimulating effect, an increased physical endurance, alleviate temporary fatigue, improve nervous system functions, and combinations of any of the foregoing. In additional embodiments, the edible strip composition includes a therapeutically effective amount of active agent(s) to provide sleep aid. | 02-28-2013 |
| 20130052235 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINE - The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer. | 02-28-2013 |
| 20130052236 | COMPOSITE POLYLACTIC ACID/ALGINATE SURGICAL BARRIER - The present disclosure provides a medical assembly comprising a surgical barrier aspect comprising polylactic acid, and a hydrophilic mucoadhesive aspect, wherein the surgical barrier aspect is provided on a first side of the assembly and the mucoadhesive aspect is provided on a second side of the assembly. The disclosure also relates to a medical assembly comprising a surgical barrier aspect, a short term mucoadhesive aspect, an intermediate term protein polymerization adhesive aspect, and a long term tissue ingrowth implant localization aspect. The aforementioned medical assemblies may be provided as layered sheet structures. Also provided are methods for preparing a medical assembly. | 02-28-2013 |
| 20130052239 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 02-28-2013 |
| 20130052240 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed. | 02-28-2013 |
| 20130052241 | NON-AQUEOUS TAXANE PRO-EMULSION FORMULATIONS AND METHODS OF MAKING AND USING THE SAME - Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations. | 02-28-2013 |
| 20130058981 | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia - The present invention relates to combination pharmaceutical compositions comprising an activated-potentiated form of an antibody to endothelial NO synthase and activated potentiated form of an antibody to brain-specific protein S-100 and its use for the treatment of vegetative-vascular dystonia (VVD) and symptoms thereof. | 03-07-2013 |
| 20130058982 | Method of treating Alzheimer's disease - The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase. | 03-07-2013 |
| 20130058983 | BISMUTH-THIOLS AS ANTISEPTICS FOR BIOMEDICAL USES, INCLUDING TREATMENT OF BACTERIAL BIOFILMS AND OTHER USES - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. | 03-07-2013 |
| 20130058984 | SINGLE-WALLED CARBON NANOTUBE/BIOACTIVE SUBSTANCE COMPLEXES AND METHODS RELATED THERETO - The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA solubilizes such nonfunctionalized single-walled carbon nanotube. | 03-07-2013 |
| 20130058985 | Spray-Pumpable Composition Suitable for Topical Skin Application - The present invention relates to a spray-pumpable composition for topical use on the skin comprising hydrophilic silicon dioxide, an emulsifier, at least one active ingredient and optionally one or more additives. The present invention further relates to a method for the preparation of a spray-pumpable composition for topical use on the skin and the use of hydrophilic silicon dioxide for the preparation of suspensions in emulsions, in particular oil-in-water emulsions. | 03-07-2013 |
| 20130058986 | SOLID DOSAGE FORMS COMPRISING AN ENTERIC COATING WITH ACCELERATED DRUG RELEASE - The present invention provides a solid dosage form including an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein the inner coating includes a partially neutralized anionic polymeric material and at least a carboxylic acid having 2 to 16 carbon atoms, the salts thereof, or mixtures of the acid and its salt; wherein the outer coating includes an anionic polymeric material which is less neutralized than the material of the inner coating or not at all neutralized. | 03-07-2013 |
| 20130058987 | ENHANCED FOLIC ACID FLUORESCENT MATERIAL, MULTIFLUORESCENT POROUS COMPOSITIONS OF MATTER AND POTENTIAL APPLICATIONS THEREOF - A method for the preparation of enhanced fluorescent folic acid mesoporous material, multifluorescent mesoporous materials, their novel properties and applications such as: a mesoporous fluorescent composition suitable for printing identification marks on metals, glass, plastic, ceramics, or paper which are visible only when excited by an external radiation; and applications in life science applications such as diagnostic, biodistribution markers, and targeted drug delivery applications. | 03-07-2013 |
| 20130058988 | Metal Cations and Metal Effect Pigments Comprising Anions Containing Phosphorus and/or Sulphur, Method for Producing Said Metal Effect Pigments and Use Thereof - The invention relates to a metallic effect pigment selected from platelet-shaped aluminum, platelet-shaped metallic pigments having a copper fraction of 60% to 100% by weight, and mixtures thereof, having a coating of silicon oxide SiOx, where x is a number from 1 to 2, where the coated metallic effect pigment comprises metal cations and phosphorus- and/or sulfur-containing anions present independently of one another on the metallic effect pigment surface and/or in the silicon oxide layer SiOx, and the element ratio in atomic fractions of metal cation MC and phosphorus P and/or sulfur S to silicon Si is defined by formulae (I) and (II): | 03-07-2013 |
| 20130064861 | COMPOSITIONS AND METHODS FOR MODIFYING IN VIVO CALCIFICATION OF HYDROGELS - Provided herein according to some embodiments of the invention are methods of inhibiting or preventing calcification of hydrogels. Such methods may include combining the hydrogel with a buffer solution having a pH lower than 7.4; forming a hydrogel by crosslinking alginate in a solution comprising a bisphosphonate compound; and/or forming a hydrogel by crosslinking a polyanionic polymer with a polyvalent cation that is not Ca | 03-14-2013 |
| 20130064862 | SYSTEMS AND METHODS FOR SHELL ENCAPSULATION - Certain aspects of the invention are generally directed to particles comprising a shell and an interior at least partially contained by the shell. In some embodiments, the particles may be treated to enhance the containment of the interior, for example to reduce transport of an agent into or out of the interior. Such particles may exhibit increased ability to encapsulate agents and/or increased storage life (e.g., due to reduced leakage). For instance, in certain embodiments, any defects, such as cracks, pores, etc. within the shell may be sealed or otherwise treated to reduce transport therethrough. In some embodiments, for instance, a first reactant in the interior of a particle may come into contact with a second reactant outside of the particle to form a solid, or other suitable product. The shell may also be treated to cause release of an agent contained within the interior, in certain aspects. | 03-14-2013 |
| 20130064863 | MULTICOMPONENT AND BIOCOMPATIBLE NANOCOMPOSITE MATERIALS, METHODS OF SYNTHESIZING SAME AND APPLICATIONS OF SAME - One aspect of the present invention relates to a method of synthesizing a multicomponent and biocompatible nanocomposite material, which includes: synthesizing a gold/hydroxyapatite (Au/HA) catalyst; distributing the Au/HA catalyst into a thin film; and heating the thin film in a reactor with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD) to form the nanocomposite material, where the nanocomposite material includes a graphene structure and Au/HA nanoparticles formed by the Au/HA catalyst and distributed within the graphene structure. In another aspect, a multicomponent and biocompatible nanocomposite material includes: a graphene structure formed with a plurality of graphene layers and Au/HA nanoparticles distributed within the graphene structure. The nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD). | 03-14-2013 |
| 20130064864 | SUBMICRON PARTICLES TO DECREASE TRANSFUSION - A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro. | 03-14-2013 |
| 20130064865 | THERAPY TO REDUCE EXTRAVASATION DAMAGE - A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons. | 03-14-2013 |
| 20130064866 | PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P - The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided. | 03-14-2013 |
| 20130064867 | NANOEMULSION RESPIRATORY SYNCYTIAL VIRUS (RSV) SUBUNIT VACCINE - The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement. | 03-14-2013 |
| 20130064868 | COMPOSITION FOR ENHANCING TRANSDERMAL ABSORPTION OF A DRUG AND PATCH PREPARATION - The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. | 03-14-2013 |
| 20130064869 | COMPOSITION FOR ENHANCING TRANSDERMAL ABSORPTION OF A DRUG AND PATCH PREPARATION - The problem of the present invention is to provide a composition which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition which shows a sufficiently high enhancing effect on transdermal absorption of a drug in a patch preparation. | 03-14-2013 |
| 20130064870 | DRY POWDER INHALATION COMPOSITION - The dry powder inhalation composition comprising
| 03-14-2013 |
| 20130071438 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERPLASIA - In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent. | 03-21-2013 |
| 20130071439 | METHODS AND COMPOSITIONS FOR TREATING BIOFILMS - Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described. | 03-21-2013 |
| 20130071440 | USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES - Particles having a tap density of less than 0.4 g/cm | 03-21-2013 |
| 20130071441 | CELL CONSTRUCT FOR CELL TRANSPLANTATION AND CELL AGGREGATE FOR CELL TRANSPLANTATION - An object of the present invention is to provide a cell construct for cell transplantation capable of having a thickness suitable for cell transplantation, preventing the necrosis of transplanted cells, and forming blood vessels in the transplantation site after transplantation. The present invention provides a cell construct for cell transplantation which comprises polymer blocks having biocompatibility and cells of at least one type, wherein the plural polymer blocks are arranged in spaces between the plural cells. | 03-21-2013 |
| 20130071442 | Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections - A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler. | 03-21-2013 |
| 20130071443 | Glycosaminoglycans - Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue. | 03-21-2013 |
| 20130071444 | Amphiphilic Cationic Polymers and Methods of Use Thereof - Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucleic acids, both in vitro and in vivo. Accordingly, the invention further provides methods of facilitating delivery of therapeutic and/or diagnostic agents to a cell and methods of treating a condition, such as a disease or infection, in an organism using the amphiphilic cationic polymers of the invention. | 03-21-2013 |
| 20130071445 | TRANSLUMINAL DRUG DELIVERY METHODS AND DEVICES - Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository. | 03-21-2013 |
| 20130071446 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 03-21-2013 |
| 20130071447 | METHODS FOR PRODUCING ECM-BASED BIOMATERIALS - A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form a flowable ECM composition. The flowable ECM composition is subjected to a centrifugal force in a mold for a period of time sufficient to distribute the ECM particles according to differences in their physical characteristics. The ECM composition is dried to form a dried ECM material having a density gradient extending from a less dense region to a more dense region. The dried ECM material may formed as a porous, substantially acellular ECM material expandable in an aqueous fluid environment by at least 100% in volume. | 03-21-2013 |
| 20130071448 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 03-21-2013 |
| 20130071449 | COATINGS OF ACRYLAMIDE-BASED COPOLYMERS - An implantable device including a conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided. | 03-21-2013 |
| 20130071450 | GELS FOR TRANSDERMAL DELIVERY - The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes. | 03-21-2013 |
| 20130071451 | CAROTENOID-CONTAINING COMPOSITION AND PRODUCTION METHOD THEREOF - A method of producing a carotenoid-containing composition including: obtaining a carotenoid-containing oil phase composition by heating an oil phase component mixed liquid containing a carotenoid component containing at least one crystalline carotenoid, and a (poly)glyceryl fatty acid ester having form 1 to 6 of a glycerin unit and from 1 to 6 of a fatty acid unit and in which the glycerin unit has at least one hydroxyl group, at a dissolution temperature of the carotenoid component or higher; and obtaining an oil-in-water emulsified composition by emulsifying under pressure the carotenoid-containing oil phase composition with an aqueous-phase composition comprising an emulsifying agent. | 03-21-2013 |
| 20130071452 | PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells. | 03-21-2013 |
| 20130078282 | FORMULATIONS DECREASING PARTICLE EXHALATION - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 03-28-2013 |
| 20130078283 | NOVEL AMPHIPHILES - Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R | 03-28-2013 |
| 20130078284 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 03-28-2013 |
| 20130078285 | IMPLANT FOR TISSUE REPAIR - Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5. | 03-28-2013 |
| 20130078286 | DRUG DELIVERY SYSTEM - The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form. | 03-28-2013 |
| 20130078287 | PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND AN H2 RECEPTOR ANTAGONIST - Pharmaceutical compositions of a H | 03-28-2013 |
| 20130078288 | Method of Treating Cancer - A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents. | 03-28-2013 |
| 20130078289 | INDIGESTIBLE POLYMER: STARCH ACETATE -BASED FILM COATINGS FOR COLON TARGETING - A colon targeted delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: a water insoluble polymer composition containing at least a starch acetate, and an indigestible polysaccharide composition. The use and method for making the same are also described. | 03-28-2013 |
| 20130078290 | Gastroretentive Dosage Forms Of GABA Analogs - The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid (“GABA”) analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant. | 03-28-2013 |
| 20130078291 | BIO-ADHESIVE AGENT COMPRISING SURFACE-MODIFIED HYDROXYAPATITE AND USE THEREOF - The present invention relates to a bio-adhesive agent comprising a surface-modified hydroxyapatite and its use. More specifically, the present invention relates to a bio-adhesive agent for the adhesion between bone and bone, bone and tissue, bone and cartilage, or bone and tendon, or for the adhesion of a shield between bones or of an artificial joint, which comprises a surface-modified hydroxyapatite as an active ingredient, wherein the surface-modified hydroxyapatite is characterized in that a certain linker compound is covalently bonded to the surface of the hydroxyapatite; a method for coating the surface of a metal prosthesis using the surface-modified hydroxyapatite; and a metal prosthesis coated with the surface-modified hydroxyapatite obtained by said method. | 03-28-2013 |
| 20130084310 | COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS - Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins. | 04-04-2013 |
| 20130084311 | Lingual Vestibular Dosage-form and Delivery System for Transmucosal Administration of Pharmaceutical Agents - A pharmaceutical delivery system enabling the oral transmucosal administration of active pharmaceutical agents in a situation where rapid transmucosal administration is preferred to prevent the delay and decomposition of the agents in passing through the intestinal tract. The delivery system comprises a supportive substrate with bilateral lingual vestibular flanges connected at the anterior midline to form a ‘U’ like shape for fitting in the potential space of the bilateral lingual vestibules, and further comprising a handle or tab for holding the device in the mouth of a patient with altered consciousness to prevent aspiration or premature swallowing. The pharmaceutical dosage-form is formulated and shaped to contact the mucosal tissues and may include mucoadhesive compounds, retentive compounds, and/or additional payload enhancers, such as permeation enhancers and flavor enhancers. | 04-04-2013 |
| 20130084312 | NANOPARTICLES FOR DELIVERY OF BIOACTIVE AGENTS - Biocompatible polymeric nanoparticles for delivery of bioactive agents, and methods for preparing the particles, are described. Polyoxalate nanoparticles of the subject technology show desired particle sizes suitable for use in drug delivery and a substantially uniform or narrow particle size distribution. The polyoxalate nanoparticles can contain water-soluble, poorly water-soluble, or water-insoluble drugs. The nanoparticles are nontoxic and are generally safe for use in humans. After being administered into the body, the nanoparticles with a high content of a bioactive agent entrapped therein can safely deliver the agent to target sites and stably release the drug at a controlled rate. | 04-04-2013 |
| 20130084313 | SUPPLEMENT FOR OSTOMY PATIENTS - The present application describes a supplement containing an enteric coated alpha-D-galactosidse and the use thereof to treat an ostomy patient. | 04-04-2013 |
| 20130084314 | Expandable Placental Membrane and Methods of Making and Storing Same - A placental membrane including a plurality of slits for increasing the membrane's capacity to expand. The slits are provided through the membrane and provided in sufficient numbers across the surfaces of the membrane to produce a mesh-like pattern in the membrane. The mesh-like pattern enables the placental membrane to be stretched and therefore increased in length and width. For ease of handling and storage, the expandable placental membrane is removably adhered to a backing, rolled into a cylinder and placed within a capped vial containing a solution of amniotic fluid cells for improving the effectiveness of the membrane. | 04-04-2013 |
| 20130084315 | CONTROLLING RESORPTION OF BIORESORBABLE MEDICAL IMPLANT MATERIAL - The resorption of a medical implant can be controlled with the use of particles embedded in a resorbable bulk material forming the implant or portion thereof. The implant can be removed from a body of a mammal by natural biological mechanisms after use. The resorption of the implant can involve swelling and/or hydrolyzing of the particles within the implant upon contact with a body fluid such that porosity and flow of fluid within the bulk material of the implant is increased. Resorption of the implant may also involve the use of particles with magnetic properties embedded within the implant such that an applied magnetic field causes the particles to vibrate within the bulk material thereby increasing the porosity and thus the flow of fluid, hence facilitating resorption of the implant. The resorption rate of the implant can be controlled by modulating swelling, hydrolysis, or movement of the embedded particles. | 04-04-2013 |
| 20130084316 | ARRAY WITH FINE PROTRUSIONS | 04-04-2013 |
| 20130089574 | METHOD OF PREVENTIVE ON-DEMAND HORMONAL CONTRACEPTION - The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse. | 04-11-2013 |
| 20130089575 | Pharmaceutical methods and topical compositions containing acitretin - The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis. | 04-11-2013 |
| 20130089576 | IMPLANTABLE EMBOLIC SCAFFOLDS THAT PROMOTE HEALING - Implant devices and structures that reduce inflammation and promote healing of the area of implant. Specifically, the use of shape memory open cell biocompatible polymer foams for implants that assist in and promote healing and especially in filling and sealing aneurisms. | 04-11-2013 |
| 20130089577 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS - Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders. | 04-11-2013 |
| 20130089578 | LIQUID INSECTICIDE INCLUDING DIATOMACEOUS EARTH - An insecticide including diatomaceous earth in a liquid mixture of water and one or more additives is provided. The diatomaceous earth may be present in an amount between at least 20 and less than 25 weight percent of the insecticide. The insecticide is applied in liquid form to surfaces for controlling the spread of insects. The liquid component of the insecticide evaporates leaving a thin layer of the dried diatomaceous earth. Insects traversing the diatomaceous earth layer are scratched and scraped by the layer, which results in water loss from the exoskeleton and eventually death. | 04-11-2013 |
| 20130089579 | Combination of Hyaluronic Acid and Prilocaine - A composition of matter comprising hyaluronic acid and/or a pharmaceutically acceptable hyaluronate salt, cross-linked hyaluronic acid and/or a pharmaceutically acceptable cross-linked hyaluronate salt, and prilocalne and/or a pharmaceutically acceptable salt thereof, and optionally at least one additive. | 04-11-2013 |
| 20130089580 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 04-11-2013 |
| 20130089581 | SKIN-FRIENDLY ADHESIVES FROM POLYALKLETHER-BASED PHOTOINITIATORS - The invention provides a method for manufacturing a skin-friendly pressure-sensitive adhesive composition, said method comprising the steps of: a. providing a matrix composition comprising a polymeric photoinitiator of the general formula (I): R | 04-11-2013 |
| 20130089582 | HYDROPHILIC GELS FROM POLYURETHANE-BASED PHOTOINITIATORS - The present invention relates to the use of polymeric photoinitiators based on polyalkyletherurethane backbones in the production of hydrophilic gels, in particular hydrogels. The invention relates to methods for manufacturing hydrophilic gels using said polymeric photoinitiators, and the hydrophilic gels thus obtained. | 04-11-2013 |
| 20130095139 | BONE MORPHOGENIC PROTEIN BINDING PEPTIDE - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. | 04-18-2013 |
| 20130095140 | Biguanide Compositions and Methods of Treating Metabolic Disorders - Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 04-18-2013 |
| 20130095141 | FOOD GRADE DRY FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME - A dry film coating composition comprising a cellulose film former, an oligofructose fiber, a plasticizing agent, and a processing aid is disclosed herein. Also provided is a film coating suspension comprising a cellulose film former, an oligofructose fiber, a plasticizing agent, a processing aid, and a solvent. The film coating suspension may be applied to a substrate, such as, for example, nutritional supplements, pharmaceuticals, tablets, capsules, softgels, granules, particles (e.g., micro- and nano-particles), agricultural seeds, and the like to form a dry film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided. | 04-18-2013 |
| 20130095142 | Lipid Emulsion Having Krill Oil As An Active Ingredient And Preparation Method Therefor - Provided is a lipid emulsion having krill oil as an active ingredient and a preparation method therefor, wherein the lipid emulsion can be used independently for oral/parenteral administration or as a daily nutrient, and preferably, as a nutritious intravenous lipid emulsion having krill oil. | 04-18-2013 |
| 20130095143 | BIOMATERIAL FROM WHARTON'S JELLY UMBILICAL CORD - The present invention relates to a biomaterial, specifically a hydrogel, based on the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans present exclusively in the Wharton's jelly of the umbilical cord (which can optionally be combined with cells as a combination therapy), and also to the methods for the production and use thereof. | 04-18-2013 |
| 20130095144 | PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS - The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars. | 04-18-2013 |
| 20130095145 | Preparation for Transnasal Application - Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance. | 04-18-2013 |
| 20130095146 | CICLESONIDE CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION - An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided. | 04-18-2013 |
| 20130095147 | SOL-GEL DERIVED BIOACTIVE GLASS POLYMER COMPOSITE - A bioactive sol-gel solution includes a biocompatible polymer, a gelable inorganic base material, and at least one calcium and phosphorous molecular species. The base material can be an alkoxide, such as TEOS. The polymer acts as a viscosity modifier to the sol or gel, increases the viscosity range over which fibers can be sprayed or spun, and broadens the time period over which fibers can be sprayed or spun. A bioactive glass composite can be formed from the bioactive sol-gel solution, including a fibrous form. Fibers can serve as a scaffolds for cell growth and in the repair of hard or soft tissue defects. | 04-18-2013 |
| 20130095148 | Dosage Forms for Tamper Prone Therapeutic Agents - A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form. | 04-18-2013 |
| 20130095149 | PROCESS FOR THE PREPARATION OF CONTROLLED-RELEASE SOLID FORMULATIONS CONTAINING OXCARBAZEPINE, AND FORMULATIONS OBTAINABLE BY SAID PROCESS - The present invention relates to a process for the preparation of controlled-release solid oral pharmaceutical formulations of oxcarbazepine, and the pharmaceutical formulations obtainable by said process. | 04-18-2013 |
| 20130095150 | STABILIZED ACTIVE COMPOUND - Stable solid compositions have a first carrier and an adsorbate having at least one active component, such as, a vitamin D derivative and a hydrophobic stabilizer thereof, wherein the first carrier is a calcium phosphate or derivatives thereof having a solubility in water lower than 0.1 wt % at room temperature. | 04-18-2013 |
| 20130095151 | BROAD SPECTRUM SUNSCREEN COMPOSITION COMPRISING 2 HYDROXY SULFOBETAINE OF CINNAMIDOALKYL AMINE - A photostable cosmetic composition for protection against UVA and UVB radiations of wavelengths between 280 and 400 nm, which comprises, in a cosmetically acceptable vehicle:
| 04-18-2013 |
| 20130095152 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF COMPLEX REGIONAL PAIN SYNDROME - A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and a method for preparing the therapeutic composition is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of complex regional pain syndrome, or the likelihood of an individual to develop complex regional pain syndrome is disclosed. | 04-18-2013 |
| 20130095153 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY - A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle. | 04-18-2013 |
| 20130101628 | NOVEL VEGF MIMETIC PEPTIDE-BASED SCAFFOLDS FOR THERAPEUTIC ANGIOGENESIS AND METHODS FOR THEIR USE - Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro. | 04-25-2013 |
| 20130101629 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF - The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies. | 04-25-2013 |
| 20130101630 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY - Provided herein is an impurity of varenicline, methylvarenicline, 6-methyl-5,8,14-triazatetracyclo[10.3.1.0 | 04-25-2013 |
| 20130101631 | METHOD AND APPARATUS FOR FORMING DELIVERY DEVICES FOR ORAL INTAKE OF AN AGENT - Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more materials with an agent or an agent-releasing formulation to form an intergraded device; folding the intergrated delivery device to form a folded integrated delivery device; and at least partially enclosing the folded delivery device to a form suitable for oral delivery. | 04-25-2013 |
| 20130101632 | NANOPARTICULATE FORMULATIONS OF MITHRAMYCIN OR MITHRAMYCIN ANALOGUES FOR TREATING CANCER - Methods and formulations for improving therapeutic potential of mithramycin (MTM) or MTM analogues are disclosed. For example, in certain aspects, methods for preparing a composition containing MTM or an MTM analogue nanoparticulate formulation and uses thereof are described. Furthermore, methods for delivering MTM or MTM analogues are disclosed. | 04-25-2013 |
| 20130101633 | ANTIMICROBIAL GELS - The present invention pertains to antimicrobial compositions comprising inter alia at least one alkenyl-and/or alkynyl-substituted polysiloxane, at least one polysiloxane comprising silicon-bonded hydrogen atoms, and at least one hydrosilylation catalyst, as well as antimicrobial silicone gels, wound dressings, and methods of preparing the above. | 04-25-2013 |
| 20130101634 | COMPOSITIONS AND METHODS FOR REDUCING MICROBIAL OVERGROWTH IN THE SMALL INTESTINES - An antimicrobial composition for reducing bacterial overgrowth in the small intestine is disclosed. The composition comprises a lytic enzyme combined with one or more anti-microbial essential oils, and a probiotic. Unlike broad spectrum antibiotics the disclosed composition does not enter the blood stream, does not destroy all intestinal microflora, and can be used on a continuing basis. | 04-25-2013 |
| 20130101635 | METHOD OF PREPARING SELF-ASSEMBLED EXTRACELLULAR MATRICES AND USE OF SELF-ASSEMBLED EXTRACELLULAR MATRICES FORMED BY USING THE METHOD - Methods of preparing a self-assembled matrix from cell-derived extracellular matrice, and of inducing cell proliferation and differentiation by using the self-assembled matrix, and applying the self-assembled matrix into cell therapy. In detail, unique extracellular matrices obtained from particular cells are collected and then subjected to decellularization in order to form a self-assembled matrix including nano fibers only formed of extracellular matrix. In addition, the matrix prepared as described above provides a platform that is effective for the induction of the mass proliferation or differentiation of cells, and thus, may be applied in manufacturing cell therapy products. | 04-25-2013 |
| 20130101636 | DIETARY SUPPLEMENTS WITH RAPID BUCCAL DISSOLUTION - There is provided a dietary supplement product comprising a sealed package containing a single dose of a dietary supplement, the dietary supplement including one or more active agents such as vitamins and mineral dispersed with a carrier so that it is in the form of a free-flowing, dry particulate which pours readily and dissolves rapidly on the tongue. | 04-25-2013 |
| 20130101637 | Bone Semi-Permeable Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 04-25-2013 |
| 20130101638 | BONE SEMI-PERMEABLE DEVICE - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 04-25-2013 |
| 20130101639 | BONE SEMI-PERMEABLE DEVICE - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 04-25-2013 |
| 20130101640 | Etanercept Formulations Stabilized with Combinations of Sugars and Polyols - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 04-25-2013 |
| 20130101641 | Periodontal Regeneration Composition and Method of Using Same - A periodontal structure regeneration composition for treatment of periodontal disease is a mixture of particles of a bone growth material and free collagen. All particles are sized to be less than 1 mm in diameter. The periodontal regeneration composition is injected into the periodontal pocket through an 18 gauge needle. The composition may contain a thickener that increases the viscosity of the composition after the material has been injected into the periodontal pocket. The composition is available in pre-filled syringes offered in a kit that may also contain strips of surgical sponge or gauze that are sized to fit within a periodontal pocket, a time of adhesive, a dental bur, a probe, a gauze placement tool, gauze counter and a brush for cleaning the dental bur. | 04-25-2013 |
| 20130101642 | METHODS AND COMPOSITIONS FOR TREATING ORAL MUCOSITIS - The present disclosure relates generally to the field of oral mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing oral mucositis are provided. Methods and compositions for treating, ameliorating and/or preventing oral mucositis are also provided. | 04-25-2013 |
| 20130101643 | METHODS AND COMPOSITIONS FOR MITIGATING PROCTITIS - The present disclosure relates generally to the field of proctitis. More particularly, methods and compositions for treating, ameliorating and/or preventing proctitis are provided. | 04-25-2013 |
| 20130101644 | TOCOTRIENOL COMPOSITIONS - Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, wherein upon mixing of the composition of matter with water the tocotrienol based composition is substantially emulsified; and wherein upon mixing of the composition of matter with water a resulting emulsion has an intensity-weighed mean droplet size of less than 700 nm are also disclosed. | 04-25-2013 |
| 20130101645 | METHODS AND COMPOSITIONS FOR TREATING MUCOSITIS - The present disclosure relates generally to the field of mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing mucositis are provided by administering a clay to the subject in need. | 04-25-2013 |
| 20130101646 | Method of Producing Microparticles - A method of producing microparticles having a median diameter up to 100 μm and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8. | 04-25-2013 |
| 20130101647 | PHARMACEUTICAL COMPOSITION IN WHICH SOLUBILITY OF PARTIALLY SOLUBLE TRICYCLIC DERIVATIVE IS IMPROVED - A pharmaceutical composition includes lipid nanoparticles which include two or more of a phospholipid, cholesterol, and an ionic lipid, and a tricyclic derivative, wherein the solubility of the tricyclic derivative is improved. It is possible to solubilize a partially soluble tricyclic derivative in a high concentration even without using a solubilization aid harmful to the human body, to maintain improved solubility even if water is added for the use as an injection, and to show stability even if stored for a long time, by preparing lipid nanoparticles. Therefore, the lipid nanoparticles of the present invention can be used for preparing a pharmaceutical preparation containing a partially soluble tricyclic derivative as an active ingredient. | 04-25-2013 |
| 20130108666 | GLASS/CARBON NANOTUBE COMPOSITE MATERIAL FOR BONE GRAFT SUPPORT | 05-02-2013 |
| 20130108667 | Method, apparatus and system for electroporation | 05-02-2013 |
| 20130108668 | Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same | 05-02-2013 |
| 20130108669 | DOPAMINERGIC NEURONS DIFFERENTIATED FROM PLURIPOTENT STEM CELLS AND USES OF THEREOF | 05-02-2013 |
| 20130108670 | COMPOSITIONS AND METHODS FOR TREATING FULL THICKNESS BURN INJURIES | 05-02-2013 |
| 20130108671 | HEMOSTATIC COMPOSITIONS | 05-02-2013 |
| 20130108672 | PHARMACEUTICAL COMPOSITIONS FOR SUBSTITUTED QUINAZOLINONES | 05-02-2013 |
| 20130108673 | Co-Therapy for Diabetic Conditions | 05-02-2013 |
| 20130108674 | OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPOSOLUBLE ACTIVE INGREDIENTS | 05-02-2013 |
| 20130108675 | ORGANIC COMPOUNDS | 05-02-2013 |
| 20130115246 | REDUCED DOSE ORAL PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The invention relates to reduced dose oral pharmaceutical composition of fenofibrate which exhibits substantial bioequivalence to Antara® Capsules under fasting condition and also capable of reducing the food effect on bioavailability of fenofibrate. Provided is a pharmaceutical composition comprising about 90 mg of fenofibrate particles having a D | 05-09-2013 |
| 20130115247 | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy - The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases. | 05-09-2013 |
| 20130115248 | DEBRIDEMENT PASTE - The present invention relates to a new and inventive composition for implant cleaning and/or debridement of hard surfaces in the oral cavity, which comprises optimally activated nanoparticles of TiO | 05-09-2013 |
| 20130115249 | Osmotic Device Containing Amantadine and an Osmotic Salt - The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat. | 05-09-2013 |
| 20130115250 | Burst Drug Release Compositions - Solid dose compositions comprising at least one low solubility pharmaceutically active ingredient, at least one low solubility filler and at least one controlled release agent. comprising at least one poorly soluble pharmaceutically active ingredient, a insoluble binder and at least one controlled release agent along with a method of manufacturing said composition are disclosed. Methods for making these compositions are also disclosed. | 05-09-2013 |
| 20130115251 | TANDEM FACIAL AMPHIPHILES - The invention provides tandem facial amphiphiles for biochemical manipulations and characterization of membrane proteins, such as intrinsic membrane proteins. Members of this new family display favorable behavior with several membrane proteins. These amphiphiles can form relatively small micelles, and small changes in amphiphile chemical structures can result in large changes in their physical properties. The tandem facial amphiphiles can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins. | 05-09-2013 |
| 20130115252 | Genipin-Rich Material and Its Use - A method of preparing genipin-rich materials from the fruit of | 05-09-2013 |
| 20130115253 | Sustained Release Suspension Preparation For Dextromethorphan - A stabilized pharmaceutical composition comprises a drug-resin complex wherein the resin has been treated with an alkaline material prior to the formation of the drug-resin complex. The drug-resin complex may further be impregnated with an alkalizing agent, L-methionine, an antioxidant agent, or a combination thereof, or be coated with a diffusion barrier. A method of preparation of the pharmaceutical composition is provided. | 05-09-2013 |
| 20130115254 | APTAMER-LOADED, BIOCOMPATIBLE NANOCONSTRUCTS FOR NUCLEAR-TARGETED CANCER THERAPY - Disclosed herein is a nanoconstruct comprising an aptamer and a gold nanostar. The nanoconstruct can be used in a method of inducing changes to a nuclear phenotype of a cell comprising transporting the nanoconstruct to a nucleus of a cell, and releasing the aptamer from a surface of the gold nanostar into the nucleus of the cell to afford deformations or invaginations in the nuclear membrane, thereby inducing changes to the nuclear phenotype. The method can be used to treat certain hyperproliferative disorders such as cancer. | 05-09-2013 |
| 20130115255 | Particulate Tissue Graft with Components of Differing Density and Methods of Making and Using the Same - Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient. | 05-09-2013 |
| 20130115256 | METHODS FOR TREATING OR PREVENTING VASCULAR GRAFT FAILURE - The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition. | 05-09-2013 |
| 20130115257 | COMPOSITIONS AND METHODS FOR REMOVAL OR DESTRUCTION OF AMYLOID FIBRIL OR AMYLOID ADHESIN COMPRISING AGGREGATES - Methods and compositions for treating biofilms and diseases associated with amyloidosis such as Alzheimer's, Parkinson's and Huntington's disease, and Type 2 diabetes, by destroying amyloid fibrils in a two-step treatment are disclosed. The first step consists of binding to the amyloid fibril an intercalating molecule with a negatively charged group such as Congo red. The second step consists of adding metal ions, such as silver, gold(I), copper(I), palladium or lead ions or metal colloids of silver or gold, which destabilize the amyloid-dye complex. This process results in a disintegration of the fibril into peptide monomers and small aggregates of monomers. | 05-09-2013 |
| 20130122051 | Methods of preparing progesterone pharmaceutical compositions - The invention provides a method of preparing a pharmaceutical composition comprising: (a) combining progesterone particles with a liquid carrier to provide a mixture; (b) wet-milling the mixture to provide a wet-milled progesterone composition; and (c) processing the wet-milled progesterone composition to provide a pharmaceutical composition. Pharmaceutical compositions prepared by the method are also provided. | 05-16-2013 |
| 20130122052 | ANTIBODY MEDIATED OSSEOUS REGENERATION - The invention relates to the field of immunologically reactive molecules used to improve implantable medical devices. Immobilization of selected antibody molecules onto the surface of medical implants enable localization and concentration of in vivo growth factors in a timely manner to enhance the wound healing process following implantation of the device. When in vivo BMP-2 growth factor was captured on an implant device by attached monoclonal antibodies, the biological activity of BMP-2 was enhanced in the vicinity of the implant device. BMP-2 growth factor-specific antibody molecules or their fragments when immobilized on titanium dental or orthopedic implants improve osseo-integration. | 05-16-2013 |
| 20130122053 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH - The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34. | 05-16-2013 |
| 20130122054 | LIPID MEMBRANE STRUCTURE HAVING INTRANUCLEAR MIGRATING PROPERTY - A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell. | 05-16-2013 |
| 20130122055 | Anionic Charge-Dynamic Polymers for Release of Cationic Agents - Materials and Methods for the generation of polyelectrolyte multilayers that can erode to release cationic components. The multilayers comprise layers that contain one or more cations and one or more charge-dynamic anionic polymers. Charge-dynamic anionic polymers contain side chains having removable functional groups. Removal of the functional groups results in a change in the net change in the charge of the polymer which can disrupt interactions between cations and the anionic polymers and facilitate release of cations. | 05-16-2013 |
| 20130122056 | Ratiometric Combinatorial Drug Delivery - The present teachings include ratiometric combinatorial drug delivery including nanoparticles, multi-drug conjugates, pharmaceutical compositions, methods of producing such compositions and methods of using such compositions, including in the treatment of diseases and conditions using drug combinations. | 05-16-2013 |
| 20130122057 | Organophosphorous, Multivalent Metal Compounds, and Bioactive Glass Material Macromolecular Network Compositions and Methods - Cements containing certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as but not limited to calcium phosphate have been found to have improved properties and form a macromolecular network in the presence of a bioactive glass material that contain silicates, phosphates, and calcium salts which can be involved in the formation of bonding sites. | 05-16-2013 |
| 20130122058 | ENGINEERING OF POLYMER-STABILIZED NANOPARTICLES FOR DRUGS WITH LOG P VALUES BELOW 6 BY CONTROLLED ANTISOLVENT PRECIPITATION - The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w/w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution. | 05-16-2013 |
| 20130122059 | SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are methods of formulating cyclosporin A Form 2. | 05-16-2013 |
| 20130122060 | USING BUCKY PAPER AS A THERAPEUTIC AID IN MEDICAL APPLICATIONS - Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site. | 05-16-2013 |
| 20130122061 | Delayed Release Tablet With Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 05-16-2013 |
| 20130122062 | POLYMERIC COMPOSITIONS CONTAINING IR-EMITTING/ABSORBING ADDITIVES AND SHAPED ARTICLES COMPRISED THEREOF - Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in the infrared region, in a wavelength range of from 2 μm to 20 μm, and also a polymeric substrate, with the proviso that the inorganic fillers may be selected from among oxides, sulfates, carbonates, phosphates and silicates, and such inorganic fillers having an average particle size of less than 2 μm. | 05-16-2013 |
| 20130122063 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 05-16-2013 |
| 20130122064 | Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration - The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration. | 05-16-2013 |
| 20130122065 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-16-2013 |
| 20130122066 | DRUG DELIVERY DEVICES AND GROWTH FACTOR FORMULATIONS FOR ACCELERATED WOUND HEALING - The present invention is directed to novel drug delivery devices and pharmaceutical compositions containing growth and differentiation factor proteins. Said devices and compositions are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. The invention is especially useful for the supportive therapy of diabetic wounds and ulcers. | 05-16-2013 |
| 20130122067 | Growth-inhibited hydroxyapatite, process for its preparation and use - The invention relates to growth-inhibited hydroxyapatite for improving bone healing. It differs from the apatites employed to date in that it releases calcium ions and phosphate ions in physiological solutions, which, unlike traditional hydroxyapatites, it does not bind. It thereby promotes bone regeneration and bone growth. The growth-inhibited hydroxyapatite contains in agglomerates of prestructured collagen templates on which hydroxyapatite crystals with a crystallite growth of below its critical nucleus radius are formed epitactically. It is prepared by the steps a) mineralization of prestructured collagen templates in supersaturated Ca- and phosphate-ion-containing solutions, where the prestructured collagen templates are capable of diffusion and/or migration, so that HAP crystallites grow epitactically on the collagen templates and the collagen templates grown together with HAP crystallites agglomerate due to their capability of diffusion and/or migration, b) separating off the agglomerates. | 05-16-2013 |
| 20130129786 | HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS - An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants. | 05-23-2013 |
| 20130129787 | ADHESIVE COMPLEX COACERVATES PRODUCED FROM ELECTROSTATICALLY ASSOCIATED BLOCK COPOLYMERS AND METHODS FOR MAKING AND USING THE SAME - Described herein is the synthesis of adhesive complex coacervates from electrostatically associated block copolymers, wherein the block copolymers comprise alternating polycationic and polyanionic blocks. Methods for making and the using the adhesive complex coacervates are also described herein. | 05-23-2013 |
| 20130129788 | Nanotubes and Compositions Thereof - The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes. | 05-23-2013 |
| 20130129789 | ANTI-BACTERIAL APPLICATIONS OF POLY-N-ACETYLGLUCOSAMINE NANOFIBERS - Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described. | 05-23-2013 |
| 20130129790 | Adjuvant Incorporation in Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 05-23-2013 |
| 20130129791 | PREPARATIONS OF EFFERVESCENT FORMULATIONS COMPRISING SECOND AND THIRD GENERATION CEPHALOSPORIN AND USES THEREOF - The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents. | 05-23-2013 |
| 20130129792 | Pharmacokinetics of S-Adenosylmethionine Formulations - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 05-23-2013 |
| 20130129793 | MEDICAL DEVICES HAVING IMPROVED PERFORMANCE - In accordance with various aspects of the invention, implantable and insertable medical devices are provided, which contain one or more polymeric regions. In one aspect, the polymeric regions comprise (a) a block copolymer that comprises a polyaromatic block and a polyalkene block admixed with (b) a sulfonated high Tg polymer. In another aspect, the polymeric regions comprise a block copolymer that comprises (a) a sulfonated polymer block and (b) fluorinated polymer block. | 05-23-2013 |
| 20130129794 | Poly(Ester Amide)-Based Drug Delivery Systems - Implantable medical devices including a coating having a bioactive agent and a poly(ester amide) polymer. Methods of forming these coatings are also described. | 05-23-2013 |
| 20130129795 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES - Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 05-23-2013 |
| 20130129796 | Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries - Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. | 05-23-2013 |
| 20130129797 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions. | 05-23-2013 |
| 20130129798 | Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles - The present invention relates to improved microparticles comprising a somatostatin analogue, a process of making said microparticles and to pharmaceutical compositions comprising the same. | 05-23-2013 |
| 20130129799 | TUMOR PROLIFERATION INHIBITOR CONTAINING ULTRASOUND-SENSITIVE SUBSTANCE AND METHOD FOR INHIBITING TUMOR PROLIFERATION BY USING TUMOR PROLIFERATION INHIBITOR AND LOW-INTENSITY PULSED ULTRASOUND WAVES - Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. | 05-23-2013 |
| 20130129800 | HYALURONIC ACID BASED HYDROGEL AND USE THEREOF IN SURGERY - The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention. | 05-23-2013 |
| 20130136773 | Expandable Placental Membrane and Methods of Making and Storing Same - A placental membrane including a plurality of slits for increasing the membrane's capacity to expand. The slits are provided through the membrane and provided in sufficient numbers across the surfaces of the membrane to produce a mesh-like pattern in the membrane. The mesh-like pattern enables the placental membrane to be stretched and therefore increased in length and width. For ease of handling and storage, the expandable placental membrane is removably adhered to a backing, rolled into a cylinder and placed within a capped vial containing a solution of amniotic fluid cells for improving the effectiveness of the membrane. | 05-30-2013 |
| 20130136774 | POLYMERIC DRUG-DELIVERY MATERIAL, METHOD FOR MANUFACTURING THEREOF AND METHOD FOR DELIVERY OF A DRUG-DELIVERY COMPOSITION - A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder. | 05-30-2013 |
| 20130136775 | HYDROPHOBIC DRUG-DELIVERY MATERIAL, METHOD FOR MANUFACTURING THEREOF AND METHODS FOR DELIVERY OF A DRUG-DELIVERY COMPOSITION - A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition. | 05-30-2013 |
| 20130136776 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 05-30-2013 |
| 20130136777 | Bone Matrix Compositions and Methods - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone, and optionally providing a tissue-derived extract and adding the tissue-derived extract to the partially demineralized bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 05-30-2013 |
| 20130142833 | CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF EMULSIONS - An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned. | 06-06-2013 |
| 20130142834 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS - The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface. | 06-06-2013 |
| 20130142835 | SYNTHETIC SCAFFOLDS AND ORGAN AND TISSUE TRANSPLANTATION - Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided. | 06-06-2013 |
| 20130142836 | COMPOSITION AND METHOD FOR INHIBITING, PREVENTING, OR AMELIORATING COMPLICATIONS ASSOCIATED WITH INGESTION OF A MEDICINAL, CHEMICAL, OR BIOLOGICAL SUBSTANCE OR AGENT - The application relates, in part, to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent. | 06-06-2013 |
| 20130142837 | CELLULOSIC GEL COMPOSITION WITH IMPROVED VISCOSITY STABILITY - The present invention is directed to cellulosic gel compositions having improved viscosity stability through the exclusion of particular antioxidants and/or the exclusion of chemical entities that tend to produce free radicals. Preferably, the composition is an ophthalmic cellulosic gel composition that is suitable as a multi-dose composition. | 06-06-2013 |
| 20130142838 | COMPOSITIONS CONTAINING MICRONIZED TANAPROGET PREPARED BY WET GRANULATION - Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic to disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 06-06-2013 |
| 20130142839 | METHOD AND SYSTEM FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN - A method and system for administering pharmaceutical agents to a subject is provided. The system includes a course of treatment regimen, which includes a prescribed order of medicine amounts for periodic administration to the subject in the prescribed order. The amount of medicine includes a dose of at least one active pharmacological agent (APA) and an amount of at least one non-active pharmacological agent (NPA). The NPA provides at least one non-visual sensory cue. The dosage amounts of the APA contained within the amounts of medicine periodically administered in the prescribed order are varied within the course of treatment regimen, and the amount of the NPA contained within the amounts of medicine periodically administered in the prescribed order are held constant within the course of treatment regimen. | 06-06-2013 |
| 20130142840 | DENSE FIBRILLAR COLLAGEN MATRICES FOR TISSUE REPAIR AND THE PREPARATION METHOD THEREOF - Method for preparing a homogeneous collagen-based material by concentration of a collagen solution, includes bringing a collagen solution into contact by way of continuous injection and use of the material for tissue repair. | 06-06-2013 |
| 20130142841 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 06-06-2013 |
| 20130142842 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 06-06-2013 |
| 20130142843 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 06-06-2013 |
| 20130142844 | TISSUE IMPLANTS FOR IMPLANTATION AND METHODS OF PREPARING THE SAME - A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material in a nuclease-containing solution, and thereafter treating the tissue material with an alkaline alcohol solution. The nuclease-containing solution includes an antimicrobial. The alkaline alcohol solution comprises sodium hydroxide and ethanol. | 06-06-2013 |
| 20130142846 | Modified Release Analgesic Suspensions - A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods. | 06-06-2013 |
| 20130142847 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY - Provided herein are compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease. | 06-06-2013 |
| 20130142848 | PREPARATION FOR TREATMENT OF SPINAL CORD INJURY - The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone. | 06-06-2013 |
| 20130142849 | CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE - The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 06-06-2013 |
| 20130149343 | Hemostatic Bioabsorbable Device with Polyethylene Glycol Binder - A hemostatic pad comprising a bioabsorbable scaffolding material; a lyophilized thrombin powder, a lyophilized fibrinogen powder, and a meltable binder powder, with all powders disposed on the bioabsorbable scaffolding material. A meltable binder such as PEG bonds the lyophilized thrombin powder and the lyophilized fibrinogen powder to the bioabsorbable scaffolding material for improved friability, wettability and performance in a use, such as for hemostatic treatment or sealing at a wound site. | 06-13-2013 |
| 20130149345 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE - The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20% (w/w) leucine, about 75% (w/w) calcium lactate, and about 5% (w/w) sodium chloride, or about 37.5% (w/w) leucine, about 58.6% (w/w) calcium lactate, and about 3.9% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders. | 06-13-2013 |
| 20130149346 | DABIGATRAN ETEXILATE-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient. | 06-13-2013 |
| 20130149347 | ISOLATED RENAL CELLS AND USES THEREOF - The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations. | 06-13-2013 |
| 20130149348 | HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than | 06-13-2013 |
| 20130149349 | USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING - TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals. | 06-13-2013 |
| 20130149350 | Pharmacokinetics of S-Adenosylmethionine Formulations - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 06-13-2013 |
| 20130149351 | POLYMER SCAFFOLDS AND THEIR USE IN THE TREATMENT OF VISION LOSS - The present invention provides for scaffolds for growing RPE cells, comprising two or more biodegradable polymers. The present invention also provides for methods for creating a scaffold for growing RPE cells. Additionally, the present invention provides for RGD peptide linked polymer scaffolds for supporting the growth of RPE cells. The present invention provides methods of culturing RPE cells using the scaffolds produced herein. The present invention also provides methods of treating vision loss through the administration of RPE cell attached RGD peptide linked polymer scaffolds produced herein. The present invention further provides kits for treating vision loss. | 06-13-2013 |
| 20130149352 | APPARATUS AND METHOD FOR THE TREATMENT OF ABNORMAL UTERINE BLEEDING - Method and apparatus are disclosed for applying a therapeutic amount of a vasoconstrictor within the vaginal canal to control abnormal uterine bleeding. The abnormal bleeding can be due to excessive menstrual blood flow, bleeding from a surgical procedure, postpartum bleeding or any other acute or chronic condition. The vasoconstrictor includes topical agents such as an alpha-adrenergic agonist, for example oxymetazoline. The vasoconstrictor can be applied within the vaginal canal using any of many delivery apparatus. The vasoconstrictor can be included on a carrier member that is positioned in the vaginal canal and remains in place for a period of time, such as a tampon. In some embodiments, the carrier member can be a polymer ring or other shape that is inserted in the upper portion of the vaginal canal, such as the formix area. | 06-13-2013 |
| 20130149353 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 06-13-2013 |
| 20130149354 | COATED ELASTOMERIC ARTICLE AND METHOD FOR MAKING A COATED ELASTOMERIC ARTICLE - An elastomeric article, such as a glove or a condom, is coated with a compound containing silicone, collagen and allantoin. | 06-13-2013 |
| 20130149355 | HYDROXYAPATITE-TARGETING POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS - Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided. | 06-13-2013 |
| 20130149356 | Muscle-based grafts/implants - The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell. | 06-13-2013 |
| 20130149357 | Porous Degradable Polyelectrolyte Microspheres as Vaccine Vector - The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release. | 06-13-2013 |
| 20130156815 | TRANSDERMAL ESTROGEN DEVICE AND DELIVERY - Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described. | 06-20-2013 |
| 20130156816 | METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE - The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture. | 06-20-2013 |
| 20130156817 | SURFACE IMMOBILIZED CHAPERONES - A container containing a therapeutic protein, characterized in that chaperones molecules are bound by a molecular linker to an inner surface of the container. The linker being interposed between the surface and the chaperone. | 06-20-2013 |
| 20130156818 | METHODS AND COMPOSITIONS FOR CONTROLLING ASSEMBLY OF VIRAL PROTEINS - Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage. | 06-20-2013 |
| 20130156819 | ISOLATION OF MESENCHYMAL STEM CELLS - The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues. | 06-20-2013 |
| 20130156820 | PRODUCTION METHOD OF TISSUE REGENERATION MATERIAL AND TISSUE REGENERATION MATERIAL - Provided is a production method of a tissue regeneration material whereby a cell suspension can be seeded and cultured on a porous support having relatively large pores. The method comprises: contacting a porous body to a holding plate having a contact angle to water of 15 to 90°, the porous body being formed of a bioabsorbable polymer material, having a thickness of 2 to 100 mm, an interconnected porous structure with a pore diameter of 180 to 3500 μm and an average pore diameter of 350 to 2000 μm, a porosity of 60 to 95%, and a compressive strength of 0.05 to 1 MPa, and being filled with a cell suspension having a cell density of 5×10 | 06-20-2013 |
| 20130156821 | SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 06-20-2013 |
| 20130156822 | DRUG DELIVERY SYSTEM AND METHOD FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASE - Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease. | 06-20-2013 |
| 20130156823 | Excipient-free Aerosol Formulation - Methods and compositions for producing formulations for orally inhaled benzodiazepines that do not require the presence of a surface modifier are described. The formulations are useful in the treatment of epileptic seizures. | 06-20-2013 |
| 20130156824 | PROTECTIVE WOUND DRESSING DEVICE FOR ORAL AND PHARYNGEAL SPACE - The present invention provides a wound dressing comprising a tessellated water-soluble molding matrix comprised of a polymer selected from the group consisting of polyvinyl alcohol, gelatin, and mixtures thereof and a 1,1-disubstituted ethylene monomer. The present invention further provides methods of using the wound dressing and kits containing the wound dressing. | 06-20-2013 |
| 20130156825 | Modafinil Formulations - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 06-20-2013 |
| 20130156826 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN - The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I). | 06-20-2013 |
| 20130156827 | SODIUM ALGINATE CROSSLINKED SLOW-RELEASE MOXIFLOXACIN MICROSPHERE, THE PREPARATION METHOD AND THE USE THEREOF, AND TARGET VASCULAR OCCLUSIVE AGENT OF THE MICROSPHERE - A sodium alginate crosslinked slow-released moxifloxacin microsphere, the preparation method of the microsphere, a vascular target embolus containing the microsphere and the use of the microsphere in preparing the vascular target embolus. The microsphere contains moxifloxacin, a drug carrier, a adsorbent, a reinforcing agent and a solidifying agent, wherein the drug carrier is sodium alginate, the adsorbent is albumin prepared from human plasma or bovine serum albumin, the reinforcing agent is gelatin or hyaluronic acid, and the solidifying agent is a divalent metal cation chosen from calcium salt or barium salt. | 06-20-2013 |
| 20130156828 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same - A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6α, 11β, 16α, 17α)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1, 4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhitbits a Relative Humidity of from 20% to 40%. | 06-20-2013 |
| 20130156829 | COATING AGENT FOR PHARMACEUTICAL SOLID PREPARATION, PHARMACEUTICAL FILM FORMULATION, AND COATED PHARMACEUTICAL SOLID PREPARATION - A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4. | 06-20-2013 |
| 20130164334 | Dual Element Odor Control In Personal Care Products - An odor control layer for personal care products includes a first portion with a formulation of activated carbon and a second portion with a formulation of nanoparticle silver. The layer can be placed in a personal care product including diapers, training pants, absorbent underpants, adult incontinence products, or feminine hygiene products. The personal care product can include a liquid-permeable bodyside liner, a liquid-impermeable outer cover affixed to the bodyside liner, and an absorbent core disposed between the bodyside liner and the outer cover. | 06-27-2013 |
| 20130164335 | METHODS AND COMPOSITIONS FOR CELLULAR DRUG RELEASE - Methods and compositions for producing a cellular drug release are disclosed. The method comprises: a) providing a composition comprising a therapeutically effective amount of a pharmacological agent adsorbed onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces; b) exposing the composition to a cell; c) causing entry of the mesoporous HAP into the cell and degradation of the HAP in the lysosomes of the cell and desorption of the agent from the mesoporous HAP; d) causing release of the desorbed agent from the lysosomes into the cytoplasm of the cell; and e) causing release of the desorbed agent to outside the cell. The composition comprises a) mesoporous HAP with hydrophobic surfaces; and b) a therapeutically effective amount of a pharmacological agent, adsorbed onto the hydrophobic surfaces of the mesoporous. HAP. The composition is characterized in that it constantly releases the agent in vivo for a period of at least 4 weeks. | 06-27-2013 |
| 20130164336 | ANTIMICROBIAL AND ANTI-INFLAMMATORY ACTION PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION AND ITS PRODUCTION PROCESS - There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio from 10:1 to 75:1 respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. Its main difference is that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 25%. The so obtained mixture is used for injection preparations. | 06-27-2013 |
| 20130164337 | ANTIMICROBIAL ACTION PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION AND ITS PRODUCTION PROCESS - There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include active agents being betalactam antibiotics and finely dispersed nanostructured silica dioxide with a weight ratio from 10:1 to 75:1 respectively. The silica dioxide particles are antibiotic molecules delivery agents into the phagocytes, which allows increasing the antimicrobial preparations concentration at inflammation areas and considerably decrease microorganisms antibiotic resistance. The mentioned production process includes mixing betalactam antibiotic with finely dispersed nanostructured silica dioxide. Its main difference is that the mentioned substances mixture with a weight ratio from 10:1 to 75:1 respectively is exposed to mechanical processing by impact and abrasive actions until a proportion of the fine powder fraction with particles smaller than 5 micrometers increases to at least 25%. The so obtained mixture is used for injection preparations. | 06-27-2013 |
| 20130164338 | TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER - The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation. | 06-27-2013 |
| 20130164339 | PLATFORM FOR ENGINEERED IMPLANTABLE TISSUES AND ORGANS AND METHODS OF MAKING THE SAME - Disclosed are engineered tissues and organs comprising one or more muscle cell-containing layers, the engineered tissue or organ consisting essentially of cellular material, provided that the engineered tissue or organ is implantable in a vertebrate subject and not a vascular tube. | 06-27-2013 |
| 20130164340 | TROPOELASTINS AND USES THEREOF - The present invention relates to biocompatible polymeric scaffold materials, methods for making the materials and methods of using the materials. More particularly, the present invention relates to implants and grafts comprising polymeric scaffold materials of cross-linked human tropoelastin polypeptides and methods of making and using the same. In addition, the present invention provides alternatively spliced tropoelastin polynucleotides and polypeptides. | 06-27-2013 |
| 20130164341 | PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS - Inclusion compounds consisting of certain Angiotensin II AT1 receptor antagonists and cyclodextrins are described. These inclusion compounds are useful in the treatment of hypertension. | 06-27-2013 |
| 20130164342 | FORMULATIONS FOR OSTEOPOROSIS - The present invention relates to effervescent formulations comprising genistein with an average particle size (d | 06-27-2013 |
| 20130164343 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS - The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances. | 06-27-2013 |
| 20130164344 | STABLE POWDER FORMULATION CONTAINING AN ANTICHOLINGERIC AGENT - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X | 06-27-2013 |
| 20130164345 | Co-Processing Method and Formulations for HIV Attachment Inhibitor Prodrug Compound and Excipients - A process for the production of a formulation of HIV attachment inhibitor piperazine tris salt prodrug compound involves dissolving the prodrug compound in a solvent to form a solution; adding a first quantity of a first anti-solvent to the solution; then dispersing a first quantity of HPMC in the solution; adding a second quantity of the first anti-solvent to the solution; dispersing a second quantity of HPMC in the solution; then adding a second anti-solvent to the solution so as to crystallize the compound with the HPMC and thereby form the formulation, wherein the second anti-solvent is a combination of acetone and isopropyl acetate (IPAC). The formulation is then washed, and dried. | 06-27-2013 |
| 20130164346 | METHOD FOR PREPARING BIOMEDICAL METAL ALLOY MATERIAL WITH MULTI-DRUG DELIVERY SYSTEM - The present invention provides a method for preparing a biomedical metal alloy material with a multi-drug delivery system. A biomedical metal alloy material with a multi-drug delivery system according to the present invention is prepared by incorporating a therapeutic agent into a biodegradable material to prepare particles containing the therapeutic agent, treating the surface of the particles containing the therapeutic agent to have a charge opposite to the surface charge of a metal alloy material, and inducing an electrostatic interaction between the surface charges of the particles containing the therapeutic agent and the metal alloy material to immobilize the surface-treated particles containing the therapeutic agent on the surface of the metal alloy material. | 06-27-2013 |
| 20130164347 | MULTILAYER POLYMERIC DRUG DELIVERY SYSTEM - The invention relates to a customizable, solvent-free sustained release medical device for wound closure, wound healing, and the sustained release of an active. The device of the invention is composed of at least a polymeric carrier layer and optionally an oxidized regenerated cellulose layer(s). Polymeric barrier layers can be added to modify the release profile (burst, time of release, etc.) of the selected bioactive agent(s). | 06-27-2013 |
| 20130164348 | MEDICAL DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS - The present invention is generally directed to medical devices, and more specifically to medical devices that are at least partially insertable or implantable into the body of a patient. The medical devices generally comprise (a) a therapeutic agent, more typically, a high-molecular-weight therapeutic agent, and (b) at least one polymeric layer, which typically acts to control the release of the therapeutic agent from the medical device. Also disclosed herein are methods of making such medical devices. | 06-27-2013 |
| 20130164349 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 06-27-2013 |
| 20130164350 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 06-27-2013 |
| 20130164351 | METHODS OF TREATING BACTERIAL INFECTIONS THROUGH PULMONARY DELIVERY OF FUSIDIC ACID - Methods for the treatment of bacterial infections in the respiratory system of a subject, such as the lungs of a subject, using fusidic acid alone or in combination with a second bacterial agent such as tobramycin, amikacin, fosfomycin or levofloxacin are described. | 06-27-2013 |
| 20130171197 | HYALURONIC ACID HYDROGEL AND USE THEREOF - The present invention provides a hydrogel comprising a poly(N-isopropylacrylamide) cross-linked hyaluronic acid. The present invention also provides a method of synthesizing a hydrogel comprising poly(N-isopropylacrylamide) cross-linked hyaluronic acid, which comprises (a) synthesizing methacrylated hyaluronic acid; and (b) copolymerizing methacrylated hyaluronic acid with N-isopropylacrylamide. | 07-04-2013 |
| 20130171198 | ANTIMICROBIAL AND VULNERARY ACTION PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION AND ITS PRODUCTION PROCESS - There is proposed herein a process for production of composite antimicrobial and vulnerary preparations for external administration, featuring a higher therapeutic efficiency in case of skin and soft tissues infections treatment. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio of (25-75 mass. %):(75-25 mass. %) respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. The process is distinct in that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 40%. | 07-04-2013 |
| 20130171199 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION - An oral controlled release pharmaceutical composition comprising a core and a polymer dispersion and its preparation method are disclosed. The core is selected from the group consisting of ‘the drug coated core’ and ‘the drug loaded core’. The drug coated core comprises an inert excipient based sphere and a coat of drug composition. The drug loaded core comprises at least a drug, a binder and at least one pharmaceutically acceptable excipient. The polymer dispersion used to coat the core comprises at least one controlled release polymer and at least one pharmaceutically acceptable excipient. The oral controlled release pharmaceutical composition further comprises an in-situ gelling system comprising at least one gelling polymer. | 07-04-2013 |
| 20130171200 | Heat Patch for Diabetes - Provided in the present invention are a composition for ameliorating or treating a diabetic condition and methods of making and using the same. | 07-04-2013 |
| 20130171201 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS - Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier. | 07-04-2013 |
| 20130171202 | Antipsychotic Injectable Depot Composition - The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks. | 07-04-2013 |
| 20130171203 | Composition And Methods For Antimicrobial Articles - A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity. | 07-04-2013 |
| 20130171204 | SOFT FOOD COMPOSITION WITH PROBIOTICS AND PREBIOTICS FOR MASKING MEDICATIONS - A soft extruded food composition containing probiotics, enzymes, and vitamins for wrapping medications, such as pills or tablets, for animal consumption. The flavor of the wrapped solid medication is masked by the food composition and thus becomes more palatable to the animal while providing additional health benefits in the form of probiotics, prebiotics, enzymes, and vitamins. | 07-04-2013 |
| 20130171205 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent. | 07-04-2013 |
| 20130171206 | METHOD FOR TREATING OR PREVENTING RENAL OR LIVER DISEASE - The methods for treatment using an adsorbent having a high adsorbability, and capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight. | 07-04-2013 |
| 20130171207 | MICELLE ENCAPSULATION OF A COMBINATION OF THERAPEUTIC AGENTS - The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations. | 07-04-2013 |
| 20130171208 | COMPOSITIONS OF NANOPARTICLES AND METHODS OF MAKING THE SAME - Disclosed herein are compositions of nanoparticles. In some embodiments, the nanoparticles are Janus particles, where each particle includes a first component and second component that are exposed to the surface of the particle. Also, disclosed are methods and systems for making a composition of nanoparticles. Finally, a method of treating a mammal by administering a composition of nanoparticles is disclosed. | 07-04-2013 |
| 20130171209 | REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE - Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient. | 07-04-2013 |
| 20130171210 | BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections. | 07-04-2013 |
| 20130171211 | METHODS AND USES FOR INHIBITING PLATELET COAGULATION - The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with Slit protein or a cell expressing a Slit protein. | 07-04-2013 |
| 20130171212 | Stable Aqueous Formulations Comprising Poorly Water Soluble Active Ingredients - A formulation includes one or more active ingredients of poor water solubility for medical or non-medical use in the rearing of animals. The formulation is suitable for administration to the animals via their drinking water. It exhibits superior stability. The formulation comprises an active ingredient, a thickener combination and water, wherein the thickener combination comprises at least one thickener selected from the following groups A, B, C and D:
| 07-04-2013 |
| 20130171213 | METHOD FOR MANUFACTURING MULTILAYERED CELL SHEET, MULTILAYERED CELL SHEET HAVING VASCULAR NETWORK OBTAINED THEREBY, AND METHOD OF USE THEREOF - A method tor producing multilayered cell sheets, including producing a vascular bed which includes an artery-vein loop and in which a capillary vascular network is constructed; layering cell sheets on the vascular bed; and perfusing a culture medium in vitro to construct a vascular network in the cell sheets. The production method enables vascular networks to he constructed in cell sheets and enables thick multilayered cell sheets to foe easily produced by layering the cell sheets. Such thick multilayered cell sheets are useful as in vivo tissue-like products for regenerative medicine for various tissues and for evaluation of drugs and the like. | 07-04-2013 |
| 20130171214 | Pharmaceutical Compositions - The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections. | 07-04-2013 |
| 20130171215 | Process for Preparing Curcumin Encapsulated Chitosan Alginate Sponge Useful for Wound Healing - A process for preparing curcumin encapsulated chitosan alginate sponge comprising the steps of: incorporating curcumin in a fluid phase of oleic acid; subjecting the mixture to a step of emulsification with chitosan solution by homogenization; emulsifying the resultant solution with alginate solution by homogenization; lyophilizing the final emulsion by freeze drying to produce curcumin loaded AC sponge. | 07-04-2013 |
| 20130177598 | DISCRETE SIZE AND SHAPE SPECIFIC PHARMACEUTICAL ORGANIC NANOPARTICLES - A pharmaceutical composition comprising protein micro and/or nanoparticles are provided. The particles have a predetermined geometric shape and a broadest dimension less than about 10 micrometers. The particles may further comprise active agents. | 07-11-2013 |
| 20130177599 | METHODS AND KITS FOR EXTENDING CONTACT LENS USE - Provided are method and kits useful for extending the wear-time of a contact lens. The method includes applying an amount of an ophthalmically acceptable solution to the contact lens to improve the comfort of the eye when the contact lens is in the eye. The solution includes an aqueous suspension and chitosan. The aqueous suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. Upon contact with tear fluid, the solution gels to a second viscosity which is greater than the first viscosity. The kit includes contact lenses, an ophthalmically acceptable solution and instructions for applying the solution to improve the comfort of the eye when the contact lens is in the eye. | 07-11-2013 |
| 20130177600 | Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs - Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity. | 07-11-2013 |
| 20130177601 | AQUEOUS COMPOSITIONS AND METHODS FOR BONE HEMOSTASIS - Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone. | 07-11-2013 |
| 20130177602 | LAYERED PHARMACEUTICAL FORMULATIONS - In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine. | 07-11-2013 |
| 20130177603 | Methods for the Preparation of Injectable Depot Compositions - Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days. | 07-11-2013 |
| 20130177604 | Compositions and Methods of Treating Metabolic Disorders - Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. | 07-11-2013 |
| 20130177605 | ORAL FILM-FORM BASE AND PREPARATION - The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 μm, and are included in particle states. | 07-11-2013 |
| 20130177606 | TRANSDERMAL THERAPEUTIC SYSTEM WITH CHOLINESTERASE INHIBITOR - The invention concerns a transdermal therapeutic system with a carbamate cholinesterase inhibitor for the treatment of mild to moderate Alzheimer's disease dementia and/or Parkinson's disease dementia. | 07-11-2013 |
| 20130177607 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 07-11-2013 |
| 20130177608 | METHOD FOR FORMING INORGANIC COATINGS - The present invention is directed to a method for forming an inorganic coating on a protein template. The method comprises contacting the template with an anionic polymer interface followed by an inorganic material for a sufficient period of time to allow mineralization of the inorganic material thus forming an inorganic coating on the template. Preferably, the coating is aligned. | 07-11-2013 |
| 20130177609 | Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs - An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective. | 07-11-2013 |
| 20130177610 | NANO-METALLIC ALLOY DELIVERY SYSTEM FOR TREATMENT OF INFECTED CELLS AND LEGIONS - A system for delivering nano-metallic alloys to infected cells in a patient is disclosed. The nano-metallic alloy may be formed from binary, triple, or quadruple elemental compositions complexed in predetermined percentages of monosodium phosphate monohydrate and disodium phosphate heptahydrate. The nano-metallic alloy may be capable of eliminating infectious microorganisms within infect cells or legions without harming the cells or tissues. The system may also include a method of administering a predetermined concentration of the nano-metallic alloy in the complexing solution in the vicinity of the infected cells of legions to kill the foreign matter. | 07-11-2013 |
| 20130177611 | SILK-BASED DRUG DELIVERY SYSTEM - The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer. | 07-11-2013 |
| 20130177612 | Prebiotic Formulations and Methods of Use - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes. | 07-11-2013 |
| 20130177613 | PACKAGING ASSEMBLY FOR PHARMACEUTICAL COMPOSITION INCLUDING PIMOBENDAN - A packaging assembly or kit includes packaging material containing a solid formulation including pimobendan dispersed in a polyvalent acid. The kit may also include a package leaflet or user instruction including the information concerning use of the solid formulation, for example, via the oral route for the prevention and/or treatment of congestive heart failure in a mammal in need of such prevention or treatment, preferably in a dog, cat or rodent. | 07-11-2013 |
| 20130183349 | METHOD FOR CONTROLLED RELEASE OF PARATHYROID HORMONE FROM CROSS-LINKED HYALURONIC ACID HYDROGEL - A method for locally controlled release of an effective amount of PTH(1-34) by a hyaluronic acid based hydrogel that can injected intra-articularly for the treatment of osteoarthritis is provided. | 07-18-2013 |
| 20130183350 | IMMUNOGENIC COMPOSITIONS - This disclosure relates to immunogenic compositions comprising an isolated immunogenic | 07-18-2013 |
| 20130183351 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 07-18-2013 |
| 20130183352 | NANOFIBER SCAFFOLDS AND METHODS FOR REPAIRING DAMAGED CARDIAC TISSUE - Compositions are provided comprising a nanofiber scaffold that is seeded with one or more relevant cells and has a basketweave configuration that mimics the structure of a tissue, such as a cardiac tissue. Methods for treating damaged cardiac tissue in a subject are also provided and include applying an effective amount of the composition to damaged cardiac tissue. Methods for making nanofiber scaffold compositions are further provided and include electrospinning a biodegradable polymer onto a mandrel to create a mat of electrospun nanofibers, dividing the mat into nanofiber strips; and weaving the strips into a nanofiber scaffold having a basketweave configuration that mimics the structure of a tissue. | 07-18-2013 |
| 20130183353 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 07-18-2013 |
| 20130183354 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT USING TARGETED CARBON NANOTUBES - A method for detecting and/or destroying cancer tumors is based on the concept of associating a linking protein or linking peptide to carbon nanotubes to form a protein-carbon nanotube complex. | 07-18-2013 |
| 20130183355 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES - Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described. | 07-18-2013 |
| 20130183356 | IMMUNITY INDUCER - The purpose is to provide an immunity-inducing agent which can be implanted or injected in vivo by a simple operation and is capable of activating the in vivo immunological actions without causing adverse side effects. An immunity-inducing agent comprising β-tricalcium phosphate (β-TCP) having a porosity of 50% or less is implanted or injected in vivo, particularly in the vicinity of a lesion area (non-lesion area) such as cancer. Lymphocytes such as T cells, B cells and NK cells or a dendritic cell can be induced in the vicinity of β-TCP, and a lymphadenoid tissue is formed in which lymphocytes are localized at a high density. Examples of the dosage form of the immunity-inducing agent include particles or granules having a particle or grain size of equal to or greater than 0.05 μm and less than 25 μm, as well as tablets or columellas. | 07-18-2013 |
| 20130189312 | NOVEL COATING SYSTEM - The present patent application relates to a novel coating system, coated compositions with such a coating system, as well as to the use of such compositions in the production food, feed, dietary supplements and/or pharmaceutical products, as well as to food, feed, dietary supplements and/or pharmaceutical products comprising such compositions. | 07-25-2013 |
| 20130189313 | ADHESIVE COMPLEX COACERVATES AND METHOD OF MAKING AND USING THEREOF - Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. They have numerous biological applications as bioadhesives and drug delivery devices and are particularly useful in underwater applications and situations where water is present such as, for example, physiological conditions. | 07-25-2013 |
| 20130189314 | ENTERIC-COATED HT-2157 COMPOSITIONS AND METHODS OF THEIR USE - Drug compositions comprising the compound HT-2157 and their therapeutic uses, including the treatment of CNS disorders and cognitive impairments and the modulation of cognitive function, are disclosed. More particularly, the present invention relates to enteric-coated formulations comprising HT-2157 that reduce the appearance of clinically relevant methemoglobinemia relative to administration of non-enteric-coated formulations comprising HT-2157. | 07-25-2013 |
| 20130189315 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer. | 07-25-2013 |
| 20130189316 | NANOEMULSION COMPOSITION CONTAINING VITAMIN K - In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP. | 07-25-2013 |
| 20130189317 | NOVEL DOSAGE AND FORMULATION - The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide. | 07-25-2013 |
| 20130189318 | Solid dispersions comprising tacrolimus - A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability. | 07-25-2013 |
| 20130189319 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors. | 07-25-2013 |
| 20130189320 | METHOD OF PREPARING A CONTROLLED RELEASE PARTICLE OF SOY ISOFLAVONE WITH BIODEGRADABLE POLYMER USING A SUPERCRITICAL FLUID EXTRACTION OF EMULSION (SFEE) PROCESS - A method of preparing a controlled release particle of soy isoflavone (e.g. genistein) with a bio-degradable polymer is disclosed herein. The method employs a supercritical fluid extraction of emulsion (SFEE) process for encapsulating soy isoflavone into a bio-degradable polymer matrix (e.g. PLGA) to form a particle which is suitable for oral administration or inhalable administration in a controlled release manner and with an improved bioavailability of the soy isoflavone. A system for preparing the controlled release particle of the soy isoflavone with the bio-degradable polymer using the SFEE process is also disclosed herein. | 07-25-2013 |
| 20130189321 | Parental Composition Comprising Microsperes with a Diameter between 10 and 20 Microns - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. | 07-25-2013 |
| 20130189322 | Chromatographic Media for Storage and Delivery of Therapeutic Biologics and Small Molecules - Described are composite materials and methods of making and using them for the storage and delivery of unstable drugs or biologics. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through the support member; a macroporous cross-linked gel, comprising a plurality of macropores; a therapeutic agent; and a stabilizing agent. | 07-25-2013 |
| 20130189323 | ANTIBACTERIAL AND OSTEOINDUCTIVE IMPLANT COATING, METHOD OF PRODUCING SUCH COATING, AND IMPLANT COATED WITH SAME - A calcium phosphate/copper coating for an implant is provided which includes highly porous calcium phosphate and predominantly discontinuously distributed copper. The highly porous calcium phosphate first forms a highly porous calcium phosphate layer in which the copper has been incorporated so as to be discontinuously distributed, to form the calcium phosphate/copper coating. Further provided are a method of producing such a calcium phosphate/copper coating and an implant coated therewith. | 07-25-2013 |
| 20130189324 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION - Dry powder formulations comprising a corticosteroid and a beta | 07-25-2013 |
| 20130189325 | METHODS OF APPLYING COATING MATERIALS FOR SOLID MEDICINES - A method improves stability of drugs in a solid pharmaceutical formulation against oxygen and water vapor by coating the solid pharmaceutical formulation with a coating material including a high hydrogen-bonding resin and a swelling clay. | 07-25-2013 |
| 20130189326 | METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY - The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nanosilicate platelets. | 07-25-2013 |
| 20130189327 | LIVER ORGANOID, USES THEREOF AND CULTURE METHOD FOR OBTAINING THEM - The invention relates to a liver organoid, uses thereof and method for obtaining them. | 07-25-2013 |
| 20130189328 | PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L | 07-25-2013 |
| 20130189329 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES - Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups. | 07-25-2013 |
| 20130189330 | Enteral Nutrient - Provided is an enteral nutrient which, although containing a soy protein as a protein source, does not cause a rapid increase in viscosity and inhomogeneity due to aggregation or thermal denaturation by heating for sterilization or formulation step and is thus stable, and shows a good taste without giving any sense of bitterness and coarseness on the throat inherent to soybean. The enteral nutrient is an enteral nutrient of acidic type which comprises a protein, a fat, a carbohydrate, a vitamin, a mineral and a food fiber and has a pH of 3.0 to 4.5, wherein a soy protein containing 20 to 40% of a peptide fraction having a molecular weight of less than 6000 is formulated in an amount of 5 to 65% of the total protein. | 07-25-2013 |
| 20130195921 | METHODS FOR REGULATING GELATION OF HYDROGEL SOLUTIONS AND USES THEREOF - The present invention provides a method for preparing chitosan and xylan composite thereto-gelling solutions to allow regulating the conditions in which the chitosan and xylan solution will gel. The present invention also provides methods for using chitosan/xylan solutions as compositions and for using chitosan/xylan solutions in vitro and in vivo. A thermally-responsive composite hydrogel has been developed and synthesized from the natural polymers chitosan and xylan. The new material is a viscous liquid at room temperature, but turns to a solid gel at physiological temperature (37 C). Rate of gelation is controlled with addition of a salt solution. Applications are for tissue engineering and local delivery of therapeutic agents, including proteins and drugs, as wells as cells. | 08-01-2013 |
| 20130195922 | METHODS AND COMPOSITIONS FOR TREATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 08-01-2013 |
| 20130195923 | MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES - Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided. | 08-01-2013 |
| 20130195924 | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE HAVING HYDROPHOBIC PROPERTIES AND AT LEAST ONE COMPOUND SELECTED FROM AMONG SIALOGLYCOSPHINGOLIPIDS, GLYCOSPHINGOLIPIDS OR A MIXTURE OF SIALOGLYCOSPHINGOLIPIDS AND GLYCOSPHINGOLIPIDS - This invention discloses water soluble pharmaceutical compositions including at least one therapeutically active substance and at least one compound selected from the sialoglycosphingolipids, the glycosphingolipids or a mixture of sialoglicosphingolipids and glycosphingolipids, in which at least one of the therapeutically active substances is a drug with hydrophobic characteristics. In particular, sterile compositions for i.v. administration, composed of nano-glycosphingolipids micelles or modified glycosphingolipids, which can be coated with albumin in a noncovalent form and which allow transport and controlled release of highly hydrophobic molecules are disclosed. | 08-01-2013 |
| 20130195925 | ANTI AGING APPLICATION AND METHOD FOR TREATING AGING - There is a topical anti-aging composition which is configured to interfere with the production of tyrosinase, as well as melanin by reacting with melanocytes as well as reacting with, or acting on keratinocytes. The anti-aging composition comprises an emulsion comprising a plurality of active ingredients comprising a plurality of pigmentation reducing elements which are configured to interrupt or prevent the production of tyrosinase and melanin. In addition there are a plurality of antioxidants a plurality of anti wrinkling agents a plurality of anti-inflammatory agents at least one additional agent comprising at least one of an emollient, a proactant and a conditioning agent. | 08-01-2013 |
| 20130195926 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE - The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject. | 08-01-2013 |
| 20130195927 | CERIUM OXIDE NANOPARTICLES AND ASSOCIATED METHODS FOR PROMOTING WOUND HEALING - Novel compositions and methods for the treatment and promotion of wound healing are disclosed herein. There is included a method for treating a wound including administering to a subject in need thereof a wound composition comprising an effective amount of ceria nanoparticles. | 08-01-2013 |
| 20130195928 | CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH - The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition. | 08-01-2013 |
| 20130195929 | ACTIVE INGREDIENT DELIVERY SYSTEM WITH AN AMORPHOUS METAL SALT AS CARRIER - An active ingredient delivery system and a method of making or using the same, wherein the delivery system includes an active ingredient and a carrier component of an amorphous metal salt, with the active ingredient at least partly fixed to and partly encapsulated by the carrier component. The active ingredient may be a bitter tasting polyphenol such as a flavonoid. | 08-01-2013 |
| 20130195930 | Inulin and Inulin Acetate Formulations - The disclosure provides compositions that include microparticles or nanoparticles of beta inulin or inulin acetate and an active agent, where the active agent is contained within individual microparticles or nanoparticles. The active agent can be, for example, a vaccinating antigen, an antigenic peptide sequence, or an immunoglobulin. The compositions can be incorporated into various formulations for administration to a subject such as a human or animal. The invention further provides methods of using the compositions and formulations, including methods of stimulating an immune response in a subject, or enhancing an immune response in a subject, for the purpose of treating, preventing, or inhibiting an infectious disease, autoimmune disease, immunodeficiency disorder, neoplastic disease, degenerative disease, an aging disease, or a combination thereof. | 08-01-2013 |
| 20130195931 | ANTIMICROBIAL COMPOSITE - An antimicrobial composite which comprises a first, liquid-permeable layer which is substantially completely bonded to a second liquid-absorbing layer. The first layer comprises a coating of at least one antimicrobial metal as such on the side which is bonded to the second layer. Substantially no antimicrobial metal in elemental form is present on exterior surfaces of the composite. | 08-01-2013 |
| 20130195932 | ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS - The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions comprising an antigen and a self-adjuvanting carrier, useful for inducing antigen-specific mucosal and systemic immune responses in the host upon immunization via a mucosal route such as intranasal. The vaccine compositions comprise multivalent cations in association with a plurality of spherical archaeal polar lipid aggregates containing aqueous compartments, the AMVAD structure, formed by the interaction of archaeosomes and antigen(s) with multivalent cations such as Ca | 08-01-2013 |
| 20130195933 | PHARMACEUTICAL COMPOSITION AND USE - An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided. | 08-01-2013 |
| 20130195934 | METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY - Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug. | 08-01-2013 |
| 20130195935 | ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 08-01-2013 |
| 20130195936 | OPHTHALMIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS - The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature. | 08-01-2013 |
| 20130195937 | USE OF CARBON NANOTUBES FOR PREVENTING OR TREATING BRAIN DISEASE - A method for preventing or treating a brain nervous disease includes administering to a subject in need thereof a therapeutically effective amount of a carbon nanotube, wherein the nervous disease is a brain disease or a traumatic central nervous system injury. The composition of the present invention enables patients to recover from physical damage to the brain, exhibits superior efficacy for inhibiting the onset of Parkinson's disease and strokes in animal models for Parkinson's disease and strokes, and the cytotoxic effects of beta amyloid in beta amyloid toxicity tests. Therefore, the composition of the present invention can be effectively used in the preparation of medicine for protecting cranial nerves, therapeutic agents for preventing or treating brain disease, or therapeutic agents for treating traumatic injuries to the central nervous system. | 08-01-2013 |
| 20130195938 | METHOD OF MODIFYING DISSOLUTION RATE OF PARTICLES BY ADDITION OF HYDROPHOBIC NANOPARTICLES - Method of modifying dissolution rate of a plurality of particles in an aqueous-based solvent by adding hydrophobic surface modified nanoparticles to the plurality of particles, and exposing the plurality of particles to the aqueous-based solvent. | 08-01-2013 |
| 20130195939 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE - This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta. | 08-01-2013 |
| 20130195940 | METHOD TO INHIBIT RECRUITMENT OF MONOCYTES AND MACROPHAGES BY AN ICAM-3 INHIBITOR - The present disclosure relates generally to methods and materials for modulating the recruitment of macrophages or monocytes to sites at which they may contribute to disease initiation or progression. Embodiments of the disclosure comprise providing a modulator of the activity of ICAM-3 or proximal to the site. | 08-01-2013 |
| 20130202654 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament. | 08-08-2013 |
| 20130202655 | Vaccines, Methods of Administering Vaccines, Methods and Products for Treating and/or Delaying Onset of Dysplastic Lesions, and Wafers for Oral Administration - Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material. | 08-08-2013 |
| 20130202656 | SYSTEMS AND KITS FOR THE FABRICATION OF TISSUE PATCHES - Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. | 08-08-2013 |
| 20130202657 | FOAMS OR PARTICLES FOR APPLICATIONS SUCH AS DRUG DELIVERY - The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02. For example, a precursor to the foam, containing a pharmaceutically active agent, may be mixed with a foaming agent, then the pressure decreased to cause the foaming agent to expand, thereby causing a foam to form. The foam may then be subsequently ground or milled, or otherwise processed to form particles. | 08-08-2013 |
| 20130202658 | Compositions Comprising Buprenorphine - This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof. | 08-08-2013 |
| 20130202659 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 08-08-2013 |
| 20130202660 | FUNCTIONAL NANOSTRUCTURED CHITOSAN COATINGS FOR MEDICAL INSTRUMENTS AND DEVICES - Disclosed herein is an approach for coating a biocompatible material, in particular chitosan, onto a surface in need thereof. This approach results in a coating that is highly uniform, even on irregular surfaces, and enables ready adjustment of the morphology of the coated material. A convenient means to add a functional property to the biocompatible material by incorporation of functional additives is also provided. | 08-08-2013 |
| 20130202661 | FORMULATIONS OF VILOXAZINE - Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed. | 08-08-2013 |
| 20130202662 | o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME - An O/W/O emulsion composition having at least one of lignan-class compounds dissolved in an internal oil phase is disclosed. This composition can be produced by a process comprising the steps of 1) dissolving at least one of lignan-class compounds in oil or fat to prepare a lignan-class compound dissolving liquid; 2) emulsifying the lignan-class compound dissolving liquid in a water phase to form an O/W emulsion; and 3) further emulsifying the O/W emulsion in an oil phase to prepare an O/W/O emulsion. | 08-08-2013 |
| 20130202663 | REMEDY - It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated. | 08-08-2013 |
| 20130202664 | MEDICAL ADSORBENT AND METHOD FOR PRODUCING SAME - A medical adsorbent for oral administration that has low dosage and excellent adsorptive capacity and selective adsorption for toxins to be removed, and is also economical and environmentally friendly. The medical adsorbent comprises granular activated carbon that is activated carbon obtained by carbonization and activation of refined cellulose or regenerated cellulose, and having a mean pore diameter of 1.5 to 2.2 nm, a BET specific surface area of 700 to 3000 m | 08-08-2013 |
| 20130209518 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 08-15-2013 |
| 20130209519 | FORMULATIONS OF FLIBANSERIN - The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin. | 08-15-2013 |
| 20130209520 | FOAMS, INCLUDING MICROCELLULAR FOAMS, CONTAINING COLLOIDAL PARTICULATES - The present invention generally relates to foams and particles made from such foams, for applications such as drug delivery. The foams or particles may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foams may include colloidal particulates. A first aspect of the present invention is generally related to polymer-based foams or particles containing pharmaceutically active agents. In some cases, the foam or particle may contain smaller colloidal particulates therein. Such colloidal particulates may be used, for example, to limit the amount of material within certain regions of the foam, or exclude pharmaceutically active agents from being located within certain portions of the foam, which may useful for enhancing release of pharmaceutically active agents from the foam. In some cases, the colloidal particulates may cause the foam or particle to have an unexpectedly high specific surface area. The foam, in certain embodiments, can exhibit a relatively high loading of the pharmaceutically active agent. The foam may be microcellular in certain instances. The foam may also be created using a supercritical fluid, for example, supercritical C0 | 08-15-2013 |
| 20130209521 | NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. | 08-15-2013 |
| 20130209522 | Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft - In some embodiments, the invention provides an implant comprising a uniform mixture of degradable polymer, bone, and a drug. In some embodiments, the drug comprises an antibiotic. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for an amount of time longer than an amount of time that a pathogen is senescent. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for at least eight weeks, or at least ten weeks, or at least twelve weeks post-implantation. In some embodiments, the therapeutic level is maintained at an implantation site of the implant. | 08-15-2013 |
| 20130209523 | Amorphous Medicinal Fine Particles Produced By Pulsed Laser Ablation In Liquid And The Production Method Thereof - The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase transition process to covert an initial crystalline structure into an amorphous solid, technical difficulties with handling a hydraulically-pressed target are overcome. The laser- |
